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CHAPTER 1
General introduction of gut wall
integrity
9
1
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 9
1.1 INTRODUCTION
The primary function of the intestine is the absorption of dietary nutrients. To
this end, the intestinal epithelium has to be permeable for nutrients and
macromolecules important for growth and development. However, the intake
of nutrition exposes the epithelium to a wide variety of antigens from food and
microbiota and its products 1,2. The second function of the intestine is therefore
to provide an effective barrier to these potentially harmful luminal antigens,
toxins and microbiota 1,2. Different types of (intestinal) pathology, in which
failure of gut wall integrity potentially plays an important role, are explicated in
paragraph 1.2 3. Several physical/anatomical and immunological barriers have
evolved to prevent invasion of foreign or endogenous threats from the intestinal
lumen to the sterile interior milieu of the host, which will be discussed in
paragraph 1.3. Furthermore, attention is paid to detection methods for the
assessment of intestinal barrier loss in man (paragraph 1.4).
10
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1.2 THE IMPORTANCE OF EVALUATION OF GUT WALL INTEGRITY
Early diagnosis and follow-up of intestinal damage in clinical medicine
Evaluation of intestinal pathology in patients of all age-groups has been a
challenge for clinicians. Numerous patients present with abdominal complaints,
which are frequently aspecific and therefore correspond to pathologies of most
intra- and even some extra-abdominal organs. Laboratory tests and imaging
techniques are often helpful in revealing disorders of organs, including the liver,
pancreas, heart and kidneys. However, it is currently still difficult to diagnose
intestinal pathology in patients presenting with abdominal complaints 4,5. The
current standard technique for assessing intestinal status is endoscopy with
bowel biopsy, which is often inadequate as it is invasive, sometimes requires
sedation, is expensive and only assesses the function of the biopsied fraction.
Moreover, for patients who are neutropenic and/or thrombocytopenic, the
procedure is physically hazardous and often ethically unacceptable. Therefore, a
major delay in diagnosis is often present in patients with e.g. necrotizing
enterocolitis (NEC), chemotherapy-induced mucositis, acute mesenteric
ischemia and celiac disease 4,6. A diagnostic delay results in postponed correct
treatment, which is accompanied by higher morbidity and mortality rates. In line
with these diagnostic concerns, the follow-up of numerous intestinal diseases is
hampered by the absence of non-invasive, rapid diagnostic means to assess
intestinal damage for evaluation of the effects of treatment on the recovery of the
disorder 4.
This leads to the following clinical questions:
1) Are proteins, released from cytosol of enterocytes or from tight junctions
upon damage, potentially useful as non-invasive markers to diagnose
intestinal disease?
2) What is the value of the assessment of such proteins in the follow-up of
intestinal disease?
Potential involvement of the gut in the development of postoperative or
posttraumatic complications
Patients undergoing major surgery or sustaining severe trauma are at risk of
developing morbidity and mortality from post-operative or post-traumatic
systemic inflammatory response syndrome (SIRS), sepsis and multiple organ
failure (MOF). The development of such potentially lethal complications in
relatively healthy surgical or trauma patients is poorly understood 7,8.
Experimental animal studies have generated the hypothesis that the intestines
are central in the origin of post-operative and post-traumatic sequelae 9-13.
11
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Human studies have contributed insufficiently to gain insight in the
applicability of this hypothesis 8. Recognition of patients at risk of developing
post-operative or post-traumatic SIRS, sepsis and MOF is important, since
patients with these clinical syndromes have the highest noncardiac mortality
rate of patients in the intensive care unit (ICU) 9-15.
Experimental animal models, resembling the clinical situation of major
surgery and trauma, show that haemorrhagic shock leads to disruption of the
gut wall integrity, measured by derangement of tight junctions and elevated
circulating levels of Fatty Acid Binding Proteins (FABP), originating from
damaged intestinal epithelial cells 16,17. Moreover, leakage of macromolecules,
microbial products and microbiota from the intestinal lumen to the circulation
and mesenteric lymph nodes, spleen and liver occurs 11,17. The inflammatory
response to microbial products as endotoxin has been reported to be induced
via various rapidly induced innate immune mechanisms, ranging from Toll Like
Receptors to complement activation 18-20. Supportive for the importance of the
gut in the development of postoperative complications is that protection of the
gut wall integrity in haemorrhagic shocked animals by administration of
probiotic strains, which inhibit the adhesion of enteric pathogens to intestinal
epithelial cells, can result in abrogation of both local and systemic
inflammatory responses 21. However, administration of probiotic strains may
also have unwanted side-effects, including disruption of intestinal tight
junctions and increase of bacterial translocation 22.
Studies in patients undergoing major gastro-intestinal, cardiac or vascular
surgery, investigating the role of the gut in the development of post-operative
complications, are largely restricted to data on increased intestinal permeability
for sugars, 51Cr-EDTA and the circulatory levels of endotoxin 23-29. An increased
intestinal absorption of sugars or 51Cr-EDTA, indirect measures for gut barrier
loss, in patients following major surgery support data obtained from animal
studies, indicating that the gut barrier is injured after major surgery 24,25,27,29,30.
However, other reports show no changes in intestinal permeability 26,31.
Moreover, the value of measuring gut integrity with the use of sugar probes is
argued 32,33. Similar results are reported on the development of endotoxaemia.
Several authors report on increased circulating levels of endotoxin or reduced
values of anti-endotoxin antibody during major surgery, suggesting leakage of
gut derived bacterial products from the gut lumen into the circulation due to an
impaired epithelial barrier, whereas others show unaltered endotoxin
concentrations 25,28,34. Data showing better survival in patients with pre-
operatively higher anti-endotoxin titres support the theory of intestinal
contribution in the development of postoperative complications 35. In
12
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conclusion, the debate regarding the involvement of the gut in patients
undergoing major surgery is still open.
This leads to the following pathophysiological questions:
1) Is the gut wall integrity impaired in patients undergoing major (non-
abdominal) surgery?
2) Does a relationship exist between gut wall integrity loss and the development
of post-operative complications in patients?
3) Can these findings be studied in a human model of intestinal ischemia-
reperfusion?
13
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1.3 THE COMPOSITION OF THE GUT WALL
The gut wall forms a physical/anatomical and immunological barrier. The
physical/anatomical barrier of the gut is formed by a monolayer of epithelial
cells, originating from multipotent stem cells present in the crypt. The epithelial
cells together with the lamina propria form the mucosa of the intestine 1,2,36.
The epithelial stem cells give rise to four major epithelial cells: 1) the absorptive
enterocytes, which make up >80% of all small intestinal epithelial cells, 2) the
goblet cells, which produce a variety of mucins and trefoil peptides, 3) the
enteroendocrine cells, which export peptide hormones and 4) the Paneth cells,
which secrete a wide variety of antimicrobial peptides (Figure 1).
Figure 1: the composition of the small intestine
Tight junctions (TJ) are the major complexes responsible for the adherence of
intestinal epithelial cells to each other and are in this context an important part
of the intestinal barrier (Figure 2) 36,37. TJ are built up by multiple proteins:
occludins and members of the claudin family are the major sealing proteins.
The sealing proteins interact with cytoplasmic proteins, including zonula-
occludin proteins (ZO), functioning as adaptors between the TJ proteins and
actin and myosin contractile elements within the cells 37. Breakdown of this
barrier potentially leads to the translocation of luminal antigens, microbiota
and their toxic products into the circulation. The layers next to the mucosa, the
submucosa, muscularis and serosa, are also of importance, although they are
not in direct contact with the lumen. Injury of these layers can result in
14
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transmural damage of the intestine and lead to a serious complication: passage
of the luminal content into the abdominal cavity.
Figure 2: composition of tight-junctions (in green (left) and in detail (right)) between neighbouring
enterocytes (in yellow)
Next to the physical/anatomical barrier, there is also an immunological barrier.
The intestinal epithelium is not merely a static barrier, but also has a number of
specialized protective adaptations 1,2. Enterocytes are considered to actively
participate as innate immune sensors of microbial pathogens and commensal
organisms 38. Host recognition of microbial components is achieved by so-called
pattern recognition receptors (PRRs), such as the NOD-like (NLRs) and Toll-like
receptors (TLRs). Muramyl dipeptide (MDP), derived from peptidoglycan, is
present in the cell wall of virtually all bacteria and recognized by NOD2, a PRR
expressed in intestinal epithelial cells 38 including Paneth cells 39. Paneth cells
secrete defensins, antimicrobial peptides, in the villous crypt, maintaining its
sterility. Moreover, we recently reported that Paneth cells are equipped with the
proper molecules to recognize and signal endotoxin, one of the most potent
immunostimulatory products derived from Gram-negative bacteria (own
unpublished results). Continuous antimicrobial protection of the crypt is of
crucial importance, since the pluripotent stem cells are located there. Damage
to stem cells would have severe consequences for the maintenance of the
homeostasis of normal gut epithelium 40. Goblet cells secrete mucus, a
composition of glycoproteins and water, which provides a filter overlying the
intestinal epithelium. Additionally goblet cells secrete trefoil peptides, small
proteins needed for epithelial growth and repair. Furthermore, gut-associated
lymphoid tissue (GALT) is present in the lamina propria and provides immune
surveillance. Sampling of luminal antigens occurs by M-cells and dendritic
cells (DC), which present antigens to T and B cells, thereby inducing an effector
15
General introduction of gut wall integrity
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 15
immune response. This response includes secretion of large amounts of IgA by
plasma cells. This secretory IgA covers the mucosal surface and has a major role
in excluding antigen from passing the epithelium 1,2.
16
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1.4 ASSESSMENT OF GUT WALL INTEGRITY (IN MAN)
Plasma/serum, urinary and faecal markers are currently available as useful tools
to study the condition of the gut wall in man. In this paragraph a brief
description of these tests is provided analogue to the previous described
physical/anatomical (I) and the immunological (II) components of the gut wall.
I Physical/anatomical components of the gut wall
Ia. Condition of enterocytes
Measurement of endogenous cytosolic enterocyte proteins in urine or plasma have
been shown to be useful to estimate enterocyte damage. Fattty Acid Binding
Proteins (FABP) comprise a class of low molecular weight (14-15 kDa) cytosolic
proteins found in high concentrations in tissues involved in the uptake and
consumption of fatty acids. Intestinal Fatty Acid Binding Protein (I-FABP) is
primarily limited to mature enterocytes of the small and large intestine 41,42. It
circulates in low amounts in the blood stream of healthy individuals. I-FABP is a
useful plasma marker for early enterocyte cell death and levels rise rapidly after
episodes of acute intestinal ischaemia and inflammation 41-43. The level of
circulating I-FABP has been reported to correlate with the histological status of the
epithelium after intestinal ischaemia-reperfusion in experimental studies 44-46. A
second gut-specific FABP is Ileal-Bile Acid Binding Protein (I-BABP), which is
exclusively present in mature enterocytes of the jejunum and ileum 47. Enterocytes
also contain Liver-FABP (L-FABP), which is localized in small amounts in the
mature enterocytes of the small and large intestine but in abundance in the liver 41.
Next to FABP, Glutathione S-Transferases (GST) are a family of more or less tissue
specific cytosolic enzymes. These proteins are involved in the detoxification of a
range of xenobiotic compounds by conjugation to glutathione and grouped into
species-dependent families based on their isoelectric point 48. Alpha and pi GST
are found in the small and large intestine 49. However, they are not organ-specific,
since they are also expressed in liver and kidney 50. Plasma levels of alpha GST are
elevated upon ischemic intestinal damage 51. In conclusion, I-FABP and I-BABP
are most promising endogenous enterocyte proteins (markers) to assess enterocyte
injury, since these proteins are specifically expressed in the gut and released
immediately into the circulation upon cell damage.
Ib. Functional enterocyte mass
Functional enterocyte mass is reflected by levels of circulating citrulline, an
amino acid not incorporated into proteins 52-54. Differentiated small intestinal
enterocytes specifically produce citrulline from glutamine and are responsible
17
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for the major part of the total amount of circulating citrulline 54,55. Declined
circulating levels of citrulline provide evidence for the loss of small bowel
epithelial cell mass, as is shown in haemopoietic stem cell transplant recipients
suffering from severe oral and gastrointestinal mucositis following intensive
myeloablative therapy 52-54.
Ic. Condition of tight junctions
Currently, invasive intestinal biopsies provide the only possibility to detect tight
junction breakdown. Endoscopy for biopsy is a time-consuming and invasive
procedure.
Id. Intestinal permeability
Intestinal permeability is frequently assessed using oral ingestion of various
relatively small to large-sized probe molecules and measurement of their
urinary excretion 3,8,32. Large molecules are thought to traverse the epithelium
by paracellular pathways via tight junctions between the enterocytes.
Permeability of the tight junctions presumably increases in diseased or
damaged mucosa, resulting in increased absorption of large molecules. Small
molecules are postulated to predominantly pass by transcellular pathways
through aqueous pores in the enterocyte membranes that are too small to
permit the passage of large molecules. The ratio of urinary excretion of the
relatively large molecule is compared with that of the relatively small molecule.
When a large and small molecule are combined in the test solution at a fixed
concentration ratio, the effects of variables, such as gastric emptying, intestinal
transit time, and renal clearance will apply equally to both. Thus, the urinary
excretion ratio between these two molecules is expected to be only influenced
by the difference in gut permeability for each molecule.
Disaccharides (lactulose) or Poly-ethylene-glycol (PEG)-3350 are frequently
used as orally ingested large molecules and monosaccharides (mannitol, L-
rhamnose) or PEG-400 are used as small molecular probes 32. Subsequently, the
renal excretion of the two probes is monitored over a defined interval (mostly 5
hours), and permeability is then expressed as the quotient (ratio) of the urinary
recovery of the large molecule divided by the small molecule 32. It is assumed
that the used probes are non-fermentable by bacteria in the gastrointestinal lumen
and that they are not metabolized in the body. These molecules are also supposed
to be excreted in urine in proportion to the amount that has been absorbed
through the intestinal mucosa 32. Thus far, contrasting results have been reported
for intestinal permeability tests using dual probe molecules in several studies 8,33.
This is mainly attributed to a number of assumptions that have to be made to
18
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simplify the interpretation of these tests 32,33. Especially pathways of intestinal
permeation of the different molecules and the mechanism by which permeability
is altered are as yet incompletely understood.
Ie. Translocation of bacteria and their products
Breakdown of the mucosal barrier potentially leads to translocation of
microbiota or their toxic products. Two promising plasmamarkers, reflecting
translocation of bacteria or their products, are D-lactate and endotoxin
(lipopolysaccharide, LPS), which are metabolic products or components of the
commensal bacteria of the gastrointestinal tract. D-lactate is only produced by
bacteria as a product of bacterial fermentation 56. Baseline levels of D-lactate in
healthy subjects are very low, but the exact mechanism by which D-lactate
enters the bloodstream is unknown. Increased levels of D-lactate have been
correlated with conditions in which the number of bacteria elevates rapidly,
including in patients with bacterial overgrowth due to infection, short bowel
syndrome and mesenteric ischaemia 57,58. LPS, the major constituent of the
outer membrane of Gram-negative bacteria, is released from bacteria when
replicating or dying 59. Increased circulating LPS levels have been related to an
impaired mucosal barrier. The presence of LPS can be measured directly in
blood, e.g. by the Limulus Amoebocyte Lysate (LAL) assay 60. In addition, anti-
LPS antibodies can be measured by endotoxin-core antibody (EndoCAb), an
indirect measurement of LPS leakage into the circulation 61. A drop in levels of
circulating anti-LPS antibodies is considered to indicate consumption of
antibodies to LPS by exposure to LPS 27.
If. Transmural damage
Any part of the gastro-intestinal tract may undergo damage to all layers of the GI
wall from a variety of causes, releasing gastric or intestinal contents into the
peritoneal cavity, which potentially cause peritonitis. Symptoms develop suddenly,
with severe pain followed shortly by signs of (septic) shock. If a perforation is
noted, immediate surgery is necessary, because mortality from peritonitis increases
rapidly. The diagnosis of transmural damage (i.e. perforation) of a gastro-intestinal
organ usually depends on the detection of free intraperitoneal air, which is most
often located in the right subphrenic space. Traditionally, a chest X-ray and a plain
abdominal X-ray in the upright position, or, more recently, ultrasonography are the
diagnostic tools used to detect free air. However, the sensitivity of these tools is
<80%. Currently, a computed tomography (CT) scan is sometimes performed,
which may detect free intraperitoneal air as well as small fluid collections and
subtle tissue-infiltration at different locations.
19
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Ig. Splanchnic perfusion
Numerous clinical conditions are accompanied by a reduced splanchnic blood
flow, including vascular disease, major surgery and various types of shock.
Prolonged hypoperfusion of the splanchnic region will inevitably lead to
hypoxic tissue injury. Furthermore, the splanchnic region is an important source
and target of inflammatory mediators, which have a major impact on both
systemic and regional blood flow and tissue function 62. Gut mucosal perfusion
can be invasively measured by gastric tonometry. Gastric tonometry assesses
the pCO2 in the gastric mucosa, taking into account that an increase in tissue
CO2 production accompanies anaerobic metabolism, signifying the
effectiveness of regional splanchnic perfusion 63.
II Immunological components of the gut wall
Gut wall inflammation
A broad range of pathologies can lead to intestinal inflammation: neoplasia,
inflammatory bowel disease (IBD), infections, auto-immune diseases (e.g.
celiac disease), ischemia-reperfusion, intestinal hypoperfusion, and e.g. the use
of non-steroidal anti-inflammatory drugs. Generally, defects or increased
permeability of the mucosal barrier will cause intestinal inflammation in
response to the enormous number of bacteria present in the bowel. The
pathogenesis of inflammatory intestinal diseases implies the recruitment of
leukocytes into the intestinal wall 64. Activated neutrophils infiltrate the mucosa
and their products can be detected in faeces due to release into the intestinal
lumen. Obviously, changes in neutrophil release products can also be detected
in plasma/serum, but plasma/serum levels may also be increased by various
conditions other than gut inflammation. Therefore, faecal markers of
neutrophils are specific for the detection of inflammatory intestinal diseases.
Numerous neutrophil derived proteins present in stool have been studied,
including calprotectin, lactoferrin and elastase 64. The most promising marker is
calprotectin, because of its remarkable resistance to proteolytic degradation
and its stability in stool kept on room temperature for at least 7 days 65.
Calprotectin, also known as MRP-8/MRP-14 or S100A8/A9 complex, is a
36 kDa calcium and zinc binding protein that plays a regulatory role in the
inflammatory process. It constitutes about 60% of the soluble proteins in
human neutrophilic cytosol and is also found in monocytes, macrophages and
ileal tissue eosinophils. It is released during cell activation or cell death and has
antiproliferative, antimicrobial and immunomodulating functions 64,65.
Fecal calprotectin is nowadays used in clinical practice to evaluate
disease activity in the follow-up of patients treated because of active IBD 64. It
20
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was found that faecal calprotectin levels correlated well with endoscopic as
well as histological disease activity of patients with IBD 64. Moreover, recent
studies showed that normalization of calprotectin levels in patients with
established IBD is a strong indicator of mucosal healing. Furthermore, several
studies showed that calprotectin was a very sensitive detection marker of
inflammation in patients with inflammatory bowel disease (IBD, Crohn’s
disease and ulcerative colitis) compared with healthy controls and patients with
irritable bowel syndrome (IBS), though not a specific marker as increased levels
were also found in neoplasia, infections, and polyps 64. Bunn et al confirmed
these results on calprotectin levels in children with IBD 66,67. Carroll et al stated
that fecal calprotectin might be a useful marker of gastrointestinal mucosal
inflammation in neonates in a pilot study comparing seven patients with proven
necrotizing enterocolitis (NEC) with seven healthy peers 68.
21
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1.5 AIMS TO BE STUDIED
On the basis of the questions brought forward in paragraph 1.2 concerning the
importance of the evaluation of gut wall integrity, the following aims are subject
of this thesis.
aim 1: development and analysis of markers for human gut wall integrity, in
particular for enterocyte and TJ condition (Chapter 2)
aim 2: analysis of markers for compromised gut wall in patients with overt
intestinal damage and in patients with suspected intestinal disease to
distinguish the target disease from other pathologies (Chapter 3)
aim 3: investigate the integrity of the gut wall in critically ill patients and in
patients undergoing major (non-abdominal) surgery (Chapter 4)
aim 4: clarify the sequelae of intestinal ischemia-reperfusion in a human
model (Chapter 5)
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CHAPTER 2
Development and analysis of
markers for human gut wall
integrity
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2.1 INTRODUCTION
To study the first aim: development and analysis of markers for human gut wall
integrity, in particular for enterocyte and TJ condition, attention was paid to the
investigation of characteristics of FABP and TJ in human and animal studies. In
the first study the distribution and microscopic localization of FABP in the
human gastrointestinal tract was analyzed after collection of histological
normal human intestinal full thickness tissue during routine surgery (paragraph
2.2). In the same study, the release of FABP was evaluated in patients with
apparent intestinal damage, i.e. celiac disease. In the next study, the release and
clearance of FABP was studied during surgery by collection of blood from
efferent and afferent vessels of the intestine, liver and kidney during surgery
(paragraph 2.3). Finally, a potential new marker to analyze the condition of
tight junctions was studied in a translational setting of rats undergoing
hemorrhagic shock and patients with inflammatory bowel disease (IBD)
(paragraph 2.4).
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2.2 A pilot study on the non-
invasive evaluation of intestinal
damage in celiac disease using
I-FABP and L-FABP
Joep P. M. Derikx, Anita C. E. Vreugdenhil, Anita M. Van den Neucker,
Joep Grootjans, Annemarie A. van Bijnen, Jan G. M. C. Damoiseaux,
L. W. Ernest van Heurn, Erik Heineman, Wim A. Buurman
Journal of Clinical Gastroenterology, in press.
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ABSTRACT
Background and goals
In the clinical management of celiac disease, new non-invasive tools for
evaluation of intestinal damage are needed for diagnosis and for follow-up of
diet effects. Fatty acid binding proteins (FABP) are potentially useful for this
purpose since these are small cytosolic proteins present in enterocytes and
sensitive markers for intestinal mucosal damage. First, the distribution and
microscopic localization of FABP in the healthy human intestine was examined.
Second, levels of circulating FABP were measured in patients with celiac
disease before and after introducing a gluten-free diet (GFD) and in healthy
controls.
Study
The distribution and microscopic localization of FABP in normal human
intestinal tissue was assessed using surgical intestinal specimens of 39 patients.
Circulating levels of Intestinal (I)-FABP and Liver (L)-FABP were determined in
26 healthy volunteers and 13 patients with biopsy proven celiac disease. Ten of
these patients were re-evaluated within one year after starting GFD.
Results
I- and L-FABP are predominantly present in the small intestine, mainly the
jejunum. Moreover, FABP are expressed in cells on the upper part of the villi,
the initial site of destruction in celiac disease. Circulating levels of FABP are
significantly elevated in untreated patients with biopsy proven celiac disease
compared to healthy controls (I-FABP: 784.7 pg/ml vs. 172.7 pg/ml, p<0.001;
L-FABP: 48.4 ng/ml vs. 10.4 ng/ml, p<0.001). In response to GFD these
concentrations normalize.
Conclusions
Results of this pilot study strongly suggest that FABP can be used as a non-
invasive method for assessment of intestinal damage in celiac disease. Besides
an additional role in the diagnosis of celiac disease, FABP potentially enable
non-invasive monitoring of the GFD effects.
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INTRODUCTION
Celiac disease is an immune-mediated disorder characterized by atrophy of
intestinal villi, with a relatively high prevalence. The mucosal destruction has
serious consequences including malabsorption, malnutrition and failure to
thrive in young children. In the long term refractory sprue and enteropathy-
associated T-cell lymphoma may develop despite a strict gluten-free diet
(GFD).1-3 A major concern in the clinical management of celiac disease is the
necessity of mucosal biopsies of the proximal small bowel for evaluation of
intestinal damage and confirmation of the diagnosis.1-3 In children, mucosal
biopsies are taken using gastroduodenoscopy under general anaesthesia. This is
an invasive and expensive procedure with the risk of complications and a
substantial emotional impact on the child and its parents/caretakers. Besides
these diagnostic concerns, the follow-up of celiac disease is hampered by the
absence of a sensitive non-invasive test for evaluation of the effects of a GFD on
the recovery of intestinal epithelial cells. Serum anti-endomysial antibodies
(IgA-EMA) and anti-tissue transglutaminase (IgA-tTG) antibody levels are well
established markers for screening in older children and adults, but are due to
their long half-life not accurate enough for evaluation of the diet effect in celiac
disease.4,5 Moreover, seronegative celiac disease is frequently present in
patients with only minor pathological changes in the intestinal mucosa and in
older patients with more severe disease.6-8 Furthermore, the reliability of the
serological tests for either monitoring compliance or histological response to
treatment is still under discussion. 9-12
New diagnostic markers for intestinal damage are needed to enable non-
invasive diagnosis and rapid evaluation of the effects of GFD and gluten
challenge.
Previous studies have identified fatty acid binding proteins (FABP) as
circulating and urinary markers for intestinal epithelial cell damage in
mesenterial thrombosis and necrotising enterocolitis.13, 14 FABP are cytosolic
proteins present in enterocytes which are rapidly released into the systemic
circulation upon cell damage since these proteins are unbound and very small
(15 kDa). Three FABP subtypes are present in the gut; intestinal fatty acid
binding protein (I-FABP), liver fatty acid binding protein (L-FABP) and ileal bile
acid binding protein (I-BABP).15 Pelsers et al. reported that I-FABP and L-FABP
are present in the small and large bowel with predominance in the jejunum.16
The first objective of this pilot study was to assess the distribution and the
microscopic localization of FABP in the human gastrointestinal tract. Second,
the potential usefulness of FABP as markers for intestinal epithelial damage in
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celiac disease was examined. Circulating FABP levels in celiac disease were
compared with levels in healthy volunteers. Third, we studied whether FABP
levels normalize after starting a GFD and therefore if assessment of circulating
levels of FABP are possibly of value in the follow-up of celiac disease.
MATERIALS AND METHODS
Distribution and microscopic localization of FABP in normal human
intestine
To study the distribution and microscopic localization of I-FABP and L-FABP
throughout the gastrointestinal tract, histological normal human intestinal full
thickness tissue was obtained during routine surgery (such as closure of stoma)
of 39 patients (18F:21M; mean age: 6.5 years, range: 5 days-60 years) at the
University Hospital Maastricht after appropriate informed consent. Stomach
(n=2), duodenum (n=3), jejunum (n=7), ileum (n=22), caecum (n=2), appendix
(n=3), ascending colon (n=9), transversal colon (n=2), descending colon (n=2)
and sigmoid colon (n=12) were collected. The tissue samples were directly
frozen in liquid nitrogen or fixed in formalin and embedded in paraffin. The
study was approved by the local medical ethical committee.
Expression and quantification of FABP from stomach to sigmoid colon was
performed by western blot analysis and enzyme-linked immunosorbent assay
(ELISA).
Before analyses, intestinal tissue samples were homogenized in lysis
buffer (200mM NaCl, 10 mM Tris base, 5 mM EDTA, 10% Glycerin, 1 mM
PMSF, 0.1 U/ml Aprotinin and 1 µg/ml Leupeptin) using an Ultra-Turrax
homogenizer (IKA Werke, Breisgau, Germany). Homogenates were centrifuged
at 1000 g, and supernatants, containing the cytoplasmic proteins, were collected.
First, expression of FABP was semi-quantified by western blotting. Total
protein concentrations were determined using the Bradford method. Aliquots
with equal amounts of protein were heated at 100ºC for 5 min in SDS sample
buffer, separated on 15% SDS-polyacrylamide gels and transferred to
polyvinylidene fluoride membrane (Immobilin P, Millipore, Bedford, MA). After
transfer of proteins, a blocking step, antibody incubation and washing of the
membrane, were performed in PBS with 3% non-fat dry milk and 0.05%
Tween. Anti human I-FABP and L-FABP antibodies were kindly provided by
Hycult Biotechnology (HBT, Uden, the Netherlands). Membranes were
incubated with the appropriate horseradish peroxidase-conjugated secondary
antibodies (DAKO, Denmark). Positive bands were visualized using
chemiluminescence (Supersignal, Pierce, Rockford, IL).
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Second, concentrations of tissue I-FABP and L-FABP per gram wet tissue were
determined using highly specific commercially available ELISA that selectively
detects human I-FABP (standard: 20-5,000 pg/ml) and L-FABP (standard: 0.1-
25.0 ng/ml), provided by HBT.
In addition, the microscopic localization of FABP in the intestine was
performed with immunohistochemistry on paraffin embedded sections. Sections
cut at 4 µm were deparaffinized and pre-treated with 0.3% hydrogen peroxide
in methanol for 15 min to block endogenous peroxidase activity. After blocking
the non-specific antibody binding using 5% BSA, the sections were incubated
with specific antibodies to human I-FABP and L-FABP (both kindly provided by
HBT) at room temperature for 45 min. After washing, an appropriate biotin-
conjugated secondary antibody was used. Binding of the primary antibody was
demonstrated by the streptavidin-biotin system (DAKO, Denmark) and
visualized by applying 3-amino-9-ethylcarbazole (AEC; Sigma, St. Louis, MO).
Nuclei were counterstained with haematoxylin. The stained slides were
photographed by a Nikon eclipse E800 microscope with a Nikon digital camera
DXM1200F. No significant staining was detected in slides incubated with
control rabbit serum and/or mouse IgG instead of the primary antibody
indicating the absence of significant background staining.
Patients with celiac disease and healthy volunteers
Thirteen patients with newly diagnosed celiac disease who visited the University
Hospital Maastricht between 2000 and 2004 were retrospectively studied. We
included all patients of whom rest-serum, which was stored at -80°C until analysis,
was collected maximally three months before celiac disease was diagnosed. The
diagnosis was confirmed by histological establishment of duodenal villous atrophy.
None of the included patients was IgA deficient. In 10 of 13 patients a second
serum sample was collected within one year after starting the GFD. From the
hospital charts, the following data were recorded: age, sex, gastrointestinal signs
and symptoms, serum levels of anti-endomysial (Scimedx, Denville, New Jersey)
and anti-tissue transglutaminase IgA antibodies (Phadia GmbH, Freiburg, Germany)
(routinely measured by the laboratory of clinical immunology in the University
Hospital Maastricht) and histological findings of the small intestinal biopsy.
Twenty-six healthy volunteers (M:F = 17:9) were recruited to establish normal
values for serum I-FABP and L-FABP. The mean age in this control group was 22
years (range: 1-61 years).
Serum I-FABP and L-FABP concentrations were determined using previously
described ELISAs that detect human I-FABP and L-FABP, kindly provided by HBT.
The local ethics committee approved the study.
35
New markers for gut wall integrity
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 35
Statistical analyses
Statistical analyses were performed with Prism 4.0 for Windows (GraphPad
Software Inc. San Diego, CA). Intestinal and serum FABP concentrations were
presented as mean ± standard error (SEM). Normality of all data obtained was
verified by Kolmogorov-Smirnov test.
Concentrations of serum FABP were compared between patients with
celiac disease and healthy individuals using unpaired t-test. Levels of serum
FABP of untreated patients were compared with levels after introduction of a
GFD using paired t-test.
In order to find the cut-off point of FABP serum levels that most accurately
discriminate patients with celiac disease from healthy individuals, a receiver
operating characteristic (ROC) curve was drawn by plotting sensitivity against
1-specificity for all possible serum FABP thresholds. The overall accuracy of
serum FABP in detecting celiac disease was summarized using the area under
the curve (AUC), with an AUC of 0.5 indicating no discrimination ability.
Ninety-five percent confidence intervals (CI) for the sensitivity, specificity,
positive and negative likelihood ratios (LR) were calculated for the best cut-off
values, defined as the maximal sum of sensitivity and specificity. A p-value
below 0.05 was considered statistically significant.
RESULTS
Distribution of I-FABP and L-FABP in normal human intestine
The concentration of I-FABP varies along the small intestine, and is low in the
complete colon (results from ELISA are shown in Figure 1a; results from western
blot analysis are not shown). Maximal I-FABP expression is found in the
jejunum (22.5 (±7.3) µg I-FABP/g tissue) with lower expression in the ileum and
duodenum (4.8 (±1.6) µg I-FABP/g tissue and 4.6 (±0.6) µg I-FABP/g tissue,
respectively). Expression throughout the whole colon is minimal (0.5 (±0.1) mg
I-FABP/g tissue).
The distribution pattern of L-FABP in the healthy human gastrointestinal
tract is comparable with that of I-FABP (Figure 1b). The jejunum contains the
highest concentration of L-FABP (829.6 (±96.1) µg L-FABP/g tissue), whereas
the rest of the small intestine (ileum: 105.3 (±25.0) µg L-FABP/g tissue) and
colon (102.3 (±15.4) µg L-FABP/g tissue) contain low concentrations.
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Figure 1: Distribution of I-FABP (a) and L-FABP (b) in histologically normal human intestine. Data
are mean values with SEM from 39 patients.
Microscopic localization of FABP in normal human intestine
Intensive immunostaining for I-FABP and L-FABP was observed in the healthy
ileal and jejunal epithelium, mainly in the absorptive cells. Figure 2 is a
representative image for the ileum and jejunum, showing the presence of both
I-FABP and L-FABP in the cytoplasm of the mature enterocytes and goblet cells
in the upper half of the villi, whereas cells in the crypts were not
immunopositive.
The healthy colon showed immunoreactive cytoplasm of the epithelial
cells in the upper half of the crypts for I-FABP and L-FABP (data not shown).
FABP were not detected in cells in the bottom of the crypts.
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Figure 2: Immunolocalization of L-FABP (a) and I-FABP (b) at a 100x magnification in normal
jejunum. In image (c), the primary antibody is replaced by control serum. I-FABP and L-FABP are
immunostained in the upper half of the villus.
Baseline characteristics of patients with celiac disease and healthy
individuals
Celiac disease was confirmed in 13 patients by biopsy of the small intestine; 3
patients had Marsh-stage 2 and 10 patients had Marsh-stage 3 (Table 1). The
mean age was 30 years (range: 1-70 years). In 11 patients anti-endomysial
antibodies (IgA-EMA) were present, while in 1 patient (patient 5) IgA-EMA was
not detected and in 1 patient (patient 3) IgA-EMA level was borderline positive.
Antibodies directed against tissue transglutaminase (IgA-tTG) were detected in
12 patients, while in 1 patient (patient 3) IgA-tTG was absent. Of the whole
group, 1 patient did not clinically respond to a GFD (patient 13); gastro-
intestinal symptoms persisted and repeated duodenal biopsies showed
inflammation in the intestine and atrophy of the intestinal villi. Despite this
disease activity, IgA-tTG became negative and IgA-EMA showed borderline
values within one year of GFD. In all other patients symptoms disappeared after
elimination of gluten from the diet. However, IgA-tTG and/or IgA-EMA
remained positive in 5 patients.
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Serum I-FABP and L-FABP levels in patients with celiac disease
The mean serum I-FABP concentration in normal healthy individuals was
172.7±20.2 pg/ml. The mean serum I-FABP concentration in patients with
celiac disease (784.7±145.5 pg/ml) was 4.5 times higher than in serum of
normal individuals (p<0.001, Figure 3a). Also serum L-FABP levels were
significantly higher in patients with celiac disease compared with healthy
volunteers (48.4±11.6 ng/ml vs. 10.4±0.7 ng/ml, p<0.001, Figure 3b).
The ability of serum I-FABP and L-FABP concentrations to discriminate
between patients with celiac disease and healthy individuals was analyzed by
ROC curves (Figures 4a, b). The ROC curve for serum I-FABP yielded a high
AUC (0.90 (95% CI: 0.76-1.05) p<0.001) with an optimal cut-off value of 405.1
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Table 1: baseline characteristics of 13 patients with celiac disease and their serologies and
circulating FABP values at the moment of diagnosis and within 1 year after the start of the gluten-
free diet (GFD). IgA-tTG: >10 U/ml=positive, 7-10 U/ml=borderline, <7 U/ml=negative. IgA-EMA:
titre 1:10 (starting dilution) = positive.
IgA-tTG: anti-tissue transglutaminase antibodies; IgA-EMA: anti-endomysial antibodies;
neg=negative; pos=positive; I-FABP: intestinal-fatty acid binding protein; L-FABP: liver-fatty acid
binding protein
* Patient 13 is the only patient with persisting gastrointestinal complaints after introduction of
GFD. Repeated duodenal biopsies of this patient showed an inflammatory response in the small
intestine, possibly explained by a refractory sprue syndrome.
Patient Age at Marsh- IgA-tTG at Iga-EMA at I-FABP at L-FABP at IgA-TtG IgA-EMA I-FABP L-FABP
diagnosis classifi- diagnosis diagnosis diagnosis diagnosis within 1 within 1 within 1 within 1
(years) cation (U/ml) (titre) (pg/m) (ng/ml) year GFD year GFD year (pg/m) year
(U/ml) (titre) (ng/ml)
1 65 3 120 pos 766 65.8 - - - -
2 1 3 462 pos 1136 93.7 1 neg 206 7.3
3 70 3 1 borderline 459 26.4 1 neg 260 16.8
4 62 2 92 pos 695 35.7 25 pos 403 15.3
5 62 2 12 neg 445 19.8 8 pos 359 9.6
6 1 3 >5000 pos 1944 146.1 - - - -
7 9 2 81 pos 241 9.3 - - - -
8 4 3 155 pos 451 23.6 1 pos 41 19.0
10 8 3 108 pos 587 6.9 13 pos 57 8.6
11 51 3 255 pos 1277 93.2 7 pos 192 11.7
13* 47 3 27 pos 1386 63.0 1 borderline 643 34.3
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pg/ml. The ROC curve of L-FABP had an AUC of 0.86 (95% CI: 0.70-1.02,
p<0.001) and the best threshold level of serum L-FABP in separating patients
with celiac disease from healthy individuals was 18.1 ng/ml
Figure 3: Elevated concentrations of serum I-FABP (a) and L-FABP (b) in patients with celiac
disease compared to healthy individuals. The line represents the mean value of serum FABP levels.
Figure 4: Serum levels of I-FABP (a) and L-FABP (b) discriminate between patients with celiac
disease and healthy individuals. The ability of serum FABP levels to discriminate was assessed by
ROC curves (sensitivity vs. 100%-specificity), obtained by varying the cut-off values of
concentrations.
Serum I-FABP and L-FABP values were measured in 10 patients within 1 year
after starting the GFD (Figure 5). These patients had a significant reduction in I-
FABP from a mean level of 725.5±134.4 pg/ml before the introduction of GFD
to 266.8 pg/ml (range: 41.0-642.6 pg/ml) within 1 year of GFD (p=0.002).
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Mean serum L-FABP concentration decreased significantly from 40.9±10.0
ng/ml at the moment of diagnosis to 15.3 ng/ml (range: 7.3-34.3 ng/ml) in
patients on GFD (p=0.025). Nine of 10 patients tested within 1 year of GFD
obtained I-FABP serum values below the cut-off value of 405.1 pg/ml. In 1
patient I-FABP levels remained enhanced (patient 13, Table 1). In this patient
gastrointestinal symptoms persisted and repeated duodenal biopsies showed
inflammation and atrophy of villi. For L-FABP similar data were obtained. Eight
of 10 patients tested within 1 year of GFD had L-FABP serum values below the
threshold value of 18.1 ng/ml. One of the patients with elevated circulating
values of L-FABP within 1 year of GFD (patient 13, Table 1) had continuing
abdominal symptoms and villus damage on biopsies.
Figure 5: Serum I-FABP (a) and L-FABP (b) concentration before and after starting a gluten-free diet
(GFD).
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DISCUSSION
The value of the biomarkers I-FABP and L-FABP in the evaluation of intestinal
damage and recovery of the intestinal mucosa in celiac disease was studied.
Currently, duodenal biopsy is required for establishing mucosal damage and
villous atrophy. A non-invasive diagnostic method for confirmation of the
diagnosis celiac disease is urgently needed in addition to the serological tests.
Besides new diagnostic tools for celiac disease, there is a strong need for
reliable markers detecting recovery of the intestinal mucosa in response to a
GFD, since the currently used serologic tests have poor correlation with
mucosal damage. Therefore, in this study serum FABP concentrations as
markers for epithelial cell damage were measured in patients with celiac
disease before and after introduction of the GFD.
First, the expression of I-FABP and L-FABP in the different segments of the
human intestine was evaluated. I-FABP and L-FABP are expressed in the
mucosa of the entire small intestine and have a predominant expression in the
jejunum. I- FABP and L-FABP are in particular highly expressed in cells present
on the tops of the villi. Since villous atrophy in the small intestine is the
hallmark of celiac disease 1, we consider circulating levels of FABP to be
potential markers of disease activity in celiac disease. The presence of FABP on
the tops of the villi, the initial site of destruction in celiac disease, makes
circulating I-FABP and L-FABP also potentially useful in an early stage of celiac
disease.
The data of the present pilot-study show that I- and L-FABP serum levels
are significantly increased in untreated celiac disease compared to healthy
controls and are sensitive markers for intestinal damage in celiac disease.
However, in one untreated patient the I-FABP and L-FABP concentration was
below the cut-off value as determined in this study (patient 9). Histological
evaluation of the biopsy of this patient showed a Marsh 3b classification,
representing a substantial loss of the absolute enterocyte mass and especially
the villous enterocytes; thus, a loss of cells containing FABP. It is conceivable
that, because of extensive denudation, the amount of ‘shedding’ cells that
contain FABP is low, resulting in low circulating FABP values.
In one patient with Marsh 3 (patient 3) IgA-tTG was not elevated and IgA-
EMA showed a borderline result. However, I-FABP and L-FABP were both
above cut-off values. These findings further emphasize that FABP measurements
can contribute to screening for celiac disease.
In all but one patient in this study the I- and L-FABP concentration
normalized after implementation of the GFD. In this single patient (patient 13)
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gastrointestinal complaints also persisted and repeated duodenal biopsies of this
patient showed an inflammatory response in the small intestine, possibly
explained by a refractory sprue syndrome. IgA-tTG levels became negative in
this patient after introduction of the GFD and IgA-EMA titres decreased to
borderline levels. This discrepancy between serologic titres and recovery of the
intestinal damage after start of GFD was also found in earlier studies.9-12 The
finding of persistent elevated FABP concentrations in this patient further signifies
the potential usefulness of circulating levels of FABP as markers to follow-up
celiac disease activity. All the other patients improved clinically on GFD, which
was consistent with FABP recovery; repeat biopsies were not performed.
The results of this study suggest that assessment of circulating FABP
concentrations seem very valuable to monitor the effect of GFD on recovery of
the intestinal mucosa in celiac disease. This is in line with earlier observations
from animal studies showing that serum levels of I-FABP correlate with the
phases of histological mucosal injury after intestinal ischemia-reperfusion.15,17,18
This finding is of major clinical importance since there are no non-invasive tools
to evaluate diet effects and therapy compliance. IgA-EMA and IgA-tTG,
frequently used for this purpose in clinical practice, were shown to be poor
predictors of dietary transgression.9-12
In contrast to I-FABP, L-FABP shows a multi-tissue expression. Besides the
expression in the intestine, L-FABP is also present in hepatocytes and tubular
cells of the kidney.15 Increased L-FABP levels in serum can therefore be derived
from other organs then the intestine. I-FABP is exclusively expressed in the
intestine and the test accuracy of I-FABP is higher than for L-FABP. Therefore I-
FABP measurement is preferable for diagnosis and follow-up in celiac disease.
Prior studies demonstrated that the renal clearance of FABP is very fast;
the half-life of L-FABP was approximately eleven minutes.19 From these data it
can be hypothesized that urinary FABP levels correlate with plasma levels and
disease activity. One of our future goals is to evaluate the correlation of urinary
FABP levels with intestinal damage in celiac disease.
Based on the data of this pilot study, we speculate that in children with
both a strong clinical suspicion of celiac disease and positive serological tests,
establishment of a pattern of high circulating I-FABP levels at diagnosis,
followed by declined levels after gluten elimination and increased levels after
gluten challenge might contribute to the clinical management of celiac disease.
Further studies are necessary to determine whether assessment of intestinal
epithelial cell damage by FABP analysis can replace the invasive procedure of
endoscopy and mucosa biopsy. In particular for children the drawing of blood
or even the mere sampling of urine will be an important advantage above
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endoscopy. Besides a possible additional role for FABP in the diagnosis of
celiac disease, assessment of urinary concentration of I-FABP and L-FABP may
provide a new important non-invasive tool to monitor the short-term response
to a GFD and in this way contribute importantly to the follow-up of celiac
patients. A prospective study is now performed to further evaluate the value of
FABP in the clinical management of celiac disease.
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ABSTRACT
Background
Liver failure following liver surgery is caused by an insufficient functioning
remnant cell mass. This can be due to insufficient liver volume and can be
aggravated by additional cell death during or after surgery. The aim of this study
was to elucidate the causes of hepatocellular injury in patients undergoing liver
resection.
Methods
Markers of hepatocyte injury (AST, GSTa, and L-FABP) and inflammation (IL-6)
were measured in plasma of patients undergoing liver resection with and
without intermittent inflow occlusion. To study the separate involvement of the
intestines and the liver in systemic LFABP release, arteriovenous concentration
differences for L-FABP were measured.
Results
During liver manipulation, liver injury markers increased significantly. Arterial
plasma levels and transhepatic and transintestinal concentration gradients of L-
FABP indicated that this increase was exclusively due to hepatic and not due to
intestinal release. Intermittent hepatic inflow occlusion, anesthesia, and liver
transection did not further enhance arterial L-FABP and GSTa levels.
Hepatocyte injury was followed by an inflammatory response.
Conclusions
This study shows that liver manipulation is a leading cause of hepatocyte injury
during liver surgery. A potential causal relation between liver manipulation and
systemic inflammation remains to be established; but since the inflammatory
response is apparently initiated early during major abdominal surgery,
interventions aimed at reducing postoperative inflammation and related
complications should be started early during surgery or beforehand.
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INTRODUCTION
Liver failure is a severe complication of liver surgery, occurring when there is
insufficient remnant cell mass postoperatively. This can be due to excessive
resection, leaving a too small remnant liver volume, but in some cases liver
failure occurs in patients with a seemingly sufficient remnant liver volume 1. In
these cases the functional capacity of the remaining cell mass is probably
impaired by secondary processes. Recognition and modulation of factors
impairing cell survival is crucial to enhance liver function following liver
surgery. In this context much attention has been paid to the effects of ischemia
and reperfusion.
Ischemia-reperfusion is a frequently encountered phenomenon in liver
resection, caused by temporary occlusion of blood flow to the liver (Pringle
maneuver), which is a popular way to reduce blood loss during parenchymal
liver transection. Ischemia-reperfusion induces energy depletion and
generation of reactive oxygen species. Although several endogenous protection
mechanisms aimed at supporting cell survival are activated during
ischemiareperfusion 2, excessive energy depletion or oxidative stress ultimately
results in apoptotic or necrotic cell death.
Interestingly, it has been shown that plasma levels of markers for
hepatocellular injury increase before liver transection and before application of
the Pringle maneuver, suggesting that factors other than ischemia-reperfusion
may cause hepatocyte demise during liver surgery 3. In this context a role has
been proposed for the hepatotoxic effects of anesthesia 4, the effects of systemic
inflammation, probably secondary to intestinal manipulation 5, and the effects
of manipulation of the liver itself during perihepatic dissection and
mobilization 6. The aim of this study was to elucidate the causes of early
hepatocellular injury in patients undergoing liver resection.
METHODS
Patients
Patients undergoing liver resection for secondary tumors in an otherwise
healthy liver were studied (Table 1). All patients were anesthetized according to
institutional routines using isoflurane and propofol. Surgery was commenced
using a subcostal bilateral incision. Olivier retractors (Copharm, Abcoude,
Holland) or Omni-Tracts were used to improve exposure. Before parenchymal
division the liver was mobilized as described elsewhere, followed by
intraoperative ultrasound 7. Cholecystectomy was performed routinely before
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liver transection. All patients had indwelling radial artery catheters placed for
continuous monitoring of arterial blood pressure and blood sampling.
Patients were nonrandomly assigned to one of two protocols (described
below). Assignment was based upon the surgeon’s preference of using the
Pringle maneuver or not. If applied, an intermittent Pringle maneuver (15 min
of ischemia, 5 min of reperfusion) was used by rubberband ligation of the
hepatoduodenal ligament.
Effects of intermittent Pringle maneuver on hepatocellular injury
From nine patients undergoing liver resection with intermittent Pringle
maneuver, arterial blood was sampled preoperatively before and after each
period of 15 min of ischemia and 5 min of reperfusion and 90 minutes
postoperatively. Systemic concentrations of two markers of hepatocellular
injury, aspartate amino transferase (AST) and glutathione-s-transferase-a (GSTa),
were measured as well as plasma levels of liver-type fatty acid binding protein
(L-FABP). Methods of blood processing and laboratory analyses are described
below. In addition, plasma levels of the inflammatory cytokine interleukin-6 (IL-
6) were measured as described below.
Source and fate of L-FABP
From ten patients undergoing liver resection without the Pringle maneuver,
arterial blood was sampled preoperatively and before liver transection.
Simultaneous with the second arterial blood sample, blood was drawn from the
portal vein, a hepatic vein, and the right renal vein by direct puncture to assess
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Table 1: Patient characteristics
Hepatectomy w/o IPM (n=11) Hepatectomy with IPM (n=9)
Age (years) 57 (36-72) 54 (33-75)
Male: Female 9:2 5:4
AST (IU/L) 26 (13-40) 23 (7-37)
LDH (IU/L) 337 (1-558) 377 (295-490)
Albumin (g/L) 39.0 (33.9-43.9) 37.6 (33.7-43.9)
CRP (mg/L) 3.5 (<1.0-8.7) 5.0 (<1.0-8.7)
Bilirubin (µmol/L) 13.4 (7.7-18.7) 12.9 (8.4-21)
IPM = intermittent Pringle maneuver
Blood chemistry was obtained during routine assessment 1 day preoperatively. Values are
expressed as median (range)
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concentration gradients across organs. It should be noted that at this timepoint
surgical procedures were identical in all patients, irrespective of the eventual
application of a Pringle maneuver. L-FABP plasma concentrations were
measured as described below and arteriovenous concentration differences
were calculated to study the contribution of the intestines and the liver to
systemic L-FABP release and to study renal clearance of L-FABP. Renal
clearance was calculated by dividing the arteriovenous concentration gradient
by the arterial concentration (uptake/influx). This quotient was multiplied by the
percentage of blood flowing through the kidney to calculate fractional plasma
clearance.
Effects of anesthesia and intestinal manipulation
To differentiate the effects of anesthesia induction, laparotomy, and intestinal
manipulation from the effects of liver manipulation, a control group consisting of
four patients undergoing lower abdominal surgery (1 rectopexia, 2 proctectomy,
1 sigmoidal resection) was studied. Plasma was sampled before surgery and at
40-min intervals during surgery to determine L-FABP concentrations.
Blood processing and analysis
Blood samples were collected in prechilled EDTA vacuum tubes (BD
vacutainer, Becton Dickinson Diagnostics, Aalst, Belgium) and kept on ice.
Blood was centrifuged at 4000g for 10 min. Plasma was immediately stored at
-80°C until analysis. L-FABP and IL-6 were determined using commercially
available enzyme-linked immunosorbent assays (ELISA) (kindly provided by
Hycult Biotechnology, Uden, The Netherlands), GSTa was measured by ELISA
as described earlier 8, 9. AST was determined by the clinical chemistry
laboratory of the University Hospital Maastricht.
Ethics
The studies were approved by the Medical Ethics Committee of the University
Hospital Maastricht and all subjects gave written informed consent.
Statistics
Normality of all data obtained was verified by Lillieford’s test (all p > 0.10).
Data are presented as mean with standard error of the mean (SEM). A paired t
test was used to test the significance of changes in the various plasma
concentrations. Arteriovenous concentration gradients were tested versus a
theoretical mean of zero using a one-sample t test 10. Pearson’s test for
correlations was used to test the significance of correlations. Statistical
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calculations were made using Prism 4.0 for Windows (GraphPad Software Inc.,
San Diego, CA). A p value less than 0.05 was considered to indicate statistical
significance.
RESULTS
Patient outcome
No signs of organ failure or other major complications were observed
postoperatively during the hospital stay of all patients.
Estimation of hepatocellular injury and intestinal injury after organ
manipulation
Systemic levels of damage markers
During assessment of resectability, prior to organ transection, mean arterial L-
FABP plasma concentration increased 55-fold (p = 0.002) (Fig. 1a). Surprisingly,
arterial L-FABP levels did not change significantly during subsequent
intermittent Pringle maneuver, indicating that neither intermittent ischemia-
reperfusion nor liver transection significantly aggravated the hepatocellular
injury caused by early perioperative processes. Immediately postoperatively,
systemic L-FABP levels were found to be decreasing. Systemic plasma levels of
GSTa (Fig. 1b) and AST (Fig. 1c) also increased significantly before liver
transaction and before ischemia-reperfusion.
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Figure 1: Mean (SEM) arterial L-FABP (a), GSTα (b), and AST (c) levels in patients undergoing liver
surgery with intermittent Pringle maneuver (n=9). Plasma levels of all liver injury markers
increased early during surgery, during liver manipulation (p<0.05). Intermittent pringle maneuver
(2x 15min ischemia and 5 min reperfusion) did not cause significant changes in arterial L-FABP
and GSTα levels, wheareas AST gradually kept increasing. L-FABP and GSTAα levels decreased
immediately postoperatively (p= 0.03 and p= 0.004, respectively).*p < 0.05, ns= not significant;
I= ischemia, R= reperfusion.
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Effects of lower abdominal surgery on liver injury
In patients undergoing lower abdominal surgery, the mean LFABP
concentration remained below 15 ng/ml, underlining the effect of direct
manipulation of the liver on the elevation of L-FABP plasma levels during liver
surgery (Fig. 2).
Figure 2: Mean (SEM) plasma L-FABP levels in four patients undergoing lower abdominal surgery
without manipulation of the liver. No changes in L-FABP concentration were observed.
Organ-specific FABP release
Since L-FABP is expressed in both the liver and the intestines, we performed an
organ balance analysis to reveal the origin of circulating L-FABP. The data show
that L-FABP was specifically released from the liver and not from the intestines.
In addition, organ balance analysis showed an active renal uptake of L-FABP
from circulation (Fig. 3).
Figure 3: Mean (SEM) arteriovenous concenration gradients of L-FABP across the intestines (portal
vein minus artery), the liver (hepatic vein minus portal vein), and the kidney in patients
undergoing liver resection (n=10). L-FABP was specifically released from the liver (p<0.0001 vs.
zero) and removed from circulaion by the kidneys (p<0.0001 vs. zero)
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Renal clearance of FABPs
The kidneys efficiently removed L-FABP from circulation. Renal clearance of L-
FABP correlated directly with their respective arterial concentrations (Fig. 4),
resulting in a fractional extraction rate (arteriovenous gradient/arterial
concentration · 100%) [11] of approximately 30%. Assuming that renal blood
flow per minute approximates 22% of the total blood volume [12], renal
plasma L-FABP clearance can be calculated to equal 6.6%/min (30% ·
22%/min), resulting in a plasma half-life of about 11 min.
Figure 4: Fractional renal clearance of L-FABP in patients undergoing liver resection (n=10). From
the fractional renal extraction of FABPs (approximately 30 %) and renal blood flow (22% of total
blood volume per minute) [12], a plasma half life of FBAPs off 11 min can be calculated. [A] =
arterial concentration, [RV] = renal venous concentration.
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Interleukin-6 levels during liver surgery with intermittent Pringle maneuver
The inflammatory response to liver surgery was investigated using IL-6 as a
parameter. Arterial IL-6 levels remained unaltered during manipulation of the
liver, when L-FABP, AST, and GSTa levels were increasing. In contrast, a
significant increase of systemic IL-6 plasma levels was found after 15 min of
hepatic inflow occlusion (Fig. 5). This increase was progressive throughout the
remainder of the study period.
Figure 5: mean (SEM) arterial IL - 6 concentration before, during, and after live resection with
intermittent Pringle maneuver (n=9). *= first timepoint where p<0.05 vs. baseline;.
DISCUSSION
The present study was designed to determine the cause of early hepatocellular
injury during liver resection. Previous publications already showed elevated
plasma levels of markers of liver damage prior to liver transection and hepatic
inflow occlusion 3, 6. These observations suggested that mechanisms other than
ischemia-reperfusion injury could contribute to peri- and postoperative cell
death and organ dysfunction. We showed that direct manipulation of the liver
during surgery is a leading cause of hepatocellular injury.
Arterial L-FABP and GSTa plasma levels increased following the start of
the operation and reached a plateau before liver transection and ischemia-
reperfusion. Surprisingly, we found no additional effect of organ transection or
intermittent Pringle maneuver on these increased LFABP and GSTa plasma
levels. The apparent resistance of the liver to an ischemic insult however, is in
line with previous data by Figueras et al. 13 who showed no effect of the extent
of inflow occlusion in patients with a normal liver, although in their study livers
of patients with cirrhosis appeared to be more vulnerable to hepatic inflow
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occlusion. In addition, other authors who showed a progressive release of GSTa
following a Pringle maneuver applied prolonged and continuous inflow
occlusion 6, which is known to aggravate hepatocellular injury compared to the
intermittent Pringle maneuver 14.
Previous authors who observed an early increase in plasma
concentrations of transaminases and GSTa have ascribed this phenomenon to
the hepatotoxic effects of anesthesia 4, systemic inflammation after intestinal
manipulation 5, and the effects of manipulation of the liver itself during
perihepatic dissection and mobilization 6. We were able to rule out the first two
factors as potential causes of early hepatocyte injury since a similar increase of
L-FABP plasma concentrations did not occur in patients undergoing lower
intestinal surgery. These patients were anesthetized in a similar manner as the
patients undergoing liver resection and underwent extensive intestinal
manipulation.
By elimination of other potential causes, it thus must be concluded that
increasing L-FABP levels occurs during and due to liver manipulation in
patients undergoing liver resection. By measuring concentration gradients
across the intestines and the liver, we were able to show that the increased L-
FABP levels during liver manipulation are exclusively due to L-FABP release
from the liver. Some intestinal L-FABP release could have been expected when
L-FABP, which is also expressed by the intestines, would have been released
from injured enterocytes, but the absence of intestinal L-FABP release clearly
indicates that organ manipulation during liver resection results in
hepatocellular injury without causing intestinal injury.
Finally, we were able to rule out systemic inflammation as a leading cause
of hepatocellular injury since L-FABP peak levels were reached already before
the onset of the inflammatory response. Arterial IL-6 plasma levels increased
between 90 and 125 min after laparotomy, which approximates the established
time lag between an inflammatory stimulus and IL-6 release 15. This suggests that
the inflammatory response is triggered by an early event during the operation.
According to the ‘‘danger model’’ hypothesis of Matzinger 16, cell injury
leads to the release of immunostimulatory proteins or nucleotides, so-called
danger signals, that activate the immune system and induce systemic inflammation
17. In line with this theory, we consider that early hepatocyte damage due to liver
manipulation could give rise to the release of such ‘‘danger signals’’ and contribute
to systemic inflammation. Consequently, liver manipulation-induced hepatocyte
injury may be a trigger for the inflammatory response to surgery. Mechanistic proof
for this theory, however, is difficult to obtain in vivo.
Both L-FABP and GSTa decreased immediately following surgery, in contrast to
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the more classic marker of hepatocyte injury, AST. The ongoing increase of
plasma levels of such markers following liver surgery has been regarded as a
sign of ongoing hepatocellular injury and impending liver failure 18. Our study
shows that the late postoperative peak of AST is more likely to be a reflection of
slow leakage than of ongoing injury, since the leakage of small-molecular
proteins L-FABP and GSTa decreased within 90 min. As a consequence, L-FABP
and GSTa are probably more sensitive for detecting ongoing hepatocyte injury
and impending liver failure than AST. To prove this assumption, however, a
large prospective study is needed. The rapid decline of L-FABP and GSTa is a
result of their rapid renal clearance. Arterial renal venous concentration
gradients showed that the kidneys remove approximately 30% of L-FABP in a
single pass, leading to a calculated LFABP half-life of 11 min.
We did not explore potential mechanisms of liver manipulation-induced
cell injury. Earlier studies showed that liver mobilization and assessment of
resectability significantly reduced hepatic venous oxygen saturation 19, 20. This
could also be a cause of hepatocyte damage in our case, although we did not
measure hepatic oxygen saturation. It is not clear whether hepatic oxygen
saturation decreased due to physical obstruction of the blood stream or whether
it decreased secondary to other processes 21, 22. Alternatively, cell damage may
occur as a direct consequence of mechanical impact 23.
In summary, it was previously believed that vascular occlusion and
parenchymal transection were the major reasons for hepatocyte injury during
liver surgery. This study demonstrates that liver manipulation is a leading cause
of hepatocyte injury during liver surgery. A potential causal relation between
liver manipulation and systemic inflammation remains to be established.
However, since the inflammatory cascade is apparently initiated early during
major abdominal surgery, interventions aimed at reducing postoperative
inflammation and related complications should be started early during surgery
or beforehand.
57
New markers for gut wall integrity
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 57
REFERENCES
1. Wigmore SJ, Redhead DN, Yan XJ, et al. (2001) Virtual hepatic resection using three-
dimensional reconstruction of helical computed tomography angioportograms. Ann
Surg 233:221–226
2. Patel A, van de Poll MC, Greve JW, et al. (2004) Early stress protein gene expression in
a human model of ischemic preconditioning. Transplantation 78:1479–1487
3. Boschetto A, Dondero F, Tonini V, et al. (2005) Intra-operative liver injury is not only
related to vascular clamping [abstract]. HPB 7:P25
4. Clarke RS, Doggart JR, Lavery T (1976) Changes in liver function after different types of
surgery. Br J Anaesth 48:119–128
5. Hiki N, Shimizu N, Yamaguchi H, et al. (2006) Manipulation of the small intestine as a
cause of the increased inflammatory response after open compared with laparoscopic
surgery. Br J Surg 93:195–204
6. Chouker A, Martignoni A, Schauer RJ, et al. (2005) a-Gluthathione s-transferase as an
early marker of hepatic ischemia/reperfusion injury after liver resection. World J Surg
29:528–534
7. Dejong CHC, Garden OJ (2003) Neoplasms of the liver. In: Majid AA, Kingsnorth A
(eds) Advanced surgical practice. London, Greenwich Medical Media, pp 146–156
8. Mulder TP, Peters WH, Court DA, et al. (1996) Sandwich ELISA for glutathione S-
transferase alpha 1-1: plasma concentrations in controls and in patients with
gastrointestinal disorders. Clin Chem 42:416–419
9. Steegers EA, Mulder TP, Bisseling JG, et al. (1995) Glutathione S-transferase alpha as
marker for hepatocellular damage in preeclampsia and HELLP syndrome. Lancet
345:1571–1572
10. Motulsky HJ (2003) Comparing a mean or median to a theoretical value. Prism 4
Statistics Guide: Statistical analyses for laboratory and clinical researchers. GraphPad
Software Inc., San Diego, CA, pp 35–39
11. Van de Poll MC, Siroen MP, van Leeuwen PA, et al. (2007) Interorgan amino acid
exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin
Nutr 85:167–172
12. Riddez L, Hahn RG, Brismar B, et al. (1997) Central and regional hemodynamics
during acute hypovolemia and volume substitution in volunteers. Crit Care Med
25:635–640
13. Figueras J, Llado L, Ruiz D, et al. (2005) Complete versus selective portal triad clamping
for minor liver resections: a prospective randomized trial. Ann Surg 241:582–590
14. Belghiti J, Noun R, Malafosse R, et al. (1999) Continuous versus intermittent portal triad
clamping for liver resection: a controlled study. Ann Surg 229:369–375
58
Chapter 2
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 58
15. Lin E, Calvano SE, Lowry SF (2000) Inflammatory cytokines and cell response in
surgery. Surgery 127:117–126
16. Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305
17. Barrat FJ, Meeker T, Gregorio J, et al. (2005) Nucleic acids of mammalian origin can act
as endogenous ligands for Toll-like receptors and may promote systemic lupus
erythematosus. J Exp Med 202:1131–1139
18. Panis Y, McMullan DM, Emond JC (1997) Progressive necrosis after hepatectomy and
the pathophysiology of liver failure after massive resection. Surgery 121:142–149
19. Kretzschmar M, Kruger A, Schirrmeister W (2003) Hepatic ischemia-reperfusion
syndrome after partial liver resection (LR): hepatic venous oxygen saturation, enzyme
pattern, reduced and oxidized glutathione, procalcitonin and interleukin-6. Exp Toxicol
Pathol 54:423–431
20. Kainuma M, Fujiwara Y, Kimura N, et al. (1991) Monitoring hepatic venous hemoglobin
oxygen saturation in patients undergoing liver surgery. Anesthesiology 74:49–52
21. Schemmer P, Enomoto N, Bradford BU, et al. (2001) Activated Kupffer cells cause a
hypermetabolic state after gentle in situ manipulation of liver in rats. Am J Physiol
Gastrointest Liver Physiol 280:G1076–1082
22. Schemmer P, Enomoto N, Bradford BU, et al. (2001) Autonomic nervous system and
gut-derived endotoxin: involvement in activation of Kupffer cells after in situ organ
manipulation. World J Surg 25:399–406
23. Lazarowski ER, Homolya L, Boucher RC, et al. (1997) Direct demonstration of
mechanically induced release of cellular UTP and its implication for uridine nucleotide
receptor activation. J Biol Chem 272:24348–24354
59
New markers for gut wall integrity
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 59
2.4 Urine based detection of
intestinal tight junction loss
Geertje Thuijls, Joep P. M. Derikx, Jacco-Juri de Haan, Joep Grootjans,
Adriaan de Bruïne, Ad A. M. Masclee, Erik Heineman, Wim A. Buurman
Journal of Clinical Gastroenterology, in press.
60
Chapter 2
Joep Derikx druk:proefschrift  20-04-2009  16:10  Pagina 60
ABSTRACT
Background
Tight junction breakdown, with loss of the important sealing protein claudin-3,
is an early event in the development of intestinal damage. Therefore non-
invasive analysis of intestinal tight junction status could be helpful in early
detection of intestinal injury.
Aim
To investigate the usefulness of urinary claudin-3 as marker for intestinal tight
junction loss.
Methods
A rat hemorrhagic shock model and a human setting of known intestinal
damage, i.e. patients with relapsed inflammatory bowel disease (IBD), were
used to investigate intestinal tight junction status by immunohistochemical
staining and urinary claudin-3 levels by western blot.
Results
In rats claudin-3 urine levels increased rapidly after histologically proven
intestinal tight junction loss, with significantly elevated levels at 90 minutes
after shock compared to sham operated animals (mean±SEM: 611±101
intensity (INT) , n=6 versus 232±30 INT, n=6; p<0.05).
Moreover, in colonic biopsies of patients with IBD relapse claudin-3
staining was reduced compared to biopsies of patients with IBD without signs
of disease. Concomitantly, significantly increased claudin-3 urine levels were
found in these patients (502±67 INT, n=10) compared to patients with IBD in
remission (219±17 INT, n=10, p<0.001) and healthy volunteers (225±38 INT,
n=10, p<0.001).
Conclusion
Here we show for the first time in both an experimental and clinical setting a
strong relation between intestinal tight junction loss and urinary claudin-3
levels. These findings suggest that measurement of urinary claudin-3 can be
used as non-invasive marker for intestinal tight junction loss. This offers new
opportunities for early diagnosis and follow-up of intestinal injury.
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INTRODUCTION
Gut wall integrity loss, including breakdown of tight junctions, is an early event
in intestinal damage.1-3 Currently, invasive intestinal biopsies provide the only
possibility to detect tight junction breakdown.2 Since endoscopy for biopsy is a
time-consuming and invasive procedure, a non-invasive method for detection of
tight junction breakdown would facilitate detection of tight junction loss. Such
assay could help in early diagnosis of disease in patients with intestinal damage,
including neonates suspected for necrotizing enterocolitis, patients suspected for
inflammatory bowel disease or celiac disease. Reliable markers for intestinal
tight junction loss will also be useful for follow-up of patients with intestinal
damage, for evaluation of therapy effects and for prediction of disease relapse.
Moreover, markers for tight junction integrity loss can be helpful in the elucidation
of the pathophysiology of diseases in which injury of the gut plays a role.
Tight junctions serve as a fence separating the internal environment of the
host from the gut luminal content, thereby preventing exposure of the internal
milieu to potentially harmful microbiota and microbial products. Tight junctions
consist of a large complex of proteins, including claudins (22kDa) which are
mainly responsible for the intestinal barrier function and are present in
abundance between adjacent healthy intestinal epithelial cells.1-5 Especially
claudin-3 is an important sealing claudin, expressed in high quantity in the
intestine.4 The amount of claudin-3 in the intestine decreases following tight
junction integrity loss.2 The small size, the abundant endogenous intestinal
expression and the paracellular localisation make claudin-3 a suitable candidate
as urinary marker for early non-invasive detection of intestinal tight junction
integrity loss. The aim of this pilot study is to investigate whether intestinal tight
junction loss results in the appearance of claudin-3 in the urine and
subsequently to assess the potential usefulness of claudin-3 as urine marker for
the non-invasive detection of intestinal tight junction loss.
METHODS
Experimental design
A rat hemorrhagic shock (HS) model and a human setting of intestinal disease
with known tight junction loss were studied. Both studies are conducted after
approval of the local ethical committees (Animal Care Committee of Maastricht
University and Medical Ethical Review Board of Maastricht University Medical
Centre).
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Rat hemorrhagic shock procedure
Sprague-Dawley rats were allocated to 5 groups (n=6 per group) before the start
of the experiments. Control rats (group 1) were sacrificed without intervention.
The other rats were exposed to non-lethal HS after 18 hours fasting as
previously described.6 Briefly, rats were anesthetized with isoflurane (induction
4%, maintenance 1.5%). The femoral artery was aseptically dissected and
cannulated with polyethylene tubing (PE-10) containing heparinized saline (10
IU/ml). Mean arterial blood pressure (MAP) and heart rate (HR) were assessed
continuously. After 30 minutes acclimatization period, 2.1 mL blood /100 g of
body weight was withdrawn (representing approximately 30–40% of the
circulating volume) at a rate of 1 mL/minute. Groups 2, 3, 4, and 5 were
sacrificed at 15, 30, 60 and 90 minutes after shock, respectively. At sacrifice
urine and tissue samples were taken. The severity of the HS as reflected by
changes in MAP, HR, and hematocrit was similar for all animals studied. These
data are comparable with previously published data, using the same HS
model.7,8
Human setting of intestinal disease
Urine samples were obtained after informed consent from 10 patients with
active IBD (4 Crohn’s disease, 6 ulcerative colitis) (4 male, 6 female), with a
median age of 37 years (range 10-68 years). Ten urine samples of healthy
volunteers (4 male, 6 female), median age 30 years (range 27-60 years), and 10
urine samples of patients with IBD in remission (5 Crohn’s disease, 5 ulcerative
colitis) (5 male, 5 female), median age 38 years (range 15-61 years) were
studied. Colonic biopsies of patients with IBD were taken for routine patient
care and used for this study to assess histological tight junction status.
Immunohistochemistry for claudin-3
Immunohistochemistry for claudin-3 on rat colon and human colonic biopsies
was performed. Briefly, rat colon and human colonic biopsies, fixed overnight
in 4% formaldehyde, were embedded in paraffin and sectioned at 3 µm. The
section were deparaffinised in xylol and endogenous peroxidases were blocked
in 3% H2O2/methanol. Sections were stained for 1 hour at room temperature
with Rabbit anti-Claudin-3 ((34-1700), Zymed Laboratories, San Francisco, CA).
This was followed by 30 minutes incubation with poly-HRP-GAM/R/R IgG
(ImmunoLogic, Duiven, the Netherlands) and visualized by applying
diaminobenzidine (DAB) (Dakocytomation, Glostrup, Denmark). Nuclei were
counterstained with haematoxylin. The distribution of claudin-3 was recorded
at a magnification of 400x using the Metasystems Image Pro System (black and
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white charge-couple device camera; Metasystems, Sandhausen, Germany)
mounted on a Leica DM-RE microscope (Leica, Wetzler, Germany). All images
were taken at equal time-exposures after being normalized to negative control
sections without primary antibody, to exclude for non-specific binding of the
secondary antibody. At least 25 microscopic fields for each tissue section were
examined.
Western blot for urinary claudin-3
Claudin-3 urine levels were analyzed by western blotting. First, to correct for
urinary dilution all urine samples were adjusted to urinary creatinine levels.
Creatinine is a well established marker reflecting the degree of urinary dilution.
Second, equal amounts of each sample (adjusted to urinary creatinine levels)
were separated by SDS-PAGE gel, transferred to PVDF-membrane and probed
using primary antibody to claudin-3 (Rabbit anti-Claudin-3 (34-1700), Zymed
Laboratories, San Francisco, CA). After incubation with goat anti rabbit HRP-
conjugated secondary antibody (Jackson, West Grove, PA), signal was detected
by supersignal west pico chemiluminescence substrate (Pierce, Etten-Leur, the
Netherlands). Band intensity was semi-quantitatively analyzed using Quantity
One (Biorad, Hercules, CA).
Statistical analysis
Gaussian distribution was tested using the Kolmogorov-Smirnov test. One-way
ANOVA, with post-hoc Bonferroni multiple comparison test, was used for
between group comparison. P < 0.05 was considered statistically significant.
Data are expressed as mean ± SEM of intensity using an arbitrary measure
(INT).
RESULTS
Intestinal claudin-3 loss
Immunostaining of claudin-3 was seen in junctional and basolateral cell
membranes in the colon of control rats. Hemorrhagic shock led to a significant
reduction of claudin-3 staining in the colon in animals sacrificed 60 minutes
after the induction of shock (Fig. 1A).
In line with the animal data, less claudin-3 staining was observed in
colonic biopsies of patients with IBD relapse, mainly at the junctional
membranes, compared to colonic biopsies of patients with IBD without signs of
disease (Fig. 1B). These data indicate that the protein claudin-3 is lost upon
intestinal injury.
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Figure 1: (A) Representative photographs of claudin-3 (DAB-stained) in longitudinal (A1.) and
transversal (A2.) colonic sections of healthy rats and rats sacrificed 60 minutes following
induction of shock. Claudin-3 is present in the colon of control rats in junctional and basolateral
cell membranes (A1.1 + A2.1). After hemorrhagic shock, staining is reduced (A1.2 + A2.2). N=6
per group, 400x magnification.
(B) Representative photographs of claudin-3 (DAB-stained) in longitudinal (B1.) and transversal
(B2.) colonic biopsy sections of patients with IBD (ulcerative colitis). Claudin-3 (DAB-stained) is
present in junctional and basolateral cell membranes in colonic biopsies of patients with IBD
without signs of disease (B1.1 + B2.1). Reduced staining of claudin-3 in colonic biopsies of
patients with IBD relapse was observed, mainly at the junctional membranes of the epithelial cell
(B1.2 +B2.2). N=4 per group, 400x magnification.
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Increased urinary claudin-3 levels
Western blot analysis showed the presence of claudin-3 in urine of sham
operated rats (232 ± 30 INT). Significantly increased claudin-3 levels were
detected in urine, corrected for urinary concentration occurring in shock, at 90
minutes after induction of hemorrhagic shock (611 ± 101 INT , p<0.05),
following histologically proven loss of intestinal claudin-3 observed at 60
minutes after induction of hemorrhagic shock (Fig. 2).
Figure 2: A significant increase in claudin-3 urine levels is detected in rats sacrificed 90 minutes
after shock compared to controls, reflecting intestinal tight junction loss. Values are expressed as
mean ± SEM, n=6 per group.
Also in the human setting, significantly increased claudin-3 urine levels were
found in patients with IBD relapse (502 ± 67 INT) compared to healthy
volunteers (225 ± 38 INT, p<0.001) and to patients with IBD in remission (219
± 17 INT, p<0.001) (Fig. 3), which was in line with reduced claudin-3 staining
in patients with IBD relapse, compared to patients with IBD in remission.
Figure 3: A significant increase in claudin-3 urine levels in patients with active IBD compared to
healthy volunteers and patients with IBD in remission was observed, indicating that tight junction
loss was detectable in urine. Values are expressed as mean ± SEM, n=10 per group.
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DISCUSSION
Non-invasive detection of tight junction loss could help in early diagnosis and
follow-up of patients with intestinal diseases like necrotizing enterocolitis, IBD
or celiac disease.
To evaluate the usefulness of urinary claudin-3 as non-invasive marker to
assess intestinal tight junction loss we first used an experimental animal model
with proven tight junction loss.6,9 Recently we observed in this experimental rat
HS model that intestinal barrier loss is present without systemic inflammation
within 90 minutes after induction of hemorrhagic shock (manuscript in
preparation). To rule out the effect of systemic inflammation on tight junction
status, because systemic inflammation can lead to tight junction loss in other
organs besides the gut, we used this HS model to investigate whether intestinal
tight junction loss results in the appearance of claudin-3 in the urine. To
translate our data to a clinically relevant human setting, patients with IBD were
included.
This pilot study shows that intestinal claudin-3 immunostaining was
decreased in both an animal and a human model for intestinal damage,
reflecting loss of claudin-3 upon intestinal barrier damage. More importantly,
urinary claudin-3 levels were elevated when intestinal tight junction loss
occurred, strongly indicating that elevated urinary claudin-3 levels reflect loss
of tight junctions.
Although, it has previously been shown that besides in the intestine,
claudin-3 is also expressed in tight junctions of liver, kidney and lung.5 We
recently showed in the same experimental rat HS model that no significant loss
of claudin-3 occurred in the liver and kidney.9 In addition, others showed that
HS does not result in early pulmonary tight junction loss, in absence of severe
associated factors, like massive inflammation.10,11
In this study, immunohistochemistry was performed on intestinal tissue
specimens to objectify loss of claudin-3 at a histological level, showing
reduced claudin-3 staining in the intestinal specimens after induction of HS and
in patients with IBD relapse. Therefore we consider that the urinary claudin-3
levels reflect intestinal tight junction loss. The amount of claudin-3, detected in
urine of sham operated rats and healthy human volunteers, is most likely
related to the level of turnover of intestinal epithelium.
The observed increase of urine claudin-3 after immunohistologically
observed intestinal claudin-3 reduction indicates loss of claudin-3 into the
blood circulation and subsequent clearance in urine. In contrast to the current
data, a number of previous studies show internalization of tight junction
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proteins, including claudins during paracellular barrier loss, intercellular
movement and epithelial turnover.12,13 We suppose that during epithelial
turnover as well as during barrier loss both internalization of claudins and
claudin loss and successive urinary excretion take place. The latter is supported
by the decreased intestinal expression of claudin-3 after hemorrhagic shock on
western blot as we showed in a previous study.9
To translate the animal data to a human setting, colonic biopsies and urine
of patients with objectified intestinal disease, i.e. patients with relapsed
inflammatory bowel disease (IBD), were studied. First, we showed reduced
intestinal tight junction staining in patients with IBD relapse. This is supported
by recent findings of Zeissig et al. who showed disturbance of barrier function
and reduced presence of claudin proteins including claudin-3, in intestinal
biopsies of patients affected with IBD.2 Second, concomitant to the reduced
intestinal claudin-3 staining, we showed elevated urinary claudin-3 levels.
These preliminary data suggest that urinary claudin-3 can be used to detect
intestinal tight junction loss in the human setting. Since urinary claudin-3
measurement is not specific for intestinal tight junction loss, this test should be
performed based on clinical arguments.
In conclusion; we show for the first time in both an experimental and a
clinical setting a strong relation between intestinal tight junction loss and
urinary claudin-3 levels. These findings suggest that measurement of urinary
claudin-3 can be used as non-invasive marker for intestinal tight junction loss.
This offers new possibilities for early diagnosis and follow-up of patients with
intestinal diseases by detection of tight junction loss. Furthermore, the ability to
measure claudin-3 urinary levels could contribute to the elucidation of the
pathophysiology of gut related diseases in man.
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CHAPTER 3
Analysis of markers for
compromised gut wall in patients
with overt gut damage and in
patients with suspected intestinal
disease to distinguish the target
disease from other pathologies
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3.1 INTRODUCTION
To investigate the second aim: i.e. analysis of markers for compromised gut wall
in patients with overt gut damage and in patients with suspected intestinal
disease to distinguish the target disease from other pathologies, the usefulness
of non-invasive tests for enterocyte damage, TJ disruption and gut wall
inflammation was evaluated. These human studies regarded different phases of
diagnostic studies. Diagnostic tests aim at discriminating between clinically
“normal” and “abnormal”. New diagnostic tests should subsequently answer
the following 4 questions before implementation of the new test in daily
clinical practice can be contemplated 1. Question 1: Do patients with the target
disorder have different test results compared to normal individuals? The answer
requires comparison of test results among individuals with the disease and
individuals that are disease-free. This question was piloted in a child receiving
high-dose chemotherapy (paragraph 3.2) and in a study with adult patients
receiving myeloablative conditioning for haematopoietic stem cell
transplantation (HSCT) (paragraph 3.3). A major risk in these patients is the
development of mucosal barrier injury, potentially resulting in serious
complications. The identification of mucosal barrier injury in patients before
and after myeloablative conditioning was investigated using plasma levels of
FABP. In another n=1 study, the potential development of intestinal epithelial
cell damage was monitored using plasma FABP measurement in a child
undergoing gastroschisis-repair (paragraph 3.4). Question 2: Are patients with
certain test results more likely to have the target disorder than patients with
other test results? This question is also answered by comparison of test results
among patients with the targetdisease and healthy individuals, but now test
characteristics as sensitivity, specificity and likelihood ratios are estimated. This
phase was applied in the study concerning patients with celiac disease and in
patients with appendicitis. In patients with celiac disease the diagnostic
accuracy of circulating levels of FABP was investigated and in patients with
appendicitis the usefulness of neutrophil activation products was studied
(paragraph 2.2 and 3.5). Question 3: Among patients in whom it is clinically
sensible to suspect the target disorder, does the test result distinguish those with
and without the target disorder? To get the appropriate answer, a consecutive
series of such patients should be studied. This phase was performed in
evaluating diagnostic tests in the study of neonates suspected for necrotizing
enterocolitis (NEC), since the results of phase 1 and 2 studies were already
reported by other authors. Neonates admitted to our neonatal intensive care
unit, suspected for NEC, were consecutively included in the study (paragraph
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3.6 and 3.7). Aim of the study was to differentiate NEC from other neonatal
diseases that present with abdominal signs and symptoms suspicious of NEC
using non-invasive tests for enterocyte damage (urinary FABP), TJ disruption
(urinary claudin-3) and gut wall inflammation (faecal calprotectin). Question 4:
Do patients who undergo the diagnostic test fare better (in their ultimate health
outcomes) than similar patients who do not? The question has to be answered
by randomizing patients to undergo the test of interest or another (or no) test.
No study was performed regarding phase 4 questions.
REFERENTIES
1. Sackett DL, Haynes RB. The evidence base of clinical diagnosis. London: BMJ
Publishing Group, 2002.
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3.2 Detection of chemotherapy
induced enterocyte toxicity with
circulating Intestinal Fatty Acid
Binding Protein
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ABSTRACT
Background
Cytotoxic gastro-intestinal (GI) mucositis is a difficult to diagnose complication
of chemotherapy. It contributes potentially to local invasion by microorganisms
and, subsequently, to systemic infection in neutropenic patients.
Patient and methods
We report a neutropenic girl with a cervical rhabdomyosarcoma, treated with
ifosfamide, vincristine, and actinomycin D (IVA), who developed repetitive
periods of diarrhea, fever and abdominal complaints after each cytostatic
treatment. Circulating levels of Intestinal Fatty Acid Binding Protein (I-FABP), a
small cytosolic protein constitutively present in mature enterocytes, and
inflammatory mediators were measured during five consecutive weeks.
Results
Strongly elevated plasma levels of I-FABP, representing enhanced enterocyte
cell death, associated very well with periods of fever, severe intestinal
complaints and peak values of IL-6, IL-8 and CRP after chemotherapy.
Conclusion
This case is the first to show that plasma I-FABP levels allow early detection of
chemotherapy induced enterocyte cell death.
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IINTRODUCTION
Mucositis is a well known adverse effect of chemotherapy. Next to oral mucositis,
gastro-intestinal (GI) mucositis is increasingly recognized as chemotherapy
associated toxicity. The consequences of GI mucositis are diarrhea, fever,
inflammation with pain and risk for bacteremia and sepsis 1. A means of
objectively and early monitoring of GI mucositis is necessary, since the
diagnosis is currently based on signs and symptoms 2. Moreover, there is a need
for tools to study the pathobiology of GI mucositis. Enterocyte loss is
considered to be an important aspect of the pathophysiology of GI mucositis;
therefore evidence of enterocyte cell death was monitored in the circulation.
This case is the first to show an association of severe enterocyte damage with
known complications of chemotherapy induced GI mucositis.
REPORT OF A CASE
A 2-year old neutropenic girl with cervical rhabdomyosarcoma was admitted to
the Pediatric Intensive Care Unit for chemotherapy induced septicemia with
diarrhea and fever (>38.5ºC). Chemotherapy consisted of ifosfamide, vincristine,
and actinomycin D (IVA) once in three weeks. This treatment is known to cause
severe infection in 26% of treatment episodes 3. Before, the patient showed
twelve episodes of bacteremia, defined as positive blood cultures, with diarrhea,
abdominal complaints and fever during eleven cytostatic treatments, resulting in
severe discomfort. The patient recovered rapidly after each episode of bacteremia.
The signs and symptoms of the patient (diarrhea, fever, abdominal
complaints) are suggestive for GI mucositis as source for bacteremia. Direct
evidence for intestinal mucosal damage in these patients with inexplicable
systemic infectious complications is nevertheless not readily available,
although ultrasound and computed tomography can help to differentiate GI
complications in neutropenic patients 4, 5.
Intestinal Fatty Acid Binding Protein (I-FABP) has been reported to be a useful
plasma marker for early enterocyte cell death 6. The small (14-15 kDa) cytosolic I-
FABP is present in mature enterocytes of small and large intestine and released as
soon as the cell membrane integrity is compromised. I-FABP is not normally found
in plasma, but is rapidly detectable following acute intestinal ischemic cell death 6.
During five consecutive weeks clinical signs were recorded and EDTA
plasma was sampled. Plasma I-FABP was determined, using a human I-FABP
ELISA that selectively detects human I-FABP (standard: 20-5000 pg/ml),
provided by HBT (Uden, the Netherlands). In order to asses the systemic
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inflammatory response, circulating C-Reactive Protein (CRP), Interleukin-6 (IL-
6) and Interleukin-8 (IL-8) were measured. CRP was routinely determined; IL-6
and IL-8 were measured using in house ELISAs.
The patient experienced a bacteremic period with fever and diarrhea
following the first cytostatic treatment and fever and diarrhea following the
second treatment in the study-period of five weeks (Figure 1). A blood culture was
positive for coagulase negative staphylococci. Both cytostatic treatments involved
severe discomfort: diarrhea, fever and abdominal complaints. Interestingly,
plasma I-FABP values associated very well with periods of fever and severe
intestinal complaints seven days after first cytostatic treatment, and three and ten
days after the second treatment. Peak values of five to twenty-fold raised I-FABP
levels preceded the intestinal complaints and fever by approximately 4-24 hours.
Each rise of I-FABP was followed by a rapid decline. At time points of high I-FABP
levels also peak values of CRP were found. Both IL-6 and IL-8 were increased at
the moment of maximal rise in I-FABP levels. These data indicate that the mucosal
cell damage, as assessed by enhanced I-FABP plasma levels, was accompanied
by a systemic inflammatory response, a characteristic of GI mucositis 7.
Figure 1: A 2-year old girl with rhabdomyo-
sarcoma had three episodes of gastrointestinal
mucositis and bacteremia following two
cystostatic treatments (CT) consisting of ifosfamide, vincristine, and actinomycin D (IVA).
Gastrointestinal mucostitis was accompanied by increased plasma intestinal fatty acid binding
protein (I-FABP), reflecting enterocyte damage, raised C-reactive protein levels, and fever. Blood
culture (BC) was positive for coagulase-negative staphylococci.
77
New markers for gut wall integrity in health and disease
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 77
DISCUSSION
Fatty Acid Binding Proteins (FABPs) belong to a family of proteins that facilitate
intracellular long-chain fatty acid transport. These relatively small (14-15kDa)
cytosolic proteins are promising biomarkers for monitoring tissue damage in a
number of organs: e.g. liver, kidney, intestine 8. Next, FABPs are used as
markers for colorectal cancer and renal cell carcinoma 9, 10. Potentially,
measurement of the renal FABP-types (H- and L-FABP) could give information
on renal toxicity in patients receiving ifosfamide. In the present study an ELISA
that specifically quantifies I-FABP, as a specific marker for intestinal mucosal
damage, has been used to assess GI mucositis.
So far, diagnosis of GI mucositis is limited to scales scoring subjective
symptoms and functional changes with ultrasonography and computed
tomography as potentially helpful tools for the detection of neutropenic
enterocolitis 4, 5. The data presented here show that plasma I-FABP represents a
promising objective and early tool for the assessment of chemotherapy induced
intestinal mucosal damage.
Following the first cytostatic treatment a significant increase in I-FABP
levels was seen after seven days. This increase paralleled the inflammatory
response, measured by raised plasma CRP and fever. The second cytostatic
treatment was rapidly followed by an increase in circulating I-FABP, possibly
indicative for a lack of sufficient intestinal mucosal repair after the first
cytostatic treatment. After the second cytostatic treatment two I-FABP peaks
were seen, of which the second was accompanied by a strong systemic
inflammatory response, shown by increased IL-6, IL-8 and CRP levels and fever.
The diagnosis of GI damage with I-FABP offers an important step towards
a better insight in the pathophysiology of chemotherapy induced GI mucositis.
Since I-FABP measurement can be performed rapidly and with high sensitivity,
such measurements may offer new therapeutic options.
The mechanism of chemotherapy induced GI mucositis remains unclear.
Recently, mucositis development has been divided into five phases: initiation,
primary damage response, signal amplification, ulceration and healing 11. At
this stage we cannot discriminate between direct chemotherapy induced toxic
enterocyte cell death and inflammation related enterocyte damage. However,
the present data show that intestinal mucosal cell death in patients after
chemotherapy is accompanied by a rapid increase of CRP, suggesting an
involvement of an inflammatory process in the development of cell death. The
cumulative release of I-FABP can be used to estimate the extent of damage,
taking into account the renal FABP clearance rate.
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This case is the first to show that measurement of circulating I-FABP offers a
valuable addition to the assessment of GI mucositis. This is important, because
intestinal mucosal damage provides a portal of entry for GI microorganisms or
initiates the systemic inflammatory response by itself, resulting in severe
abdominal complaints with fever and sepsis.
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SUMMARY
Background
Intestinal mucosal barrier injury (MBI), resulting from myeloablative
conditioning for haematopoietic stem cell transplantation (HSCT) is an
important cause of morbidity. Despite its frequency, recognition presents a
challenge, while the aetiology needs still to be unravelled. The relationship
between enterocyte mass and enterocyte loss was explored by examining
citrulline serum levels and by assessing circulating I-FABP and I-BABP, proteins
released by dying mature enterocytes.
Patients and methods
34 adult patients with haematological malignancy received allogeneic HSCT
(HSCT day 0) 12 days after being given idarubicin, cyclophosphamide and total
body irradiation as myeloablative conditioning, a regimen known to induce
oral and intestinal MBI. Serum levels of citrulline, I-FABP and I-BABP were
measured on HSCT days -12, -6, 0, +7, +14, +21.
Results
Myeloablative conditioning resulted in a significant decrease in serum citrulline
with the nadir on HSCT day +7; thereafter levels rose gradually. Simultaneously,
a significant decrease in I-FABP and I-BABP levels occurred from the day of
transplant until day +14.
Conclusions
Simultaneous reduction and subsequent increase of citrulline, and I-FABP, I-
BABP levels following cytotoxic treatment show that enterocyte mass
corresponds to lower rate of dying enterocytes, indicating reduced turnover of
enterocytes. Assessment of enterocyte turnover and mass offers opportunities
for evaluation of new MBI therapies.
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INTRODUCTION
Mucosal Barrier Injury (MBI) of the digestive tract is an inevitable and frequent
side-effect of the intensive myeloablative conditioning employed to prepare for
haematopoietic stem cell transplantation (HSCT). MBI presents with oral
mucositis and corresponding gastro-intestinal signs and symptoms of mucositis,
such as abdominal pain, diarrhoea, vomiting and weight loss 1, 2. MBI together
with profound neutropenia predispose patients to local invasion by
microorganisms and, subsequently, to systemic life-threatening infections 2, 3.
MBI has been attributed to the high physiological proliferation and
turnover of intestinal epithelial cells, which are highly susceptible to cytotoxic
therapy 2, 4, 6. Evidence for the loss of small bowel epithelial cell mass has been
provided by declined serum levels of citrulline in HSCT recipients suffering
from severe oral and gastrointestinal mucositis following intensive
myeloablative therapy 7, 8. The levels of circulating citrulline, an amino acid not
incorporated into proteins, reflect functional enterocyte mass. Differentiated
small intestinal enterocytes specifically produce citrulline from glutamine and
are responsible for the major part of the total amount of serum citrulline 9, 10.
The origin of the reduced functional intestinal epithelial cell mass is
hitherto unclarified. Both an increased cell death of enterocytes and a reduced
turnover might explain the reduced functional enterocyte mass. Measurement
of endogenous cytosolic enterocyte proteins, such as Fatty Acid Binding
Proteins (FABP) have been shown to be useful to estimate enterocyte loss, e.g.
after episodes of acute intestinal ischemia and inflammation, including
necrotizing enterocolitis 11, 13. FABP comprise a class of low molecular weight
(14-15 kDa) cytosolic proteins found in high concentrations in tissues involved
in the uptake and consumption of fatty acids 14. Intestinal Fatty Acid Binding
Protein (I-FABP) is primarily limited to mature enterocytes of small and large
intestine. It circulates in low amounts in the blood stream of healthy individuals
11. Ileal-Bile Acid Binding Protein (I-BABP) is exclusively present in mature
enterocytes of the jejunum and ileum 15, 16. Liver-FABP (L-FABP) is localized in
small amounts in the mature enterocytes of the small and large intestine but in
abundance in the liver 14.
The expression of L-FABP and I-FABP mRNA and proteins was barely
affected during the phase of crypt and villous damage in rats treated with the
cytostatic drug methotrexate (MTX) unlike what was found for other enterocyte
markers, including glucose transporter 5 (GLUT5), carbamoylphosphatate
synthase (CPS), sucrase-isomaltase (SI), sodium glucose co-transporter 1
(SGLT1) and lactase. This was underscored by immunohistochemistry 17.
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In the present study circulating levels of FABP were determined longitudinally
along with citrulline serum levels in a cohort of HSCT recipients suffering from
severe mucositis after intensive myeloablative conditioning in order to relate
the known reduced functional enterocyte mass with enhanced cell death or
reduced turnover of enterocytes.
PATIENTS AND METHODS
Patients
Between July 1999 and July 2002, 34 adult patients admitted to the department
of Haematology, Radboud University Nijmegen Medical Centre, received a T-
cell depleted sibling HSCT on HSCT day 0 to treat haematological malignancy
and consented to participate in the study 7, 18. The preparative myeloablative
conditioning regimen consisted of idarubicin starting 12 days before transplant
(HSCT day -12), followed by cyclophosphamide on HSCT days -6 and -5 and a
total of 9 Gray total body irradiation on HSCT days -2 and -1. All patients
received cyclosporin and the same anti-infective prophylaxis as well as
empirical antibiotic therapy when fever occurred. The local ethics committee
approved the study.
Citrulline assay
Serum had been collected on HSCT days -12, -6, 0, +7, +14 and +21. In
practice, some samples were not taken. The serum was stored in aliquots at -
80ºC until further analysis. Citrulline concentrations were measured (µM) by a
standard procedure for determining amino acids 7.
I-FABP assay
Serum I-FABP was determined using a highly specific commercially available
enzyme-linked immunosorbent assays (ELISA) that selectively detects human I-
FABP (standard: 20-5,000 pg/ml) (provided by Hycult Biotechnology, Uden, the
Netherlands).
I-BABP assay
The I-15P expression vector pET/Hu I-15P, which contains cDNA encoding
human I-BABP, was kindly donated by Dr. Fujii 15, 16. Prokaryotic protein
expression was achieved by transformation of pET/Hu I-15P into BL21 cells.
After harvesting and lysing of the cells, the recombinant human I-BABP was
purified with an ion-exchanger (DE-52, Whatman, Kent, UK) and gel filtration
(Superdex-75 column, Pharmacia GE Healthcare, Diegem, Belgium). The
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antiserum against recombinant human I-BABP was obtained by immunizing of
New-Zealand white rabbits with I-BABP and adjuvant carried out under a
protocol approved by the Institutional Animal Care Committee of the University
of Maastricht. The rabbit antiserum was purified by affinity chromatography on
protein A-sepharose.
The following ELISA was developed to measure human I-BABP. Anti-I-BABP IgG
was coated at a concentration of 2.5 µg/ml in PBS 1 hour at 37ºC on a 96-well
plate (Immuno-Maxisorp; Nunc, Roskilde, Denmark). Free sites were blocked
by 1 h of incubation with 1% BSA in PBS at room temperature. Test samples as
well as human recombinant I-BABP, used as standard, were incubated for 1 h
at room temperature. Then biotinylated anti-I-BABP IgG was added as the
detection antibody for 1 h at room temperature. HRP-streptavidin conjugate
(Zymed Laboratories, Inc., San Francisco, CA) was used to develop the color
reaction in combination with 3,3,5,5-tetramethylbenzidine (Kirkegaard & Perry
Laboratories, Gaithersburg, MD) and H2SO4. Color intensity was measured by
determining the absorbance at 450 nm using a micro-ELISA reader. The
detection range was 0.32-5 ng/ml. The specificity of the rabbit anti-human I-
BABP was tested by incubating human recombinant I-FABP, L-FABP and lysed
human ileum and colon together with the standard human recombinant I-BABP.
The anti-I-BABP specifically reacted with human I-BABP, human ileum, but not
with human colon, I-FABP or L-FABP.
Statistical analysis
Statistical analysis was performed using Prism 4.0 for Windows (GraphPad
Software Inc. San Diego, CA). Concentrations were presented as mean ± standard
error (SEM). Normality of all data obtained was verified by Kolmogorov-Smirnov
test. Distribution of serum citrulline and FABP concentrations did not pass the
normality test on HSCT day +7 for citrulline and I-BABP and on HSCT day 0, +7
and +14 for I-FABP. Therefore, Friedman two-way analysis of variance by ranks
was used to analyze changes between HSCT days in serum citrulline and FABP
levels. A Wilcoxon matched pairs test was used to calculate significant differences
of serum citrulline and FABP with respect to baseline (HSCT day -12).
Correlations were calculated using Spearman correlation coefficient. A p-value
below 0.05 was considered to be statistically significant.
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RESULTS
Patient characteristics
Of the original 34 patients 5 patients were excluded from this study, because
blood was collected on less than 3 study days. The remaining 29 patients
(11F:18M) had a mean age of 49 years (range: 25-65 years). Nine patients had
acute myeloid leukaemia, 6 had non-Hodgkin lymphoma, 5 had acute
lymphoblastic leukaemia, 5 had myelodysplastic syndrome, 2 had chronic
myeloid leukaemia, and one patient each had myeloproliferative disease,
chronic lymphocytic leukaemia and myelofibrosis. All had received a T-cell
depleted sibling HSCT to treat their haematological malignancy
Transplant-related complications
All patients suffered from severe oral and intestinal mucosits 18. All except 1
patient were treated empirically for fever during neutropenia with a
cephalosporin. 9 patients had bacteraemia due to oral viridans streptococci
occurring between HSCT days +1 and +8. Acinetobacter baumanii was
recovered from a single aerobic blood culture from one patient on day +1 after
transplant but no other Gram negative bacilli were recovered from blood
cultures or surveillance specimens of any other patient during the study period.
There were 8 serious adverse events resulting in death. 4 patients died
because of an infectious event: one on HSCT day +9 because of sepsis
syndrome, another on HSCT day +12 because of sepsis syndrome after
Streptococcus mitis bacteraemia, one on HSCT +13 due to invasive Candida
infection and a fourth on HSCT day +21 because of invasive pulmonary
aspergillosis. Another 4 patients died because of a non-infectious event due to
multi-organ failure on HSCT days +13 and +43 respectively and one because of
grade IV acute GvHD on HSCT day +55 and the other due to cerebral
haemorrhage after primary graft rejection on HSCT day +56. Although the
mortality rate is high, it is not markedly higher than what has been reported 19.
This particular intensive preparative myeloablative conditioning regimen
consisted of idarubicin, cyclophosphamide and total body irradiation and was
used to counterbalance the increased graft rejection and increased relapse rate
associated with the T-cell depletion used at that time.
Serum citrulline concentrations after myeloablative conditioning regimen
for HSCT
The mean (SEM) initial citrulline serum concentration on HSCT day -12 was
31.6 (1.6) µM, which was comparable to baseline values in previous study 7.
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Following HSCT, a significant decrease in serum citrulline concentrations was
observed (Friedman test: p<0.0001) with the nadir observed on HSCT day +7
(10.5 (1.5) µM, Figure 1, see Figure 2a for 7 individual patients). At the last
study day (HSCT day +21), the mean serum citrulline value (15.1 (1.4) µM) had
increased, but was still significantly lower than baseline (p=0.0005). Since
serum citrulline concentration had been shown to be a reliable marker of
functional enterocyte mass, our data indicate that myeloablative therapy,
accompanied by symptoms and signs of severe mucosal damage, results in
clear transient reduction in the small intestinal epithelial cell mass 7.
Figure 1: Serum citrulline concentrations after myeloablative conditioning regimen for HSCT.
Serum citrulline concentrations declined significantly at HSCT day -6 and remain decreased until
HSCT day +21, indicating rapid and continuous loss of small bowel enterocyte mass following
intensive myeloablative therapy.
Serum I-FABP and I-BABP concentrations after myeloablative conditioning
regimen for HSCT
In the untreated situation, substantial variability in I-FABP serum concentrations
was noted, ranging from 20 to 336 pg/ml (Figure 3a, see Figure 2b for 7
individual patients). Following myeloablative conditioning regimen for HSCT,
the Friedman test indicated a significant decrease in serum I-FABP values
during the study period (p=0.0009). Serum I-FABP levels remained unchanged
at HSCT day -6 (67.9 (13.6) pg/ml, p=0.416). From HSCT day 0 a significant
decrease of I-FABP levels (27.6 (4.2) pg/ml, p=0.001) compared to day -12 was
found, which proceeded until HSCT day +14. The decrease in serum I-FABP
concentration between HSCT day -6 and 0 occurred in all but one patient. The
lowest mean I-FABP concentration measured was found on HSCT day +7 (21.1
(1.1) pg/ml), similar to the nadir of serum citrulline values. However, in contrast
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to serum citrulline levels, I-FABP returned to baseline levels on HSCT day +21
(86.3 (28.6) pg/ml, p=0.922).
Similar to the I-FABP levels, also for I-BABP serum concentration
substantial variation was present before treatment with a myeloablative
conditioning regimen for HSCT, ranging from 0.6 to 8.5 ng/ml (Figure 3b, see
Figure 2c for 7 individual patients). Following preparative regimen, the
Friedman test indicated significant reduction in serum I-BABP levels during the
study period (p<0.0001). Serum I-BABP levels showed from HSCT day -6
onwards a significant decrease (2.1 (0.6) ng/ml, p=0.004) compared to HSCT
day -12. This diminution continued until HSCT day +14. The decrease in serum
I-BABP concentration between HSCT day -12 and -6 occurred in 26 out of 29
patients. The nadir mean I-BABP concentration was found on HSCT day 0 (0.8
(0.1) ng/ml). In accordance with the normalisation of serum I-FABP levels on
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Figure 2: Serum citrulline, I-FABP and I-BABP concentrations for 7 individual patients after
myeloablative conditioning regimen for HSCT. Serum citrulline (a), I-FABP (b) and I-BABP (c)
concentrations show that almost all patients follow the same pattern.
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HSCT day +21, a return to baseline levels of serum I-BABP on HSCT day +21
was found (3.7 (1.6) ng/ml, p=0.470 vs HSCT day -12). Interestingly, all serum
I-FABP levels correlated significantly with serum I-BABP levels (Spearman
r=0.436, p<0.0001).
Ratio of serum I-FABP:citrulline and I-BABP:citrulline after myeloablative
conditioning regimen for HSCT
In order to study whether the functional cell mass is directly related to the loss of
villous enterocytes, the ratio of serum values of I-FABP and citrulline was
determined at each time point. At baseline the mean ratio I-FABP:citrulline was
27.6 (4.8) (Figure 4a). The ratio remained unchanged during the complete study
period (Friedman test: p=0.600), indicating that a lower mass of functional small
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Figure 3: Serum I-FABP and I-BABP concentrations after myeloablative conditioning regimen for
HSCT. Serum I-FABP (a) and I-BABP (b) concentrations decreased significantly at HSCT day 0 and
returned to baseline levels at HSCT day +21, indicating loss of turnover of intestinal epithelial
cells followed by a recovery after 3 weeks in patients undergoing intensive myeloablative therapy.
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bowel enterocytes is accompanied by loss of enterocytes. Only on HSCT day +21
a higher mean ratio was found (66.5 (24.2)) compared to all preceding study days,
caused by a relative elevation of I-FABP rather than citrulline levels. However, this
increased ratio was not significant (p=0.424) compared to HSCT day -12.
The specificity of I-BABP for mature enterocytes of jejunum and ileum
allows us to relate the loss of enterocytes of the jejunum and ileum with
functional cell mass. Before treatment the mean ratio I-BABP:citrulline was 11.6
(1.9) (Figure 4b). The ratio remained unaltered during the study period
(Friedman test: p=0.460), indicating that the mass of small bowel enterocytes is
related with the loss of jejunal and ileal enterocytes.
Figure 4: Ratio of serum I-FABP:citrulline and I-BABP:citrulline after myeloablative conditioning
regimen for HSCT. Ratio of serum I-FABP:citrulline (a) and I-BABP:citrulline (b) remains unaltered
in patients with intensive myeloablative therapy, indicating that the loss of small bowel enterocyte
mass correlates with a deficit of turnover of intestinal epithelial cells.
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DISCUSSION
Human histological studies on intestinal mucositis are nearly impossible due to
the severity of mucositis and increased bleeding tendency. Therefore,
circulating levels of citrulline and enterocyte cytosolic proteins I-FABP and I-
BABP are investigated longitudinally in a cohort of patients receiving the same
intensive myeloablative conditioning for HSCT. A substantial variation in
circulating levels of both FABP before treatment is observed, which is
comparable with data of healthy individuals 20. The expression of both I-FABP
and I-BABP is limited to differentiated enterocytes present on the upper one
third part of the villus in the small intestine 11, 16. These FABP-containing cells
are known to detach from the villus or die at the end of their lifespan 21. Taking
into consideration the very short half-life of these proteins (approximately 11
minutes), we consider that the baseline I-FABP and I-BABP circulating levels
represent the continuous release of FABP originating from mature detaching or
dying enterocytes. Some of the baseline FABP (and citrulline) serum levels
might also relate to previous chemotherapy. Since the main loss of enterocytes
in the healthy intestine consists of senescent enterocytes which detach into the
gut lumen at the end of their lifespan, the steady state circulating levels of FABP
represent the loss of enterocytes, and thus also the production of enterocytes or
in other words the turnover of enterocytes.
Interestingly, a minor increase in the amount of serum FABP was found
only in three patients after initiation of the myeloablative conditioning regimen.
This indicates that no direct (small) bowel epithelial cell damage occurred
during this preparative regimen for HSCT at this time. However, following the
preparative regimen levels of both I-BABP and I-FABP declined in virtually
every case. These data show that less cytosolic content of enterocytes is
released into the circulation than under normal, healthy circumstances,
indicating a decreased rate of dying enterocytes. This, in turn, suggests a
reduced turnover of enterocytes after myeloablative conditioning.
This is the first study to report on specific changes in I-BABP levels,
representing specific jejunal and ileal enterocyte loss, using a newly developed
ELISA for measurement of serum and plasma I-BABP. Our study shows a very
rapid decrease in I-BABP circulating levels, a representative of diminished small
intestinal turnover of enterocytes following onset of therapy. This occurred one
week earlier than the marked reduction in I-FABP which is present in
enterocytes of the whole intestine. This is consistent with the enhanced
susceptibility of small bowel enterocytes to myeloablative regimen and is
clearly shown by the rapid alteration of the circulating marker I-BABP.
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Significantly lower serum citrulline concentrations, an indicator for the
functional small bowel epithelial cell mass, occur two weeks after the start of
myeloablative therapy lagging one week behind diminished I-BABP levels, and
correspond with the decreased I-FABP circulating levels. Importantly, it took
about three weeks before levels of circulating FABP increased towards normal
values, indicating an elevated turnover of enterocytes, which most likely
reflects recovery by proliferation. Similarly, rising serum citrulline
concentrations indicate an initiation of the recovery of functional enterocyte
mass on HSCT day +21. The simultaneous alterations of serum levels of I-BABP,
I-FABP (representing loss of cells present in the jejunum-ileum and total
intestine, respectively), and serum concentrations of citrulline (representing
total small intestinal enterocyte mass) indicate that turnover and mass of
intestinal epithelium are directly related. This is further supported by the ratios
of serum I-FABP:citrulline and I-BABP:citrulline, which clearly indicate that the
turnover of (small) intestinal epithelial cells corresponds to the small bowel
epithelial cell mass throughout the entire study period.
From these data, we conclude that the reported reduction in enterocyte
mass is directly related to a reduced turnover of enterocytes. This lower
turnover could be caused by a reduced number of enterocyte stem cells, which
is in line with the kinetics of injured gut epithelium after radiotherapy and
chemotherapy 4-6, 22. Human duodenal biopsies of patients receiving non-
intensive chemotherapy showed induction of apoptosis in the intestinal crypts,
using TUNEL technique and electron microscopy, which occurred before
hypoplastic villous atrophy, loss of enterocyte cell height and decreased mitotic
count 4. Presumably, apoptosis reduced the net functional stem cell population.
The authors concluded that the chemotherapy-induced apoptosis of intestinal
crypts in patients was not accompanied with mucosal destruction, but rather
with morphometric reduction in crypt size and proliferation 4. Also the recently
defined five-phase process of the pathobiology of mucositis described that
radiation or chemotherapy leads to direct and indirect injury to epithelial stem
cells, resulting in a loss of renewal capacity in the early phase of ‘primary
damage response and signal amplification’ 6. Rats treated with methotrexate
(MTX) showed a similar inhibition of epithelial proliferation, decreased crypt
depth, and crypt cell apoptosis in the small intestine 5. In line with these data,
we showed no increase of circulating I-FABP and I-BABP levels, indicating no
(small) intestinal mucosal cell damage. Our data are supported by the work of
Vigneulle et al. in nonhuman primates who show that following radiation-
induced intestinal injury an ablation of intestinal epithelial stem cells leads to a
compensatory reduction in villus length (loss of total villous cell mass), which
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our work indicates to be accompanied by a reduction in loss of senescent cells
(cell turnover) 22. The compensatory regeneration of stem cells and villus
epithelial cells took more than five weeks to result in a complete recovery,
which is in line with our data on continuous low levels of circulating citrulline
after myeloablative conditioning 22. Our data indicate that the loss of senescent
cells prevails the complete recovery period.
Intestinal mucositis is a well known adverse effect of myeloablative
therapy, and a risk factor for mortality and relapse in patients undergoing
autologous stem cell transplantation, probably due to necessary reductions in
treatment intensity and sometimes cessation of treatment 23. New therapies to
treat this toxicity are being developed, which are aimed at protection and
enlargement of the enterocyte mass 24, 25. Combined measurement of the
turnover (serum FABP level) and mass (serum citrulline levels) of enterocytes
offers the new modality to evaluate such novel treatments in patients.
REFERENCES
1. Peterson DE, Cariello A. Mucosal damage: a major risk factor for severe complications
after cytotoxic therapy. Semin Oncol 2004; 31: 35-44.
2. Niscola P, Romani C, Cupelli L et al. Mucositis in patients with hematologic
malignancies: an overview. Haematologica 2007; 92: 222-231.
3. Blijlevens NM. Implications of treatment-induced mucosal barrier injury. Curr Opin
Oncol 2005; 17: 605-610.
4. Keefe DM, Brealey J, Goland GJ et al. Chemotherapy for cancer causes apoptosis that
precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47: 632-637.
5. Verburg M, Renes IB, Meijer HP et al. Selective sparing of goblet cells and paneth cells
in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol
2000; 279: G1037-1047.
6. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
7. Blijlevens NM, Lutgens LC, Schattenberg AV et al. Citrulline: a potentially simple
quantitative marker of intestinal epithelial damage following myeloablative therapy.
Bone Marrow Transplant 2004; 34: 193-196.
8. Lutgens LC, Blijlevens NM, Deutz NE et al. Monitoring myeloablative therapy-induced
small bowel toxicity by serum citrulline concentration: a comparison with sugar
permeability tests. Cancer 2005; 103: 191-199.
9. Crenn P, Coudray-Lucas C, Thuillier F et al. Postabsorptive plasma citrulline
concentration is a marker of absorptive enterocyte mass and intestinal failure in
humans. Gastroenterology 2000; 119: 1496-1505.
92
Chapter 3
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 92
10. van de Poll MC, Ligthart-Melis GC, Boelens PG et al. Intestinal and hepatic metabolism
of glutamine and citrulline in humans. J Physiol 2007; 581: 819-827.
11. Lieberman JM, Sacchettini J, Marks C et al. Human intestinal fatty acid binding protein:
report of an assay with studies in normal volunteers and intestinal ischemia. Surgery
1997; 121: 335-342.
12. Kanda T, Fujii H, Tani T et al. Intestinal fatty acid-binding protein is a useful diagnostic
marker for mesenteric infarction in humans. Gastroenterology 1996; 110: 339-343.
13. Derikx JP, Evennett NJ, Degraeuwe PL et al. Urine based detection of intestinal mucosal cell
damage in neonates with suspected necrotising enterocolitis. Gut 2007; 56: 1473-1475.
14. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of
tissue injury. Clin Chim Acta 2005; 352: 15-35.
15. Fujita M, Fujii H, Kanda T et al. Molecular cloning, expression, and characterization of
a human intestinal 15-kDa protein. Eur J Biochem 1995; 233: 406-413.
16. Watanabe K, Hoshi N, Tsuura Y et al. Immunohistochemical distribution of intestinal 15
kDa protein in human tissues. Arch Histol Cytol 1995; 58: 303-306.
17. Verburg M, Renes IB, Van Nispen DJ et al. Specific responses in rat small intestinal
epithelial mRNA expression and protein levels during chemotherapeutic damage and
regeneration. J Histochem Cytochem 2002; 50: 1525-1536.
18. Blijlevens NM, Donnelly JP, Naber AH et al. A randomised, double-blinded, placebo-
controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant
patients. Support Care Cancer 2005; 13: 790-796.
19. Schaap N, Schattenberg A, Bar B, et al. Outcome of transplantation for standard-risk
leukaemia with grafts depleted of lymphocytes after conditioning with an intensified
regimen. Br J Haematol 1997; 98: 750-759.
20. Derikx JP, Poeze M, van Bijnen AA et al. Evidence for intestinal and liver epithelial cell
injury in the early phase of sepsis. Shock 2007; 28: 544-548.
21. Bullen TF, Forrest S, Campbell F et al. Characterization of epithelial cell shedding from
human small intestine. Lab Invest 2006; 86: 1052-1063.
22. Vigneulle RM, Rao S, Fasano A et al. Structural and functional alterations of the
gastrointestinal tract following radiation-induced injury in the rhesus monkey. Dig Dis
Sci 2002; 47: 1480-1491.
23. Fanning SR, Rybicki L, Kalaycio M et al. Severe mucositis is associated with reduced
survival after autologous stem cell transplantation for lymphoid malignancies. Br J
Haematol 2006; 135: 374-381.
24. Blijlevens NM, Sonis ST. Palifermin (recombinant keratinocyte growth factor-1): a
pleiotropic growth factor with multiple biological activities in preventing
chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817-826.
25. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol 2007;
19: 323-327.
93
New markers for gut wall integrity in health and disease
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 93
3.4 Does gut damage occur
around closure of gastroschisis
with bladder herniation?
Joep P. M. Derikx, Jolanda M. L. G Gehlen, Nicholas J. Evennett,
Mark A. H. B. M. van der Hoeven, Annemarie A. van Bijnen, Wim A. Buurman,
Erik Heineman
Submitted.
94
Chapter 3
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 94
ABSTRACT
Reduction of organs during gastroschisis repair is often accompanied by
elevated abdominal pressure, subsequent splanchnic mucosal hypoperfusion
and intestinal epithelial cell damage, leading to complications as abdominal
compartment syndrome, necrotizing enterocolitis and ventilator dependence.
Furthermore, postoperative initiation and increase of enteral nutrition are at
present guided by observation and physical examination, which have
limitations. We report a patient with gastroschisis with rarely observed
association of a bladder evisceration. The defect was effectively primarily
closed guided by measurement of abdominal pressure by an indwelling urinary
catheter. Intestinal mucosal cellular condition was monitored by assessment of
urinary I-FABP. The reduction of organs did neither lead to increased I-FABP
levels, nor to elevated intravesical pressure. Oral feeding could be started and
increased successfully postoperatively. The level of urinary I-FABP was
associated with intestinal functional recovery.
This case shows that intestinal mucosal cell damage, which is a major
source of complications during and after gastroschisis repair, did nor occur
during primary closure of the abdominal wall after gastroschisis, neither during
the start and increase of enteral feeding.
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INTRODUCTION
With an incidence of approximately 1:9000 live births, gastroschisis is a
relatively common congenital disorder. 1 Diagnosis and treatment have become
well standardized and good survival data are reported for the majority of
patients. However, postoperative complications still occur, including necrotizing
enterocolitis (NEC), bowel infarction, and ventilator dependence. 1 It has been
suggested that most of these complications after reduction of organs result from
increased intra-abdominal pressure, leading to abdominal compartment
syndrome, which causes inadequate perfusion and subsequent damage of the
highly susceptible luminal surface of the intestinal mucosa. 1, 2 Gastric
tonometric assessment of gastro-intestinal mucosal hypoperfusion and
intravesical bladder monitoring, an indirect assessment of intra-abdominal
pressure, are invasive tools that have been reported to allow estimation of intra-
abdominal pressure and to predict the safety of primary and secondary
closures. 2, 3 Furthermore, postoperative initiation and increase of enteral
nutrition are at present guided by observation and physical examination, which
have their limitations. Therefore, there is a clinical need to study the intestinal
mucosal condition shortly after closure of the abdominal wall as well as the
condition of the intestinal mucosa during start and increase of enteral nutrition.
Recently we showed that urine based detection of intestinal mucosal cell
damage in neonates is possible with the use of Intestinal Fatty Acid Binding
Protein (I-FABP). 4 The small cytosolic I-FABP is a protein specifically present in
mature enterocytes of small and large intestine and released as soon as the cell
membrane integrity is compromised after episodes of acute intestinal ischemia
and inflammation. 4, 5 Due to its small molecular weight (14-15 kDa), I-FABP
present in the systemic circulation passes the glomerular filter (fractional renal
excretion: 28%, half-life time: 11 minutes 6) and can readily be detected in
urine. I-FABP is not expressed in the urinary tract mucosa. In 17 prematures
with gastrointestinal symptoms suspicious for NEC urinary I-FABP proved to be
a simple, non-invasive marker enabling early and specific detection of intestinal
mucosal cell damage, a hallmark of NEC. 4 Therefore, neonates who ultimately
developed NEC could be distinguished in an early stage from the neonates who
finally developed other neonatal diseases that present with abdominal signs,
such as sepsis and constipation. 4 In conclusion, urinary values of I-FABP
provide actual information on intestinal mucosal cell damage. This new non-
invasive diagnostic tool was used to monitor the intestinal mucosal condition in
a patient who presented with gastroschisis.
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CASE REPORT
A 3060-g female infant was born at 38 1/7 weeks of gestation by caesarean
section after antenatal diagnosis of gastroschisis. The parents were consanguine
and from Turkish origin. At inspection, the gastroschisis surprisingly included
evisceration of stomach, colon, small bowel, bladder, uterus, Fallopian tubes
and ovaries (Fig. 1). At 3 hours after birth, the baby underwent surgery. Intra-
operative measurement of abdominal pressure was performed with an
indwelling urinary catheter to monitor the development of increased intra-
abdominal pressure. 3 During surgery, malrotation was found accompanied by
a very small descending colon, without signs of atresia. The defect of the
abdominal wall was 3 cm. Reduction of the organs could easily be performed,
after manual stretching of the abdominal wall, where after the defect was
closed primarily. The maximal intravesical pressure during the operation was 18
mm Hg. The intravesical pressure one day after surgery was decreased to 13
mm Hg. Ventilatory support was abandoned within 24 hours after surgery. Four
days after surgery, minimal enteral feeding was started without problems.
The baby made excellent clinical progress during the first three weeks and
was transported from the Neonatal Intensive Care Unit (NICU) to the Medium
Care Unit. Enteral feeding was introduced progressively.
At day 21 the neonate developed fever with thrombocytopenia. Blood
cultures were positive for Enterobacter cloacae. An abdominal ultrasound was
performed in search for the source of the sepsis. While no gut abnormalities or
abnormal fluid collections were noted, significant hepatosplenomegaly and
distension of the gallbladder full of sludge were observed. The differential
diagnosis included among others secondary hemophagocytic lymphioblasto-
cytosis, because of the sepsis, the Turkish ethnicity, the thrombocytopenia and
hepatosplenomegaly. However, the definite diagnosis could not be established
because the infant died 36 days after surgery, despite receiving multiple
aggressive antibiotic regimes. Consent for autopsy was not obtained.
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Figure 1: Gastroschisis with evisceration of stomach, colon (C), microcolon (MC), small bowel
(SB), bladder (B), uterus (U), Fallopian tubes (F) and ovaries.
Spot urine samples were collected daily using a bag-catch method until
increased enteral feeding was tolerated successfully and the neonate was
transferred from the NICU to the Medium Care Unit after the gastroschisis
repair. Urinary I-FABP was measured using a commercially available I-FABP
ELISA that selectively detects human I-FABP (standard: 20-5,000 pg/ml), kindly
provided by HBT (Uden, the Netherlands). Measurement of urinary creatinine
was performed by the department of clinical chemistry in our hospital to correct
for the dilution. In a previous study, a value of 2 pg/nmol for the urinary I-FABP
(pg/ml) to Creatinine (Cr, µmol/ml) ratio allowed us to distinguish NEC or
intestinal necrosis from other gastro-intestinal diagnosis. 4 Written consent was
obtained from both parents prior to inclusion, and the study was conducted
with approval from the local medical ethical committee.
During the first two days after the gastroschisis repair, the urinary I-
FABP:Cr of the patient was below the detection limit, indicating that the
reduction of the organs did not lead to intestinal mucosal cell damage (Fig. 2).
Two days after the operation, a small rise in urinary I-FABP:Cr from below the
detection limit to 1.25 pg/nmol was found and remained stable during the next
two days, after which a decline was found. Interestingly, increase of the enteral
feeding, did not lead to changed urinary I-FABP:Cr levels. This observation
correlates very well with the peri-operative low intravesical pressures and
beneficial clinical data, such as normal temperature, good toleration of
initiation and advancement of enteral feeding.
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Figure 2: Reduction of herniated organs and increase of enteral feeding did not lead to
significantly elevated urinary I-FABP:Creatinine levels, reflecting intestinal mucosal cell damage.
DISCUSSION
Gastroschisis is a paraumbilical abdominal wall defect with unknown
aetiology, usually right sided, through which intra-abdominal contents,
commonly the intestines and stomach, eviscerate. There may be also herniation
of the liver and the spleen, the Fallopian tubes, ovaries, testicles and bladder. 1
The here reported herniation of the bladder is rarely observed. In an 18 year
review by Novotny et al. 69 patients were studied, three (4.3%) had bladder
evisceration. 7
Fear described in 1878 a surgical repair of gastroschisis consisting of
primary closure with fatal outcome. In 1966 Izant et al described manual
stretching of the abdominal wall to enlarge the abdominal cavity. 8 This
technique is still used today, and was also performed in our case. In 1967
Schuster et al. described the first method of staged closure. 9 Since Moore and
Stokes described in 1953 the physiologic consequence of increased intra-
abdominal pressure on pulmonary function, surgeons have tried to minimize
the sudden increased abdominal pressure after closure of the abdominal
wall. 10
So far, diagnosis of elevated intra-abdominal pressure during and after
reduction of organs is based on invasive, indirect measures such as
determination of bladder pressure and gastric mucosal PiCO2.
2, 3 Previous
studies showed that visceral circulation is well preserved when intra-abdominal
pressure does not exceed 20 mm Hg with reduced gastro-intestinal and
pulmonary related morbidity and mortality as result. 3, 11
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Increased intra-abdominal pressure leads to hypoperfusion of the intra-abdominal
organs including the kidneys and gastrointestinal tract. 2 The intestinal mucosa is
particularly susceptible for hypoperfusion-induced damage and is believed to be
a major cause of complications in these patients. Therefore, assessment of
intestinal mucosal damage may be an early indicator of increased intra-
abdominal pressure with reduced splanchnic blood flow and postoperative
complications. In a previous study, we showed that splanchnic hypoperfusion
correlates significantly with the release of small cytosolic proteins specifically
located in mature enterocytes (I-FABP) into the circulation and urine. 12 In line
with these data, this case shows that reduction of the eviscerated organs and
primary closure did neither lead to an increase of intra-abdominal pressure,
measured by bladder pressure, nor to a significant elevation of urinary I-FABP:Cr
levels. Furthermore, the start and increase of enteral feeding was not
accompanied by significant alteration of urinary I-FABP:Cr levels. The minimally
changing urinary I-FABP:Cr ratio is a representative of the continuous release of
FABP originating from mature detaching or dying enterocytes or in other words
the normal physiologic turnover of enterocytes. 13 Unfortunately, this case report
does not provide data on intestinal epithelial cell damage after enteral feeding
was tolerated successfully and the neonate was transferred from the NICU to the
Medium Care Unit after the gastroschisis repair. Of course, it would have been
interesting to determine the ratio of urinary I-FABP:Cr when the neonate became
septic and subsequently died, especially since this would have revealed whether
the origin of sepsis would have been based on intestinal ischemia. However, the
aim of the study was to determine intestinal mucosal cell damage with a non-
invasive test during gastroschisis-repair until full enteral feeding was reached.
This case shows that intestinal mucosal cell damage, which is a major
source of complications during and after gastroschisis repair, did nor occur
during primary closure of the abdominal wall after gastroschisis, neither during
the start and increase of enteral feeding. Further research into the value of the
prospective measurement of urinary I-FABP in neonates with gastro-intestinal
compromise will determine its role as a non-invasive diagnostic tool of the
intestinal mucosal condition.
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ABSTRACT
Background
Diagnosis of acute appendicitis (AA) remains a surgical dilemma, with negative
appendectomy rates of 5–40%, and perforation suggestive for late operative
intervention in 5-30%. The aim of this study is to evaluate new plasma markers,
representing early neutrophil activation, to improve diagnostic accuracy in
patients suspected for AA.
Methods
Sixty patients who underwent surgery for suspected AA were included
(M:F=31:29) and blood sampled. Plasma concentrations of three neutrophil
proteins were measured: myeloperoxidase (MPO), lactoferrin (LF) and
calprotectin (CP). Controls consisted of 27 healthy volunteers.
Results
Mean plasma concentrations for MPO, LF and CP were significantly higher in
51 patients with proven AA (respectively: 107ng/ml, 983ng/ml, 824ng/ml), than
in 27 healthy volunteers (respectively: 48ng/ml, p<0.01; 210ng/ml, p<0.001;
248ng/ml, p<0.001). The plasma concentration for CP was significantly higher
in 51 patients with proven AA, than in 9 patients without proven AA (824ng/ml
versus 426ng/ml, p<0.05). Area under the curve of MPO, LF and CP was 0.81,
0.95 and 0.91. Cut-off values, evaluated with ROC curves for MPO (54ng/ml),
LF (310ng/ml) and CP (385ng/ml), showed clinically relevant positive
likelihood ratios (LRs) of 2.81, 8.60, 6.86 and negative LRs of 0.33, 0.16, 0.05,
respectively.
Conclusion
The circulating neutrophil activation product CP is significantly increased in
patients with proven AA compared to patients without proven AA and healthy
volunteers, making CP a promising new marker for AA diagnosis.
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INTRODUCTION
Acute appendicitis (AA) is a common clinical entity with significant morbidity
and mortality, particularly at the extremes of age, mainly because of the
atypical clinical presentation leading to a low diagnostic and therapeutic
accuracy 1-3.In general, the risk of 2 primary adverse outcomes must be
balanced in diagnosis and consequent management of suspected AA: firstly,
misdiagnosis leads to removal of a normal appendix and secondly, delayed
diagnosis may lead to perforation and peritonitis. Since delayed diagnosis and
treatment of AA are associated with an increased rate of perforation, with
resulting increased morbidity and mortality rates, timely intervention is crucial
1.To reduce the risk of appendiceal perforation, surgeons have traditionally
favored early appendectomy. As a consequence, the appendix is normal in
approximately 5-40 % of patients who undergo explorative laparotomy for
suspected AA 4.However, perforation of an inflamed appendix still occurs in 5-
30 % of patients treated surgically for suspected AA 4.
To improve the diagnostic accuracy of patients suspected for AA, the value
of diagnostic imaging modalities and conventional inflammatory parameters
has been studied. Studies performed in research environments report good
results for diagnostic imaging in patients with clinically high probability of AA
5-7. However, a population-based cohort study showed that the frequency of
misdiagnosis leading to unnecessary appendectomy and the frequency of
perforation did not change with the introduction of computed tomography and
ultrasonography 8. No major improvement of diagnostic accuracy was found
using white blood cell count (WBC) and C-reactive protein (CRP) 9, 10.
The pathophysiology of AA is characterized by defects in or increased
permeability of the mucosal barrier, leading to inflammation and concomitant
sequestration of large numbers of neutrophils into the gut wall 1.The neutrophil
proteins myeloperoxidase (MPO), lactoferrin (LF) and calprotectin (CP) are
released upon neutrophil activation and readily detectable in feces, as observed
in patients with inflammatory bowel disease 11-14. Appendicitis is an acute
inflammatory disease, which makes a fecal test too time-consuming and not
suitable for diagnosis of acute disease onset.
Diagnostic tests aim at discriminating between clinically “normal” and
“abnormal”. Research to develop new diagnostic tests should subsequently
answer the following research questions: Phase 1 question: Do patients with the
target disorder have different test results from normal individuals? The answer
requires comparison of test results among patients with the disease and people
known not to have the disease (healthy individuals). Phase 2 question: Are
104
Chapter 3
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 104
patients with certain test results more likely to have the target disorder than
patients with other test results? This question is also answered by comparison of
test results among patients with the disease and healthy individuals, but now
test characteristics such as sensitivity, specificity and likelihood ratio are
estimated. Phase 3 question: Among patients in whom it is clinically sensible to
suspect the target disorder, does the test result distinguish those with and
without target disorder? To get the appropriate answer, a consecutive series of
such patients should be studied. Phase 4 question: Do patients who undergo
the diagnostic test fare better (in their ultimate health outcomes) than similar
patients who do not undergo the diagnostic test? The question have to be
answered by randomizing patients to undergo the test of interest or another (or
no) test 15.
This pilot study is the first to investigate the usefulness of circulating
neutrophil activation products MPO, LF and CP in diagnosing AA. Therefore we
address the phase 1 and 2 questions.
MATERIALS AND METHODS
Patients
From May 2004 to July 2005, 60 patients suspected for acute AA who
underwent appendectomy were consecutively included at the emergency
department of the University Hospital of Maastricht (31 males, 29 females;
mean age 33 years, age range 6-77 years). Also 27 healthy volunteers were
included in this study to obtain reference values for plasma concentrations of
MPO, LF, CP and CRP (20 males, 7 females; mean age 24 years, age range 3-
61 years). Informed consent was obtained from each participant, and the study
was approved by the local ethics committee.
On admission to the emergency department EDTA plasma samples were
collected and stored at -20°C until analyses. Diagnosis was based on findings
during surgery and histopathological examination of the appendix. Finally, 2
groups were identified. Group 1, patients with proven AA, is the group with
confirmed appendicitis by histopathology, (n=51, 28 males, 23 females; mean
age 34 years, range 6-77 years). Out of the 51 appendicitis specimens, 4 (8%)
showed acute mucosal inflammation indicating catarrhal appendicitis. Thirty-
seven (72.5%) showed signs of a suppurative (phlegmonous) appendix, and in
10 cases (19.5%) the final diagnosis of a gangrenous (necrotizing) appendix
was defined. Group 2, patients without proven AA, consists of patients with
suspicion of appendicitis without AA (n=9, 3 males, 6 females; mean age 30
years, age range 11-52 years), based on findings during laparoscopic surgery
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(n=3) or histopathological examination (n=6). The diagnoses in these patients
without AA were gynaecological problems (n=2), diverticulitis (n=1), fecal
impaction (n=1), unknown (n=5).
Methods
MPO, LF and CP concentrations in plasma samples were determined using
standard ELISAs kindly provided by HyCult biotechnology (Hbt, Uden, the
Netherlands). The detection limits for MPO, LF and CP were 4 ng/ml, 50 ng/ml
and 10 ng/ml, respectively. The human MPO, LF and CP ELISA kits are solid-
phase enzyme-linked immunosorbent assays based on the sandwich principle
with a working time of 3? hours. CRP and WBC concentration were measured
for routine patient care and retrospectively collected.
Statistics
Statistical analysis was performed with GraphPad Prism 4 for Windows (GraphPad
Software Inc., San Diego, CA). Normality was tested using Kolmogorov-Smirnov
test and normal distribution was found for plasma CP and WBC. The distribution
of plasma MPO, LF and CRP did not pass the normality test. Therefore, one-way
ANOVA, with post-hoc Bonferroni multiple comparison test, was used for
between group comparisons for CP. Unpaired T-test was used for WBC. Kruskal-
Wallis, with post hoc Dunn’s multiple comparison test, was used for between
group comparisons for MPO, LF and CRP. Data are presented as mean ± standard
error (SEM).
In order to find the cutoff points of plasma MPO, LF, CP and CRP levels
that most accurately discriminate patients with AA from healthy volunteers,
Receiver Operating Characteristics (ROC) curves were drawn by plotting
sensitivity against 1-specificity for all MPO, LF, CP and CRP thresholds. The
overall accuracy of the plasma markers was summarized using area under the
curve (AUC). Best cutoff point is defined as the maximum sum of sensitivity and
specificity. These cutoff points were used to calculate sensitivity, specificity,
positive and negative likelihood ratios (LRs). P<0.05 was considered statistical
significant.
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RESULTS
Of the 60 patients undergoing surgery for suspected AA, 51 had histopatho-
logically confirmed AA and 9 patients had a normal appendix confirmed during
surgery (n=3) or by histopathological examination (n=6). Mean plasma
concentrations for MPO, LF and CP were all higher in the 51 patients with
proven AA (respectively: 107 ± 12.07 ng/ml, 983 ± 154.7 ng/ml, 824 ± 70.03
ng/ml), than in 27 healthy volunteers (respectively: 48 ± 2.28 ng/ml, 210 ±
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Figure 1: MPO (a), LF (b), CP (c) and CRP (d)
plasma concentrations for patients with suspected
AA undergoing surgery with final diagnosis
appendicitis, non-appendicitis and for healthy
volunteers. WBC (e) plasma concentrations for
patients with suspected AA undergoing surgery
with final diagnosis appendicitis and non-
appendicitis. Plasma samples are collected on
admission to the emergency department.
(Outcome is reported as mean ± SEM)
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18.30 ng/ml, 248 ± 22.17 ng/ml, p<0.001) (Figure 1a, b and c). The plasma
concentration for CP was significantly higher in 51 patients with proven AA,
than in 9 patients without proven AA (824 ± 70.03 ng/ml versus 426 ± 83.86
ng/ml, p<0.05), while there was no statistically significant difference in MPO
and LF plasma concentration between patients with proven AA and patients
without proven AA (respectively: 107 ± 12.07 ng/ml versus 61 ± 12.16 ng/ml
and 983 ± 154.7 ng/ml versus 392 ± 36.56 ng/ml, p>0.05).
The ideal cut-off values evaluated with ROC to discriminate patients with AA
from healthy volunteers yielding the maximum sum of sensitivity and specificity,
for MPO (54ng/ml), LF (310ng/ml) and CP (385ng/ml), showed a specificity of
73%, 90%, 86% and a sensitivity of 76%, 86%, 96%, respectively (Figure 2). This
resulted in positive LRs of 2.81, 8.60, 6.86 and negative LRs of 0.33, 0.16 and
0.05, respectively. The area under the curve for MPO, LF and CP in the diagnosis
of AA was 0.81 (0.71-0.91), 0.95 (0.90-1.0) and 0.91 (0.85-0.98) (Table 1).
Mean plasma concentration for CRP was higher in the 51 patients with
proven AA (94.9 ± 15.54 ng/ml), than in 27 healthy volunteers (13.4 ± 0.90 ng/ml,
P<0.01) (Figure 1d). The ideal cut-off value evaluated with ROC to discriminate
patients with AA from healthy volunteers for CRP showed a specificity of 75% and
a sensitivity of 76%. The resulting positive LR was 3.04 and the negative LR was
0.32. The area under the curve was 0.77 (0.66-0.88) (Table 1).
Both CRP and WBC plasma concentrations were not statistically significant
different between patients with proven AA and patients without proven AA
(respectively: 94.9 ± 15.54 ng/ml versus 52.1 ± 25.04 ng/ml and 16.8*109 ±
0.64*109/L versus 14.8*109 ± 2.69*109/L, p>0.05) (Figure 1d and e).
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Table 1: Overall accuracy (AUC) and cutoff points, defined as the maximum sum of sensitivity and
specificity, using ROC curves, with corresponding sensitivity, specificity, positive and negative LRs
for MPO, LF and CP to differentiate between patients with appendicitis and healthy volunteers.
Conc.
Marker (ng/ml) Sensitivity Specificity LR+ LR- AUC (95% CI)
MPO 54.1 0.76 0.73 2.81 0.33 0.81 (0.71-0.91)
LF 309.6 0.86 0.90 8.60 0.16 0.95 (0.90-1.0)
CP 384.6 0.96 0.86 6.86 0.05 0.91 (0.85-0.98)
CRP 15.9 0.76 0.75 3.04 0.32 0.77 (0.66-0.88)
MPO = myeloperoxidase, LF = lactoferrin, CP = calprotectin, CRP = C-reactive protein, LR =
likelihood ratio.
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DISCUSSION
Early and correct diagnosis for appendicitis is crucial at the one hand to prevent
perforation with resultant morbidity, and at the other hand to avoid unnecessary
surgery. Surgeons rely on disease history and clinical examination for
diagnosing AA. Laboratory investigations (CRP, WBC) and expensive advanced
imaging techniques can help to improve diagnostic accuracy. As promising as
these tests might seem, diagnostic accuracy improved only marginally in recent
decades and as a consequence both negative appendectomy rates and
perforation rates remain high 4, 8. In line with recent literature the sensitivity,
specificity and LRs for CRP reported in this study are not sufficient for
diagnosing appendicitis with a very high probability.
In this pilot study, addressing the phase 1 and 2 question, to analyze new
tests for the diagnosis of AA we evaluated the usefulness of the neutrophil
activation markers MPO, LF and CP to improve diagnostic accuracy in patients
with suspected AA. The tests are relatively simple and cheap ELISA assays that
can be performed in clinical laboratories within 4 hours. The proteins showed
clinically relevant positive LRs, especially for LF and CP, and negative LRs. LRs
are used and considered as most important for evaluation of a clinical test,
because they summarize information on both sensitivity and specificity and
provide discriminative power of the test. LRs are clinical relevant and
applicable because they change the diagnostic probability to a working
diagnosis, showing how a particular test result predicts the risk of disease.
Furthermore LRs are independent of the prevalence of disease among the
studied patients, unlike positive and negative predictive values, and can
therefore be generalized to other settings 16, 17.
Elevated WBC levels measured in patients with appendicitis are mainly
caused by increased neutrophil numbers. During appendicitis the transformation
of neutrophils from passively circulating cells to potent effector cells is
mediated by exocytosis of granules and cytosolic proteins leading to the release
of MPO, LF and CP. Therefore, we consider neutrophil activation products more
specific for detection of appendicitis then WBC. Neutrophil granules contain
antimicrobial and potentially cytotoxic substances that are delivered to the
exterior of the cell following degranulation. MPO and LF are present in
polymorphonuclear neutrophil granules. MPO (150 kDa) is a microbicidal
hemoprotein stored in azurophilic granules of neutrophils and macrofages.
MPO produces hypochlorous acid and tyrosyl radicals, both cytotoxic agents
that kill bacteria 18. LF (78 kDa) is a glycoprotein mainly stored in specific
granules. Upon activation it is called lactoferricin and possesses antimicrobial
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activity against a broad spectrum of Gram-positive and Gram-negative bacteria.
The antimicrobial activity is exerted by impairment of bacterial growth by
sequestration of iron, and by causing bacterial cell lysis by binding to the cell
membrane 18. CP (36 kDa) is a heterodimer of two calcium binding cytosolic
proteins, MRP14 and MRP8, constituting 60% of soluble proteins in
neutrophils. CP is released upon neutrophil activation, and has bacteriostatic
and cytokine-like effects in the local environment 12. CP is also present in
monocytes and mucosal epithelial cells 19.Therefore leakage of epithelial cells
can also contribute to elevated plasma levels of CP. Recently Sudan et al.
showed that fecal CP is a useful marker for intestinal allograft monitoring 19.
Fecal CP levels were significantly higher in patients with allograft rejection than
in patients with viral or non-specific enteritis. Research on inflammatory bowel
disease showed elevation of fecal CP in patients with active disease, with good
correlation between amount of CP and the degree of mucosal damage
measured endoscopically and between amount of CP and the extensiveness of
inflammation assessed by leukocyte scan 13, 20, 21.
CP is the most promising marker for diagnoses of acute appendicitis, with
high positive LR and a low negative LR. Relevant characteristics of CP in this
respect are the fact that it is released immediately upon inflammation and
epithelial cell damage, both present in appendicitis. In this study the phase 1
and 2 questions comparing test results between patients with appendicitis to
healthy controls are answered. Furthermore CP plasma levels are significantly
higher in patients operated for suspected AA with final diagnosis AA compared
to patients without AA. In conclusion; a relatively simple and low cost ELISA
assay seems of value for diagnosing AA.
Next step is to study the phase 3 question; the accuracy of these markers
in all patients admitted to the hospital with a clinical suspicion of AA.
Furthermore, we suggest that a single marker may not be sufficient for
diagnosing appendicitis with a very high probability. Further tests should be
developed to combine these with the promising marker CP and thereby achieve
even higher likelihood ratios.
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3.6 Urine based detection of
intestinal mucosal cell damage in
neonates with suspected
necrotising enterocolitis
Joep P. M. Derikx, Nicholas J. Evennett, Pieter L. J. Degraeuwe, Twan L. Mulder,
Annemarie A. van Bijnen, L. W. Ernest van Heurn, Wim A. Buurman,
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Necrotizing Enterocolitis (NEC) is a severe gastrointestinal disease with a
mortality of 20-40%, affecting predominantly premature neonates. 1 In
particular in the early phase of the disease, NEC continues to present a
considerable diagnostic challenge to the attending clinician. The signs and
symptoms of NEC are frequently non-specific, including gastro-intestinal
problems such as abdominal distension and feeding intolerance, which are also
amongst the most prevalent presenting features in neonatal sepsis. 2 The
diagnosis is further hampered by the limited diagnostic accuracy of the
laboratory and radiological tests currently in use. 3,4
Histopathologically, NEC is characterized by intestinal coagulative or
ischemic necrosis, starting at the mucosa and extending into the submucosa
and muscularis externa. 1 We sought a non-invasive test to find evidence of
enterocyte cell death in infants with gastrointestinal symptoms suspicious for
NEC, in order to differentiate NEC from other neonatal diseases that present
with abdominal signs.
Intestinal Fatty Acid Binding Protein (I-FABP) has been reported to be a
useful plasma marker for early enterocyte cell death. 5,6 The small (14-15 kDa)
cytosolic I-FABP is specifically present in mature enterocytes of small and large
intestine and released as soon as the cell membrane integrity is compromised.
I-FABP is present in very low amounts in plasma of healthy individuals, likely
representing the normal turnover of enterocytes, but levels rapidly rise after
episodes of acute intestinal ischemia and inflammation, including NEC. 5-8
Due to its small molecular weight, I-FABP present in the systemic
circulation passes through the glomerular filter (fractional renal excretion: 28%,
half-life time: 11 minutes) and can readily be detected in urine. 9 I-FABP is not
expressed in the urinary tract mucosa. Therefore, urinary values of I-FABP
provide specific information about the number of dying intestinal epithelial
cells. Given the age and birth weight of our population of interest, there are
important advantages to sampling urine instead of plasma. 10, 11
Over an 18 month period, 17 consecutive neonates were identified in the
neonatal intensive care unit at the University Hospital Maastricht, in whom
NEC was suspected. Inclusion criteria were the presence of at least one clinical
gastrointestinal sign (abdominal distension or discoloration, increased gastric
residues, bloody stools), causing sufficient clinical concern to require an
abdominal X-ray (AXR), and/or to stop enteral feeding. Written consent was
obtained from both parents prior to inclusion, and the study was conducted
with approval from the local medical ethical committee.
Urine was collected daily using a bag-catch method for at least one week
once appropriate consent was obtained. All neonates produced urine at a
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minimal rate of 1.9 ml/kg/hr. Samples were centrifuged at 4,000 x G for 15
minutes, aliquoted and stored at -20ºC until analysis. Urinary I-FABP was
measured using a commercially available I-FABP ELISA that selectively detects
human I-FABP (standard: 20-5,000 pg/ml), kindly provided by HBT (Uden, the
Netherlands). Values were expressed as a ratio (units pg/nmol) of I-FABP (pg/ml)
to creatinine (Cr, µmol/l), in order to compensate for variations in the
concentration of the urine. Urinary I-FABP:Cr levels were compared between
neonates with NEC and other final diagnoses with Mann Whitney test.
Five out of the 17 infants with suspected NEC subsequently developed NEC
stage IIa (pneumatosis intestinalis on AXR, confirmed by a paediatric radiologist)
or higher. Of the remaining 12 patients suspected for NEC, there were seven
cases of sepsis, one ileal atresia with intestinal necrosis, two patients for whom
a diagnosis of constipation was ultimately given, one patient with Hirschsprung’s
disease, and finally one patient born with gastroschisis who later developed
signs and symptoms of NEC after gastroschisis-repair. In the neonates who
developed NEC, the average gestational age was 32 3/7 weeks, the average age
at diagnosis was 14 days, and the average birth weight was 1,500g. For the
neonates who subsequently received different diagnoses, the average gestational
age and weight were 30 4/7 weeks and 1,487g, respectively.
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Figure 1: In the first urine sample of neonates with suspected necrotising enterocolitis (NEC), the
mean urinary I-FABP:Cr ratio was significantly higher in neonates who ultimately developed NEC
or intestinal necrosis (3.9 pg/ nmol, range 2.3 to 6.6) than in those without NEC (1.2 pg/nmol,
range 0.1 to 1.8) (p= 0.001). Cr, creatine; I-FABP, intestinal fatty acid binding protein.
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In the first urine sample, the median urinary I-FABP:Cr ratio was significantly
higher in neonates who ultimately developed NEC or intestinal necrosis (3.9,
range: 2.3-6.6 pg/nmol) than in patients without NEC (1.2, range: 0.1-1.8
pg/nmol, p=0.001) (Fig 1). A value of 2 pg/nmol could distinguish neonates
with NEC or intestinal necrosis from the other neonates. None of the patients
without either NEC or intestinal necrosis were found to have an I-FABP:Cr ratio
in excess of 2 pg/nmol over the first week.
In the present study urinary I-FABP, a specific marker for intestinal
mucosal damage, was measured using ELISA to identify patients with NEC. This
study is the first to show that measurement of urinary I-FABP offers valuable
additional information in the early diagnosis of NEC. Furthermore, whilst
previous studies have assessed the feasibility of plasma I-(and L-)FABPs in
identifying patients with NEC when compared to healthy controls 7,8, this is the
first study which prospectively identifies neonates with NEC, amongst a
population of preterm infants who present with gastrointestinal symptoms.
In our small series, a value of 2 pg/nmol for the urinary I-FABP:Cr ratio
was accurate to distinguish the group with NEC or intestinal necrosis from the
other diagnoses.
NEC is a complex and likely multi-factorial disease for which the
aetiology remains incompletely understood. However, intestinal epithelial cell
death is an important early hallmark 1 which is in line with the observed
increased urinary I-FABP. Moreover, normalization of the urinary I-FABP:Cr
ratio correlated well with clinical improvement, at least in the short term.
Given the ease and frequency with which urine can be collected, without
adverse consequences for the baby, the feasibility of urinary I-FABPs as a
screening tool for NEC needs to be further evaluated in a prospective trial.
Finally, as the cumulative release of I-FABP can be used to estimate the extent
of intestinal damage, it may also help to guide treatment strategies, such as the
timing of surgery (if required), the duration of antibiotic therapy, and selecting
the ideal time at which enteral feeding should be re-initiated.
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ABSTRACT
Background
Diagnosis of the severe gastrointestinal neonatal disease necrotising
enterocolitis (NEC) remains challenging since clinical, radiological and
laboratory markers lack specificity. The aim of this study is to improve
diagnostic accuracy for diagnosing NEC by using non-invasive markers
representing important histopathological factors; gut wall integrity loss (urinary
I-FABP and urinary claudin-3) and gut wall inflammation (faecal calprotectin).
Methods. Twenty-nine consecutive neonates suspected for NEC were
included and urine and faeces samples were collected. Urinary concentrations
of I-FABP and claudin-3 and faecal concentration of calprotectin were
measured.
Results
Twelve of the 29 neonates suspected for NEC developed NEC Bell stage IIA or
higher. The other patients had sepsis (13), obstipation (1), morbus Hirschsprung
(1), gastroschisis (1) and colitis (1). Mean I-FABP, claudin-3 and calprotectin
levels were significantly higher in neonates with NEC (5.75 ± 0.84 pg/nmol;
1267.0 ± 175.6 INT; 519.3 ± 106.7 ug/g faeces) than in neonates with other
final diagnosis (0.85 ± 0.64 pg/nmol, p<0.0001; 459.2 ± 108.1 INT, p=0.0003;
103.9 ± 39.29 ug/g faeces). Area under the receiver operating characteristic
curve of I-FABP, claudin-3 and calprotectin was 1.0 (p<0.001), 0.84 (p=0.002)
and 0.94 (p=0.001).
Conclusion
The urinary markers I-FABP and claudin-3, representing gut wall integrity loss,
and the faecal marker calprotectin, representing gut wall inflammation, were
significantly increased in neonates with NEC compared to neonates with other
final diagnosis, making them promising new markers for early diagnosis for
NEC.
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INTRODUCTION
Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease with a high
morbidity and mortality (20-40%), affecting predominantly premature neonates 1.
NEC continues to present a diagnostic challenge to clinicians, in particular in the
early phase of the disease. The initial clinical manifestations of NEC, including
gastro-intestinal problems such as abdominal distension and feeding intolerance,
are frequently non-specific and indistinguishable from other gastrointestinal
disorders and sepsis 2. The diagnosis is further hampered by the limited diagnostic
accuracy of the laboratory and radiological tests currently in use 3, 4.
NEC is pathofysiologically characterized by defects in or increased
permeability of the intestinal epithelial barrier, leading to inflammation 1, 5. We
sought non-invasive tests to find evidence of loss of the intestinal epithelial
lining and gut wall inflammation in neonates with gastrointestinal symptoms
suspicious for NEC, in order to differentiate NEC from other neonatal diseases
that present with abdominal signs. Therefore, we used urinary and faecal
markers to study the condition of enterocytes and tight-junctions, the two
components comprising the intestinal epithelial lining, and intestinal wall
inflammation in neonates suspected for NEC.
Intestinal Fatty Acid Binding Protein (I-FABP) has been reported to be a
useful plasma marker for enterocyte cell damage 6, 7. I-FABP, a small (14-15
kDa) cytosolic, water-soluble protein, is specifically present in mature
enterocytes of small and large intestine and is released as soon as the cell
membrane integrity is compromised. I-FABP is present in low amounts in
plasma of healthy individuals, likely representing the normal turnover of
enterocytes, but levels rapidly rise after episodes of acute intestinal ischemia
and inflammation, including NEC 6-9. Due to its small molecular weight, I-FABP
present in the systemic circulation passes through the glomerular filter
(fractional renal excretion: 28%, half-life time: 11 minutes) and can readily be
detected in urine 10. I-FABP is not expressed in the urinary tract mucosa.
Therefore, urinary values of I-FABP provide specific information about the
number of dying intestinal epithelial cells.
The intestinal epithelial lining is also formed by tight junctions between
neighbouring enterocytes. These tight junctions consist of a large complex of
intra- and extracellular proteins, including claudins (22kDa) 11, 12. Especially
claudin-3 is an important sealing claudin, expressed in high quantity in the
intestine 11. Claudin-3 is found to disappear rapidly from the tight junction
following hemorrhagic shock and intestinal inflammatory disease and is
released into the urine 13 (own unpublished data).
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In the early phase of NEC, the disease is characterized by both loss of intestinal
epithelial lining and intestinal inflammation with sequestration of large
numbers of neutrophils into the gut wall 1, 5. Intestinal neutrofielinflux and
–activation causes degranulation of calprotectin, a heterodimeric peptide (36
kDa) constituting 60% of cytosolic content of neutrophils. After neutrophil
degranulation, calprotectin is readily detectable in faeces and plasma.
Furthermore it is remarkably resistant to degradation by faecal bacteria, making
faecal calprotectin a suitable marker for gut wall inflammation 14-16.
This study aims at improving diagnostic accuracy for diagnosing NEC, by
using non-invasive tests to find evidence of gut wall integrity loss and gut wall
inflammation in infants with gastrointestinal symptoms suspicious for NEC.
Given the age and birth weight of our population of interest, there are important
advantages to sampling urine and faeces instead of plasma 17, 18.
PATIENTS AND METHODS
Patients and sample collection
Between July 2005 and March 2008, 29 consecutive neonates were identified
in the neonatal intensive care unit at the Maastricht University Medical Centre,
in whom NEC was suspected. Suspicion of NEC was defined as the presence of
abdominal distension, causing sufficient clinical concern to require an
abdominal X-ray (AXR), and/or to stop enteral feeding. Written consent was
obtained from both parents, and the study was conducted with approval from
the local medical ethical committee.
Urine and faeces was collected immediately upon suspicion of NEC. Urine
was obtained by placing a dental rolls cotton (Schein demedis dental, Almere, the
Netherlands) in the diaper of the neonate. Once the roll was filled with urine, it
was placed in a sterile 5 ml syringe (Becton Dickinson, Oxford, UK), expressed
into sterile Micronics (Micronic B.V., Lelystad, the Netherlands) and stored at -
20ºC until analysis. All neonates produced urine at a minimal rate of 1.9 ml/kg/hr.
Faeces was sampled from the diaper and frozen at -20ºC until analysis. Twenty-
one neonates produced stool within 12 hours after they were suspected for NEC.
Samples were taken an average 1.5 days before final diagnosis.
Markers for systemic inflammation
In order to study the usefulness of the classical systemic inflammatory markers in
the early diagnosis of NEC, platelet count, leukocyte count, and C-reactive protein
(CRP) were routinely determined in the first plasma upon suspicion of NEC by the
clinical chemistry laboratory of the Maastricht University Medical Centre+.
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Urinary I-FABP measurement
Urinary I-FABP was measured using a commercially available enzyme-linked
immunosorbent assays (ELISA) that selectively detects human I-FABP (standard:
20-5,000 pg/ml), kindly provided by Hycult Biotechnology (Uden, the
Netherlands). Values were expressed as a ratio (units pg/nmol) of I-FABP (pg/ml)
to creatinine (Cr, µmol/l), in order to compensate for variations in the
concentration of the urine.
Urinary claudin-3 measurement
Urinary claudin-3 levels were analyzed by western blotting. Equal amounts of
each sample (adjusted to urinary creatinine levels) were separated by SDS-
PAGE gel, transferred to PVDF-membrane and probed using primary antibody
to claudin-3 (Rabbit anti-Claudin-3 (34-1700), Zymed Laboratories, San
Francisco, CA). After incubation with goat anti rabbit HRP-conjugated
secondary antibody (Jackson, West Grove, PA), signal was detected by
supersignal west pico chemiluminescence substrate (Pierce, Etten-Leur, the
Netherlands). Band intensity was semi-quantitatively analyzed using Quantity
One (Biorad, Hercules, CA).
Faecal calprotectin measurement
After thawing of the faeces, 100 mg was weighed and 4.9 ml extraction buffer
(0.1M Tris, 0.15mM NaCl, 1.0M urea, 10mM CaCl2·2H2O, 0.1M citric acid,
0.5% BSA, pH 8.0) was added. After 30 minutes of shaking, 1 ml of the
suspension was centrifuged at 10,000 rpm for 20 minutes at 4ºC and the
supernatant was aliquoted and stored at -20ºC 19. The calprotectin
concentration was measured in the lysate using the commercially available
calprotectin ELISA (standard 0.78-50 ng/mL), kindly provided by Hycult
Biotechnology. The faecal concentration of calprotectin is given in µg
calprotectin per gram faeces.
Statistical analyses
Statistical analyses were performed with Prism 4.0 for Windows (GraphPad
Software Inc. San Diego, CA). Concentrations of the studied urinary and faecal
were presented as mean ± standard error (SEM). Normality of all data obtained
was verified by Kolmogorov-Smirnov test. Levels of the markers were compared
between neonates who ultimately developed NEC and neonates with other
final diagnoses using unpaired t-test.
Receiver operating characteristic (ROC) curves were used to study
diagnostic accuracy of the markers in detecting NEC, represented by area under
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the curve (AUC), with an AUC of 0.5 indicating no discrimination ability and
an AUC of 1.0 indicating maximal discrimination ability. A p-value below 0.05
was considered statistically significant.
The STARD statement for reporting studies of diagnostic accuracy were
used in this study 20 (figure 1).
RESULTS
Patient characteristics
Between July 2005 and March 2008, 29 consecutive neonates were identified
in the neonatal intensive care unit at the Maastricht University Medical Centre,
in whom NEC was suspected. Twelve of the 29 neonates ultimately developed
NEC Bell stage II (pneumatosis intestinalis on abdominal X-ray) or higher. Of
the remaining 17 patients suspected for NEC 13 patients had sepsis; one had
obstipation; one had morbus Hirschsprung; one had gastroschisis; one had a
colitis (table 1).
No significant differences were observed between the NEC group versus
the patient group with other final diagnoses in gestational age and birth weight
(table 1).
123
New markers for gut wall integrity in health and disease
Table 1: Characteristics of neonates suspected for NEC who ultimately developed NEC and other
final diagnoses. No statistically significant differences were observed between the two groups.
NEC Other diagnoses
Gestational age 31+1 weeks 31+6 weeks
Birth weight 1410 grams 1528 grams
Sex M:V= 8:4 M:V=8:9
Final diagnoses NEC ≥ Bell stage II (12) sepsis (13)
obstipation (1)
morbus Hirschsprung (1)
gastroschisis (1)
colitis (1)
Total 12 17
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Laboratory tests currently in use
Laboratory tests currently in use for diagnosing NEC in infants with
gastrointestinal symptoms suspicious for NEC are platelet count, leukocyte
count, and CRP. Platelet count and leukocyte count were not statistically
significant higher in the plasma samples of patients with NEC (254.3*103/l ±
96.5 and 12.2*103/l ± 2.5, respectively) than in the plasma samples of neonates
with other final diagnoses (190.9*103/l ± 30.83 and 13.2*103/l ± 2.3,
respectively, P>0.05) (figure 2A+B). Mean plasma CRP level was statistically
significant higher in the NEC group (125.8 mg/l ± 31.7) versus the patient group
with other final diagnoses (37.7 mg/l ± 11.9, p=0.0057) (figure 2C).
The area under the curve for CRP in the diagnosis of NEC was 0.82
(95%CI= 0.65-0.98, p=0.007).
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Figure 2: Laboratory tests currently in use: platelet
count (2A), leucocyte count (2B), CRP (2C). Plasma
platelet count and leucocyte count were not
different between neonates with NEC and neonates
with other final diagnoses. Mean plasma CRP level
was significantly higher in neonates with NEC.
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Urinary I-FABP levels was significantly higher in patients with NEC
Mean urinary I-FABP:Cr ratio was statistically significant higher in neonates
who eventually developed NEC (5.75 ± 0.84), than in those with other final
diagnoses (0.85 ± 0.64, p<0.0001) (figure 3A). Furthermore all neonates with
NEC had a urinary I-FABP:Cr value higher than 2 pg/nmol, whereas all
neonates without NEC had values below 2 pg/nmol. A value of 2 pg/nmol
discriminated between neonates with NEC and the remainder.
The area under the curve for I-FABP in the diagnosis of NEC was 1.00
(95%CI= 1.00-1.00, p<0.001).
Urinary Claudin-3 levels was significantly higher in patients with NEC
Recently it has been discovered that the detection of the tight junction protein
claudin-3 in the urine signifies the breakdown of intestinal tight junctions.
Therefore, the urinary excretion of claudin-3 was studied in neonates in whom
NEC was suspected. Mean urinary claudin-3 level was statistically significant
higher in neonates who eventually developed NEC (1267.0 ± 175.6), than in
those with other final diagnoses (459.2 ± 108.1, p=0.0003) (figure 3B).
Figure 3: New non-invasive test for diagnosing NEC.
A. Mean urinary I-FABP:Cr ratio was significantly
higher in neonates with NEC than in neonates with
other final diagnoses
B. Mean urinary claudin-3 level was significantly
higher in neonates with NEC than in neonates with
other final diagnoses
C. Mean faecal calprotectin level was significantly
higher in neonates with NEC than in neonates with
other final diagnoses
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The area under the curve for claudin-3 in the diagnosis of NEC was 0.84
(95%CI= 0.69-0.99, p=0.002).
Faecal calprotectin levels was significantly higher in patients with NEC
The mean calprotectin level was statistically significant higher in neonates who
eventually developed NEC (519.3 ± 106.7), than in those with other final
diagnoses (103.9 ± 39.29, p=0.0003) (figure 3C). One outliers was found in the
group of patients with other diagnoses than NEC. The patient with the highest
faecal calprotectin level in this group was a patient with a fulminate sepsis.
The area under the curve for faecal calprotectin in the diagnosis of NEC
was 0.94 (95%CI= 0.84-1.04, p=0.001).
DISCUSSION
Early and correct diagnosis for NEC is crucial at the one hand to prevent delay
in diagnosis of NEC and consequent morbidity and mortality, and at the other
hand to avoid over treatment in neonates suspected for NEC with other final
diagnosis. Neonatologists and (pediatric) surgeons rely on signs and symptoms
for diagnosing NEC. Laboratory investigations (CRP, WBC, platelets) and
advanced imaging techniques can help to improve diagnostic accuracy. As
promising as these tests might seem, diagnostic accuracy improved only
marginally in recent decades 3, 4. Therefore, we aimed at improving diagnostic
accuracy for diagnosing NEC by using markers representing important
histopathological factors; gut wall integrity loss and gut wall inflammation 1, 5.
Gut wall integrity loss was studied by measuring urine levels of I-FABP,
indicating epithelial cell damage and claudin-3, representing tight junction
loss. Faecal calprotectin was used to study gut wall inflammation. To investigate
the clinical usefulness of these markers we prospectively included all neonates
suspected with NEC. Our study showed that urinary I-FABP, urinary claudin-3
and faecal calprotectin were significantly higher in neonates suspected for NEC
who ultimately developed NEC compared to neonates with other final
diagnosis. The classical laboratory test plasma CRP also showed significantly
higher levels in neonates suspected for NEC who ultimately developed NEC
compared to neonates with other final diagnosis, in contrast leucocyte count
and platelet count could not differentiate between the two groups. Furthermore,
the overall accuracy of the markers tested was summarized using area under
the curve (AUC). The AUC of I-FABP was maximum (1.0), while the AUC of
calprotectin, claudin-3 and CRP were also high.
Furthermore, while previous studies have assessed the feasibility of using
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plasma I-FABP to identify patients with NEC compared with healthy controls,8,
9 this is the first study which prospectively identified neonates with NEC among
a population of preterm infants who presented with gastrointestinal symptoms.
One study showed that faecal calprotectin could differentiate between
neonates with NEC compared to healthy matched controls,5 while another
prospective study showed that faecal calprotectin could not identified neonates
with NEC among a population of neonates with a very low birth weight 21. Our
study shows diagnostic accuracy of faecal calprotectin in the early diagnosis of
NEC. This is the first study to use measurement of urinary claudin-3 in the early
diagnosis of NEC.
We choose not to combine the AUCs of the markers because I-FABP
already had maximum AUC, therefore it was impossible to get better results
with a combination of markers. Although I-FABP resulted in a maximal
distinction between the groups, we assume that measurement of the other
markers might contribute to the diagnosis of NEC. In this study we included 29
neonates suspected for NEC, an increased sample size could result in altered
AUCs of the markers which could necessitates combining the used markers.
All the new markers were tested in non-invasively collected material,
which is of great advanced compared to the plasma tests currently in use,
because blood withdrawal for diagnostics is the mean cause of anaemia in
neonates 17, 18.
Given the ease and frequency with which urine and faeces can be
collected without adverse consequences for the baby, the usefulness of urinary
I-FABPs, claudin-3 and faecal calprotectin will be evaluated in daily clinical
practice by prospective measurement of these markers in neonates suspected
for NEC.
Finally, as the cumulative release of I-FABP, claudin-3 and calprotectin can
be used to estimate the extent of intestinal damage, it may also help to guide
treatment strategies, such as the timing of surgery (if required), the duration of
antibiotic treatment, and selection of the ideal time for reintroducing enteral
feeding.
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CHAPTER 4
Gut wall integrity loss in critically
ill patients and in patients
undergoing major (non-abdominal)
surgery
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4.1 INTRODUCTION
To study the third aim: investigate the integrity of the gut wall in critically ill
patients and in patients undergoing major (non-abdominal) surgery, the gut wall
integrity was analyzed in 4 clinical studies. First, the development of intestinal
damage and its correlation with splanchnic perfusion was investigated in post-
surgical critically ill patients (paragraph 4.2). In the second study, the
occurrence of intestinal epithelial cell damage was investigated in critically ill
patients with meningococcal sepsis, a different primary source of sepsis
(paragraph 4.3). Third, the development of gut wall integrity loss was assessed
peri-operatively in patients undergoing major (non-abdominal) surgery, i.e.
repair of a thoraco-abdominal aneurysm of the aorta and spinal fusion repair
(paragraph 4.4 and 4.5, respectively). Two of the most extensive and complex
surgical procedures are open surgical repair of thoracic aortic aneurysms (TAA)
and thoracoabdominal aortic aneurysms (TAAA) that are associated with
significant postoperative morbidity and mortality. In order to prevent
peroperative ischemic injury of visceral organs, extracorporeal circulation
(ECC) technique has been implemented in open TAA repair to provide
(retrograde) distal aortic perfusion (DAP) via the femoral artery. In case of TAAA
repair involving the origin of visceral arteries, ECC with DAP is combined with
selective organ perfusion catheters (DAP and SP) to provide designated visceral
arteries directly with blood. Finally, the development of gut wall integrity loss
was studied in patients undergoing major spinal fusion surgery, which is
characterized by long operation time, significant blood loss, prolonged
systemic hypotension and the potential development of postoperative
complications. This type of surgery was chosen because it does not directly
compromise the intestines by intestinal manipulation or the use of
extracorporeal circulation.
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4.2 Evidence for intestinal
epithelial and liver cell injury in
the early phase of sepsis
Joep P. M. Derikx, Martijn Poeze, Annemarie A. van Bijnen, Wim A. Buurman,
Erik Heineman
Shock (2007) 28: 544-8.
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ABSTRACT
The development of sepsis and multiple organ failure (MOF) are important
determinants of the outcome in critically ill patients. Hepatosplanchnic
hypoperfusion and resulting intestinal and hepatic cell damage have been
implicated as central events in the development of sepsis and MOF. Our aim
was to study (1) the relation between intramucosal perfusion and intestinal and
hepatic cell damage in an early phase of sepsis, (2) the correlation of these
parameters with mortality. Two groups of patients were consecutively selected
after ICU admission: patients with postoperative abdominal sepsis (n=19) and
patients with pneumonia-induced sepsis (n=9). Intramucosal perfusion was
assessed by gastric tonometry (Pr-aCO2-gap, PiCO2). Circulating levels of
Intestinal Fatty Acid Binding Protein (I-FABP) and Liver (L)-FABP were used as
markers for respectively intestinal and hepatic cellular damage. Outcome was
determined on day 28. Pr-aCO2-gap correlated with I-FABP (Pearson’s r2=0.56,
p<0.001) in all patients and gastric mucosal PiCO2 correlated significantly with
I-FABP (r2=0.57, p=0.001) in patients with abdominal sepsis. At ICU
admission, non-survivors had significantly higher I-FABP and L-FABP values
than survivors (I-FABP: 325 vs. 76 pg/ml, p<0.04; L-FABP: 104 vs. 31 ng/ml,
p<0.04). Especially patients with abdominal sepsis were responsible for high
admission I-FABP and L-FABP levels in non-survivors (I-FABP: 405 vs. 85 pg/ml,
p<0.04; L-FABP: 121 vs. 59 ng/ml, p<0.04). This study shows that splanchnic
hypoperfusion correlates with intestinal mucosal damage and that elevated
plasma levels of I-FABP and L-FABP are associated with a poor outcome in
critically ill patients with abdominal sepsis.
134
Chapter 4
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 134
INTRODUCTION
Patients with systemic inflammatory response syndrome (SIRS) and sepsis have
an increased risk of developing multiple organ failure (MOF). Patients with these
clinical syndromes have the highest non-cardiac mortality rate of patients in the
intensive care unit (ICU) 1. Recognition of patients at risk of developing MOF is
therefore important. Especially patients undergoing major surgery often develop
systemic inflammatory response syndrome (SIRS) 2-4. Pathophysiological
phenomena in the hepatosplanchnic area as compromised hepatosplanchnic
perfusion leading to intestinal and hepatic damage have been widely postulated
to play a central role in the transition of SIRS and sepsis into MOF 5-9. Such a
cellular damage causes release of constitutive hepatic and intestinal proteins in
the circulation, which can act as “danger signals” and activate the immune
system, resulting in the amplification of a deleterious systemic inflammatory
response, which subsequently is responsible for MOF 10.
In this study, two of the above mentioned key factors of this hypothesis
have been objectivated clinically. Firstly, mucosal hypoperfusion was assessed
by gastric tonometry 11, an invasive measurement of increased tissue CO2
production, accompanying hypoperfusion 12. Secondly, cell damage of
intestinal and hepatic origin was recorded as plasma levels of Intestinal Fatty
Acid Binding Protein (I-FABP) and Liver-FABP (L-FABP). I-FABP is a plasma
marker for early intestinal epithelial cell damage as occurs during gut ischemia
reperfusion injury, chemical epithelial cell toxicity and intestinal transplant
rejection 13,14. The small (14-15 kDa) cytosolic I-FABP is solely present in
mature enterocytes of small and large intestine and released as soon as the cell
membrane integrity is compromised and appears rapidly in the circulation after
intestinal epithelial cell damage 13. L-FABP is present in low amounts in mature
enterocytes of small and large intestine and in abundance in the liver 15.
The aim of this preliminary prospective cohort study is to investigate the
relation between intramucosal oxygenation and perfusion deficits and intestinal
and liver damage, and mortality in critically ill patients with an early phase of
sepsis.
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MATERIALS AND METHODS
Patients
After approval of the study by the Ethical Committee, patients were
consecutively included after written informed consent by the next of kin. Patients
were included in the study during the first 24 hrs after admission to the intensive
care unit.
Two groups of septic patients were prospectively identified. Firstly, a high-
risk surgical patient group with a presumed impaired splanchnic perfusion
caused by postoperative peritonitis: the abdominal sepsis group. These patients
had four-quadrant peritonitis based upon intestinal leaks after primary
abdominal procedures. Secondly, a group without presumed impaired
splanchnic perfusion included patients with a non-abdominal derived sepsis
caused by pneumonia: the pneumonia-induced sepsis group. Both abdominal
and pneumonia-derived sepsis were primary reason for admission to the ICU.
The selection of these groups was made prior to the analysis of blood samples.
All patients suffered from septic shock, defined by systemic inflammatory
response syndrome (SIRS), for which two or more of the following criteria must
be positive: (1) tempe¬rature >38° or <36°C; (2) heart rate >90 bpm; (3)
respiratory rate >20 breaths per minute or PaCO2 <32 mmHg; (4) white blood
cell count >12,000 mm-3, <4,000 mm-3, or >10% immature (band) forms, plus
infection and hypotension despite adequate fluid resuscitation. Pneumonia was
defined by an infiltrate on chest radiograph, signs of SIRS and/or at least one of
the following: (1) positive quantitative culture of a sample obtained by
bronchoalveolar lavage (>104 cfu/ml) or protected specimen brush (>103
cfu/ml); (2) positive blood culture unrelated to another source and obtained
within 48h before and after respiratory sampling. Exclusion criteria were: age
<18 years, uncontrollable hemorrhage, cardiogenic shock, the presence of
neoplastic disease, or an underlying disease expected to be rapidly fatal.
Plasma samples were obtained at day 0-7, 14, 21 and 28 after admission
to ICU.
SOFA-score, hematological profiles and blood chemistry were daily
recorded. On day 28, outcome was determined by classifying each patient
either as survivor or non-survivor.
Sixty-nine healthy volunteers (M:F = 40:29) were recruited to establish
normal values for plasma I-FABP and L-FABP. Mean age was 48 years (range:
25-65 years).
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Measurements of gastric mucosal tonometry
A gastric tonometry catheter (14F, Datex Ohmeda, Finland) was introduced for
measurement of intramucosal carbon dioxide pressure (PiCO2 in kPa)
throughout the ICU stay, using the gas-automated capnograph (Tonocap TC-
200, Datex-Ohmeda, Finland).
Gastric tonometry measurements (PiCO2, and mucosal-arterial pCO2 gap
(Pr-aCO2-gap)) were measured at 10-minute intervals using gas-automated
capnography at the same time-intervals as blood was collected. The pCO2
values of the blood gases were corrected for the central blood temperature
measurements, using the formulas provided by the manufacturer (ABL 100,
Radiometer, Copenhagen). Patients were not fed enterally during the first 24
hours after admission to the ICU, and thereafter feeding was halted for 2 hours
before measurement of gastric mucosal tonometry.
Sample analyses
Plasma I-FABP and L-FABP were determined using highly specific commercially
available enzyme-linked immunosorbent assays (ELISA) (kindly provided by
Hycult Biotechnology, Uden, the Netherlands). AST and ALT were determined
by the clinical chemistry laboratory of the University Hospital Maastricht.
Statistics
Statistical analysis was performed with SPSS® 11.0. Data were presented as
mean ± standard error or percentages. Patients were analyzed comparing data
between the prospectively defined abdominal and pneumonia-induced sepsis
group and between survivors and non-survivors. Concentra¬tions of I-FABP and
L-FABP were compared by Mann-Whitney’s U test. Correlations were
calculated using Pearson’s correlation coefficient after assessment of normal
distribution. A p-value below 0.05 was considered to be statistically significant.
RESULTS
Patients/demographics
In total, 28 patients with an early phase of sepsis were recruited (Table 1); 17
patients had proven bacterial etiology. In total 19 patients with abdominal sepsis
and 9 patients with pneumonia-induced sepsis were included. Of the 19 patients
with abdominal sepsis, 8 died because of MOF after a median period of 4 days.
Of the 9 patients with pneumonia, 4 died because of MOF after a median period
of 5 days. There was no difference in both subgroups with abdominal and non-
abdominal sepsis in outcome (p=0.5), age, gender and SOFA-score.
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Gastric mucosal hypoperfusion correlates with intestinal mucosal damage
in patients with abdominal sepsis
First, we investigated the proposed correlation between hepatosplanchnic
hypoperfusion and intestinal and hepatic damage. To this end we studied the
relation between gastric mucosal perfusion and circulatory levels of I-FABP and
L-FABP.
In our patients with sepsis Pr-aCO2-gap correlated significantly with
plasma concentrations of I-FABP (Pearson’s r2=0.56, p<0.001). Gastric mucosal
PiCO2 correlated also significantly with plasma concentrations of I-FABP
(r2=0.57, p=0.001, Figure 1) in patients with abdominal sepsis. There was a
weak, non-significant correlation between gastric mucosal PiCO2 and plasma
I-FABP in patients with pneumonia-induced sepsis (Pearson’s r2=0.48, p=0.08).
Gastric mucosal PiCO2 or Pr-aCO2-gap and plasma L-FABP did not correlate in
either of the patient groups with sepsis (Pearson’s r2=0.1, p=0.4).
These data show a direct relationship between gastric mucosal PiCO2, a
measure for splanchnic hypoperfusion and plasma I-FABP, a marker for
intestinal mucosal damage.
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Table 1: Patient characteristics
Variables Total group Survivors Non-survivors P-value
Number 28 16 12
Age (yrs) 64 ± 13 60 ± 12 67 ± 14 0.1
Gender (% Female) 39 42 38 0.7
Culture positive sepsis 17/28 6/16 11/12 0.2
Candida 0 3
E. coli 2 3
Enterobacter 0 1
Enetrococcus 2 0
Klebsiella 0 1
Proteus 1 0
Pseudomonas 1 3
Abdominal vs. 19 vs. 9 11 vs. 5 8 vs. 4 0.7
pneumonia-induced
sepsis
SOFA-score 8.5 ± 0.7 7.9 ± 2.9 9.0 ± 3.5 0.4
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Figure 1: Correlation between splanchnic hypoperfusion ( PiCO2) and plasma levels of intestinal
mucosal cell damage (circulating I-FABP) at the same time point. Circulating I-FABP correlated
significantly with gastric mucosal PiCO2 (r2 = 0.57; P = 0.001) in patients with abdominal sepsis.
There is no correlation between plasma valeus of I-FABP and gastric mucosal PiCO2 (r2 = 0.48; P
= 0.08) in patients with pneumonia-induced sepsis.
Mucosal hypoperfusion and circulating levels of markers for intestinal and
hepatic damage correlate with outcome
Gastric mucosal PiCO2 and circulating values of I-FABP and L-FABP were
compared between abdominal and pneumonia-induced sepsis and between
survivors and non-survivors. Gastric mucosal PiCO2 and Pr-aCO2-gap at ICU
admission were significantly higher in non-surviving patients (p=0.04 and
p<0.05, resp.). Moreover, non-surviving patients with abdominal sepsis had
significant higher PiCO2 values than surviving patients with abdominal sepsis
(p=0.001) (data not shown).
The highest plasma values of both I-FABP and L-FABP were measured
directly at ICU admission. After stabilization and initiation of treatment in the
ICU a rapid decline of FABP-levels was seen in most patients (Figure 2). Non-
survivors had significant higher admission values of both circulating FABPs than
survivors (I-FABP: 325 vs. 76 pg/ml, p<0.04; L-FABP: 104 vs. 31 ng/ml, p<0.04,
Figure 3). Interestingly, especially critically ill patients with abdominal sepsis
showed high levels of FABPs on admission in non-survivors compared to
survivors: I-FABP: 405 vs. 85 pg/ml, p<0.04; L-FABP: 121 vs. 59 ng/ml, p<0.04.
Comparison of plasma values of I-FABP and L-FABP from 69 healthy volunteers
(I-FABP: 106 ± 10 pg/ml; L-FABP: 19 ± 11 ng/ml) with patients with
pneumonia-induced sepsis (I-FABP: 91 ± 21 pg/ml, p=0.851; L-FABP: 43 ± 11
ng/ml, p=0.096), showed that intestinal mucosal and hepatic cellular damage
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was not significantly enhanced in the early phase of patients with pneumonia-
induced sepsis.
Since L-FABP is primarily present in the liver and to a much lower degree
also in intestine and kidney, the site of release of L-FABP was assessed by
correlating L-FABP with known markers of hepatic cellular damage AST and
ALT and with the intestinal mucosal damage marker I-FABP in patients with
maximal increased levels of FABPs. All values of plasma L-FABP correlated
significantly with plasma AST (Pearson’s r2=0.97, p<0.001) and plasma ALT
(Pearson’s r2=0.87, p<0.001), while circulating L-FABP and I-FABP did not
correlate (Pearson’s r2=0.23, p=0.2). These data strongly suggest that plasma L-
FABP represents primarily the presence of specific liver injury, while I-FABP
reflects intestinal damage.
Figure 2: Time course of I-FABP (A) and L-FABP (B) plasma levels. The highest plasma levels of I-
FABP (A) and L-FABP (B) were measured directly after ICU admission.
Figure 3: Admission I-FABP (A) and L-FABP (B) plasma valeus and survival in abdominal and
pneumonia-induced septic patients. At the time of admission, nonsurvivors had significantly
higher I-FABP (A) and L-FABP (B) valeus than survivors. Critically ill patients with abdominal
sepsis were especially responsible for high admission levels of I-FABP (A) and L-FABP (B) in
nonsurvivors. # survivors vs. nonsurvivors, P< 0.04. *Abdominal vs. pneumonia-induced sepsis,
P< 0.04. Broken lines give normal plasma valeus of I-FABP and L-FABP.
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DISCUSSION
This study investigates the association of hepatosplanchnic hypoperfusion,
objectivated by gastric mucosal PiCO2 11, 12, with intestinal and hepatic cell
damage by measurement of plasma I-FABP and L-FABP 13-15 in critically ill
patients. Subsequently, the putative association of mucosal hypoperfusion and
of intestinal and hepatic damage with the outcome of sepsis was studied. We
report that splanchnic hypoperfusion (gastric mucosal PiCO2) in the early
phase of abdominal sepsis correlates strongly with intestinal mucosal damage
(plasma I-FABP). The fact that PiCO2 does not correlate well with plasma levels
of I-FABP in patients with pneumonia-induced sepsis is unclear. Because of the
rapid clearance of FABPs, enhanced plasma levels reflect almost directly
intestinal and hepatic epithelial cell death. This study shows that elevated
plasma I-FABP and L-FABP are associated with a poor outcome in septic
patients and especially in patients with abdominal sepsis. This is consistent with
the hypothesis that intestinal and hepatic damage caused by hypoperfusion
leads to the amplification of the systemic inflammatory response during sepsis
resulting in MOF and increased mortality. Further conformation is however
needed to proof the hypothesis. In line with our results, assessment of FABPs
can be used in further studies to unravel the pathophysiology that underlies
sepsis. Moreover, if FABPs could be established as reliable or pathognomonic
early indicators for intestinal and hepatic cell damage, these markers may
provide new clinical diagnostic and predictive markers for outcome in septic
patients. It is interesting to note that in patients with pneumonia-induced sepsis
mucosal hypoperfusion and intestinal cell damage occurred to a lesser degree
and lacked a relation with outcome.
Our work is supported by earlier studies reporting intraoperative
splanchnic hypoperfusion or release of I-FABP separately in patients with sepsis
16-18, and finding mucosal acidosis and raised plasma I-FABP to be predictive for
mortality in critically ill high-risk surgical patients 19, 20. Previous studies using
gastric tonometry to evaluate splanchnic hypoperfusion, mainly used gastric
intramucosal pH (pHi) to evaluate splanchnic hypoperfusion 16, 19. The present
study reports the direct indices PiCO2 and Pr-aCO2-gap, which are recently
consented to be most specific, clinical available, parameters for splanchnic
perfusion 21. Our data are in line with studies showing that disturbances in
PiCO2 and Pr-aCO2-gap are determinants for outcome in critically ill patients,
especially in patients with abdominal sepsis. It should be mentioned however
that others challenged this conclusion 22, 23. The heterogeneity of groups and
thus the heterogeneity in pathophysiology could underlie the difference in
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results. In addition however, this study is the first to describe a correlation
between mucosal perfusion and oxygen defects and enhanced circulating I-
FABP, intestinal damage. It is not easily proven that intestinal cell death as
detected with plasma I-FABP is a direct result of mucosal perfusion deficiency.
This assumption is however strongly strengthened by data showing that intestinal
ischemia reperfusion leads to rapid I-FABP release 13, 24, 25.
The role of intestinal compromise in sepsis has been studied using markers
for plasma levels of endotoxin and gut wall integrity. Sugar absorption tests and
circulating IgM and IgG anti-endotoxin antibodies as markers for gut mucosal
barrier loss, demonstrated that gut barrier dysfunction was associated with major
surgery. However, no difference in these measurements between septic and non-
septic patients was reported 26. We consider that such tests for gut integrity
reflect different, most likely later phases in the development of gut compromise
in high-risk surgical patients than phenomena of hypoperfusion and epithelial
cell death which can be assessed by gastric tonometry and circulating FABPs.
The reduced mucosal perfusion and the proposed resulting intestinal and
hepatic cellular damage is most likely caused by the circulatory perturbation in
sepsis. The fact that FABP levels normalized after admission to ICU strongly
supports the importance of vasocontrol treatment in such patients. We consider
that the observed intestinal cellular damage is involved in the enhancement
and prolongation of sepsis leading to a poor outcome.
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ABSTRACT
Objective
The pathophysiological sequelae of meningococcal sepsis (MS) are mainly
caused by deregulated microvasculature function, leading to impaired tissue
blood flow. Since especially mature enterocytes are known to be susceptible to
altered perfusion, we aimed to investigate: (1) the development of enterocyte
damage, (2) the relation between enterocyte damage and severity of disease
and outcome, in children with MS.
Design
Retrospective human study.
Setting
Paediatric intensive care unit (PICU) at a university hospital.
Patients
19 consecutively included children with MS were studied during their PICU stay.
Interventions
None for the study.
Measurement and Main results
Circulating levels of I-FABP, a small cytosolic protein constitutively present in
mature enterocytes and released upon cell injury, were assessed. Severity of
disease was represented by meningococcal-specific Rotterdam Score (RS),
generic Paediatric Risk of Mortality II (PRISM II) score and circulating
interleukine-6 (IL-6). Clinical outcome was measured by length of PICU-stay
and number of ventilator days.
Highest plasma I-FABP values were measured on PICU admission. At the
time of admission, 8 of 19 patients had higher I-FABP plasma levels than the
upper reference limit of 30 healthy volunteers. In all survivors I-FABP levels
declined to normal values within 12 hours after starting intensive treatment,
while the three non-survivors maintained elevated I-FABP plasma levels. A
significant correlation was found between I-FABP and RS, PRISM II, IL-6 at
admission (Spearman r2= 0.402, p=0.006; r2=0.243, p=0.045; r2=0.687, p
<0.001, respectively). Next, a significant correlation was found between I-FABP
and clinical outcome.
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Conclusions
Elevated plasma I-FABP is found in 8 out of 19 children with an early phase of
severe MS, suggesting the presence of enterocyte damage. Moreover, prolonged
enterocyte damage is found in non-survivors. Further studies are needed to clarify
the potential role for assessment of plasma I-FABP in monitoring treatment of MS.
INTRODUCTION
Meningococcal sepsis (MS) is one of the most severe infections in childhood. It
is well known for its sudden onset and rapid progression to septic shock.
Despite early use of antibiotics, aggressive haemodynamic support and life-
sustaining care, the overall mortality of children with MS remains significant (2-
12%) 1-3. Furthermore, MS is associated with severe morbidity, including limb
necrosis and multiple organ failure (MOF) 2,4.
Dysregulation of microvasculature function is a major pathophysiological
event in patients with MS 4. The development of septic shock and MOF in MS
is explained by a complex of phenomena, including hypovolaemia resulting
from increased vascular permeability, pathological vasoconstriction and
vasodilatation, loss of thromboresistance, intravascular coagulation and
profound myocardial dysfunction. These processes lead to impairment of the
microvascular blood flow in tissues and organs, causing ischemic injury 4.
Organs that are mostly affected include kidneys, lungs and splanchnic organs 4.
The mature intestinal mucosal cells are especially susceptible to
hypoperfusion and ischemia 5, 6. Damage of intestinal mucosa can lead to local
inflammation, impaired barrier function, and thereupon potentially to
translocation of micro-organisms 6-9. This translocation can result in a
derailment of local inflammation and subsequently amplification of a systemic
inflammatory response, as is mainly shown in animal studies 10, 11. Studies in
critically ill adults also indicate that intestinal damage caused by splanchnic
hypoperfusion is associated with the transition of the systemic inflammatory
response syndrome (SIRS) into sepsis and septic shock 12-15.
Intestinal fatty acid binding protein (I-FABP) is a small (14-15kDa)
cytosolic protein constitutively present in mature enterocytes and released
upon cell injury 16, 17. I-FABP circulates in low amounts in the blood stream of
healthy individuals. The levels of circulating I-FABP correlate with the extent of
splanchnic hypoperfusion in adult critically ill patients 15. Assessment of plasma
I-FABP levels makes it possible to evaluate gut mucosal damage in disease
conditions associated with redistribution of blood flow to vital organs at the
expense of the splanchnic circulation.
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The primary aim of this retrospective study was to investigate the presence of
gut mucosal damage by (serial) assessment of plasma I-FABP levels in children
with MS during the first 48 hours after admission. Our second aim was to study
the relation between the presence of gut mucosal damage and severity of
disease, intravascular thrombosis and clinical outcome.
MATERIALS AND METHODS
Patients
Children between the ages of 6 months and 16 years consecutively admitted to the
paediatric intensive care unit (PICU) of the Maastricht University Medical Centre,
between October 2006 and October 2007 were retrospectively enrolled in the
study. All children fulfilled the diagnosis of MS as defined according to the sepsis
criteria of the Society of Critical Care Medicine and the American College of Chest
Physicians (SCCM/ACCP), adapted to infants and children (18), in combination
with petechiae and/or purpura and a positive blood or spinal fluid culture with
Neisseria meningitidis. All patients had an indwelling arterial catheter. Children
with known abdominal disease were excluded, because such a disease could be a
cause of intestinal epithelial damage and corroborate the data. All children were
treated according to institutional guidelines, including aggressive treatment of
respiratory and circulatory failure with mechanical ventilation, large volume
intravenous fluid replacement, vaso-active and inotropic drugs (norepinephrine
dopamine), and intravenous antibiotics. Continuous enteral feeding was started
within the first 24 hours after admission in all patients and increased in volume
during the next days according to our standard feeding protocol. Normal plasma
values of I-FABP were established from thirty healthy volunteers (median age: 5.8
years, range: 1-14 years), which consisted of children that consecutively
underwent minor non-abdominal surgery (e.g. removal of K-wires, circumcision).
The study was approved by the local Medical Ethical Committee.
Clinical parameters
To assess severity of illness the Rotterdam score (RS) was calculated. The RS is
a prognostic score validated to indicate severity of disease in children with MS
19. Further, also the Paediatric Risk of Mortality II (PRISM II) score was assessed,
which is a validated generic scoring system to predict risk of mortality in
heterogeneous groups of paediatric ICU patients 20. Disseminated intravascular
coagulation (DIC) was assessed using the global coagulation test score for DIC
as described by Dhainaut et al. 21. Clinical outcome of the disease was assessed
as length of stay in the PICU and number of days on the ventilator.
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Blood analysis
Blood sampling
Arterial blood samples were routinely collected directly after admission and
subsequently 6, 12, 24 and 48 hours after admission for measurement of C-
reactive protein (CRP), creatinine, platelet count, lactate, blood gasses,
creatinine and potassium among other routine measurements. The remainder of
the blood was centrifuged 15 minutes at 4000 rpm at 4°C to obtain plasma and
stored in aliquots at -80°C. This leftover plasma was used in the present study
for determination of I-FABP and IL-6.
Laboratory determinations
CRP, lactate, base excess, creatinine, potassium, platelet count, D-Dimer and
prothrombin time were measured by the clinical chemistry or haematological
laboratory of the Maastricht University Medical Centre. Plasma I-FABP was
determined by using a highly specific commercially available enzyme-linked
immunosorbent assay (ELISA) that selectively detects human I-FABP (standard: 20-
5,000 pg/ml, kindly provided by Hycult Biotechnology, Uden, the Netherlands).
IL-6 was determined using an in-house ELISA as described previously 22. The
detection limit of IL-6 was 0.01 ng/ml.
Statistical analysis
Statistical analysis was performed with GraphPad PRISM 4.0 for Windows®
(GraphPad Software Inc. San Diego, CA). Normality of all data was verified by
Kolmogorov-Smirnov test. The plasma values of I-FABP were compared
between patients at time of admission and healthy children using unpaired t-
test. Friedman two-way analysis of variance by ranks was used to analyze
changes in plasma I-FABP levels of MS patients between different time points.
A post-hoc Dunn’s multiple comparison test was used to calculate significant
differences of plasma values of I-FABP with respect to baseline (t=0).
Correlations between plasma I-FABP levels at admission and RS, PRISM II,
circulating IL-6, plasma creatinine, DIC-score, length of PICU-stay and number
of ventilator days were calculated using Spearman rank correlation coefficient.
Data are presented as median (range). Statistical significance was defined as
p<0.05.
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RESULTS
Patients
Nineteen patients with MS were enrolled in the study. Patient characteristics are
shown in Table 1. Three patients died: one 14 hours after admission because of
refractory circulatory shock (patient A), the second patient died 20 hours after
admission because of brain death (patient B) and the third patient died 19 days
after admission after withdrawing treatment, because of extended gut necrosis
incompatible with life (patient C).
Gut mucosal damage in children with meningococcal sepsis
To investigate the occurrence of intestinal damage in the early stage of MS,
circulating levels of I-FABP, representing enterocyte cell death, were determined
longitudinally, at admission and subsequently at 6, 12, 24 and 48 hours after
admission.
The highest plasma values of I-FABP were measured at admission on the
PICU (median 298 pg/ml, range: 25-4,351 pg/ml; Figure 1). MS patients had
significantly elevated I-FABP levels at the time of admission, compared to the
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Table 1: Patient characteristics
Variable (n=19) Median (range)
Age - months 29 (11-186)
Bodyweight - kg 13 (7-60)
Sex (no (%) male) 9 (50)
PRISM II 1 16 (2-52)
RS2 at admission – 2 (– 8-5)
Length of stay in PICU 3 – days 5 (1-30)
Requirement for mechanical ventilation – no. (%) 14 (78)
Ventilator days 4 (0-11)
Presence of skin necrosis – no. (%) 7 (39)
Maximum dose of dopamine (µg/kg/min) 20 (0-20)
Maximum dose of norepinephrine (µg/kg/min) 0.2 (0-9.5)
DIC score 4 5 (1-7)
1 PRISM II: Pediatric Risk of Mortality II
2 RS: Rotterdam Score
3 PICU: paediatric intensive care unit
4 DIC: disseminated intravascular coagulation
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thirty healthy children (p=0.004), who had median circulating I-FABP values of
183 (25-346) pg/ml. At the time of admission, 8 of the 19 patients had higher I-
FABP plasma levels than the upper reference limit of the healthy volunteers
(mean I-FABP+2*standard deviation=399 pg/ml). I-FABP plasma values
declined significantly in 48 hours (Friedman p<0.01). After 6 hours, only 4
patients had I-FABP levels exceeding 399 pg/ml. Interestingly, in all survivors I-
FABP levels declined to normal values (<399 pg/ml) within 12 hours after
starting intensive medical treatment, while the three non-survivors maintained
elevated I-FABP plasma levels.
Since I-FABP is rapidly cleared by the kidneys, we investigated whether
elevated I-FABP levels could be caused by compromised renal function. No
correlation was found between plasma creatinine levels and plasma I-FABP
levels at time of admission in our study group (Spearman r2= 0.049, p=0.394
data not shown). This suggests that high circulating I-FABP levels are primarily
due to intestinal damage, and not to renal failure.
Figure 1: Plasma I-FABP values in individual patients during early phase of MS. Raised I-FABP
levels were present in 8 of the 19 patients with MS compared with the upper reference limit (URL)
of the 30 healthy volunteers (mean I-FABP+2*standard deviation=399 pg/ml). In all survivors,
plasma I-FABP levels declined within 12 hours to normal; in non-survivors, however, plasma I-
FABP levels remained high, despite intensive treatment. Upper dotted line represents the URL of
plasma I-FABP levels of 30 healthy children; lower dotted line represents the mean value . A, B, C
depict the values of the three patients who died.
Our data indicate that intestinal damage is present in a significant part of
the children with meningococcal sepsis in an early stage. Moreover, the
persistence of high I-FABP plasma levels in non-surviving children and rapid
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normalization of I-FABP values in surviving children, suggest a relationship
between extent of intestinal damage and mortality.
Patient A (Figure 1) was an 11 months old girl who developed immediately
after admission widespread ecchymoses, limb ischemia and necrosis, and signs
of multiple organ failure. She died 14 hours after admission from refractory
septic shock. Plasma I-FABP level was 3,337 pg/ml at admission and remained
high (2,164 pg/ml) 12 hours after admission. Patient B was an 11 months old girl
who developed severe ischemia and necrosis of all four limbs and multiple
organ failure within 12 hours after admission to the PICU. She developed
clinical symptoms of brain death and the EEG was isoelectric. Further treatment
was withheld and she died 20 hours after admission. In this girl plasma values of
I-FABP were high at moment of admission (4,352 pg/ml) with continuous
elevated levels at 6 hours (3,024 pg/ml). Patient C was a 12 months old boy who
developed severe limb ischemia and necrosis, multiple organ failure, epileptic
seizures and a distended abdomen. Peritoneal dialysis was started for renal
failure. After 72 hours his circulatory condition gradually improved. On day 7 he
became severely septic again, while still on the ventilator and was treated for
suspected peritonitis. Because of an increasingly distended abdomen and
persistent metabolic acidosis, laparotomy was performed which showed
complete necrosis of the small and large bowel and multiple perforations.
Treatment was withheld and the patient died. I-FABP plasma level was high at
admission (1,327 pg/ml) and increased towards a peak of 5,858 pg/ml at 24
hours after admission. The last collected sample, 48 hours after admission,
showed an I-FABP level which was still elevated (3,060 pg/ml).
The extent of gut mucosal damage is correlated with severity of disease and
clinical outcome
Next, we investigated whether the extent of intestinal damage was related to
severity of disease, by correlating plasma I-FABP levels with RS, Prism II score and
plasma IL-6 values, a classical sepsis parameter. A significant correlation was
found between I-FABP and RS at admission (Spearman r2= 0.402, p=0.006, Figure
2A). I-FABP also correlated significantly with PRISM II score (r2=0.243, p=0.045).
Furthermore, I-FABP plasma concentrations correlated significantly with plasma
IL-6 values at admission (Spearman r2=0.687, p< 0.001, Figure 2B). Interestingly,
all patients with plasma I-FABP levels higher than 399 pg/ml showed IL-6 levels
above 100 pg/ml. Next, to assess the relation between intestinal mucosal cell
damage and intravascular thrombosis, the correlation was determined between
plasma I-FABP levels and DIC-score at admission: I-FABP correlated significantly
with DIC-score at admission (Spearman r2=0.565, p=0.005).
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To study the relation between early presence of intestinal epithelial cell injury
and outcome, we investigated the correlation between plasma I-FABP values at
admission and number of days on the PICU and number of days at the
ventilator. A significant correlation was found for both parameters (r2= 0.457,
p=0.006 for length of PICU-stay and rs=0.357, p=0.019 for number of
ventilator days).
These data indicate a strong relationship between gut mucosal damage,
measured by I-FABP, and severity of disease (represented by the RS, PRISM II),
IL-6, DIC and clinical outcome.
Figure 2: Correlation of intestinal epithelial cell damage (plasma I-FABP levels) and severity of
disease at admission. Circulating I-FABP correlates significantly with the Rotterdam Score (RS) (A)
and IL-6 (B) (r2=0.402, p=0.006 and r2=0.687, p< 0.001, respectively) in patients with
meningococcal sepsis at time of admission to the PICU.
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DISCUSSION
The presence of intestinal epithelial cell damage in the early phase of MS in
children was studied by assessment of plasma levels of I-FABP, a small protein,
exclusively present in the cytosol of mature enterocytes and rapidly released
upon ischemic cellular injury 16. Subsequently, the correlation between
intestinal damage and severity of MS, DIC and clinical outcome was
investigated.
The principal findings of this study are: (1) intestinal epithelial cell damage
was present in a large part (8/19) of the patients in an early phase of MS; (2) the
extent of intestinal epithelial cell damage at the moment of admission to the
PICU correlated with severity of disease, diffuse intravascular coagulation and
clinical outcome; (3) in all survivors, plasma I-FABP levels declined to normal
values within 12 hours after starting intensive medical treatment. In non-
survivors, however, plasma I-FABP levels remained high, despite intensive
treatment. Since our study group consisted only of 19 children, these results
have to be confirmed in a larger population.
Primarily animal studies have provided evidence that the gut plays an
important role in the transition of systemic inflammatory response (SIRS) into
sepsis and multiple organ failure (MOF) 6, 9, 11, 12. SIRS potentially leads to
splanchnic hypoperfusion, because blood is shifted away from the splanchnic
organs towards the more vital organs (heart, brain). Especially the mature
enterocytes are susceptible to hypoperfusion and will be damaged, which leads
to loss of the intestinal barrier and translocation of microbiota and microbial
products 5, 7, 8, 10. These danger signals possibly amplify the systemic
inflammation by further release of cytokines, eventually resulting in a
deregulated inflammatory response and MOF 6, 9, 12. This is indeed confirmed
by studies in adults and children with non-intestinal origin of sepsis, showing
that increased intestinal permeability and low values of antibodies directed
against the core of endotoxin (EndoCAb) are associated with the development
of sepsis, multiple organ dysfunction syndrome and poor outcome 14, 23, 24.
The presence of intestinal epithelial cell damage in our patients with more
severe sepsis (as shown by high RS scores and high IL-6 levels) suggests that
intestinal hypoperfusion occurs in these patients. Although there is a lack of
reports on the assessment of splanchnic perfusion in children with MS, previous
studies in critically ill adult patients have shown that SIRS, sepsis and shock can
lead to splanchnic hypoperfusion 15, 25. Furthermore, splanchnic hypoperfusion
is known to result in intestinal mucosal cell damage, in our study assessed by
plasma levels of I-FABP 15. In line, the level of circulating I-FABP has been
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reported to correlate with the histological status of the epithelium after
intestinal ischemia-reperfusion 26, 27. In order to further unravel the role of
splanchnic hypoperfusion on gut mucosal damage, it would be interesting to
additionally measure gut perfusion by gastric tonometry in the acute phase of
MS in children 28.
The marked decrease of plasma I-FABP levels in all surviving children
within 12 hours after admission to the PICU suggests that our aggressive
medical treatment, targeting haemodynamic stabilization, improved intestinal
perfusion, resulting in a rapid reduction of further intestinal epithelial cell
damage. Besides compromised organ perfusion due to vasoregulatory
disturbances, peripheral microcirculation in MS patients is also negatively
affected by intravascular thrombosis. Indeed a strong correlation was found
between gut mucosal damage severity of DIC in the children with MS in the
present study. We speculate that uncontrolled thromboresistance and
intravascular coagulation on top of splanchnic hypoperfusion may have
contributed to the extreme high plasma I-FABP levels on admission in the three
non-surviving MS patients and the persistence of elevated plasma I-FABP levels
in spite of our attempts to restore organ perfusion by high volume fluid therapy
and vaso-active and inotropic therapy.
Assessment of plasma levels of I-FABP in children with MS may have
important clinical implications. The adequacy of treatment of circulatory failure
in MS is currently monitored using indirect parameters of tissue perfusion and
oxygenation, including blood pressure, urine output, metabolic status (lactate,
base deficit) skin temperature and capillary refill time 29. However, these
parameters do not reflect the actual defects in (peripheral) tissue perfusion and
subsequent tissue damage. Assessment of plasma I-FABP levels offers the
possibility to monitor the presence of intestinal epithelial cell damage as a
consequence of splanchnic hypoperfusion, which could help to monitor
treatment directed at restoration of peripheral perfusion and prevention of
organ damage. Additionally, the serial assessment of plasma I-FABP levels can
provide important information about gut integrity since intestinal necrosis, a
life-threatening complication in children with MS, may also be reflected by
prolonged high I-FABP plasma levels. This is illustrated by one of the three dead
children in our study, and is also in line with previous reports, showing serious
intestinal complications in children with MS, including gastrointestinal
perforation and haemorrhage from small bowel ulceration 30, 31. Early detection
of intestinal necrosis may then result in timely resection of the necrotic and
perforated part of the intestines.
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CONCLUSIONS
Our data are the first to report the presence of intestinal epithelial cell damage
in children in the early phase of severe MS. Furthermore, our data show that
only in non-surviving children intestinal epithelial cell damage persisted during
circulatory stabilization. Further studies are needed to clarify the diagnostic
potential of assessment of plasma I-FABP in monitoring the treatment of MS in
the acute phase and during follow-up.
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ABSTRACT
Objectives
Visceral injury and inflammation are evaluated in patients undergoing
extracorporeal circulation (ECC) either with distal aortic perfusion (DAP) during
thoracic aortic aneurysm (TAA) repair or DAP and selective organ perfusion
(DAP & SP) during thoracoabdominal aortic aneurysm (TAAA) repair.
Summary Background Data
Visceral hypoperfusion and subsequent visceral injury, mainly to the gut, have
been implicated as central events in the development of systemic inflammatory
response syndrome (SIRS) and organ dysfunction after major surgery. Patients
undergoing DAP or DAP & SP are exposed to artificial visceral perfusion,
potentially leading to the development of intestinal injury and systemic
inflammation.
Methods
To assess visceral injury arteriovenous differences of Fatty Acid Binding Proteins
were measured for the gut (I-FABP and L-FABP) and left kidney (L-FABP) along
with systemic plasma concentrations. Systemic ALT was used as liver injury
marker. Plasma IL-6 and IL-8 denoted systemic inflammation.
Results
During ECC systemic I-FABP and L-FABP levels increased in both groups,
representing intestinal injury. Significantly elevated levels of I-FABP (P < 0.001)
and L-FABP (P < 0.001) were found in the DAP & SP group, after ECC was
stopped and normal circulation restored. Liver and renal tubular cell injury was
not detected. Significant increases in systemic IL-6 and IL-8 values were
measured only in patients undergoing DAP & SP. Additionally, the extent of
intestinal injury correlated positively with systemic inflammation.
Conclusion
This study shows the development of intestinal mucosal injury during ECC with
DAP or DAP & SP, indicative of insufficient intestinal perfusion. Intestinal injury
was associated with a systemic pro-inflammatory response.
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INTRODUCTION
Open surgical repair of thoracic aortic aneurysms (TAA) and thoracoabdominal
aortic aneurysms (TAAA) are extensive, complex procedures that are associated
with significant post-operative morbidity and mortality. Post-operative
complications include respiratory failure, renal and liver dysfunction, spinal
cord injury, and gastrointestinal complications.1-3
Experimental studies of major surgery and trauma suggest that intestinal
injury and hypoperfusion of visceral organs lead to initiation of a systemic pro-
inflammatory response.4, 5 Therefore, visceral protection during aortic surgery is
warranted.6, 7
The extracorporeal circulation (ECC) technique has been implemented in
open TAA repair to provide (retrograde) distal aortic perfusion (DAP) via the
femoral artery. In case of TAAA repair involving the origin of visceral arteries,
ECC with DAP is combined with selective organ perfusion catheters (DAP & SP)
to provide designated visceral arteries directly with blood.8, 9 The rationale
behind DAP and DAP & SP is to reduce ischemic injury of visceral organs, in
particular the highly susceptible intestinal mucosa.10
The advantages of visceral protection notwithstanding, ECC during cardiac
surgery provides antegrade aortic perfusion of visceral organs and is still
associated with loss of intestinal barrier function seen as endotoxin
translocation, indicating intestinal mucosal injury.11-13 The development of
intestinal organ injury during antegrade aortic perfusion is strongly associated
with gastrointestinal complications and mortality.14, 15 Moreover, recent
publications suggest ECC with antegrade aortic flow to result in a poorly
understood state of ‘functional’ hypoperfusion of visceral organs, which is
related to visceral injury and the induction of SIRS.14, 16, 17
The quantification of (subclinical) visceral injury during open TAA / TAAA
repair could provide valuable information on the perfusion adequacy of ECC
with either DAP or DAP & SP. Therefore, in this study we measured intestinal
and renal release of fatty acid binding proteins, small cytosolic proteins that
leak from injured cells into the circulation, and systemic plasma ALT to evaluate
liver injury. The pro-inflammatory cytokines IL-6 and IL-8 were measured to
assess systemic inflammation. The aim of the present study was to investigate
the development of visceral injury in patients undergoing either DAP or DAP &
SP, and to evaluate the relation of visceral injury to the systemic inflammatory
response in these patients.
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METHODS
Patient Population
Patients that underwent elective open TAA or TAAA repair between January
2006 and April 2007 at the University Hospital Maastricht or the University
Hospital Aachen were included in the study. The study was approved by the
local Institutional Review Board of both institutes, and written informed
consent was obtained from every patient.
Pre-operative clinical data were prospectively collected from the patient’s
medical record. Crawford’s classification was used to specify TAAA type.18
Surgical Procedure
In all patients the same anesthetic protocol was used. The following anesthetic
and surgical procedure has been described previously in detail.9, 19 Collapse of
the left lung in all patients except type IV TAAA was enabled by either a double-
lumen endotracheal tube or a selective left main bronchial blocker. Induction of
anesthesia was achieved with etomidate and sufentanil, and maintained with
sufentanil and ketamine. All patients were placed in a left helical position, and
thoracotomy or thoracolaparotomy through the sixth intercostal space (eighth
intercostal in patients with TAAA type IV aneurysms) was performed.
After heparinization, (0.5 mg/kg), for all patients ECC with DAP was
established after cannulation of the left pulmonary vein and the femoral artery,
connected to a centrifugal pump. Alternatively, the femoral vein was cannulated
with a long cannula placed in the vena cava inferior close to the right atrium; in
all cases an oxygenator was part of the ECC. For DAP & SP, a 4-branched tubing
system was connected to the ECC and 4 catheters with inflatable tips and flow
probes were used for selective perfusion of the celiac axis, the superior
mesenteric artery and both renal arteries.
Typically, the aortic reconstruction was done from proximal to distal.
During proximal cross-clamping, transsection of the aorta, and completion of
the proximal anastomosis, DAP was maintained at a mean pressure of 60
mmHg or higher. After abdominal aortotomy, all four selective perfusion
catheters were installed in patients undergoing TAAA repair. In ten patients
(N=10) we evaluated directly after insertion the mean blood flow through each
individual SP catheter (see Table 1).
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Table 1: Characteristics of patients undergoing open TAA / TAAA repair.
ECC with ECC with
DAP DAP & SP P-value
Total procedures (N) 8 22
TAA 8 -
TAAA * - 22
TAAA II - 3
TAAA III - 9
TAAA IV - 10
Male (N) 4 11 1.000
Dissection 4 2 0.033
Mean age (yr) 60.0 (3.4) 63.5 (2.7) 0.483
BMI ** (kg/m2) 26.9 (1.2) 23.9 (0.8) 0.058
Diabetes - 2 1.000
Hypertension 5 17 0.643
Smoked 4 19 0.395
Hypercholesterolemia 1 11 0.099
Chronic renal failure - 2 1.000
CAD ^ 1 2 1.000
COPD ^^ - 5 0.280
ACC # time (min) 86 (9) 86 (7) 0.986
ECC time (min) 131 (36) 142 (9) 0.677
Flow SP catheter † (mL/min)
Celiac axis - 202.0 (33.2)
Superior mesenteric artery - 311.6 (30.4)
Left renal artery - 212.6 (33.3)
Right renal artery - 186.4 (27.7)
Total operation time (min) 326 (17) 399 (15) 0.015
Classification according to Crawford.18 ** BMI, body mass index; ^ CAD, coronary artery disease;
^^ COPD, chronic obstructive pulmonary disease. # ACC, aorta cross clamp; Continues variables
are expressed as mean (SEM). †Flow in SP catheter was measured in ten (N=10) patients
undergoing ECC with DAP & SP.
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In general, the celiac axis, superior mesenteric artery and the right renal artery
were anastomosed simultaneously as an island in the aortic graft. Just before
finishing the anastomosis, the perfusion catheters were removed, indicating that
ischemic time is limited to the timeframes of insertion and removal of the
catheters. In most cases, the left renal artery was treated with a selective graft
using selective perfusion during end-to-end anastomosis. After completion of
the anastomosis, the tip of the catheter was withdrawn into the graft, and
perfusion continued, until implantation into the aortic tube graft was
accomplished.
Blood Sampling
Peripheral arterial blood was drawn at set time-points (Fig. 1) from the radial
artery pre-operatively (Pre-op), while creating access to the aorta, but before
clamping the aorta and ECC was initiated (Cannulation), during ECC just before
ending DAP or DAP & SP (ECC), 15 minutes after the proximal aortic cross
clamp was removed and reperfusion (R) initiated (15 min R), at 2 hours, 6 hours
and 10 hours in the reperfusion phase (2 hrs R, 6 hrs R and 10 hrs R), as well
as at day 1 and 2 postoperatively (Day 1 and Day 2). Whole blood was
collected in EDTA vacutainers (Becton Dickinson, Franklin Lakes, NJ) and
immediately put on ice. Blood was centrifuged and plasma was stored in
aliquots at - 20° C until further analysis.
To enable venous blood sampling from the intestines and left kidney in
eight patients (N = 8) undergoing DAP & SP, a 16 G single lumen central
venous catheter kit was used to cannulate the portal vein (Terumo Corporation,
Tokyo, Japan), and a 18 G intravenous catheter (Venflon, Becton Dickinson,
Franklin Lakes, NJ) was used to cannulate the left renal vein prior to starting
ECC. This enabled us to sample specific arterial and venous blood from the gut
and the left kidney in order to calculate organ release and consumption of
plasma proteins. Blood was taken from these cannulas before ECC, during ECC
with DAP & SP when a sample was taken from the arterial line of the ECC as
well, and at 15 minutes reperfusion (Fig. 1).
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Figure 1: Timeline of blood sampling. At given time-points blood was drawn from the radial artery
line and arterial line of the extracorporeal circulation (ECC). Patients undergoing open TAA repair
received ECC with distal aortic perfusion (DAP-group), whereas ECC with DAP and selective
organ perfusion was used in patients undergoing open TAAA repair (DAP and SP-group). To
enable simultaneaous arterial and venous organ blood sampling, in 8 patients receiving ECC with
DAP and SP, a venous catheder was inserted in the portal vein, as well as the left renal vein. This
allowed specific calculation of arteriovenous concentration differences for the gut as well as the
left kidney. PV, portal vein; RV, renal vein; aECC, arterial line of ECC.
Measurements
Visceral Organ Injury
Fatty acid binding proteins (FABP) are small cytosolic proteins (15 kDa) that are
abundantly expressed in visceral tissue and can be used as sensitive plasma
markers to detect early cellular injury.20, 22 Two types of FABP, intestinal-type
FABP (I-FABP) and liver-type (L-FABP), are expressed at the tips of the villi of
intestinal mucosal epithelial cells. I-FABP is only present in intestinal mucosal
cells; in contrast, L-FABP is also expressed in hepatocytes, and to a lesser extent
in renal tubular cells, and increased plasma levels could therefore represent
hepatocyte or renal tubular cell injury as well.23 In order to evaluate
hepatocellular injury systemic common liver injury marker ALT was measured.
Furthermore, to study renal tubular cell injury as cause of elevated circulating
L-FABP levels, the arteriovenous concentration difference for the left kidney
([arterial concentration] – [venous concentration] / [arterial concentration] x
100%) of L-FABP was calculated in eight patients (N = 8) undergoing DAP & SP.
Plasma I-FABP and L-FABP levels were analyzed using Enzyme Linked
Immuno Sorbent Assays (ELISA). These commercially available ELISA kits were
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kindly provided by Hycult biotechnology (Uden, the Netherlands) and were
used according to manufacture guidelines. The detection limit was 41 pg/mL for
I-FABP and 102 pg/mL for L-FABP.
Systemic Inflammatory Response
The plasma levels of the cytokines IL-6 and IL-8 were assayed to determine the
systemic inflammatory response following TAA / TAAA repair. IL-6 and IL-8 are
commonly used as general inflammatory markers, amongst others produced by
stimulated monocytes and activated endothelium, and considered key players
in the development of SIRS after major trauma and surgical stress.17, 24, 25
IL-6 and IL-8 ELISA techniques have been described elsewhere.26 Briefly,
96-well plates (Greiner Bio-One, Kremsmünster, Austria) were coated overnight
(4° C) with the appropriate antibodies. Monoclonal antibodies 5E1 and 3E3
were used as coating for IL-6 and IL-8, respectively. Free sites were blocked
with 1% bovine serum albumin in PBS.
Samples and standard dilution series were incubated for 2 hours. Human
recombinant IL-6 and IL-8 were used for standard titration curves. Washing
buffer contained 0.1% Tween-20. Biotinylated anti-human IL-6 and IL-8 were
developed in our own laboratory and used as detection antibodies. Finally,
3,3’,5,5’-tetramethyl-benzidine (TMB) was used as a substrate and the reaction
was stopped by adding 1M H2SO4. Plasma samples were analyzed in the same
run spectrophotometrically (450 nm) using an automated ELISA reader. The
detection limits for the assays were 12.3 pg/mL (IL-6) and 46.0 pg/mL (IL-8).
Statistical Analysis
All data are expressed as mean ± standard error of the mean (SEM). Kolmogorov-
Smirnov test was used to test for Gaussian distribution. Student’s T-test for
independent-samples and Chi-square test, followed by Fisher’s exact test when
needed, were used to test differences between pre-operative patient
characteristics. Changes in parameters over time were tested using repeated
measures ANOVA, followed by paired Student’s T-tests versus Pre-op values with
post-hoc Bonferroni correction, if significant differences were found. In the same
way changes in arteriovenous concentrations differences of plasma proteins were
tested, with values measured during Cannulation as reference. To characterize the
total amount of intestinal injury and systemic inflammation during the study
period, area under the curve (AUC) for I-FABP and L-FABP, as well as IL-6 and IL-
8 was calculated for each patient. To assess association between intestinal mucosal
cell injury and inflammation Spearman correlation analysis between AUCI-FABP,
AUCL-FABP, AUCIL-6, and AUCIL-8 was performed. Mann Whitney U test was used
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to calculate differences in AUC for each parameter between both patient
groups. Statistical calculations were made using SPSS 15.0 for Windows (SPSS,
Inc., Chicago, IL), and GraphPad Prism software (GraphPad Software, Inc. San
Diego, CA). A P-value < 0.05 was considered to indicate statistical significance.
RESULTS
Patient Characteristics and Intra-Operative Data
Thirty consecutive patients that underwent TAA (N=8) or TAAA (N=22) repair
were included in the study. Table 1 shows pre-operative clinical data of patients
undergoing ECC with DAP (TAA patients) or DAP & SP (TAAA patients). No
significant differences in pre-existing co-morbidities were present in the two
patient groups studied, except for the co-existence of an aortic dissection (DAP
N = 4 / 8 versus DAP & SP N = 2 / 22, P = 0.033). Nevertheless, aortic
dissection did not influence the surgical approach to repair the aneurysm.
Aorta cross-clamp time (ACC), total ECC time and total operation time
were noted during all procedures. ACC and total ECC time did not differ
significantly between both groups. However, a significant difference in total
operation time was found, reflecting the operative complexity of patients
undergoing TAAA repair (DAP 326 (17) minutes, and DAP & SP 399 (15)
minutes, P = 0.015).
Extracorporeal Circulation and Intestinal Mucosal Injury
Pre-operative I-FABP levels (DAP 326.8 (84.8) pg/mL, and DAP & SP 411.7
(82.4) pg/mL, Fig. 2A) were comparable to the values measured in a healthy
population,27 demonstrating the absence of intestinal mucosal cell injury.
Manipulation of visceral organs to create access to the aorta, did not lead to
elevated circulating I-FABP levels. In contrast, during ECC I-FABP levels
increased in both groups representing the development of intestinal mucosal
injury which was supported by statistically significant repeated measures
ANOVA in both groups (DAP, P < 0.05; DAP & SP, P < 0.0001, data not shown).
Shortly after artificial circulation was terminated and normal circulation was
restored, plasma I-FABP levels increased further (DAP 763.9 (200.7) pg/mL, P >
0.05; DAP & SP 2351.0 (378.1) pg/mL, P < 0.001) and remained elevated for
six hours. The release of I-FABP in patients undergoing DAP & SP was clearly
more pronounced than in patients undergoing DAP, indicating more intestinal
injury in the DAP & SP group. Total AUC of systemically measured I-FABP was
calculated for both groups and revealed significantly more I-FABP release in the
DAP & SP patient group (P < 0.05, data not shown).
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Figure 2: Elevated plasma I-FABP and L-FABP levels in patients undergoing DAP or DAP and SP.
A ,highest values for I-FABP reflecting intestinal injury were found during reperfusion for both
groups. B, systemic plasma L-FABP values measured in both patient groups mimicked I-FABP
release, potentially represented as mean ± SEM and are compared with preoperative values. Data
were analyzed using paired Student t-test with posthoc Bonferroni correction. *P< 0.01; **P <
0.001
Intestinal mucosal cell injury leads next to I-FABP release to L-FABP
release, although, plasma L-FABP increase can also be caused by liver and
renal tubular cell injury. L-FABP plasma levels showed a similar pattern as I-
FABP, potentially supporting intestinal injury (Fig. 2B). The total calculated
AUCL-FABP was significantly higher in patients undergoing DAP & SP (P < 0.01,
data not shown).
To ascertain the intestinal origin of the released I-FABP and L-FABP during
and shortly after ECC, the arteriovenous concentration differences were
measured in eight patients (N = 8) undergoing DAP & SP (Fig. 3A). In line with
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the systemic measurements, before starting ECC there was no fractional
increase in I-FABP indicating the absence of I-FABP release (+ 0.3 (1.8) %).
However, during ECC with DAP & SP a significant release of I-FABP was found
(+ 53.5 (11.2) %, P < 0.001), which still occurred at 15 minutes after ECC had
been stopped (+ 28.0 (3.3) %, P < 0.05). Similar to the I-FABP release reported
above, no detectable L-FABP release from the gut was found before starting
ECC with DAP & SP (+ 1.9 (2.8) %). During ECC with DAP & SP, L-FABP release
from the intestinal mucosa increased significantly (+ 103.0 (17.5) %, P < 0.001)
and release of L-FABP, specifically indicating intestinal injury, was still
statistically significant shortly after ECC perfusion was terminated and normal
circulation was restored (+ 51.5 (13.9) %, P < 0.05).
Since L-FABP is next to the gut also expressed in liver and kidneys, we
studied hepatocellular and renal tubular cell injury. To exclude liver injury, ALT
was measured at three different time-points (Fig. 3B); ALT, a cytosolic enzyme
mainly expressed in the liver, was not elevated in the early reperfusion phase or
at post-operative day 1. These data support the intestinal origin of L-FABP
release during open TAA / TAAA repair.
Potentially, renal tubular cell injury also results in elevated plasma L-FABP
concentrations. Therefore, to evaluate release from injured renal tubular cells,
we measured arteriovenous concentration differences of L-FABP for the left
kidney from the same eight patients as reported above. The calculated mean
arteriovenous concentration difference before going on ECC was - 21.5 (4.0) %.
During ECC with DAP & SP (- 27.6 (6.0) %) and after ECC, when the patients
were on normal visceral circulation again (- 22.8 (4.4) %), arteriovenous
concentration differences were not significantly altered compared to values
before ECC, indicating an absence of release from injured renal tubular cells
(data not shown).
To analyze correlations between intestinal organ injury markers I-FABP
and L-FABP, the total AUCI-FABP and AUCL-FABP, of all patients undergoing ECC
(N = 30) were correlated (Fig. 5). A strong positive correlation was found
between AUCI-FABP and AUCL-FABP (r 0.70, P < 0.0001).
Taken together, the circulating plasma levels of both I-FABP and L-FABP
were elevated during ECC and a further increase was observed in the early
phase of restored normal circulation in patients undergoing open TAA / TAAA
repair. This indicates intestinal injury, with release of these proteins being more
prominent when ECC with DAP & SP was used.
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Systemic Inflammatory Response and Extracorporeal Circulation during TAA
/ TAAA repair
Circulating pro-inflammatory cytokines IL-6 and IL-8 were measured in order to
evaluate the inflammatory response associated with TAA / TAAA repair. Plasma
concentrations of IL-6 before ECC started were not significantly different from
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Figure 3: Intestinal I- FABP and intestinal L-FABP release was evaluated using arteriovenous
concentration difference in 8 patients undergoing ECC with DAP and SP. Arterial blood from the
radial artery (or the arterial line of the ECC ) and the portal vein were simultaneously sampled and
intestinal I-FABP and L-FABP release was calculated using the following formula: venous
concentration minus arterial concentration divided by arterial concentration x 100% A, significant
release of I-FABP and L-FABP from the gut was observed during ECC and directly in the
reperfusion phase when normal visceral circulation was restored. B, circulating concentrations
ALT, a specific liver enzyme was measured preoperatively, at 2 hours reperfusion and at day 1
postoperatively. ALT levels showed no signifficant increase at the given time points, indicating no
significant liver injury. Values are shown as mean ± SEM and compared with preoperative values
(or values found during Cannulation for Fig. 3A) using paired Student t-tests with posthoc
Bonferroni correction. *P< 0.05; **P< 0.001
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baseline values (Fig. 4A). Although changes in plasma IL-6 levels were observed
in both patient groups, the mean IL-6 values measured in the DAP patients
group were not statistically significantly altered during the studied period
(ANOVA P > 0.05, data not shown). During visceral perfusion using ECC
combined with DAP & SP plasma IL-6 levels increased significantly, indicating
the development of a systemic inflammatory response (ANOVA P < 0.0001,
data not shown). Release of IL-6 continued until peak-values were reached 2
hours after reperfusion (DAP & SP 295.7 (62.7) pg/mL, P < 0.001), whereas after
6 hours reperfusion and later plasma values lowered, but remained elevated
until day 2 post-operative.
The pro-inflammatory cytokine IL-8, a strong neutrophil attractant, was
detectable in pre-operatively taken blood samples from five out of twenty-two
patients who underwent DAP & SP (Fig. 4B). Initially, plasma IL-8 curves
mimicked IL-6 kinetics, starting to increase during the reperfusion phase in both
groups. However, further increase in plasma IL-8 levels in patients who
underwent ECC with DAP was relatively small (ANOVA P > 0.05, data not
shown), whereas increase in plasma IL-8 was significant in patients who
underwent ECC with DAP & SP (ANOVA P < 0.0001, data not shown), with
peak values found at 2 hours reperfusion (227.4 (43.5) pg/mL, P < 0.05),
indicating a strong pro-inflammatory, chemotactic response in these patients. At
postoperative day 2, plasma IL-8 had almost disappeared, being non-detectable
in patients who underwent DAP, and only detectable in plasma from four out of
twenty-two patients who underwent DAP & SP.
The increase of IL-6 and IL-8 observed during TAA / TAAA repair, indicates
the development of a systemic inflammatory response after DAP or DAP & SP;
IL-8 release was significant in patients undergoing DAP & SP only, signifying a
strong systemic neutrophil attractive response in this patient group.
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Intestinal Injury and Systemic Inflammation in Patients Undergoing
Extracorporeal Circulation
To investigate whether intestinal injury was related to the systemic
inflammatory response, correlations of AUCI-FABP with AUCIL-6 and AUCIL-8 (Fig.
5) were analyzed in all patients undergoing ECC (N = 30). AUCI-FABP correlated
significantly with both AUCIL-6 (r 0.64, P < 0.001) and AUCIL-8 (r 0.54, P < 0.01),
indicating an association between the extent of intestinal organ injury and
systemic inflammation, underlining the need for intestinal organ protection
during TAA / TAAA repair.
172
Chapter 4
Figure 4: The systemic inflammatory response is initiated during ECC.A, increased levels of the
pro-inflammatory cytokine IL-6 are found in patients receiving DAP and SP (TAAA patients) during
artificial visceral perfusion using ECC. Peak values were reached at 2 hours reperfusion (2 hours
R). B, marked IL-8 release in patients receiving DAP and SP. After initial release during ECC
combined with DAP and SP, peak plasma values for patients undergoing TAAA repair were found
at 2 hours reperfusion (2 hours R). Values are mean ± SEM and compared with preoperative values
using paired Student t-tests with posthoc Bonferroni correction. *P< 0.05; **P < 0.001.
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Figure 5: Association between intestinal mucosal cell injury and systemic inflammation in
patients undergoing open TAA/TAAA repair. Total AUCs of I-FABP, L-FABP, IL-6, and IL-8 of the
patient were measured from preoperative up until day 2 postoperative. Data are matched
observations, and degree of correlation is represented by Spearman r. Visceral injury, denoted by
AUCI-FABP, strongly correlated with AUCL-FABP, AUCIL-6, and AUCIL-8. These data suggest
intestinal injury to play a significant role in systemic inflammation in patients undergoing open
TAA/TAAA repair.
DISCUSSION
In this study intestinal mucosal cell injury, but not hepatic or renal tubular cell
injury, occurred in patients undergoing elective open TAA or TAAA repair,
despite artificial visceral perfusion using ECC with either DAP (TAA patients) or
ECC with DAP & SP (TAAA patients). The extent of intestinal injury and pro-
inflammatory reaction was more pronounced in patients undergoing DAP & SP.
Furthermore, intestinal injury correlated positively with markers of systemic
inflammation.
Visceral perfusion by means of ECC is used to ensure volume and pressure
controlled blood flow to abdominal organs, preventing the deleterious effects of
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intestinal injury.3 ECC with antegrade aortic perfusion is a well-known
technique used in cardiac surgery and acknowledged to induce intestinal
injury.11 Holmes et al. showed elevated urine I-FABP levels following CABG
surgery and suggested that intestinal mucosal injury plays a role in inducing a
complicated post-operative course.14 The use of ECC with either DAP or DAP &
SP in patients undergoing open TAA / TAAA repair was first described in the
1980s, and these techniques have since been further refined.28, 29 We described
our first experiences with ECC and DAP or DAP & SP in the mid-90s, and both
were considered safe techniques to prevent postoperative renal injury, assessed
by urine output and serum creatinine following TAA / TAAA repair, and possibly
intestinal injury, by subjective observation of the intestines and intestinal
motility peri- and post-operatively.8, 19
In the present study, the development of injury to visceral organs was
investigated using measurements of plasma I-FABP and L-FABP for intestinal,
ALT for hepatic, and L-FABP for renal tubular injury. Our data show
development of intestinal injury during artificial perfusion of the viscera using
ECC, and shortly thereafter when normal perfusion to the viscera was restored.
ECC with DAP caused elevated plasma levels of I-FABP and L-FABP, and ECC
with DAP & SP led to significantly elevated circulating I-FABP and L-FABP
levels, despite the intended protective effect of artificial visceral perfusion in
patients undergoing open TAA / TAAA repair. The arteriovenous concentration
differences over the intestines demonstrate significant release of I-FABP and L-
FABP in patients undergoing ECC with DAP & SP. During reperfusion the
systemic plasma concentration of both I-FABP and L-FABP initially further
increased, suggesting either continued wash-out of these proteins from the
injured gut mucosa or sustained hypoperfusion injury leading to continued
enhanced release of both proteins. These data are in line with low flow states in
patients with hypovolemic or cardiogenic shock and inherent blood flow
redistribution towards the heart and central nervous system at the expense of
visceral organs. The intestinal mucosal epithelial cells are due to the specific
anatomy of the small intestinal villus more susceptible to visceral hypoperfusion
than hepatocytes or renal epithelial cells. In particular the cells at the tip of the
villus, which contain I-FABP and L-FABP, are due to the sympathetic innervation
of the arterioles and vascular anatomy of the villus, most vulnerable to
hypoperfusion.10, 11 At this moment we investigate the mechanisms that
potentially underlie this visceral hypoperfusion.
Total intestinal injury seen during ECC was assessed by AUCI-FABP, and
correlated positively with the AUCIL-6 and AUCIL-8, suggesting an association
between the extent of intestinal mucosal injury and the extent of systemic
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inflammation. Morariu et al. (2005) studied the alleged protective use of
dexamethasone on the inflammatory response and intestinal injury after CABG
surgery with the use of antegrade aortic perfusion.17 Even though the
inflammatory response was attenuated by dexamethasone, no effect on
intestinal injury markers was seen, hereby suggesting the inflammatory
response to be a result and not so much a cause of intestinal injury.
Pharmacological approaches to reduce visceral hypoperfusion and its
sequelae can be directed at either improvement of perfusion or reduction of
ischemic injury. Increasing microcirculatory blood flow, especially in the
intestines, by pharmacological intervention (e.g. ACE-inhibitors, ET-receptor
antagonists or catecholamine therapy) has been shown beneficial in animal
studies,30, 32 Furthermore, also antioxidant therapy (e.g. nitroxide, ascorbic acid
or mannitol) has been shown effective in reducing ischemic injury to the
intestines in animals.33, 34 Future studies are needed to evaluate such
interventions in the human setting.
The differences in extent of intestinal injury that was observed between
DAP during open TAA repair and DAP & SP during open TAAA repair is not
easily clarified. Aortic cross clamp times or total perfusion times were similar
between the groups. The most likely explanation for the difference in intestinal
injury is a more prominent hypoperfusion of the intestines during ECC with DAP
& SP. Idu et al. showed in a pig model a significant decrease in blood flow per
minute to the cranial mesenteric artery when clamping the aorta and perfusion
was taken over with ECC and selective organ perfusion.35 Also, Leijdekkers et al.
calculated that the flow to visceral organs during ECC with DAP & SP is limited
and insufficient to maintain tissue perfusion due to the internal diameter in SP
catheters used in patients undergoing open TAAA repair.36 The flow administered
through the selective organ perfusion catheter system during aortic clamping
may be too low in our patients, creating an absolute state of ‘functional’
hypoperfusion to the intestines. It is of interest however that during the
reperfusion phase especially in the DAP & SP group the intestinal injury further
increases. This suggests that during ECC a process has been initiated that results
in ongoing increased intestinal mucosal cell injury, potentially through a
prolonged ‘functional’ hypoperfusion. The mechanisms leading to visceral
hypoperfusion during and after ECC in patients undergoing open TAA / TAAA
repair remain to be resolved. Such information will be instrumental in
developing strategies to prevent the intestinal injury and subsequent systemic
inflammatory response induced by ECC with DAP or DAP & SP.
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CONCLUSION
Increased plasma I-FABP and L-FABP levels, representative of intestinal injury,
and elevated plasma IL-6 and IL-8 concentrations, indicative of systemic
inflammation, were observed in patients undergoing open TAA / TAAA repair,
despite ECC with either DAP or DAP & SP. Our data show that intestinal injury
precedes the development of a systemic inflammatory response and correlates
positively with the extent of systemic inflammation, supporting the hypothesis
that intestinal tissue injury is involved in the development and extent of a
systemic inflammatory response.
REFERENCES
1. Rectenwald JE, Huber TS, Martin TD, et al. Functional outcome after thoracoabdominal
aortic aneurysm repair. J Vasc Surg 2002; 35(4):640-7.
2. Gloviczki P. Surgical repair of thoracoabdominal aneurysms: patient selection,
techniques and results. Cardiovasc Surg 2002; 10(4):434-41.
3. Achouh PE, Madsen K, Miller CC, 3rd, et al. Gastrointestinal complications after
descending thoracic and thoracoabdominal aortic repairs: a 14-year experience. J Vasc
Surg 2006; 44(3):442-6.
4. Fink MP. Gastrointestinal mucosal injury in experimental models of shock, trauma, and
sepsis. Crit Care Med 1991; 19(5):627-41.
5. Moore FA. The role of the gastrointestinal tract in postinjury multiple organ failure. Am
J Surg 1999; 178(6):449-53.
6. MacArthur RG, Carter SA, Coselli JS, LeMaire SA. Organ protection during
thoracoabdominal aortic surgery: rationale for a multimodality approach. Semin
Cardiothorac Vasc Anesth 2005; 9(2):143-9.
7. Welborn MB, Oldenburg HS, Hess PJ, et al. The relationship between visceral ischemia,
proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal
aortic aneurysm repair. Crit Care Med 2000; 28(9):3191-7.
8. Jacobs MJ, de Mol BA, Legemate DA, et al. Retrograde aortic and selective organ
perfusion during thoracoabdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg
1997; 14(5):360-6.
9. Jacobs MJ, Mommertz G, Koeppel TA, et al. Surgical repair of thoracoabdominal aortic
aneurysms. J Cardiovasc Surg (Torino) 2007; 48(1):49-58.
10. Takala J. Determinants of splanchnic blood flow. Br J Anaesth 1996; 77(1):50-8.
176
Chapter 4
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 176
11. Ohri SK, Somasundaram S, Koak Y, et al. The effect of intestinal hypoperfusion on
intestinal absorption and permeability during cardiopulmonary bypass.
Gastroenterology 1994; 106(2):318-23.
12. Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric
intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary
bypass. Jama 1996; 275(13):1007-12.
13. Rossi M, Sganga G, Mazzone M, et al. Cardiopulmonary bypass in man: role of the
intestine in a self-limiting inflammatory response with demonstrable bacterial
translocation. Ann Thorac Surg 2004; 77(2):612-8.
14. Holmes JHt, Lieberman JM, Probert CB, et al. Elevated intestinal fatty acid binding
protein and gastrointestinal complications following cardiopulmonary bypass: a
preliminary analysis. J Surg Res 2001; 100(2):192-6.
15. Bolcal C, Iyem H, Sargin M, et al. Gastrointestinal complications after cardiopulmonary
bypass: Sixteen years of experience. Can J Gastroenterol 2005; 19(10):613-7.
16. Sato K, Sogawa M, Namura O, Hayashi J. Deterioration of body oxygen metabolism by
vasodilator and/or vasoconstrictor administration during cardiopulmonary bypass.
Asaio J 2006; 52(1):96-9.
17. Morariu AM, Loef BG, Aarts LP, et al. Dexamethasone: benefit and prejudice for
patients undergoing on-pump coronary artery bypass grafting: a study on myocardial,
pulmonary, renal, intestinal, and hepatic injury. Chest 2005; 128(4):2677-87.
18. Crawford ES. Thoraco-abdominal and abdominal aortic aneurysms involving renal,
superior mesenteric, celiac arteries. Ann Surg 1974; 179(5):763-72.
19. Jacobs MJ, Eijsman L, Meylaerts SA, et al. Reduced renal failure following
thoracoabdominal aortic aneurysm repair by selective perfusion. Eur J Cardiothorac
Surg 1998; 14(2):201-5.
20. Lieberman JM, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding
protein: report of an assay with studies in normal volunteers and intestinal ischemia.
Surgery 1997; 121(3):335-42.
21. Niewold TA, Meinen M, van der Meulen J. Plasma intestinal fatty acid binding protein
(I-FABP) concentrations increase following intestinal ischemia in pigs. Res Vet Sci 2004;
77(1):89-91.
22. Pelsers MM, Namiot Z, Kisielewski W, et al. Intestinal-type and liver-type fatty acid-
binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem
2003; 36(7):529-35.
23. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of
tissue injury. Clin Chim Acta 2005; 352(1-2):15-35.
24. Ytting H, Christensen IJ, Basse L, et al. Influence of major surgery on the mannan-
binding lectin pathway of innate immunity. Clin Exp Immunol 2006; 144(2):239-46.
177
Gut wall integrity loss in critical illness and surgery
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 177
25. Fiane AE, Videm V, Lingaas PS, et al. Mechanism of complement activation and its role
in the inflammatory response after thoracoabdominal aortic aneurysm repair.
Circulation 2003; 108(7):849-56.
26. Dentener MA, Bazil V, Von Asmuth EJ, et al. Involvement of CD14 in
lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by
human monocytes and alveolar macrophages. J Immunol 1993; 150(7):2885-91.
27. Derikx JP, Poeze M, van Bijnen AA, et al. Evidence for intestinal and liver epithelial cell
injury in the early phase of sepsis. Shock 2007; 28(5):544-8.
28. Laschinger JC, Cunningham JN, Jr., Nathan IM, et al. Experimental and clinical
assessment of the adequacy of partial bypass in maintenance of spinal cord blood flow
during operations on the thoracic aorta. Ann Thorac Surg 1983; 36(4):417-26.
29. Kazui T, Yamada O, Ito T, et al. [Total graft replacement of the thoracoabdominal aorta
with reconstruction of visceral branches, intercostal and lumbar arteries in expanding
chronic dissecting aneurysms of the thoracoabdominal aorta]. Nippon Kyobu Geka
Gakkai Zasshi 1989; 37(7):1436-40.
30. Bailey RW, Bulkley GB, Hamilton SR, et al. Pathogenesis of nonocclusive ischemic
colitis. Ann Surg 1986; 203(6):590-9.
31. Krejci V, Hiltebrand LB, Erni D, Sigurdsson GH. Endothelin receptor antagonist
bosentan improves microcirculatory blood flow in splanchnic organs in septic shock.
Crit Care Med 2003; 31(1):203-10.
32. Sautner T, Wessely C, Riegler M, et al. Early effects of catecholamine therapy on
mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin
shock. Ann Surg 1998; 228(2):239-48.
33. Gunel E, Caglayan F, Caglayan O, et al. Treatment of intestinal reperfusion injury using
antioxidative agents. J Pediatr Surg 1998; 33(10):1536-9.
34. Udassin R, Haskel Y, Samuni A. Nitroxide radical attenuates ischaemia/reperfusion
injury to the rat small intestine. Gut 1998; 42(5):623-7.
35. Idu MM, Heintjes RJ, Scholten EW, et al. Visceral and renal tissue oxygenation during
supraceliac aortic crossclamping and left heart bypass with selective organ perfusion.
Eur J Vasc Endovasc Surg 2004; 27(2):138-44.
36. Leijdekkers VJ, Wirds JW, Vahl AC, et al. The visceral perfusion system and distal bypass
during thoracoabdominal aneurysm surgery: an alternative for physiological blood
flow? Cardiovasc Surg 1999; 7(2):219-24.
178
Chapter 4
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 178
4.5 New insight in loss of gut
barrier during major non-
abdominal surgery
Joep P. M. Derikx, Dick A. van Waardenburg, Geertje Thuijls,
Henriëtte M. Willigers, Marianne Koenraads, Annemarie A. van Bijnen,
Erik Heineman, Martijn Poeze, Ton Ambergen, André van Ooij,
Lodewijk W. van Rhijn, Wim A. Buurman
PLoS ONE, (2008) 3: e3954.
179
Gut wall integrity loss in critical illness and surgery
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 179
ABSTRACT
Background
Gut barrier loss has been implicated as a critical event in the occurrence of
postoperative complications. We aimed to study the development of gut barrier
loss in patients undergoing major non-abdominal surgery.
Methodology/Principal Findings
Twenty consecutive children undergoing spinal fusion surgery were included.
This kind of surgery is characterized by long operation time, significant blood
loss, prolonged systemic hypotension, without directly leading to compromise
of the intestines by intestinal manipulation or use of extracorporeal circulation.
Blood was collected preoperatively, every two hours during surgery and 2, 4,
15 and 24 hours postoperatively. Gut mucosal barrier was assessed by plasma
markers for enterocyte damage (I-FABP, I-BABP) and urinary presence of tight
junction protein claudin-3. Intestinal mucosal perfusion was measured by
gastric tonometry (PrCO2, Pr-aCO2-gap).
Plasma concentration of I-FABP, I-BABP and urinary expression of
claudin-3 increased rapidly and significantly after the onset of surgery in most
children. Postoperatively, all markers decreased promptly towards baseline
values together with normalisation of MAP. Plasma levels of I-FABP, I-BABP
were significantly negatively correlated with MAP at 1/2 hour before blood
sampling (-0.726 (p<0.001), -0.483 (P<0.001), respectively). Furthermore,
circulating I-FABP correlated with gastric mucosal PrCO2, Pr-aCO2-gap
measured at the same time points (0.553 (p=0.040), 0.585 (p=0.028),
respectively).
Conclusions/Significance
This study shows the development of gut barrier loss in children undergoing
major non-abdominal surgery, which is related to preceding hypotension and
mesenterial hypoperfusion. These data shed new light on the potential role of
peroperative circulatory perturbation and intestinal barrier loss.
180
Chapter 4
Joep Derikx druk:proefschrift  20-04-2009  16:11  Pagina 180
INTRODUCTION
Patients undergoing major surgery or sustaining severe trauma are at risk of
developing morbidity and mortality from postoperative or posttraumatic
systemic inflammatory response syndrome (SIRS), sepsis and multiple organ
failure (MOF). The development of such potentially lethal complications in
relatively healthy surgical or trauma patients is poorly understood 1, 2. Moreover,
few human studies investigated the hypothesis, generated from animal studies,
that the intestines are central in the origin of postoperative and posttraumatic
sequelae 3-5. Major surgery accompanied by systemic hypotension and blood
loss is thought to lead to redistribution of blood to preserve the vital organs
(brain and heart) at the expense of the splanchnic circulation 3-5. Low mesenteric
blood flow subsequently leads to injury of the cells at the most distal point from
the mucosal blood supply, being the mature enterocytes 6.
Experimental animal models, resembling the clinical situation of major
surgery and trauma, show that haemorrhagic shock leads to disruption of the
gut barrier, measured by elevated circulating levels of Fatty Acid Binding
Proteins (FABP), originating from damaged intestinal epithelial cells and
derangement of tight-junctions 7, 8. Moreover, translocation of macromolecules,
microbial products and microbiota from the intestinal lumen to the circulation
and mesenteric lymph nodes, spleen and liver occur 5, 7. The inflammatory
response to translocated microbial products as endotoxin has been reported to
be induced via various innate immune mechanisms, ranging from Toll Like
Receptors to complement activation 9, 10.
Studies in patients undergoing major gastro-intestinal, cardiac or vascular
surgery, investigating the role of the gut in the development of postoperative
complications, are largely restricted to data on increased intestinal permeability for
sugars, 51Cr-EDTA and the circulatory levels of endotoxin 11-19. Several authors
report changes in these parameters in patients following major surgery, indicating
that the gut barrier is injured 11-14. However, other reports using these tests lack to
support these data 15-18. Moreover, the value of measuring gut barrier with the use
of sugar absorption probes is argued 19. In conclusion, the debate regarding the
involvement of the gut in patients undergoing major surgery is still open.
Plasma and urinary markers are currently available as useful non-invasive
tools to study the condition of enterocytes and tight-junctions (TJ), the two
components comprising the gut mucosal barrier. Enterocyte damage was
assessed using plasma levels of Intestinal-Fatty Acid Binding Protein (I-FABP), a
small cytosolic, water-soluble protein, primarily limited to mature enterocytes
of small and large intestine 20. I-FABP plasma levels rise rapidly after episodes
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of acute intestinal ischaemia and inflammation 20-22. Next, also circulating
levels of Ileal-Bile Acid Binding Protein (I-BABP), which is exclusively present
in mature enterocytes of the jejunum and ileum, were assessed 23. TJ between
neighbouring enterocytes are an important constituent of the intestinal
epithelial barrier 24. The transmembrane TJ protein Claudin-3, the essential
sealing protein, disappears rapidly from the TJ following haemorrhagic shock
and is released into the urine (own unpublished data).
The principal aim of this study was to investigate whether major non-
abdominal surgery leads to intestinal barrier loss.
METHODS
Study design and patients
This is a prospective clinical observational study in children undergoing spinal
fusion surgery because of scoliosis in the University Hospital Maastricht between
March 2006 and October 2007. Major spinal fusion surgery is characterized by
long operation time, significant blood loss, prolonged systemic hypotension and
the potential development of postoperative complications 25. This type of surgery
was chosen because it does not directly compromise the intestines by intestinal
manipulation or the use of extracorporeal circulation 25.
Informed, written consent was obtained by all patients or both parents/
caretakers whose information was used in the study prior to inclusion; the study
was conducted with approval from the local medical ethical committee.
Surgical procedures
Preoperative preparation and anaesthesia
Anaesthesia was induced and maintained with either a volatile based technique
with sevoflurane or an intravenous technique with propofol, combined with an
opioid and a non-depolarising muscle relaxant. Sensory evoked potentials were
monitored in patients at risk for spinal cord problems during surgery. According
to the hospital protocol an intravenous technique with propofol was used in
these patients. All patients were intubated and ventilator settings were adjusted
to obtain normocapnia. Each patient had a forced-air warming system and all
intravenous fluids were warmed to prevent hypothermia.
In addition to standard monitoring an arterial line was inserted into a
radial artery to measure arterial pressure and to sample arterial blood, and a
catheter was introduced into the bladder to measure urine output. Blood-
soaked gauzes were weighted as they were passed off the surgical field and the
blood content of the cell saver was measured to measure blood loss.
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Perioperative fluid therapy was adapted to the individual patient with the aim to
keep the patient normovolaemic throughout the operation. Isotonic crystalloids
were used for maintenance and third space losses. Blood loss was replaced 1:1
with blood or colloid or 3:1 with crystalloids. Fluid administration was guided
by calculation of maintenance and third space losses, blood loss, the arterial
blood pressure, and haemoglobin values. There was no protocol to keep the
blood pressure above or below a certain value.
Surgery
All the operations were performed by 2 senior spine surgeons (LvR and AvO)
using three fusion approaches: posterior spinal fusion (PSF), anterior spinal
fusion (ASF), and combined anterior and posterior fusion. The decision regarding
the preferred fusion was made based on curve location, aetiology, rigidity, and
the child’s age, according to the current standards of scoliosis operative repair.
In PSF, the patient was positioned prone on padded chest rolls, rolled blanket
bolster, or a Wilson spinal frame to provide adequate cushioning for the chest and
abdomen while allowing vacant space preventing abdominal pressure. The skin
was incised in a straight line over the vertebrae to be fused. Following osteotomy of
all the spinous processes and facets included at the fusion area, the vertebrae were
instrumented with combinations of pedicle-screws and hooks (CD Horizon Legacy
5.5 or 4.5 spinal systems, Medtronic, Heerlen, the Netherlands). Curve correction
was performed with a combination of derotation and compression–distraction
manoeuvres, and, if necessary, also by in situ bending of the rods. In ASF, the
patient was placed on the operating table in the lateral position. The approach is
from the convex scoliotic side. A thoracoabdominal approach, which included a
split of the diaphragm near its insertion, retroperitoneal approach, or lateral
intrathoracic approach was performed through the side of the curve convexity, with
the patient lying on his side. Following exposure of the vertebrae, the involved
discs and ribs were excised and the segmental vessels ligated or preserved. In all
cases of combined fusion, single-staged procedures were carried out.
CD Horizon Legacy 5.5 or 4.5 spinal systems were used depending on
age and weight of the patient. In case of anterior instrumentation CD Horizon
Eclipse spinal system was used (Medtronic). No drains were used.
Postoperative care
At the end of the surgery, all the children were transferred to the paediatric
Intensive Care Unit (ICU). Extubation was performed after stabilization of vital
signs and according to accepted weaning parameters (usually 4–6 hours after
surgery). Paediatric ICU management was provided by the attending physicians
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guided by the same general management strategy and consisted of intravenous
fluid administration, correction of hypovolaemia, electrolyte disturbances and/or
anaemia and analgesics (acetaminophen and morphine). Antibiotic cover
(amoxicillin with clavulanate) was given starting preoperatively until 24 hours
after the end of surgery. Oral feeding was introduced the day after surgery.
Follow-up in the ICU included a daily physical examination, vital signs
monitoring, routine blood tests, and chest radiographs or other ancillary tests as
required. The attending physicians recorded complications and events.
Blood and urine sampling
Blood samples were collected from the arterial line in pre-chilled EDTA
vacuum tubes (BD vacutainer, Becton Dickinson Diagnostics, Aalst, Belgium)
and kept on ice. Blood was centrifuged at 4°C, 4000 x G for 15 minutes.
Plasma was immediately stored in aliquots at -80°C until analysis. Blood was
sampled before surgery (after the induction of anaesthesia), at 2 hours intervals
during surgery and 2, 4, 15 and 24 hours postoperatively from the arterial line.
Fresh specimens of urine were collected from the urinary bladder catheter,
kept on ice and then frozen at -80°C in aliquots within 2 hours of collection.
Urine was collected every 20 minutes in the first 2 hours during surgery and
thereafter at the same moments as blood was sampled.
Measurements of FABP and claudin-3
Plasma concentrations of I-FABP were determined using a highly specific
commercially available enzyme-linked immunosorbent assay (ELISA) that
selectively detects human I-FABP (standard: 20-5,000 pg/ml), kindly provided
by Hycult Biotechnology (Uden, the Netherlands) and I-BABP (standard: 0.32-
5 ng/ml) as previously described 26.
Claudin-3 urine levels were analyzed by western blotting. Equal amounts of
each sample (adjusted to urinary creatinine levels) were separated by SDS-PAGE
gel, transferred to PVDF-membrane and probed using primary antibody to
claudin-3 (Rabbit anti-claudin-3 (34-1700), Zymed Laboratories, San Francisco,
CA). After incubation with goat anti rabbit HRP-conjugated secondary antibody
(Jackson, West Grove, PA), signal was detected by supersignal west pico
chemiluminescence substrate (Pierce, Etten-Leur, the Netherlands). Band intensity
was semi-quantitatively analyzed using Quantity One (Biorad, Hercules, CA).
Measurements of gastric mucosal tonometry
A gastric tonometry catheter (14F, Datex Ohmeda, Helsinki, Finland) was
introduced for measurement of intramucosal carbon dioxide pressure (PrCO2 in
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kPa) throughout the surgical procedure in the last seven patients, using the gas-
automated capnograph (Tonocap TC-200, Datex-Ohmeda).
Gastric tonometry measurements (PrCO2, and mucosal-arterial pCO2 gap
(Pr-aCO2-gap)) were measured at 30-minute intervals from the start until the end
of surgery using gas-automated capnography. The pCO2 values of the blood
gases were corrected for the central blood temperature measurements, using the
formulas provided by the manufacturer (ABL 100, Radiometer, Copenhagen,
Denmark).
Statistical analysis
Statistical analysis was performed with Prism 4.0 for Windows (GraphPad
Software Inc. San Diego, CA) and SPSS 15.0 (SPSS, Inc., Chicago, IL). Plasma
FABP concentrations were presented as mean ± standard error (SEM).
Normality of all data obtained was verified by Kolmogorov-Smirnov test.
Linear mixed model regression was used to analyze changes over time in
plasma FABP levels. Within-person correlations between mean arterial pressure
(MAP), PrCO2/CO2-gap and circulating levels of FABP at all studied time points
were computed. Mixed model analysis accounts for unbalanced numbers of
samples measured, because at some time points not all samples could be
obtained because of removal of the arterial line. Differences in plasma FABP
levels between individual time periods were compared using t tests of the
mixed model procedure. Next, to characterize the total amount of intestinal
mucosal cell injury during surgery, area under the curve (AUC) for I-FABP and
I-BABP was calculated for each patient. The AUCI-FABP and AUCI-BABP for
patients with and without early complications was compared using unpaired t
test. Early complications were defined as complications occurring in the
intraoperative or initial hospitalization period.
A p-value below 0.05 was considered to be statistically significant.
RESULTS
Patients
Twenty patients undergoing spinal fusion surgery were consecutively included
in the study, 15 girls and 5 boys. Median age was 12 years (range: 2-16 years).
Demographic, surgical and fluid balance data are presented in Table 1.
Intraoperative fluid resuscitation was adequate as evidenced by; 1) a mean
(SEM) positive fluid balance (total fluid in minus blood loss) of 13 (1) ml/kg/hr;
2) adequate diuresis; 3) low plasma lactate levels and; 4) adequate plasma
haemoglobin value (data not shown).
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Table 1: Demographic, surgical and fluid balance characteristics.
No0 AGe Weight Surgery1 Duration History2
(y) (kg) surgery (hr)
1 8 36 ASF T7-L4 6 Spina bifida hydrocephalus
2 15 40 ASF+PSF 8 cerebral palsy,
T3-S1 Spastic diplegia,IVH
3 12 51 ASF+PSF T12-L3 8 -
4 12 31 ASF+PSF 9 DiGeorge syndrome;
T2-S1 Vascular spinal cord lesion
5 13 59 PSF T4-L3 6 cleft lip nose deformity
6 11 37 PSF T3-T12 4 spina bifida occulta
7 8 45 PSF T2-L5 4 spinal muscular atrophy
8 10 48 ASF T6-T12 4 -
9 14 33 PSF T3-S1 8 spastic tetraplegia,
panencephalitis
10 15 55 ASF T6-T12 4 -
11 2 9 ASF T12-L2 2 Conradi-Hünermann
Happle syndrome
12 10 22 ASF+PSF 7 cerebral palsy,
T2-S1 spastic tertraparesis
13 15 82 ASF+PSF 7.5 -
T3-L3
14 16 54 ASF T7-T12 4 -
15 13 20 PSF T2-S1 8 spina bifida;
Arnold Chirari
Type 2 malformaiton
16 13 14 PSF T3-L4 4 Ullrich disease
17 9 16 PSF T3-L4 5 Pierre Robin
Sequence; acampolic
campomelic dysplasia
18 12 52 PSF T6-L1 5 -
19 16 55 PSF T5-L4 6.5 -
20 12 34 PSF L4-S1 6 spondylolisthesis
0 No: patient number in sequence of entrance to the study
1 ASF: anterior spinal fusion; PSF: posterior spinal fusion
2 IVH: intraventricular haemorrhage
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Early Blood loss Fluid in Diuresis Mean (range) Mean (range)
complications3 (ml/kg)4 (ml/kg)4 (ml/kg/hr)4 MAP (mmHg)4 lactate (mmol/l)4
fever, UTI 14 103 3.5 57 (52-63) 1.0 (0.8-1.2)
20 131 1.7 54 (41-66) 1.2 (1.0-1.3)
fever, pneumonia 59 163 1.1 56 (50-66) 1.9 (1.6-2.6)
melaena 32 190 1.5 59 (45-77) 1.6 (0.8-1.9)
- 53 156 2.5 65 (56-70) 1.3 (1.2-1.4)
- 11 95 1.5 81 (70-95) 1.8 (1.6-2.1)
- 14 68 1.9 55 (51-60) 0.9 (0.7-1.1)
- 13 73 4.2 66 (59-75) 1.5 (1.2-1.9)
- 91 341 5.3 65 (51-80) 1.2 (0.8-1.5)
- 5 109 1.2 79 (70-101) 2.6 (1.6-3.5)
- 1 34 0.3 58 (51-70) 1.4 (1.1-1.6)
- 9 203 1.3 50 (39-56) 1.3 (1.1-1.5)
Fever, wound 30 103 2.5 64 (53-88) 1.1 (0.9-1.2)
infection
- 4 56 0.8 71 (63-82) 0.8 (0.6-1.3)
peroperative 75 180 1.0 53 (33-78) 0.9 (0.8-1.1)
anaphylactic
shock to Venofundin
- 41 129 0.3 59 (41-72) 0.7 (0.5-0.8)
- 6 94 1.1 67 (57-93) 1.1 (0.9-1.4)
UTI 6 58 2.8 68 (60-81) 0.9 (0.7-1.1)
- 40 123 1.3 70 (58-87) 0.7 (0.6-1.0)
- 18 103 0.9 56 (49-73) 0.8 (0.7-0.9)
3 UTI: urinary tract infection
4 these parameters are measured intra-operatively
y: years, kg: kilograms, hr: hours, MAP: mean arterial pressure.
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Plasma I-FABP, I-BABP
The plasma concentration of I-FABP increased rapidly after the initiation of
surgery from a mean (SEM) baseline value of 221 (32) pg/ml shortly before start
of surgery, under anaesthesia (in-house mean normal value: 106 pg/ml, range:
41-336 pg/ml) to 348 (44) pg/ml at 2 hours after the onset of surgery (p=0.006)
(Figure 1a). Thereafter, the mean plasma levels increased further to 369 (33)
pg/ml (p<0.001) at 4 hours after initiation of surgery. The peak value of 443 (69)
pg/ml (p<0.001) was reached at 6 hours after the start of surgery, which often
represented the end of surgery. Thirteen patients showed an increase in plasma
I-FABP levels of at least twofold during surgery; while 7 patients had relatively
unchanged circulating I-FABP values. Plasma concentrations of I-FABP
decreased towards baseline values from 2 hours after the end of surgery
onwards.
Similar to the I-FABP levels, mean I-BABP plasma concentrations also
increased significantly between 2 and 8 hours after start of surgery compared to
baseline values in most of the patients (Figure 1b).
Since FABP are excreted by the kidneys, we evaluated whether high
plasma values of FABP could be caused by impaired renal function. Diuresis
during and after surgery was adequate (Table 1) and plasma creatinine values
were not elevated, which indicates that elevation of plasma FABP was caused
by enterocyte cell death.
Figure 1: Time course of mean (SEM) plasma I-FABP (a) and I-BABP (b) levels in children
undergoing spinal fusion surgery (n=20).
* p<0.05 vs. baseline values.
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Urinary claudin-3
The urinary claudin-3:creatinine ratio immediately increased during the first 20
minutes of surgery. In the next 2 hours, the claudin-3:creatinine ratio remained
high and thereafter a decrease towards preoperative values was detected (Figure 2).
Figure 2: Time course of urinary claudin-3:creatinine ratio of two representative of the last five
children undergoing spinal fusion surgery.
Gastric tonometry and mean arterial pressure in relation to intestinal damage
The very short circulating half-life of FABP (approximately 11 minutes) 27 allows
to relate the presence of enterocyte cell damage with preceding systemic
hypotension and gastric mucosal hypoperfusion. To this end within-person
correlations were studied between circulating levels of I-FABP, I-BABP and
intraoperative MAP at 1/2 hour before the blood sample was collected in which
FABP concentration was measured, and PrCO2, Pr-aCO2-gap at the same
moment of blood sampling. Interestingly, plasma levels of I-FABP, I-BABP were
significantly negatively correlated with MAP at 1/2 hour before blood sampling
(correlation: -0.726 (p<0.001); -0.483 (P<0.001), respectively), indicating a
relationship between enterocyte cell damage and preceding systemic
hypotension (Figure 3, Table 2). Furthermore, circulating values of I-FABP
correlated with gastric mucosal PrCO2 and Pr-aCO2-gap measured at the same
time points (correlation: 0.553 (p=0.040) and 0.585 (p=0.028), respectively),
whereas no correlation was observed between plasma levels of I-BABP and
PrCO2 or Pr-aCO2-gap. These data show a clear association between the most
prominent plasma marker for enterocyte cell death (I-FABP), hypotension and
splanchnic hypoperfusion, assessed by gastric mucosal PrCO2 and Pr-aCO2-gap.
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Figure 3: Translated values of plasma levels of circulating I-FABP and translated values of preceding
systemic hypotension (MAP t-1/2hr) in children undergoing spinal fusion surgery were plotted.
Circulating I-FABP correlated significantly negatively with MAP at 1/2 hour before blood sampling
(n=89, correlation: -0.726 (p<0.001). Translations of both variables are specific for an individual in
such a way that all within-person means correspond to the zeros in the plot. In this way the
variation of individual levels are cancelled and the pure association of both variables remains.
Complications
Six patients had nine early complications, including postoperative fever (n=3),
urinary tract infection (n=2), pneumonia (n=1), wound infection (n=1),
peroperative anaphylactic reaction to poly(O-2-hydroxyethyl)starch (Venofundin)
(n=1) and melaena of unknown origin (n=1).
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Table 2: Within-person correlations between enterocyte cell damage and preceding systemic
hypotension and gastric mucosal hypoperfusion.
MAP t-1/2 hr (mmHg) PrCO2 (kPa) Pr-aCO2-gap (kPa)
N 89 32 32
I-FABP (pg/ml) -0.726 (P<0.001) 0.553 (P=0.040) 0.585 (P=0.028)
I-BABP (ng/ml) -0.483 (P<0.001) -0.051 (P=0.862) -0.079 (P=0.787)
Within-person correlations between enterocyte cell damage (plasma I-FABP and I-BABP) and
preceding systemic hypotension (mean arterial pressure (MAP) at 1/2 hour before collection of the
blood sample for FABP assessment) and gastric mucosal hypoperfusion (PrCO2, Pr-aCO2-gap at the
same moment of blood sampling). N=number of measurements.
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The mean AUCI-FABP for the six patients with complications was 222 pg*hr/ml
(range: 0-493 pg*hr/ml), while for patients without complications the mean
AUCI-FABP was 81 pg*hr/ml (range: 0-222 pg*hr/ml) (p=0.032) (Figure 4). No
significant changes were found in mean AUCI-BABP during surgery between
patients with and without complications (3.1 vs. 2.0 ng*hr/ml, p=0.341).
Figure 4: Area under the curve of plasma I-FABP values (AUCI-FABP) during surgery for six patients
with early complications and 14 patients without complications. Mean AUCI-FABP was
significantly higher in patients with complications than in patients without complications
(p=0.032). The horizontal lines indicate the mean AUCI-FABP.
DISCUSSION
The data showing an early increase of circulating FABP and urinary claudin-3,
followed by rapid return towards baseline values, indicate that the patients
suffered transient injury to the mature enterocytes and their tight junctions.
Interestingly, similar kinetics of circulating FABP and urinary claudin-3 were
found in all patients, regardless of extension of surgery or amount of blood loss.
It remains to be established whether this insult is sufficient for a breakdown of
the intestinal mucosal barrier, eliciting an inflammatory response and
postoperative complications, as has been shown in animal studies 5, 8, 28.
Although this study was only set up to explore the development of intestinal
mucosal cell damage during major non-abdominal surgery, a limited analysis of
the postoperative course of patients with intestinal mucosal cell damage
revealed that higher plasma levels of I-FABP were associated with a higher rate
of postoperative complications. All possible complications are described as end
point, because this type of surgery in relatively healthy children rarely results in
important complications, including sepsis, MOF and death. Nevertheless, the
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described complications were associated with prolonged hospitalization. Taken
together, this study did not prove causality that the observed gut barrier loss and
inflammation are the inducing factors for SIRS and MOF. Additional work,
enrolling more patients, including those likely to experience serious
complications, is needed in order to fully unravel the sequelae of the observed
gut barrier loss.
Our work is supported by three previous studies showing the temporary
presence of intestinal villous cell damage, measured by increased urinary levels
of I-FABP, in patients undergoing cardiac surgery with cardiopulmonary bypass
(CPB) 29-31. In line, the patients with high urinary I-FABP levels developed
postoperative gastro-intestinal complications 29. The use of CPB was shown to
be responsible for alterations in blood flow with consequently intestinal
mucosal hypoxia and villous tip ischemia 30, 31. In our patients a similar
influence of variation in blood flow on the provocation of intestinal villous cell
injury was found, without the use of extracorporeal circulation.
Hypotension is often accepted to diminish blood loss and thereby
facilitating surgical exposure and reducing the need for blood transfusions
during e.g. oromaxillofacial, neurosurgery and major orthopaedic surgery 32, 33.
Peroperative hypotension is considered to be caused by hypovolaemia and/or
anaesthetics. It is unlikely that the children undergoing spinal fusion repair
were hypovolaemic, because fluids were administered adequately, which is
reflected by positive fluid balance, low plasma lactate levels and sufficient
diuresis. Therefore, anaesthetics are the major cause of low MAP. Propofol and
sevoflurane, which were used in almost all children as anaesthetic agents have
only minimal effects on cardiac output, but they decrease the systemic vascular
resistance significantly, resulting in hypotension 34. However, the fall in blood
pressure together with prolonged surgery and anaemia potentially results in
tissue hypoxia, represented by transient splanchnic hypoperfusion, impairment
of hepatocellular integrity, renal dysfunction and visual loss because of optic
nerve ischemia 32, 33, 35. Our study shows for the first time the relation between
accepted hypotension and the development of intestinal mucosal cellular
damage in patients undergoing major non-abdominal surgery.
The clinical consequences of our findings are challenging. It is clear that
major (non-abdominal) surgery, accompanied by accepted systemic hypotension
aimed at minimizing intraoperative blood loss, can induce splanchnic mucosal
hypoperfusion and gut barrier loss. While organ blood flow regulation is
preserved over a wide range of MAP, organ perfusion becomes pressure
dependent when the MAP decreases below a certain critical level (autoregulatory
threshold). The autoregulatory threshold varies between different organs, the
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presence of diseases and age; little data are available on the autoregulatory
threshold in children, and no studies report on the child intestinal
autoregulation. We are currently performing a study in which haemodynamic
optimization, aimed at normotension and flow-directed parameters, is intended
during major surgery in order to prevent the development of intestinal damage.
The present study concerns relatively healthy children and young
adolescents, who have an insignificant risk for important complications after
major surgery. In line, studies with older patients undergoing surgery or trauma
show that increasing age is one of the most crucial risk factors influencing
adverse outcome 36, 37. Therefore, we speculate that the loss of the intestinal
mucosal barrier as observed in our study in relatively healthy children
undergoing major non-abdominal surgery would have a larger effect on the
development of postoperative complications in older patients. Collectively, these
findings shed a new light on the potential role of intestinal barrier compromise
during major surgery, which was adapted from numerous animal studies, but
now reported in relatively healthy children and adolescents undergoing major
non-abdominal surgery. Furthermore, we consider that these results indicate a
need to re-examine currently accepted criteria of haemodynamic parameters in
patients undergoing major surgery.
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CHAPTER 5
Sequelae of human intestinal
ischemia-reperfusion
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5.1 INTRODUCTION
As altered splanchnic perfusion during major surgery and in critically ill patients
was reported to be related to the development of gut wall integrity loss in earlier
chapters, next aim was to set up a model, which made it possible to study the
consequences of controlled intestinal ischemia-reperfusion (IR) in detail in man
(paragraph 5.2). In addition, intestinal ischemia is not only encountered in
critically ill patients or in patients undergoing major surgery, it is a disease entity
itself (e.g. acute mesenteric ischemia), which is accompanied by high morbidity
and mortality rates because of its aspecific presentation and the lack of accurate
markers. Therefore, a human model for intestinal IR potentially would also
provide the opportunity to study new markers. Finally, it needs to be brought
forward that intestinal ischemia or hypoperfusion is a physiological condition
occurring during exercise both in healthy relatively untrained volunteers and in
highly trained athletes, which stresses the abdominal vasodilator reserve by
diverting blood flow from the splanchnic circulation to the exercise muscles.
This substantial reduction in blood flow is sometimes associated with symptoms
of abdominal hypoperfusion, which are almost always reversible without
intensive therapy. In conclusion, both physiological and pathophysioloical
conditions are related with the development of intestinal ischemia. In the new
human model to evaluate the effects of intestinal ischemia, the sequelae on the
epithelial lining were first studied in paragraph 5.3. As animal studies suggested
that the development of intestinal damage upon intestinal ischemia were
dependent on Mannose-binding lectin (MBL) variations, an important initiating
complement component, the amount of epithelial cell damage was related to
MBL genotypes (paragraph 5.4). Finally, the relation between ischemically
damaged intestinal epithelium and local inflammatory response was investigated
in paragraph 5.5 using the newly developed human model to evaluate the
consequences of intestinal ischemia-reperfusion.
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5.2 A new model to study
intestinal ischemia-reperfusion
damage in man
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ABSTRACT
This report describes a human in vivo ischemia reperfusion (IR) model of the
small intestine. Animal models of intestinal IR are indispensable for our
understanding of sequelae of IR induced organ damage. However, a functional
experimental IR model of the human small intestine, allowing for translational
research, can be considered critical for our pathophysiological understanding of
intestinal IR in man. Therefore patients with a healthy gut undergoing abdominal
surgery with a Roux-Y or similar reconstruction were included, creating the
opportunity to study IR of an isolated jejunal segment in a harmless model.
Ischemia was induced by non-traumatic vascular clamping followed by
reperfusion. This model can be adapted using variable ischemia and reperfusion
times. Similarly tissue and plasma can be collected at any given time point
during ischemia until end of reperfusion, only determined by progress of the
original, intended surgical procedure.
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INTRODUCTION
Acute mesenteric ischemia refers to an acute onset of hypoperfusion of the
intestine, often associated with major vascular or abdominal surgical procedures,
small intestinal transplantation, major trauma and blood loss, sepsis and
necrotizing enterocolitis (NEC) 1-3. Intestinal ischemia followed by reperfusion
(IR) complicates the treatment of critically ill patients. Furthermore, acute
mesenteric ischemia is a disease entity in itself of which diagnosis remains
difficult due to the lack of specific clinical markers 4,5. Current diagnosis of acute
mesenteric ischemia largely depends on clinical suspicion and is mainly aimed at
exclusion of different less urgent pathologies presenting with similar symptoms.
Intestinal IR has been linked to local as well as peripheral organ damage, the
systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction
syndrome (MODS), accounting for up to 70% mortality 1-3,6.
At present, our knowledge regarding mechanisms involved in IR induced
intestinal damage has evolved from research performed in animal models that
attempt to simulate human disease 2,3,7,8. Different animal models have been
developed in mice, rats, cats, dogs and pigs in which mainly ischemia of the
small intestine is studied by transient clamping of the superior mesenteric
artery. The use of animal models has identified important mechanisms
contributing to IR induced organ damage. Indisputably the data from animal
models have demonstrated the multifactorial etiology of IR damage in the
intestine 2,3,8,9. However, differences exist between various animals and
between strains of the same species regarding the results of intestinal ischemia
10,11. Furthermore, early responses that drive human intestinal injury and organ
failure in response to IR remain to be resolved. Therefore, we developed an
experimental ischemia reperfusion model of the intestine in humans creating
the possibility to address these points 12.
Several determinants were important during model development: I) No
additional invasive procedures should be needed to execute this model. II) A
variable duration of ischemia and reperfusion should be possible. III) The
possibility to collect serial and different (tissue/plasma) samples should be
created. IV) The studied intestine should be healthy and not affected by prior
inflammatory pathology. V) The small intestine should be studied. Considering
these pre-determined demands a model was developed in patients that undergo
major upper abdominal surgery with a Roux-Y or similar small intestinal
reconstruction. We included patients with pylorus preserving pancreatico
duodenectomy (PPPD) or Whipple’s procedure, pancreatico jejunostomy,
hepatico jejunostomy or Frey procedure.
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The model described is comparable with currently existing animal models.
Most animal models allow up to three hours of reperfusion after approximately
30 minutes of superior mesenteric artery clamping in order to induce ischemia
and to study early alterations of the small intestine. The duration of the ischemic
period, which is similarly induced by non-traumatic clamping of a superior
mesenteric artery branch, is variable and followed by a chosen reperfusion
time. The only determinant of the IR period is set by surgical boundaries
imposed by surgical treatment of the patient. Additionally, it has to be kept in
mind that besides ischemia reperfusion of the small intestine, intestinal
hypoperfusion could similarly be studied using a comparable setup.
The surgery takes about 3-6 hours to complete and allows for a
standardized ischemic period as well as reperfusion of up to 4 hours. Moreover,
this model offers the possibility to collect various samples at different time
points. Tissue undergoing reperfusion as well as healthy small intestinal tissue
samples can be collected. The model even allows for small intestinal sample
collection after different reperfusion times in order to study the reperfusion
phase continuously in a single patient. Since part of the small intestine is
resected according to normal surgical procedures, no extra part of the small
intestine is removed from the patient solely for study purposes, limiting patient
risk. To study either the IR induced release of proteins from the isolated part of
the small intestine or activation of plasma proteins, blood samples are collected
at different time points from the efferent vessels of the isolated jejunum and
arterial line, mostly present in left or right radial artery. This offers the possibility
to study both systemic and local effects of the IR in either plasma or serum.
Time points to collect plasma samples were: before the start of the operation
after induction of anesthesia, before induction of ischemia, immediately upon
reperfusion and every 30 minutes into the reperfusion period. Critical in this
model is the availability of patients that undergo major abdominal surgery in
which a part of the small intestine is resected. Additionally, a skilled surgical
department embedded in a hospital setting equipped to execute these or
comparable surgical procedures is needed to set up this human in vivo IR
model of the small intestine.
204
Chapter 5
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 204
MATERIALS
Reagents
• Isopentane (2-methylbutane; Across Organics). ! CAUTION Isopentane is
extremely flammable. Do not allow material to reach room temperature.
Therefore, transport it in a plastic cup in a dry ice container.
• Liquid nitrogen ! CAUTION Liquid nitrogen is extremely cold (-196°C)
and will cause skin burn if in contact for more than 1s. Take precaution
and be sure to protect eyes, fingers and exposed areas of skin.
• Dry ice ! CAUTION Dry Ice temperature is extremely cold (-78.5°C).
Handle dry ice with care and wear protective clothing and/ or appropriate
gloves whenever touching it.
• Ice (water sludge further called ice)
• 3.7%-4.0% formalin fixation (Unifix, Klinipath) ! CAUTION Irritant; wear
protective gloves.
• Glutaraldehyde ! CAUTION Severe skin and eye irritant; toxic by
ingestion.
Equipment
Sterile equipment needed during surgery for study purposes
• Ultracision Harmonic Ace (Johnson&Johnson, cat. no. ACE23P)
• Linear cutting stapler (GIA 6038S, Covidien)
• Staple cartridges (GIA 6038L, Covidien)
• Prolene 5-0 and PDS 3-0 Sutures (Johnson&Johnson)
• Sterile atraumatic vascular clamps (Bulldog, Aesculap, cat. no. BH013R)
Equipment used by researchers
• Mouth masks (3M)
• 5 ml EDTA vacuum tube (BD vacutainer, Becton Dickinson Diagnostics)
• 5 and 10 cc syringes (Becton Dickinson Diagnostics)
• 12 cm extension set (Steritex E98-3W, Codan)
• 25 G needle (BD Microlance 3, Becton Dickinson Diagnostics)
• Tissue Tek (Sakura Finetek)
• Cork sheets
• Sterile examination gloves
• Forceps (anatomical: Aesculap, cat. no. BD216R; surgical: Aesculap, cat.
no. BD501R
• Scissors (Aesculap, cat. no. BC304R)
• 2 ml sterilized tubes (Eppendorf)
• 3 ml aluminium Cryo-tubes (Sanbio)
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• Permanent marker
• Biopsy processing/paraffin embedding cassettes (Histosette II, Simport)
• 125 cc urine cup with screw cap (Böttger) to store formalin and incubate
cassettes with tissue
• Pencil
• Cellulose cover
• I-FABP ELISA (Hycult Biotechnology)
Reagent setup
--
Equipment setup
• Before entering the operating theatre, always make sure to wear a mouth
mask and keep sterile what has to be kept sterile around the operated
patient.
• It is preferred to sample blood from the mesenteric venule with 2 people
in a controlled manner, using a syringe which is connected to the needle
via a 12 cm extension set.
PROCEDURE
1) Positioning, anaesthesia of the patient (including insertion of an arterial
line) and incision of the skin according to institutional routines.
CRITICAL STEP An arterial line is needed to sample systemic blood,
which is used to measure arteriovenous concentration differences across
the studied jejunum in order to explore local release and uptake of
proteins.
2) After induction of anesthesia, before surgery the first 3cc blood sample is
taken from the arterial line (mostly radial artery) using a 5cc syringe.
Blood is transferred to a pre-chilled EDTA vacuum tube and kept on ice.
All blood is at the end of the study centrifuged at 4000 rpm, 4°C for 15
minutes to obtain plasma. Plasma is kept on ice and immediately stored in
aliquots at -80°C until analysis.
CRITICAL STEP Make sure that all EDTA tubes are labelled with the
appropriate codes.
3) First part of surgery (opening of the abdominal wall, installation of a large
self-retaining retractor) is according to standard procedures.
4) The peritoneal surface, the liver, the area around the pancreas, the
hepatoduoneal ligament and the lymph nodes around the celiac axis are
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explored for metastases and localization of the major anatomical
structures and tumor.
5) From this moment the 6 cm part of jejunum which can be studied has to
be identified (Figure 1).
Figure 1: Identification of jejunum which can be isolated for study purposes. Note the clearly
visible blood supply and drainage.
CRITICAL STEP Blood supply and drainage of the studied jejunum has to
be clearly visible and to consist of 1 central mesenteric arteriole and
venule.
6) To prevent blood flow from adjacent parts of the studied jejenunum, all
collateral vessels are dissected and clamped and cut. Therefore, the
mesentery is opened using Ultracision Harmonic Ace at the proximal and
distal part of the suitable part of jejunum from the central mesenteric
arteriole and venule until the serosa of the jejunum.
7) Isolation of the studied jejunum is performed by transsection at both ends
with a linear cutting stapler (Figure 2).
Figure 2: Isolation of the studied jejunum by a linear cutting stapler.
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8) Both ends of the isolated jejunum are fixed with a single PDS 3-0 suture
to the rest of the jejunum to prevent rotation.
CRITICAL STEP Leaving the isolated jejunum in the abdominal cavity
without re-attaching to the proximal and distal parts of the jejunum may
cause rotation around its axis, which causes disruption of the blood flow
and thus re-introducing uncontrolled ischemia.
CRITICAL STEP The central mesenteric venule draining the isolated
jejunum is dissected from its mesenteric surrounding to improve its
accessibility for blood collection.
9) A 5 cc syringe, a 12 cm extension set and a 25 G needle are given under
sterile conditions to the scrub nurse.
10) The 5 cc syringe is connected via the extension set to the 25 G needle by
the nurse.
11) One surgeon takes the isolated jejunum with the left hand and inserts the
needle into the venule, draining the isolated jejunum, while the other
surgeon draws 3 cc blood using the syringe.
CRITICAL STEP It is difficult to draw blood from the venule by a single
surgeon, because holding the jejunum, inserting the needle and drawing
of blood may become a rather uncontrolled procedure, which may cause
the needle to perforate the venule.
12) Hold a Prolene 5-0 suture with a small needle holder in order to repair the
vessel with sutures if there is continued bleeding after removal of the
needle.
13) The syringe is handed over to the researcher.
14) At the same time blood is drawn from the arterial line, as described in
point 2.
15) Blood is processed and stored as described in point 2.
16) The isolated jejunum is subjected to 30 minutes ischemia with 2
atraumatic vascular clamps which are placed from both sides over the
mesentery (Figure 3).
Figure 3: Clamping of the isolated jejunum (a) rapidly leads to discoloration of the jejunal wall (b).
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TROUBLESHOOTING
17) The isolated ischemic jejunum is placed in the abdominal cavity to
guarantee warm ischemia.
18) The patient’s temperature is constantly monitored and kept at 37°C.
19) The surgical procedure proceeds as planned.
20) After half an hour of ischemia, one third (2 cm) of the isolated ischemic
jejunum is resected for research purposes using linear cutting stapler.
21) The mesentery, near the serosa of the distal 2 cm of isolated ischemic
jejunum, is opened using electrocoagluation.
22) The distal 2 cm of the isolated ischemic jejunum are dissected using a
linear stapler.
23) This distal ischemic jejunum is handed over to the researchers.
CAUTION Avoid manipulation of the intestine, because this may cause
exogenous damage. Therefore always use forceps.
CAUTION This human material has to be processed by the researchers
wearing gloves.
24) The staples at both ends of the tissue are cut off with clean scissors and the
tissue is processed to obtain paraffin-embedded sections, frozen sections,
electron microscopy and tissue samples for PCR analysis or protein-based
applications. This is performed by the researchers and described from
points 24-36. In the meantime the surgeon continues at point 43.
Paraffin-embedded sections and H&E staining
25) Cut defined 0.5 cm thick ring-like fragments of the jejunum.
26) Immerse immediately in 3.7%-4.0% formalin fixation and incubate
overnight at room temperature.
CAUTION Irritant; wear protective gloves.
27) After 18-24 hours of formalin fixation embed the fragments of the jejunum
in paraffin.
PAUSE POINT: Samples can be stored embedded in paraffin until ready
for cutting.
28) Prepare 4 µm paraffin cross-sections.
29) Stain sections with hematoxylin and eosin using appropriate standard
procedures. Sections can be used for immunohistochemistry according to
specific research questions.
Frozen sections
30) Cut defined 0.5 cm x 0.5 cm squared fragments of jejunum
31) Immerse the jejunum with the use of forceps gently in Tissue Tek for 1
second.
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32) Adhere the jejunum in Tissue Tek to a piece of cork by dipping the
jejunum to 0.3 cm x 0.3 cm cork.
CRITICAL STEP Cork is used under the mounted tissue to enable
subsequent cutting and easy mounting on a cryotome.
33) The jejunum, embedded in Tissue Tek, immersed and mounted on cork, is
frozen in pre-chilled isopentane on dry ice.
CAUTION Isopentane is extremely flammable.
34) For cryosectioning, fix the cork on a mounting disk with tissue freezing
medium.
35) When the tissue freezing medium is frozen, prepare 4 µm frozen cross-
sections.
PAUSE POINT: Slides can be stored at -20°C until stained.
Electron microscopy
36) Electron microscopy preparation solution is pre-chilled on ice.
CAUTION Glutaraldehyde is a severe skin and eye irritant and toxic by
ingestion.
37) 2 4mm3 blocks are collected from each tissue specimen and stored in
glutaraldehyde.
38) The samples are kept cold (4°C) in glutaraldehyde solution for at least 18
hours.
39) Further preparation according to local routines.
Tissue sampling for PCR analysis or protein-based applications (e.g.
Western blot, ELISA)
40) Cut 0.5 cm x 0.5 cm squared fragments of jejunum.
41) Snap-freeze fragments in liquid nitrogen and store until use at -80°C.
CAUTION Liquid nitrogen is extremely cold (-196°C) and will cause skin
burn if in contact for more than 1s.
PAUSE POINT: Samples can be stored at -80°C until used.
42) While the researcher prepares the tissue, the surgeon removes the vascular
clamps. The reperfusion is initiated.
43) After removal of the clamp, the isolated jejunum is inspected for
restoration of blood flow.
TROUBLESHOOTING
44) Immediately thereafter, blood is collected from the mesenteric venule and
from the arterial line, as described from point 9-15.
45) Isolated jejunum and arterial and venous blood can be collected at
different time points, depending on the research questions.
CRITICAL STEP To study acute damage of the epithelial lining, it is
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recommended to take tissue and blood samples 15-30 minutes after start
of reperfusion. To study repair of the epithelium, collect samples from 60
minutes after reperfusion onwards. See anticipated results.
46) The maximum time of reperfusion of the isolated ischemic jejunum is
dependent on the surgical procedure, i.e. the moment at which the
surgeon decides that the pancreatico- or hepaticojejunal anastomosis has
to be created. In the proposed surgical procedures reperfusion time varies
from 30 minutes to 4 hours.
47) At the time the last isolated reperfused jejunum is obtained for the study,
also 2 cm of the proximal jejunum, which was not isolated and remained
untreated during the surgery, is resected using a GIA. This tissue is used as
internal control tissue: it is from the same patient and experienced similar
surgical handling as the isolated jejunum, while it was not subjected to IR.
48) Surgery continues as anticipated.
Intestinal Fatty Acid Binding Protein (I-FABP) arteriovenous concentration
differences across studied jejunum assesses epithelial cell damage
49) In arterial and venous plasma the concentrations of I-FABP are measured
by means of the commercially available enzyme-linked immunosorbent
assay (ELISA) used according to manufacture guidelines.
50) Subtract the venous from the arterial plasma levels of I-FABP, which are
collected at the same point, in order to obtain arteriovenous concentration
differences across the studied jejunum.
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TROUBLESHOOTING
Troubleshooting advice can be found in Table 1.
ANTICIPATED RESULTS
We describe a newly developed human experimental model to study intestinal IR
induced cell damage and its direct consequences. Successful ischemia is
observed almost directly after placement of the vascular clamp in the 29 patients
studied so far by both discoloration of the small jejunum wall and termination of
the peristalsis of the studied jejunum. Immediately upon reperfusion, the isolated
jejunum regains its pinkish color and motility. Histologic analysis of hematoxylin/
eosin-stained sections shows consistent results 12. The control jejunum, which
neither is isolated, nor subjected to IR, shows normal architecture. Directly after
ischemia the intestinal epithelial lining is microscopically normal, while
subepithelial spaces appear at the villus tip. However, after 25 minutes
reperfusion shedding of differentiated epithelial cells into the lumen is found with
a compromised epithelial lining. Interestingly, within 60 minutes reperfusion the
epithelial barrier reseals, while debris of apoptotic, shedded epithelial cells is
observed in the lumen. In order to further objectivate the intestinal mucosal cell
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Table 1: Troubleshooting advice
Step Problem Possible reason Solution
16 Isolated jejunum does not 1) The proximal and/ or distal part of jejunum Check whether the studied
become ischemic after is not completely stapled and dissected; jejunum is perfectly isolated
clamping collaterals remain until the point where you
2) The mesentery is not completely want to clamp
closed/ clamped; collaterals remain Use 2 stronger clamps
3) The vascular clamps are not strong enough
> 43 During reperfusion, the 1) The isolated jejunum is rotated around In both cases, reperfusion is not
isolated jejunum stays or its axis complete and not useful to study
becomes ischemic 2) The mesenteric venule is thrombotic reperfusion. Dissect the studied
(due to blood drawing?) jejunum. Next time suture the iso-
lated jejunum to the rest of the
jejunum with one or two stitches
and after each drawing of blood
control the hemorrhage.
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damage in this model, Intestinal Fatty Acid Binding Protein (I-FABP) arteriovenous
concentration differences are measured in plasma using ELISA before and after
ischemia. I-FABP is a small cytosolic protein constitutively present in mature
enterocytes and released upon cell membrane integrity loss 13-15. Mean (SEM)
arteriovenous concentration gradients of I-FABP across studied jejunum in 20
patients reveal rapid epithelial cell damage. I-FABP release increased significantly
from 328 (59) pg/ml before ischemia towards 4,096 (543) pg/ml immediately after
ischemia (p<0.001) and declined gradually to 1,204 (408) pg/ml after 2 hours
reperfusion (p<0.001) 12. In conclusion, this unique and harmless human IR
model of the jejunum enables the study of acute damage to the epithelial lining
and its subsequent repair mechanisms.
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5.3 Rapid reversal of human
intestinal ischemia-reperfusion
induced damage by shedding of
injured enterocytes and
reepithelialisation
Joep P. M. Derikx, Robert A. Matthijsen, Adriaan P. de Bruïne,
Annemarie A. van Bijnen, Erik Heineman, Ronald M. van Dam,
Cornelis H. C. Dejong, Wim A. Buurman
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ABSTRACT
Background
Intestinal ischemia-reperfusion (IR) is a phenomenon related to physiological
conditions (e.g. exercise, stress) and to pathophysiological events (e.g. acute
mesenteric ischemia, aortic surgery). Although intestinal IR has been studied
extensively in animals, results remain inconclusive and data on human intestinal
IR are scarce. Therefore, an experimental harmless model for human intestinal IR
was developed, enabling us to clarify the sequelae of human intestinal IR for the
first time.
Methods and findings
In 30 patients undergoing pancreatico-duodenectomy we took advantage of the
fact that in this procedure a variable length of jejunum is removed. Isolated
jejunum (5 cm) was subjected to 30 minutes ischemia followed by reperfusion.
Intestinal Fatty Acid Binding Protein (I-FABP) arteriovenous concentration
differences across the bowel segment were measured before and after ischemia to
assess epithelial cell damage. Tissue sections were collected after ischemia and at
25, 60 and 120 minutes reperfusion and stained with H&E, and for I-FABP and the
apoptosis marker M30. Bonferroni’s test was used to compare I-FABP differences.
Mean (SEM) arteriovenous concentration gradients of I-FABP across the
jejunum revealed rapidly developing epithelial cell damage. I-FABP release
significantly increased from 290 (46) pg/ml before ischemia towards 3,997
(554) pg/ml immediately after ischemia (p<0.001) and declined gradually to
1,143 (237) pg/ml within 1 hour reperfusion (p<0.001). Directly after ischemia
the intestinal epithelial lining was microscopically normal, while subepithelial
spaces appeared at the villus tip. However, after 25 minutes reperfusion,
enterocyte M30 immunostaining was observed at the villus tip accompanied by
shedding of mature enterocytes into the lumen and loss of I-FABP staining.
Interestingly, within 60 minutes reperfusion the epithelial barrier resealed,
while debris of apoptotic, shedded epithelial cells was observed in the lumen.
At the same time, M30 immunoreactivity was absent in intact epithelial lining.
Conclusions
This is the first human study to clarify intestinal IR induced cell damage and
repair and its direct consequences. It reveals a unique, endogenous clearing
mechanism for injured enterocytes: rapid detachment of damaged apoptotic
enterocytes into the lumen. This process is followed by repair of the epithelial
continuity within an hour, resulting in a normal epithelial lining.
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INTRODUCTION
Intestinal ischemia-reperfusion (IR) injury is an important (patho)physiological
mechanism, potentially leading to a compromised mucosal barrier in numerous
situations 1, 2. Intestinal hypoperfusion occurs during exercise both in healthy
relatively untrained volunteers and in highly trained athletes, which stresses the
abdominal vasodilator reserve by diverting blood flow from the splanchnic
circulation to the exercise muscles 3-5. This substantial reduction in blood flow is
sometimes associated with symptoms of abdominal hypoperfusion, which are
almost always reversible without intensive therapy 3-5. Stress may also lead to
symptomatic intestinal ischemia via increased catecholamine release, resulting
in severe splanchnic vasospasm 6. Furthermore, intestinal IR may be looked at as
a common pathway in several pathologies, where temporary reduction in flow
may result from inherent vascular disease (thrombosis, shock, embolism,
vasculitis) or from inflammatory diseases affecting perfusion. An example of
inherent vascular disease is acute mesenteric ischemia (AMI), which carries a
high morbidity and mortality rate, both increased by frequent delays in
diagnosis. Such diagnostic delays are mainly caused by non-specific signs and
symptoms and limited diagnostic accuracy of the laboratory and radiological
tests currently in use. Arterial and venous thromboembolisms are the main
causes of AMI 1, 2. More global hypoperfusion may result from shock. Along
these lines, intestinal IR is considered to be a crucial phenomenon involved in
the onset of necrotizing enterocolitis, in the pathogenesis of small intestinal
transplantation and rejection, and in the potential development of postoperative
or posttraumatic complications, such as systemic inflammatory response
syndrome, sepsis and multiple organ failure 2, 7, 8. Here, inflammation and
collateral damage may play a role.
Generally, IR injury starts with affecting cell metabolism, ultimately
resulting in cell death (apoptosis as well as necrosis) 9-11. Upon reperfusion,
ischemia primed cells are prone to generate toxic reactive oxygen metabolites
and release of constitutive cellular proteins upon loss of cell membrane
integrity, which can act as danger signals and activate the immune system 9-15.
In the resulting inflammatory response, local expression of adhesion molecules,
proinflammatory mediators and activation of neutrophils as well as the
complement system are central mediators of IR induced tissue injury 10,11,13-16.
This proinflammatory state increases tissue vulnerability to further injury,
resulting in the amplification and derailment of the inflammatory response,
although it is meant to be a beneficial reaction to clear damaged cells 11,14,16.
The pathophysiology of intestinal IR has hitherto mainly been studied in
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animal models (rodents, cats, dogs and pigs) by transient clamping of the
superior mesenteric artery 17-19. First event after intestinal IR in all these animals
is the appearance of subepithelial spaces at the villus tips, immediately
followed by loss of the highly susceptible mature enterocytes 17, 18. Depending
on the duration of ischemia, this sloughing may continue toward the crypt,
causing denuded villi 17, 18. In line with general IR-induced cell damage, also in
intestinal IR, apoptosis is the major mode of cell death in the destruction of
epithelial cells 20. Moreover, the disruption of the interaction between epithelial
cells and extracellular matrix (‘anoikis’) may play an important role in the onset
of apoptosis in detached enterocytes 20. Some studies report that after longer
periods of reperfusion, migration of epithelial cells to seal the exposed
basement membrane occurs, which closes the loss of epithelial continuity 19, 21.
Further studies show that reperfusion leads to inflammation, resulting in
transmural infarction 19,22-24. This inflammatory response is comparable to the
response of other organs to IR induced cell damage, including infiltration of
neutrophils and activation of complement 22, 24.
The histological consequences of human gut IR are known from patients
operated upon for different gastrointestinal disorders after obvious signs of
clinical shock or from post-mortem studies 25. Microscopic examination of gut
segments of these patients all showed characteristic mucosal lesions, ranging
from epithelial lifting at the villus tip to denuded villi with disintegrated and
hemorrhagic lamina propria 25. The histological findings concerned end-stages
of diseases and were identical to the previously described ultimate phases of
intestinal mucosal IR-induced damage in animals.
This study was directed at revealing the sequelae of intestinal IR in man in
the course of time, using a newly developed human experimental, controlled
model of 30 minutes intestinal ischemia, followed by variable periods of
reperfusion.
METHODS
Patients and experimental, surgical procedure
Thirty patients (12F:18M) with a median age of 68.5 years (range: 35-79 years)
undergoing pancreatic surgery were studied. Twenty-eight of these patients
underwent a standard pylorus-preserving or classical pancreatico-duodenectomy
(Whipple’s procedure) for benign or malignant disease, whilst two patients
underwent a Frey procedure for chronic pancreatitis. During pancreatico-
duodenectomy a variable length of jejunum is usually resected in continuity
with the specimen. Similarly, in creating a Roux-limb for the pancreatico-
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jejunostomy in Frey’s procedure, it is often necessary to resect a small segment
of jejunum that is less well perfused. We took advantage of this, which enabled
us to study IR induced cell damage in a harmless human jejunal IR model. To
that purpose, the most distal part of the jejunum to be resected with the
Whipple specimen, or the most proximal part of the Roux-limb to be used as a
pancreatico-jejunostomy in the Frey procedure, was used to isolate a 6 cm
segment of jejunum. The isolated jejunum (6 cm) was subjected to 30 minutes
ischemia followed by a median reperfusion time of 128 minutes (range: 0-210
minutes) according to the following experimental protocol.
In short, the first part of surgery (opening of the abdominal wall, installation
of a large self-retaining retractor and exploration for metastases and localization
of the major anatomical structures and tumour) was according to standard
procedures. From this moment the 6 cm part of jejunum, which was going to be
studied was identified and care was taken that the vasculature of the studied
jejunum consisted of 1 central mesenteric arteriole and venule. This was
achieved by dissection, clamping and cutting of all collateral mesenterial vessels
to the studied jejunum using Ultracision Harmonic Ace (Johnson&Johnson, cat.
no. ACE23P, Amersfoort, the Netherlands). Thereafter, the segment of jejunum
was further isolated by transsection at both ends with a linear cutting stapler
(GIA 6038S, Covidien, Zaltbommel, the Netherlands). The isolated jejunum
was then subjected to 30 minutes ischemia with 2 atraumatic vascular clamps,
which are placed over the mesentery (Bulldog, Aesculap, cat. no. BH013R,
Tuttlingen, Germany). The isolated ischemic jejunum was subsequently placed
in the abdominal cavity to guarantee warm ischemia. The surgical procedure
proceeded as planned. After half an hour of ischemia, one third (2 cm) of the
isolated ischemic jejunum was resected using linear cutting stapler to study
early phenomena during ischemia. Reperfusion was initiated by removal of the
clamps, and the isolated jejunum was inspected for restoration of blood flow. A
further segment of isolated jejunum (2 cm) was resected similarly after 25
minutes of reperfusion to study early phenomena during reperfusion. The last
part of studied jejunum was resected from 60 minutes after reperfusion onwards
to investigate late phenomena during reperfusion. At the time the last isolated
reperfused jejunum was obtained for the study, also 2 cm of jejunum, which
had not been isolated and remained untreated during the surgery, was resected
using a linear cutting stapler. This tissue was used as internal control tissue: it
was from the same patient and experienced similar surgical handling as the
isolated jejunum, while it was not subjected to IR. Then, our study-protocol was
ended and surgery continued as anticipated.
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Histological assessment
The tissue specimens obtained at four different time points during the study
(after half an hour of ischemia, after 25 minutes of reperfusion, from 60 minutes
reperfusion onwards and internal control) were immediately immersed in
3.7%-4.0% formaldehyde fixation (Unifix, Klinipath, Duiven, the Netherlands)
and incubated overnight at room temperature. Next, the formalin fixed samples
were embedded in paraffin and 4µm sections were cut. Sections were stained
with haematoxylin and eosin (H&E) using standard histological techniques.
During the conduct of the experiments, it was noted that in every jejunal
sample we collected at the time of maximal reperfusion, a milky substance
appeared from the lumen. In order to study the content of this substance, we
collected and fixed it according to the AgarCyto cell block procedure 26.
Shortly, the collected cells were fixed in Unifix (Klinipath) for 24 hours. Fixed
cells were centrifuged for 5 minutes at 1200 rpm. The pellet was carefully
resuspended in 1 ml 2% liquid agarose at 65°C (LE, analytical grade; Promega,
Madison, WI) and transferred into a 1.5-ml Eppendorf tube. The tube was
centrifuged for 5 minutes at 1000 rpm to concentrate the cells in the agar. The
agar–cell pellet was solidified at 4°C for at least 1 hour. The agar cone was
carefully taken out of the reaction tube with pointed forceps and divided in two
halves in the sagittal plane of the cone. The two agar pieces were embedded in
paraffin under standard conditions for surgical biopsies. This paraffin embedded
agar–cell pellet is called AgarCyto 26. From the AgarCyto, 4µm sections were
cut. For cytomorphologic examination, AgarCyto sections were stained with
H&E.
Immunohistochemistry
Paraffin sections were dewaxed in xylene and rehydrated in graded ethanol to
distilled water. Endogenous peroxidase activity was blocked using 0.3%
hydrogen peroxide in methanol for 12 minutes. Sections undergoing heat-
mediated antigen retrieval were placed in a cooker filled with 10 mM citrate
buffer (pH 6.0) for 10 minutes for staining with collagen IV. After blocking the
non-specific antibody binding using 5% BSA, the sections were incubated with
specific primary antibody at room temperature for 45 minutes. The following
primary antibodies were used: mouse anti-cleaved cytokeratin 18 antibody,
clone M30 (Catalogue no. 10700; Peviva, Bromma, Sweden); mouse anti-
Collagen IV, clone CIV 22 (Catalogue no. M0785; DAKO, Glostrup, Denmark);
mouse anti-smooth muscle actin (SMA), clone 1A4 (Catalogue no. M0851;
DAKO); and chicken anti-intestinal-fatty acid binding protein (I-FABP, kindly
provided by Hycult Biotechnology (HBT; Uden, the Netherlands)). After
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washing, an appropriate biotin-conjugated secondary antibody was used.
Binding of the primary antibody was demonstrated by the streptavidin-biotin
system (DAKO) and visualized by applying 3-amino-9-ethylcarbazole (AEC;
Sigma, St. Louis, MO). For I-FABP, peroxidase-conjugated rabbit anti-chicken
IgY (Catalogue no. 303-035-003; Jackson ImmunoResearch Europe, Suffolk,
UK) was used as secondary antibody and AEC was used as chromogen. For
staining of collagen IV, labelled polymer detection agent (PowerVision Poly-
HRP-anti-Mouse/Rabbit/Rat IgG (Immunologic; Duiven, The Netherlands)) was
applied followed by AEC. Nuclei were counterstained with haematoxylin. The
stained slides were photographed by a Nikon eclipse E800 microscope with a
Nikon digital camera DXM1200F. No significant staining was detected in slides
incubated with control rabbit serum and/or mouse IgG instead of the primary
antibody indicating the absence of significant background staining.
Immunofluorescence
Cryostat sections (4µm) were cut and stained for Zona Occludens-1 (ZO-1).
Briefly, slides were dried, fixed in 4% paraformaldehyde for 15 minutes and
non-specific antibody binding was blocked using 10% normal goat serum.
Next, slides were stained with anti ZO-1 (catalogue no. 61-7300; Zymed
Laboratories Inc., San Francisco, CA). Slides were incubated with a Texas Red
labelled secondary antibody (Jackson, West-Grove, PA). Subsequently, slides
were mounted using glycerol-PBS with 1, 4-diazabicyclo (2, 2, 2) octane
(DABCO) and 4, 6-diamidinol (2)-phenylindole (DAPI), and viewed with an
immunofluorescence microscope.
Blood sampling and I-FABP measurement
Arterial blood was sampled preoperatively, before the isolated jejunum was
subjected to ischemia, immediately upon reperfusion and every half hour
during reperfusion until the end of the study protocol. Simultaneous with the
second (i.e. before ischemia) and every next arterial blood sample, blood was
drawn from the venule draining the isolated jejunal segment by direct puncture
to assess concentration gradients across the isolated jejunal segment. All blood
samples were directly transferred to pre-chilled EDTA vacuum tubes (BD
vacutainer, Becton Dickinson Diagnostics, Aalst, Belgium) and kept on ice. At
the end of the study all blood samples were centrifuged at 4000 rpm, 4°C for
15 minutes to obtain plasma. Plasma was kept on ice and immediately stored
in aliquots at -80°C until analysis.
Intestinal Fatty Acid Binding Protein (I-FABP) concentrations were
measured in plasma by means of the commercially available enzyme-linked
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immunosorbent assay (ELISA) used according to manufacture guidelines and
kindly provided by HBT. I-FABP arteriovenous concentration differences were
calculated (mesenteric venule minus radial artery) before and after ischemia to
assess epithelial cell damage.
Ethics
The study was approved by the Medical Ethics Committee of the Maastricht
University Medical Centre + and all individuals gave written informed consent.
Statistics
Statistical analysis was performed using Prism 4.0 for Windows (GraphPad
Software Inc. San Diego, CA). I-FABP arteriovenous concentration gradients
were presented as mean ± standard error (SEM). Normality of all data obtained
was verified by Kolmogorov-Smirnov test. Bonferroni’s multiple comparison test
was used (after significant repeated measures ANOVA) to compare I-FABP
arteriovenous concentration differences in time. A p-value below 0.05 was
considered to be statistically significant.
RESULTS
Early phenomena during ischemia
At the end of the ischemic period of 30 minutes, H&E sections of the jejunum
showed microscopically normal epithelial lining (Figure 1A, B). However,
subepithelial spaces appeared at the villus tip. To study the epithelial cells in
more detail, immunohistochemical staining of I-FABP was performed, a small
protein present in the cytoplasma of differentiated enterocytes [27]. Further, we
stained ZO-1, a 225 kDa membrane bound protein, binding the transmembrane
tight junction proteins occludin and claudins and linking them to cytoskeletal
actin [28]. Intensive immunostaining for I-FABP was observed in the control
jejunal epithelium, mainly in the cytoplasm of the mature enterocytes and goblet
cells in the upper half of the villi, whereas cells in the crypts were not stained,
as previously observed in experiments by our group (unpublished results) (Figure
2A). A decreased staining of I-FABP was observed in jejunal mature epithelial
cells, after 30 minutes ischemia, while intense staining was found in the
subepithelial spaces (Figure 2B), indicating early leakage of I-FABP from the
cytoplasm of intestinal epithelial cells into the subepithelial space. ZO-1 was
detected at the apical pole of the epithelial cells in both the control jejunum and
the jejunum after an ischemic period of 30 minutes (data not shown).
To clarify the development of the subepithelial spaces, the basement
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membrane, demarcating the lamina propria from the epithelial cells, and the
underlying network of myofibroblasts within the villus lamina propria were
studied, by staining collagen IV and smooth muscle actin (SMA), respectively
[29,30]. A clear retraction of the basement membrane was found from the basal
pole of the epithelial cells at the tip of the villi (Figure 3A, B). In line with this,
shorter myofibroblasts were observed in a denser lamina propria (data not
shown).
Figure 1: Histological analysis of H&E-stained jejunal
sections (100x) shows a normal epithelial lining in untreated
tissue (A), and upon 30 minutes of ischemia (B). However,
subepithelial spaces (*) appear after 30 minutes ischemia
(B). After 25 minutes reperfusion shedding of mature
enterocytes into the lumen is found (C). Within 60 minutes
of reperfusion the epithelial lining is resealed, while debris
of apoptotic, shedded enterocytes (*) are found in the lumen
(D).
Figure 2: Immunolocalization of I-FABP in red (3-amino-9-
ethylcarbazole, AEC) (100x) in the control jejunum not
subjected to ischemia-reperfusion (A) shows an abundant
cytosolic presence of I-FABP in the epithelial cells of the
upper half of the villus. Upon 30 minutes ischemia (B),
cytosolic I-FABP staining is decreased in mature enterocytes
with abundant staining in the subepithelial spaces. A
decreased cytosolic staining is still observed after 25
minutes reperfusion (C). Within 60 minutes reperfusion, I-
FABP cytosolic positive cells are part of the resealed
epithelial barrier (D), while shedded I-FABP containing
enterocytes are found in the debris in the lumen.
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Figure 3: Characterization of the basement membrane with
collagen IV staining in red (AEC) shows collagen IV positive
cells directly beneath the epithelial layer in control jejunum
(100x) (A). Upon 30 minutes of ischemia, a clear retraction
is found of the collagen IV positive cells from the basal pole
of the epithelial cells at the tip of the villus, causing
subepithelial spaces (B). After 25 minutes reperfusion, the
retracted basement membrane is still observed (C). Within
60 minutes reperfusion, the collagen IV positive basement
membrane is again attached to the epithelial lining (D).
Early phenomena during reperfusion
To investigate loss of enterocyte membrane integrity, arteriovenous concentration
differences of I-FABP across the studied jejunum were measured before ischemia
and from reperfusion onwards. All individuals showed a basal release of mean
(SEM) I-FABP of 290 (46) pg/ml from the isolated jejunal segment before
ischemia, potentially reflecting the physiologic turnover of enterocytes (Figure 4).
Interestingly, I-FABP release significantly increased towards 3,997 (554) pg/ml
immediately after ischemia and upon reperfusion (p<0.001), suggesting rapid
epithelial cell damage following 30 minutes ischemia. A gradual, significant
decline to 1,143 (237) pg/ml of I-FABP release occurred within 1 hour reperfusion
(p<0.001, immediately upon ischemia vs. 1 hour reperfusion).
After 25 minutes of reperfusion, structural damage to the mucosa became
apparent, consisting of detachment of epithelial cells, particularly in the apical
regions of the villi, leading to shedding of (sheets of) mature epithelial cells into
the lumen (Figure 1C). Intestinal villus epithelial cells, which had lost the contact
with the underlying villous stroma, underwent a phenomenon called ‘anoikis’,
which refers to detachment-induced apoptosis [31]. Therefore, apoptosis was
visualized in the jejunal sections using the apoptosis marker M30, which detects
the Asp396 caspase cleavage site in cytokeratin-18 [32]. Intense M30
immunostaining was observed after 25 minutes of reperfusion at the villus tips,
at the site where extensive desquamation of the epithelial cells from the villus
tips into the intestinal lumen occurred, which was not detected in the earlier
phase (Figure 5A-C). In the shortly reperfused jejunum a substantial loss of ZO-
1 expression was shown in the sheets of shedded cells, which was accompanied
by a decreased cytoplasmatic immunoreactivity of I-FABP.
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Figure 4: Arteriovenous concentration differences of I-FABP (mesenteric venule minus radial
artery), a marker for acute enterocyte damage, across the isolated jejunal segment show rapid
significant release of I-FABP after ischemia, while concentration differences of I-FABP gradually
reduce following reperfusion. * p<0.001, # p<0.001
Figure 5: Apoptosis, assessed by M30 staining in red (AEC). An M30 positive cell (arrow) is
observed at the top of the villus in normal jejunum (100x) (A). Upon 30 minutes ischemia, no
M30 positive staining is found (B), while after 25 minutes reperfusion intense M30
immunostaining is observed at the villus tip near the shedding of mature epithelial cells into the
lumen (arrows) (C). At 60 minutes reperfusion M30 immunoreactivity is no longer detectable in
the intact, resealed epithelial barrier, while debris of M30 positive, shedded epithelial cells is
observed in the lumen (D).
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Late phenomena during reperfusion
As mentioned in the Materials and Methods section, a notable finding in all
jejunal samples collected after 30 minutes ischemia and more than 60 minutes
reperfusion was the presence of a milky substance that appeared from the
lumen. Histological analysis of this debris revealed sheets of enterocytes with
numerous apoptotic cells, assessed by H&E and M30 staining (Figure 6A, B).
The H&E staining of the jejunum, which underwent 30 minutes ischemia
and more than 60 minutes reperfusion, confirmed the debris of detached
epithelial cells in the lumen (Figure 1D). Interestingly, within 60 minutes
reperfusion the epithelial layer resealed and full confluent coverage of the villus
tip by enterocytes was observed again, indicating a recovered epithelial barrier
(Figure 1D). The cells coating the lamina propria were immunopositive for I-
FABP and ZO-1, indicating that the epithelial continuity contained viable
enterocytes with intact tight junctions (Figure 2D). Immunostaining with
collagen IV showed that the basement membrane was again attached to the
epithelial lining (Figure 3D). To investigate the status of these epithelial cells,
M30 immunostaining was performed to assess apoptosis. M30 immunoreactivity
was absent in the newly formed intact epithelium, while the debris of shedded
epithelial cells in the lumen contained apoptotic cells (Figure 5D).
Figure 6: Histological analysis of H&E stained AgarCyto-fixed debris, appearing from the lumen
of the jejunum after 30 minutes ischemia and more than 60 minutes ischemia, shows sheets of
enterocytes (100x) (A), containing many M30 positive cells (arrows) in red (AEC) (100x) (B).
DISCUSSION
This study for the first time provides insight in the sequence of events taking
place during intestinal ischemia-reperfusion (IR) in man. Intestinal IR is often
encountered in clinical practice, not only in patients presenting with abdominal
complaints, but also during e.g. exercise, major surgery and trauma [1-4,8].
Patients undergoing pancreatico-duodenectomy enabled us to create the first
human experimental model allowing detailed studies of intestinal IR induced
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cell damage, because in this procedure a variable length of healthy jejunum is
removed as part of the standard operative procedure. This controlled model
completely equals the interruption of blood flow to the small intestine, which
often occurs during repair of a (thoraco-) abdominal aneurysm of the aorta,
cardiopulmonary bypass, and intestinal transplantation.
Our study reveals that three phenomena can be distinguished following
30 minutes of human intestinal ischemia. Firstly, during the ischemic period the
epithelial integrity remained seemingly intact, while subepithelial spaces
appeared by detachment of the basement membrane from the enterocytes
without any indication for the onset of apoptosis. The presence of I-FABP
staining in the subepithelial spaces strongly indicates loss of membrane
integrity of the intestinal epithelial cells at the site of formation of subepithelial
spaces. These data are in line with the rapid increase of arteriovenous
concentration differences of I-FABP immediately upon ischemia. Secondly,
within 30 minutes reperfusion, desquamation of the intestinal epithelium at the
tip of the villi was observed into the lumen, accompanied by apoptosis of
mature epithelial cells. Thirdly, within 60 minutes reperfusion, a fully intact
epithelial lining was found, indicating rapid restoration, whereas the apoptotic
enterocytes had been shedded in the lumen. This reaction of the intestinal villi
upon ischemia reperfusion, which collectively is called restitution, was also
found in previous in vitro and in vivo animal studies after various insults, as
recently reviewed by Blikslager et al 19. However, the consequences of
intestinal IR in animal studies vary largely and seem to be dependent on the
animal model, the animal strain, preoperative care (e.g. starvation/fasting,
premedication) and duration of ischemia or hypoperfusion 17-19.
Intestinal epithelial restitution is hypothesized to be directed at repairing
the epithelial defect, which originates from the detachment of damaged
enterocytes. The appearance of subepithelial spaces during ischemia is the
actual start of the regeneration and aimed at reducing the effective size of the
injured area. The development of subepithelial spaces after splanchnic
hypoperfusion in animal studies was initially interpreted as an accumulation of
cytoplasmic fluid from ischemic damaged cells 17. Later, evidence was provided
by an in vitro model of chemically-induced injury to guinea pig ileal epithelium
that the subepithelial space resulted from the retraction of the basement
membrane by contraction of myofibroblasts 29. This retraction leads to a smaller
and denser lamina propria accompanied by some seepage of fluid from the
lamina propria cells into the newly formed subepithelial space. This is in line
with our observations that the subepithelial spaces developing after 30 minutes
of ischemia were associated with a dense lamina propria and a liquid-containing
227
Human intestinal ischemia-reperfusion
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 227
space between the basement membrane and enterocytes. Immediately after the
start of the reperfusion, the I-FABP staining of the subepithelial space strongly
indicates a loss of enterocyte membrane integrity, resulting in leakage of I-FABP
into the subepithelial space. In line, we observed immediately upon ischemia
strongly elevated arteriovenous concentration gradients of I-FABP, reflecting the
membrane integrity loss of the epithelial cells of the villus. Therefore, we
hypothesize that the enterocyte cell membrane must have lost its integrity during
ischemia.
The mature enterocytes at the tip of the villus are the cells that are most
susceptible to IR 33. This has classically been explained by their constant state
of hypoxia due to the counter current exchange mechanism of oxygen in the
villus microvasculature, wherein oxygen from arterial blood entering the villus
diffuses across to neighbouring venules travelling from the tip down toward the
base of the villus 33. As a result of this phenomenon, a steep oxygen gradient is
present in the intestinal villus with substantially lower oxygen tensions in the
villus tip than at the crypt 33. In addition, desquamation occurs of the damaged
mature enterocytes from the tip of the villi, resulting in shedding of sheets of
epithelial cells into the lumen. Apoptosis is the major form of cell death
observed after the onset of reperfusion and at the villus tip. Apoptosis of
detaching enterocytes after intestinal IR is potentially caused by loss of contact
between the epithelial cells and extracellular matrix, and between
neighbouring epithelial cells (‘anoikis’) 20,31,34. Extracellular matrix molecules
provide a constant survival signal to epithelial cells via ‚1-integrins and
cadherins as well as their adhesion-mediated signalling pathways including
focal adhesion kinase (p125fak), phosphatidylinositol 3’-kinase (PI3-K)/Akt and
mitogen-activated protein kinase (MAPK; p38) 34-37. However, senescent
enterocytes gradually loosen cell anchorage by changes of integrin expression,
cadherin binding and its signalling pathways, making them prone to be
shedded from the villus tip at the end of their lifespan, a mechanism crucial for
maintenance of homeostasis in this epithelium 35-37. Moreover, acyl-coenzyme
A synthetase 5, which is solely expressed at the villus tip, is able to sensitize
epithelial cells to apoptosis specifically triggered by the death ligand TRAIL 38.
Therefore, mature enterocytes are in an anti-adhesive and pro-apoptotic state
when they reach the villus tip, culminating in the physiologic shedding 39. This
may contribute to the rapid onset of apoptosis that we observed in the mature
and damaged enterocytes after the ischemic period, upon reperfusion.
The ultimate reparative response to the lost epithelial continuity was
observed within one hour of reperfusion, consisting of a complete resealing of the
epithelial defect overlying the basement membrane by viable, ZO-1 and FABP
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containing, epithelial cells. The presence of tight junctions and endogenous
cytosolic proteins in the repaired epithelial cells of the villus tip indicates that the
epithelial lining is rapidly restored, which is of importance to reduce the
opportunity for luminal microbiota and their products to translocate. The question
remains whether this also leads to a reestablishment of the full barrier function,
which will be assessed in future using physiological measurements by tracer or
electrophysiological studies. Previous studies reported that the migration of
epithelial cells involves alteration of enterocyte shape and phenotype, including
extension of the plasma membrane in the direction of cell migration and
assembly of new focal contacts at the leading edge 19,40,41. Epithelial migration
during restitution is enhanced by luminal contents and a variety of systemic and
local factors, including trefoil peptides, polyamines and transforming growth
factor ‚ 19,42.
The clearing mechanism of IR-induced injured cells is unique to the
intestine. In other organs or tissues, such as heart, brain, kidney, liver and
skeletal muscle, IR-induced damaged and death cells remain in situ, since they
cannot be removed from the organs or tissues and cleared from the body. In
such organs, an inflammatory response is elicited amongst others to clear away
the injured and death cells after IR 10,13-15,43. Subject of further studies is the
investigation of the inflammatory response in our controlled, experimental
model of human IR, which enabled us to clarify a gut-specific protective
mechanism for IR-induced damaged cells. Our results might explain why the
gut can tolerate 30 minutes of ischemia in events as exercise, trauma, repair of
a (thoraco-) abdominal aneurysm of the aorta, and cardiopulmonary bypass.
REFERENCES
1. (2000) American Gastroenterological Association Medical Position Statement:
guidelines on intestinal ischemia. Gastroenterology 118: 951-953.
2. Oldenburg WA, Lau LL, Rodenberg TJ, Edmonds HJ, Burger CD (2004) Acute
mesenteric ischemia: a clinical review. Arch Intern Med 164: 1054-1062.
3. Jeukendrup AE, Vet-Joop K, Sturk A, Stegen JHJC, Senden J, et al. (2000) Relationship
between gastro-intestinal complaints and endotoxaemia, cytokine release and the
acute-phase reaction during and after a long-distance triathlon in highly trained men.
Clin Science 98: 47-55.
4. Perko MJ, Nielsen HB, Skak C, Clemmesen JO, Schroeder TV, et al. (1998) Mesenteric,
coeliac and splanchnic blood flow in humans during exercise. J Physiol 513: 907-913.
229
Human intestinal ischemia-reperfusion
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 229
5. Rokyta R, Matejovic M, Novak I, Zeman V, Krouzecky A, et al. (2002) Submaximal
exercise in healthy volunteers: the relationship between gastric mucosal and systemic
energy status. Pflügers Arch - Eur J Physiol 443: 852–857.
6. Veenstra R, Geelkerken R, Verhorst P, Huisman A, Kolkman J (2007) Acute stress-related
gastrointestinal ischemia. Digestion 75: 205-207.
7. Fukatsu K, Sakamoto S, Hara E, Ueno C, Maeshima Y, et al. (2006) Gut ischemia-
reperfusion affects gut mucosal immunity: a possible mechanism for infectious
complications after severe surgical insults. Crit Care Med 34: 182-187.
8. Mallick IH, Yang W, Winslet MC, Seifalian AM (2004) Ischemia-reperfusion injury of the
intestine and protective strategies against injury. Dig Dis Sci 49: 1359-1377.
9. Semenza GL (2000) Series introduction: tissue ischemia: pathophysiology and
therapeutics. J Clin Invest 106: 613-614.
10. Lee JM, Grabb MC, Zipfel GJ, Choi DW (2000) Brain tissue responses to ischemia. J
Clin Invest 106: 723-731.
11. Carden DL, Granger DN (2000) Pathophysiology of ischaemia-reperfusion injury. J
Pathol 190: 255-266.
12. Matzinger P (2007) Friendly and dangerous signals: is the tissue in control? Nat
Immunol 8: 11-13.
13. Jaeschke H (2003) Molecular mechanisms of hepatic ischemia-reperfusion injury and
preconditioning. Am J Physiol Gastrointest Liver Physiol 284: G15-26.
14. Blaisdell FW (2002) The pathophysiology of skeletal muscle ischemia and the
reperfusion syndrome: a review. Cardiovasc Surg 10: 620-630.
15. Daemen MA, de Vries B, Buurman WA (2002) Apoptosis and inflammation in renal
reperfusion injury. Transplantation 73: 1693-1700.
16. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM (2004) The role of the
complement system in ischemia-reperfusion injury. Shock 21: 401-409.
17. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN (1970) Intestinal mucosal lesion in
low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch
Surg 101: 478-483.
18. Park PO, Haglund U, Bulkley GB, Falt K (1990) The sequence of development of intestinal
tissue injury after strangulation ischemia and reperfusion. Surgery 107: 574-580.
19. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J (2007) Restoration of barrier
function in injured intestinal mucosa. Physiol Rev 87: 545-564.
20. Ikeda H, Suzuki Y, Suzuki M, Koike M, Tamura J, et al. (1998) Apoptosis is a major
mode of cell death caused by ischaemia and ischaemia/reperfusion injury to the rat
intestinal epithelium. Gut 42: 530-537.
21. Park PO, Haglund U (1992) Regeneration of small bowel mucosa after intestinal
ischemia. Crit Care Med 20: 135-139.
230
Chapter 5
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 230
22. Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, et al. (2005) Gastrointestinal
ischemia-reperfusion injury is lectin complement pathway dependent without
involving C1q. J Immunol 174: 6373-6380.
23. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, et al. (2003) The two faces of IKK and
NF-kappaB inhibition: prevention of systemic inflammation but increased local injury
following intestinal ischemia-reperfusion. Nat Med 9: 575-581.
24. Panes J, Granger DN (1998) Leukocyte-endothelial cell interactions: molecular
mechanisms and implications in gastrointestinal disease. Gastroenterology 114: 1066-
1090.
25. Haglund U, Hulten L, Ahren C, Lundgren O (1975) Mucosal lesions in the human small
intestine in shock. Gut 16: 979-984.
26. Kerstens HM, Robben JC, Poddighe PJ, Melchers WJ, Boonstra H, et al. (2000)
AgarCyto: a novel cell-processing method for multiple molecular diagnostic analyses of
the uterine cervix. J Histochem Cytochem 48: 709-718.
27. Pelsers MM, Hermens WT, Glatz JF (2005) Fatty acid-binding proteins as plasma
markers of tissue injury. Clin Chim Acta 352: 15-35.
28. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM (1998) The tight junction protein ZO-
1 establishes a link between the transmembrane protein occludin and the actin
cytoskeleton. J Biol Chem 273: 29745-29753.
29. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, et al. (1999) Myofibroblasts.
II. Intestinal subepithelial myofibroblasts. Am J Physiol 277: C183-201.
30. Kuhn K (1995) Basement membrane (type IV) collagen. Matrix Biol 14: 439-445.
31. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces
apoptosis. J Cell Biol 124: 619-626.
32. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, et al. (1999)
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed
during early apoptosis. J Pathol 187: 567-572.
33. Blikslager AT (2008) Life in the gut without oxygen: adaptive mechanisms and
inflammatory bowel disease. Gastroenterology 134: 346-348.
34. Hofmann C, Obermeier F, Artinger M, Hausmann M, Falk W, et al.(2007) Cell-cell
contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology
132: 587-600.
35. Fouquet S, Lugo-Martinez VH, Faussat AM, Renaud F, Cardot P, et al. (2004) Early loss
of E-cadherin from cell-cell contacts is involved in the onset of Anoikis in enterocytes.
J Biol Chem 279: 43061-43069.
36. Vachon PH, Harnois C, Grenier A, Dufour G, Bouchard V, et al. (2002) Differentiation
state-selective roles of p38 isoforms in human intestinal epithelial cell anoikis.
Gastroenterology 123: 1980-1991.
231
Human intestinal ischemia-reperfusion
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 231
37. Dufour G, Demers MJ, Gagne D, Dydensborg AB, Teller IC, et al. (2004) Human
intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation
and roles of protein kinase B/Akt isoforms. J Biol Chem 279: 44113-44122.
38. Gassler N, Roth W, Funke B, Schneider A, Herzog F, et al. (2007) Regulation of
enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology 133: 587-
598.
39. Bullen TF, Forrest S, Campbell F, Dodson AR, Hershman MJ, et al. (2006)
Characterization of epithelial cell shedding from human small intestine. Lab Invest 86:
1052-1063.
40. Moore R, Carlson S, Madara JL (1989) Rapid barrier restitution in an in vitro model of
intestinal epithelial injury. Lab Invest 60: 237-244.
41. Moore R, Madri J, Carlson S, Madara JL (1992) Collagens facilitate epithelial migration
in restitution of native guinea pig intestinal epithelium. Gastroenterology 102: 119-130.
42. Podolsky DK (1997) Healing the epithelium: solving the problem from two sides. J
Gastroenterol 32: 122-126.
43. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:
1121-1135.
232
Chapter 5
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 232
5.4 Mannose-binding lectin null
alleles are associated with
preserved epithelial cell integrity
following intestinal ischemia
reperfusion in man
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INTRODUCTION
Intestinal ischemia reperfusion (I-IR) injury has a multifactorial etiology,
involving activation of complement. Mannose-binding lectin (MBL) is
considered to be an important initiating complement component with
considerable variation in activating properties and plasma levels between
individuals. These variations are caused by three first exon mutations (at codons
52, 54 and 57) and polymorphisms in the promoter region (at position -550
(H/L) and -221 (X/Y)) of the structural gene (mbl2).1 Patients were classified
according to their first exon structural genotype; A/A, A/O and O/O, where any
of the three first exon variations is coded as O. Homozygous or heterozygous
carriers of variant mbl2 alleles express a disrupted MBL protein without
apparent complement activating properties that confers an increased
susceptibility to infectious diseases.2 Theoretically, this increased susceptibility
to infection would be anticipated to be eliminated as a consequence of
evolutionary pressure. Considering the high prevalence of nearly 40% of MBL
null variants in the Caucasian population, a broader role of MBL with a
significant biological advantage for such variant alleles should be considered.
Patients and methods
During a pylorus preserving pancreatico-duodenectomie (PPPD) part of the
small bowel is resected, providing the opportunity to study ischemia
reperfusion induced cell damage in a harmless human IR model of the jejunum.
A six centimeter long segment of the jejunum was subjected to 30 minutes of
ischemia and reperfusion (mean 128 minutes (30-240)). Ischemia was induced
using two non-traumatic vascular clamps, bilaterally clamping both afferent
and efferent branches of the vasculature. Ischemia was objectivated
macroscopically by discoloration of the jejunum outer wall and termination of
the peristalsis of the jejunum. Following thirty minutes of ischemia, reperfusion
was restored by removing the vascular clamps, immediately checking
reperfusion signs (regaining of color, restoration of gut motility and sampling of
the venous outflow). For the remainder of the procedure the IR specimen was
kept in the abdominal cavity. Local ethical approval and informed consent were
obtained. 29 Individuals were consecutively included. Due to incomplete
reperfusion 2 individuals were excluded before analysis. Data from 27
remaining individuals were analyzed by one-way analysis of variance (ANOVA)
and unpaired two-tailed Students T-test.
As a measure for intestinal epithelial cell damage arteriovenous plasma
differences in intestinal-fatty acid binding protein (I-FABP) levels were assessed
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before ischemia, directly upon and every thirty minutes during reperfusion in
afferent (A) and efferent (V) mesenteric blood samples drawn from the isolated
bowel segment (∆(V-A)).3 By subtracting arterial I-FABP concentration from
detected venous levels, either release or consumption can be easily assessed. In
addition, arteriovenous plasma differences in MBL levels were established and
the MBL genotype was assessed retrospectively by means of quantitative-PCR
analysis, using sequence-specific primers.4
RESULTS
The amount of epithelial cell damage varied significantly between the carriers
of different mbl2 genotypes (ANOVA, p = 0.02), with peak levels in I-FABP
release detected immediately upon reperfusion in every included individual.
Homozygous wildtype individuals (A/A, N=14; 64% men) showed a maximal
mean (± SEM) I-FABP release of 4,960 pg/ml (± 780 pg/ml) immediately after
reperfusion. Interestingly, heterozygous (A/O, N=11; 55% men) and
homozygous (O/O, N=2; two women) carriers of variant MBL alleles showed
maximal mean I-FABP release of 2,560 pg/ml (± 690 pg/ml) (p = 0.03
compared to A/A) and 240 pg/ml (± 60 pg/ml) (p = 0.04 compared to A/A),
respectively (Fig. 1). I-FABP levels between A/O and O/O individuals were
statistically similar (p = 0.19). The data were corroborated by histological
analysis of tissue samples collected at the end of reperfusion. Large amounts of
epithelial cellular debris in A/A individuals, whereas lesser debris was observed
in A/O and O/O genotype carriers (Fig. 1).
The data indicate that MBL influences intestinal epithelial cell integrity in
an immediate and non-complement dependent manner during ischemia,
considering the different peak I-FABP levels immediately upon reperfusion.
Analysis of the MBL levels in afferent and efferent blood samples from the
reperfused ischemic jejunum during both early and prolonged reperfusion,
revealed no MBL consumption (Fig. 2. p = 0.19). This suggests that activation
and binding of plasma MBL during reperfusion does not occur. The data
indicate a protective role for the MBL variant gene products, possibly on the
intracellular level.
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Figure 1: Intestinal epithelial damage.
Maximal epithelial damage, represented by peak I-FABP levels observed at the very beginning of
reperfusion, was calculated from the arteriovenous difference in I-FABP levels across an isolated
bowel segment before and after ischemia (∆(V-A)). Epithelial damage was virtually absent in
homozygous (p=0.03) and reduced in heterozygous (p=0.04) carriers of variant mbl2 alleles when
compared to their homozygous wildtype counterparts. The difference between heterozygous
variant and homozygous variant individuals was statistically similar (p=0.19). Integral I-FABP
release correlated with individual peak I-FABP levels in response to IR. Genotypes have been
listed for all carriers. Microphotographs demonstrate cellular debris observed after IR in the
intestinal lumen. Original magnification 100x.
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Figure 2: Plasma MBL
No consumption of plasma MBL was detected when analyzing arteriovenous concentration
differences (∆ (V-A)) over the isolated jejunum segment during IR (p=0.19).
DISCUSSION
Over time, mbl2 variant genotypes have been considered both advantageous as
well as disadvantageous to human evolution. On the one hand, variant mbl2
alleles are suggested to be protective against the development of leprosy.5 On
the other hand, variant mbl2 alleles have been linked to an increased risk of
developing, atherosclerosis,6 thrombosis7 and susceptibility to infectious
diseases.2 Synthesis of MBL is mainly attributed to the liver as well as the small
intestine and results in two MBL forms, namely plasma and intracellular MBL.8, 9
Hitherto, no in vivo function of intracellular MBL has been determined.
However, convincing in vitro data show the ability of MBL to inhibit meprins,
zinc metalloproteinases associated with IR induced cell damage and
abundantly present in intestinal epithelial cells.10, 11 Taken together the data
might point towards ischemia protective properties of variant and intracellular
MBL, associated with far-reaching beneficial qualities without an apparent
immunological function.
If confirmed in a larger patient cohort, our data may explain why mutations in
the MBL coding sequence, resulting in a defective immune regulatory function
as well as reduced levels of one of our prominent innate regulators of immunity,
have survived selection pressure during human evolution.
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ABSTRACT
Background and aims
Recently, we observed that in the human small intestine ischemia is rapidly
followed by sloughing of damaged epithelial cells and repair of the epithelial
lining. This phenomenon ensures a rapid loss of apoptotic and necrotic cells.
Classically, following ischemia and reperfusion (IR), damaged cells trigger an
inflammatory response resulting in enhanced tissue damage. This study
investigates whether the observed shedding of ischemically damaged epithelial
cell lining cells affects IR induced inflammation in the human small gut.
Methods
Using a newly developed IR model of the human small intestine, the
inflammatory response is studied on cellular, protein and mRNA level. 30
Patients were consecutively included in our tertiary care hospital. Part of the
jejunum was subjected to 30 minutes of ischemia and reperfusion. Mean
reperfusion time was 123 (30-240) minutes. Ethical approval and informed
consent were obtained.
Results
Gut barrier failure, indicated by increased LPS concentration in venous effluent
blood, was not observed during IR (p=0.18). Release of TNFα from the
reperfused tissue could not be detected. Additionally, gene expression of HO-
1, IL-6, IL-8 did not alter. No endothelial activation markers or increased
numbers of inflammatory cells (p=0.71) were detected in the reperfused tissue.
Complement was not activated, indicated by C3 deposition (p=0.14). However,
in response to anoxia, HIF-1α gene expression doubled (p=0.02) whereas C3
gene expression increased 4-fold (p=0.01) over the course of IR.
Conclusions
The human small intestine is classically considered vulnerable to IR. However,
these are first human in vivo data that illustrate the jejunum’s unique ability to
prevent IR induced inflammation by shedding of damaged enterocytes. This
understanding will aid current and future developments and diagnostics within
the field of gastroenterology.
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INTRODUCTION
Recently, we demonstrated the ability of the human small intestine to rapidly
restore its epithelial architecture after massive epithelial sloughing and gut barrier
damage in response to a thirty minutes ischemic episode and reperfusion.1
Interestingly, analysis of the reperfused intestinal segment demonstrated that the
epithelial brush border and epithelial tight junctions were restored within the first
hour of reperfusion.
The presence of apoptosis or cellular damage in reperfused ischemic organs
has cardinal implications in the pathogenesis of ischemia reperfusion.2, 3 Massive
apoptosis and subsequent necrosis are considered to be functionally involved in
the induction of inflammation after organ ischemia, since therapeutic strategies
aimed at preventing IR induced apoptosis can ameliorate IR induced
inflammation.4-7 Additionally, numerous experimental studies have shown that
the inflammatory response following IR mediates the development of additional
reperfusion injury, greatly compromising organ function. Different strategies
aimed at preventing IR induced inflammation can effectively reduce ultimate
organ damage.8 The inflammatory response induced by IR is essentially
characterized by different contributors. Early after cellular injury various
cytokines, such as tumor necrosis factor-α, interleukin-1, -6, -8 or -10 and
others, are expressed.9, 10 Together with the rapid expression of adhesion
molecules by activated endothelial cells, the activation, adhesion and
sequestration of polymorphonuclear neutrophils (PMN) into the affected tissue is
induced.11 By locally releasing myeloperoxidase (MPO), reactive oxygen species
and many more of their pro-inflammatory constituents, infiltrating PMN
contribute substantially to IR induced inflammation.12, 13 Additionally the
complement system is activated, thereby triggering to formation of reactive
complement split products known as anaphylatoxins, which induce additional
PMN chemotaxis and cause organ damage.14, 15 Ultimately, complement
activation will lead to cell damage by membrane attack complex (MAC)
formation.15, 16 Normally, under healthy conditions, these innate immune
constituents protect us from harm by orchestrating a well mounted attack on
invading microorganisms, but when faced with extensive I/R injury, sufficient
means of control seem absent. In this respect, interventions aimed at preventing
complement activation,17 MAC formation,18 expression of adhesion molecules19
or PMN sequestration20, 21 all prevent additional reperfusion injury.
Taken together, the presence of apoptotic and necrotic cells following
ischemia reperfusion of the small intestine is of critical importance in the
development of an inflammatory reaction that contributes to tissue injury. From
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this we hypothesized that the remarkable ability of the human small intestine to
effectively shed apoptotic cells, losing in this way an important endogenous
inflammatory trigger, serves as a rescue mechanism, unique to the intestine,
that potentially attenuates the development of an intense IR induced
inflammatory reaction. Therefore, we studied time related characteristics of IR
induced inflammation of the human small intestine in a newly developed
human ischemia reperfusion model of the jejunum. The results indicate that
reperfused ischemic jejunum effectively discards apoptotic and damaged
epithelium, restores the epithelial gut barrier and thereby prevents the
development of a local inflammatory response.
MATERIALS AND METHODS
Patients and ethics
The study was approved by the local ethical committee. Written consent of all
patients was obtained before inclusion. We consecutively included 30 patients
over 18 years of age. The included patients were scheduled to undergo
pancreatic surgery; twenty eight underwent a pylorus preserving pancreatico-
duodenectomy (Whipple’s procedure) for benign or malignant pancreas disease
and two a Frey procedure for chronic pancreatitis. The small intestine samples
from every included patient were macroscopically assessed for evident signs of
pathology during operation and before IR procedure. Due to an incomplete
reperfusion 2 patients were excluded before further analysis.
Study model
Patients were anesthetized according to institutional routines using isoflurane
and propofol. Operation was initiated by a subcostal bilateral incision. Omni-
Tracts were used to improve exposure. Per operatively echographic confirmation
of diagnosis and disease progression was obtained. Six centimeters of the small
intestine (jejunum) resection specimen, just proximal to the ligament of Treitz at
the duodenal-jenunal transition, were mobilized and transsected using proximal
and distal universal straight endo-GIA (GIA 6038S, Covidien, MA). Both afferent
and efferent mesenteric vascular structures were previously dissected from their
surrounding tissues and remain intact. To prevent bowel rotation, compromising
segmental blood flow, the isolated segment was fixed to both the proximal and
distal small bowel continuum. Ischemia was induced using two non-traumatic
vascular clamps, bilaterally clamping both afferent and efferent branches of the
vasculature. Ischemia was objectivated macroscopically by discoloration of the
jejunum outer wall and termination of the peristalsis of the studied jejunum.
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Following thirty minutes of ischemia, reperfusion was restored by removing the
vascular clamps, immediately checking reperfusion signs (regaining of color,
restoration of gut motility and sampling of the venous outflow). For the
remainder of the procedure the IR specimen was kept in the abdominal cavity.
Serial blood samples were drawn before ischemia, on reperfusion and every
thirty minutes during reperfusion from the afferent vein draining the isolated and
ischemically damaged jejunum. Timed to the venous blood samples, blood from
the arteria radialis was collected to represent arterial intestinal inflow. The total
reperfusion time was determined by the duration of the surgical procedure, with
a maximum of 240 minutes. Reperfused ischemic intestine samples were
obtained from every patient (n=28). Healthy jejunum samples, serving as
internal controls, were obtained from 12 patients.
Immunohistochemistry
Paraffin-embedded sections from healthy and IR damaged jejunum were prepared.
Endothelial adhesion molecules E-selectin (CD-62-E, monoclonal antibody ENA1,
kindley provided by Hycult Biotechnology (Hbt, Uden, the Netherlands)),
intercellular adhesion molecule-1 (ICAM-1, monoclonal antibody HM1, Hbt) and
mucosal vascular addressin cell adhesion molecule 1 (MADCAM-1, monoclonal
antibody 314G8, Hbt), neutrophils by myeloperoxidase staining (polyclonal
antibody, A0398, DakoCytomation, Glostrup, Denmark) or human neutrophil
defensin 1-3 (monoclonal antibody, D21, Hbt) and complement component C3c
(A0062, DakoCytomation) were immunostained on paraffin embedded sections.
The sections were deparaffinized, rehydrated and blocked for 1 hour at room
temperature using 5% BSA in phosphate buffered saline (PBS) or tris buffered
saline (TBS) for HM1 and MPO. Properly diluted primary antibodies were
incubated in PBS or TBS supplemented with 0.1% BSA for 1 hour at room
temperature. After washing, specific antibody binding was detected using specific
peroxidase conjugated secondary antibodies (Jackson Immunoresearch, West
Grove, PA) or a biotinilated swine anti rabbit secondary antibody (E0432,
DakoCytomation) for detecting MPO specific binding. Next, signal enhancement
was achieved by peroxidase conjugated avidin biotin complexes. Staining was
visualized by 3-amino-9-ethylcarbazole (AEC) followed by a hematoxylin (Sigma,
St. Louis, MO) nuclear counterstaining.
ELISA
Arteriovenous concentration differences in plasma I-FABP levels were
determined by Enzyme-Linked ImmunoSorbent Assay (ELISA) before and after
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ischemia to measure intestinal mucosal cell damage.22 The I-FABP ELISA
(HK406, Hbt) was performed in accordance to the manufacturer’s guidelines. I-
FABP release was determined for every included patient.
Myeloperoxidase (MPO) was measured in tissue samples that were
homogenyzed according to the previously described western blot protocol. MPO
was measured using a commercially available solid-phase ELISA kit based on the
sandwich priciple (Hbt) in aliquots containing equal amounts (10 µg) of total
protein. The assay was performed in accordance to the manufacturer’s guidelines.
Arteriovenous concentration differences in plasma tumor necrosis factor-α
(TNFα) levels were determined by ELISA before and after ischemia as well as
during reperfusion. The TNFα ELISA was preformed as described before.23
Arteriovenous concentration differences in plasma lipopolysacharide (LPS)
levels were determined using a Limulus Amebocyte Lysate (LAL) assay before
and after ischemia as well as during reperfusion. The LAL assay (HIT 302, Hbt)
was performed in accordance to the manufacturer’s guidelines. Plasma LPS was
determined in samples collected at pre-fixed time points.
Western Blot
Western blot analyses for human C3 deposition on reperfused ischemic tissue
samples and healthy controls was performed as described before, with minor
modifications.4 Jejunal samples were homogenized in lysis buffer (200mM
NaCl, 10 mM Tris base, 5mM EDTA, 10% Glycerin, 1mM PMSF, 0.1 U/ml
Aprotinin and 1µg/ml Leupeptin). Tissue homogenates were centrifuged. The
protein concentration of the different lysates was determined using Bradford
analyses. Aliquots containing equal amounts (10 µg) of total protein were
heated and reduced, transferred to a 8% SDS-polyacrylamide gel and blotted
on an Immobilon-P polyvenylidine fluoride (PVDF) membrane (Millipore,
Bedford, MA). Blocking was performed in phosphate buffered saline (PBS)
containing 5% bovine serum albumin and 0.1% Tween-20 (Sigma). C3 was
detected in PBS 0.1% BSA 0.1% Tween-20 after overnight incubation of the
properly diluted rabbit anti human C3c (A0062, DakoCytomation, Glostrup,
Denmark). Binding of the primary antibody was detected using a biotinilated
secondary antibody to rabbit IgG (E0353, Dako) and streptavidine conjugated
peroxidase. Positive bands were visualized using chemiluminescence
(Supersignal (pico:femto 9:1), Pierce, Rockford, IL).
Real-Time Quantitatve - PCR analysis
Total RNA was extracted from healthy or IR damaged gut tissue samples using
a SV Total RNA Isolation System according to manufacturer’s guidelines
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(Promega, Madison, WI). Total cDNA was synthesized with oligo (dT) primers and
Molony murine leukemia virus reverse transcriptase. Specific primers (Sigma) for
amplification of hemoxygenase-1, hypoxia inducible factor 1-α, inteleukin-6 and
-8, TNFα and complement component C3 specific cDNA were designed using
the Primer Express software package (Applied Biosystems, Foster City, CA) and
tested for amplification of contaminating genomic DNA. To minimize the risk of
genomic amplification the primers were positioned on different exons. Primer
concentrations were optimalized and dilution curves were made from human
liver cDNA standard pool to ensure an exponential Taqman amplification for
each primer set. After normalization to endogenous reference genes RPLP0 and
cyclophyline-A the level of expression of different proteins in healthy or IR
damaged samples was determined by the comparative ∆∆CT method of relative
quantification. Primer specifications are listed in Table 2.
Statistical analysis
Data are expressed as means ± SEM and were analyzed by either paired or
unpaired two-tailed Student’s t-test depending on sample collection or by
repeated measures ANOVA (LPS release). Data were analyzed using Graphpad
Prism 4.01 for Windows (Graphpad Software, San Diego, CA). P-value ≤0.05
was considered statistically significant.
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Table 1: Sequence of primers for Q-PCR analysis
Proteins Primers
Forward Reversed
HIF-1α 3-TGAACATAAAGTCTGCAACATGGA-5 5-TGAGGTTGGTTACTGTTGGTATCATATA-3
HO-1 3-CTTCTTCACCTTCCCCAACA-5 5-GCTCTGGTCCTTGGTGTCAT-3
TNFα 3-TCAATCGGCCCGACTATCTC-5 5-CAGGGCAATGATCCCAAAGT-3
IL-6 3-TCCAGGAGCCCAGCTATGAA-5 5-GAGCAGCCCCAGGGAGAA-3
IL-8 3-CTGGGCGTGGCTCTCTTG-5 5-TTAGCACTCCTTGGCAAAACTC-3
C3 3-CCCTCATCATCTACCTGGACAAG-5 5-GCTGGATAAGCTCTACATTAAAGTATTGG-3
RPLP-0 3-GCAATGTTGCCAGTGTCTG-5 5-GCCTTGACCTTTTCAGCAA-3
Cycophilin A 3-CTCGAATAAGTTTGACTTGTGTTT-5 5-CTAGGCATGGGAGGGAACA-3
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RESULTS
Patient outcome and reperfusion period
The mean (± SEM) age of included patients (n=28) was 68 (35-79) years and
64% were male. Isolated jejunum samples were subjected to 30 minutes of
ischemia followed by a mean reperfusion time of 123 (30-240) minutes (Fig 1).
Jejunum samples subjected to IR were analyzed from 28 patients. Healthy
control samples of the jejunum were obtained from 12 patients (43%), of which
we obtained samples with reperfusion times of over 60 minutes.
Figure 1: Reperfusion times
Distribution of total reperfusion times following 30 minutes of ischemia (n=28).
Plasma LPS levels following IR
Disruption of the gut barrier may lead to translocation of microbiota and pro-
inflammatory microbial products, such as the endotoxin associated with gram
negative bacteria, lipopolysacharide (LPS). Therefore we assessed the
translocation of LPS following the rapid and temporary disruption of the
epithelial lining in response to IR observed in our model.1 LPS translocation
from the intestinal lumen was assessed by measuring arterio-venous (AV)
differences in LPS concentration across the studied jejunum, using the sensitive
LAL-assay. Surprisingly, no translocation of LPS (p = 0.18. n = 28) was detected
over the total course of reperfusion (Fig 2). The temporary loss of gut wall
integrity observed during reperfusion, which is induced by massive shedding of
apoptotic epithelial cells, does not lead to the translocation of highly pro-
inflammatory bacterial product LPS.
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Figure 2: Tissue response to IR
Illustrative of rapid gut barrier repair, no translocation of LPS could be detected during the IR
procedure. Translocation of LPS was calculated from arteriovenous differences in LPS plasma
levels across the isolated bowel segment during reperfusion (∆ (V-A). p=0.18).
Stress response
In order to demonstrate a physiological response to anoxia and to reperfusion
stress, the gene expression profile of hypoxia inducible factor-1α (HIF-1α) and
heme oxygenase-1 (HO-1) were determined in healthy and IR damaged whole
jejunum samples (n = 12). The gene expression of HIF-1α, that regulates both
the physiologic and pathophysiologic responses to ischemia, increased during
reperfusion (Table 2). In contrast, local synthesis of HO-1 was unaltered by IR
(Table 2).
Cytokine expression and endothelial activation
In order to assess the inflammatory reaction over the course of IR, serial venous
blood samples from the reperfused jejunum were analyzed for different
inflammatory markers. Additionally, the cytokine response in whole jejunum
tissue samples was studied using Q-PCR and endothelial cell activation was
assessed by immunohistochemistry on paraffin embedded whole jejunum tissue
samples. No increase in TNFα protein levels was detected in venous plasma
samples, collected from the isolated jejunum during the procedure; e.g. prior to
ischemia, directly after ischemia and every 30 minutes during reperfusion.
Compared to the TNFα levels in arterial circulation, AV-differences in TNFα
levels revealed no release of TNFα (data not shown). In line, no increase in
TNFα mRNA was detected in IR damaged jejunum samples, when compared to
healthy jejunum controls from the same patient (Table 2).
Gene expression of cytokines IL-6 (Table 2) and IL-8 (Table 2) in response
to IR differed widely and lacked to show an increase in gene expression (n =
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12). Of interest is the observation that the length of reperfusion period in
different individuals did not correlate with the IL-6 or IL-8 mRNA levels (data
not shown).
Classic in the development of extensive IR damage is the early expression of
various adhesion molecules by activated endothelial cells. Presence of E-selectin,
ICAM-1 and MADCAM-1 were analyzed using immunohistochemistry. Only 3
patient samples demonstrated sporadic and minimal expression of E-selectin (data
not shown), ICAM-1 and MADCAM-1 (Fig 3) following maximal reperfusion.
Figure 3: Endothelial activation
Compared to healthy control jejunum tissue, reperfused jejunum samples in response to 30
minutes of ischemia show an only moderate increase in ICAM-1 (upper panel) and MADCAM-1
(lower panel) expression demonstrated by terracotta red staining of the AEC. Original
magnification 200x.
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Table 2: Gene expression profiles in response to IR, calculated by comparative DDCT method of
relative quantification. * p-value ≤0.05 was considered statistically significant (n = 12)
Gene Healthy IR Fold increase (95%-CI) P - value
HIF-1α 1.00 1.91 1.91 (1.15 – 2.67) 0.02*
HO-1 1.00 1.58 1.58 (0.22 – 2.94) 0.34
TNFα 1.00 1.18 1.18 (0.56 – 1.80) 0.54
IL-6 1.00 12.31 12.31(-5.29 – 29.91) 0.18
IL-8 1.00 15.86 15.86 (0.59 – 31.13) 0.06
C3 1.00 4.09 4.09 (1.74 – 6.43) 0.01*
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Neutrophil infiltration and release of myeloperoxidase
Critical in the induction of reperfusion injury is the influx of neutrophils as well
as the release of their reactive constituents. The presence of neutrophils was
assessed using two different and widely used neutrophil markers, human
neutrophil defensin 1-3 (HNP1-3) and myeloperoxidase (MPO), both stored in
abundance in azurophilic granules of neutrophils. Microscopic analysis of
multiple high power fields (5) from different paraffin embedded tissue samples by
a blinded observer, showed that the number of PMN in the reperfused jejunum
was similar in comparison to the number of PMN observed in healthy control
jejunum samples, as detected by immunohistochemical analysis of HNP1-3 (Fig
4A. p = 0.90. n=10). In concordance, more sensitive analysis of whole jejunum
samples for total MPO content by ELISA, revealed no increase in MPO protein in
the reperfused jejunum, when compared to healthy jejunum control samples (Fig
4B. I/R = 101.0 ± 31.3 ng/mg vs Healthy = 75.9 ± 32.6 ng/mg. p = 0.71. n=12).
A small number of HNP1-3 positive PMN were observed in cellular debris in the
intestinal lumen (Fig 4A insert). The presence of these PMN in the intestinal lumen
was apparently of no considerable consequence to the remaining jejunum.
Figure 4: Neutrophil recruitment
A) No increase of PMN was observed over the course of reperfusion in response to 30 minutes of
ischemia. Detected by specific HNP1-3 staining (AEC) the number of PMN in reperfused jejunum
did not increase in comparison to healthy tissue (p=0.90). Original magnification 200x. Clearly
the PMN concentrated around the cellular debris collecting in the safe intestinal lumen (right
insert in Fig 4A. Original magnification 200x). B) Tissue MPO, assayed by ELISA, does not increase
substantially over the course of IR (p=0.71).
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Complement activation and expression in response to IR of the jejunum
As a central mediator of IR induced inflammation, complement is involved in
the development of organ damage. Complement component C3 is an important
constituent of the complement system, of which activation and deposition
indicate complement activation. Immunohistochemical analysis of healthy and
IR damaged jejunum sections revealed no increase in C3 deposition in response
to IR (Fig 5A). In order to validate these data, human C3 protein in total jejunum
tissue after reperfusion was additionally analyzed by western blot. Similar,
jejunum tissue specimens showed no increase in the presence of C3 over the
course of IR, when compared to their healthy controls (Fig 5B. I/R = 3.09 ± 1.79
relative intensity vs Healthy = 1.00 relative intensity. p = 0.140. n = 12).
Interestingly, subsequent analysis of the response to IR by the jejunum
involving C3 mRNA, using Q-PCR analysis, clearly detected C3 mRNA levels in
both healthy and IR damaged whole jejunum samples. During reperfusion, the
amount of C3 specific mRNA increased over 4 times in response to 30 minutes
of ischemia (Table 2), signifying the tissue’s responses to ischemia rather than
activation of a vigorous inflammatory reaction in response to tissue damage and
by recruitment of plasma complement components.
Figure 5: Complement activation
A) C3 was not be detected in the reperfused jejunum using immunohistochemistry. Original
magnification 200x. B) Western blot analysis, under reducing conditions, revealed no increase in
human C3 (molecular weight ± 80 kD) in whole reperfused jejunum samples, when compared to
healthy control tissue (p=0.14). C) C3 gene expression increased over 4-fold during IR of the
human jejunum (p=0.01).
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DISCUSSION
Development of IR induced organ damage is generally characterized by an
excessive and vigorous inflammatory response, mainly triggered by massive
apoptosis of cells that cannot be resolved in time by phagocytic cells and will
be become necrotic in time. Such necrotic cells are a source of damage
associated molecular patterns (DAMPS) or alarmins which recruit and activate
innate immune cells in a process aimed at restoration of homeostasis by
resolving tissue damage and promoting tissue repair.24, 25 In the context of
ischemia and reperfusion such an inflammatory reaction often results in
additional tissue damage. It has been demonstrated in the kidney as well as
other organs that IR induced inflammation and subsequent organ damage is
dependent on the development of widespread apoptosis.4 Rapid clearance of
apoptotic cells as well as therapeutic strategies to reduce apoptosis have been
shown to be critical in preventing the mostly harmful IR induced inflammatory
response.2-7, 26
Critical in the execution of apoptosis is the activation of proteolitic
enzymes, called caspases. Caspase-1, also referred to as IL-1-converting enzyme
(ICE) is also involved in the cleavage and activation of cytokines, such as IL-1, IL-
12 and IL-18.27, 28 Also the cytokine activity of TNFα, IL-6 and IL-8 is associated
with the inflammatory reaction following IR.29 As a prototypic member of the
TNF-family, TNF-α is a key mediator of acute inflammation of which expression
is readily induced following ischemia reperfusion of the rat small intestine.30
Interestingly, we did not detect an increase in TNFα message in our experiments.
Similarly, using IL-6 knockout (KO) mice, IL-6 was demonstrated as an important
component of the acute phase reaction, able to induce tissue injury and
inflammation following mesenteric ischemia and reperfusion.31 IL-6 controls
endothelial cell injury, mediating successive neutrophil influx, although anti-
inflammatory properties of IL-6 have been reported as well. Recent work on
small bowel transplantation in rats demonstrated that exogenous administration
of IL-6 to the donor prior to transplantation reduced cold IR injury associated
with small bowel transplantation.32 Also the chemokine IL-8 has been shown to
be involved in intestinal ischemia reperfusion induced inflammation.
Administration of an inhibitory anti IL-8 antibody over the course of mesenteric
IR in rats prevented neutrophil infiltration and protected the small intestine from
IR injury.33 In line with our TNFα and IL-6 data also IL-8 gene expression was not
up regulated following human intestinal ischemia reperfusion.
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E-Selectin (CD-62-E and formerly known as endothelial leucocyte adhesion
molecule-1 (ELAM-1)) has an important role in the recruitment of leucocytes to
sites of tissue injury. Its expression by vascular endothelial cells in response to
injury is readily induced by cytokines IL-1 and TNFα. Interestingly, our data
suggest that despite the massive presence of dead cells in response to an IR
period, rapid shedding of damaged epithelial debris largely averts endothelial
cell activation. Consistent with this observation, neutrophil infiltration, assessed
by HNP1-3 positive cells in IR and dependant on chemokine release,
endothelial activation and chemotaxis by anaphylatoxins, was not detected in
our experiments. In line with these data no increase in release of MPO was
observed. Although MPO is normally associated with the antimicrobial activity
of neutrophils, the presence of MPO has been demonstrated to have a clear
effect on the development of IR induced organ damage. Renal IR studies have
demonstrated that MPO itself is able to contribute to the development of organ
damage.34
The complement system is a central innate immune regulator that is activated
during intestinal IR and contributes substantially to IR induced inflammation,
organ damage and failure.16, 17, 35 Preventing complement activation has been
proven to be beneficial to organ function after IR in general and intestinal IR more
specifcally.17, 18, 36 Central in the activation of complement is the formation of C3a,
an anaphylatoxin with the ability to attract inflammatory cells into the reperfused
ischemic tissue. In our model no deposition of C3 in reperfused jejunum was
detected, using immunohistochemical and western blot analysis. Interestingly, our
results do however suggest C3 gene expression in healthy jejunum tissue as well
as an increased synthesis of C3 in response to IR. The ability of small intestinal
epithelial cells to express biological mediators such as C3 in response to IR was to
be expected since previous work demonstrated C3 gene expression in inflamed
small intestine during Crohn’s disease.37 To the best of our knowledge, however,
these are the first results that demonstrate C3 synthesis in the healthy jejunum.
Further analysis will have to elucidate the nature increased C3 expression
following IR.
The recently discovered molecular mechanism that recognizes and responds
to excessive cell death consisting of SAP130 and the macrophage inducible C-type
lectin (Mincle) fits in our observations.38 The loss of excessive numbers of dead
cells into the gut lumen prevents SAP130 released by the dead cells to reach tissue
macrophages thus largely preventing the production of inflammatory cytokines
driving rapid neutrophil infiltration. Similarly activation of complement by dead
cells is prevented therefore the PMN chemotactic factors C3a en C5a will not be
produced.
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Another mechanism of protection was suggested by the enhanced expression of
HIF-1α in the surviving epithelium. Expression of HIF-1α in response to low
oxygen tension during ischemia and early reperfusion triggers physiologic
responses characterized by activation of functional proteins mucin, P-glycoprotein,
intestinal trefoil factor and adenosine A2B receptor, aimed at preventing mucosal
inflammation.39 The role in preserving gut wall integrity in response to
inflammation as well as the exciting role of HIF-1α in different cardiac and brain
pre-conditioning IR models underlines the protective influence of increased in
HIF-1α gene expression as detected in our model in response to IR of the human
intestine.39-41
Ischemia, sensed by the small intestine, induces normal physiological and
IR induced responses. Our data provide new and compelling evidence of
increased HIF-1α and also C3 gene expression during the reperfusion period.
However, these responses are not paralleled by an IR induced inflammatory
response, since important conditions to an inflammatory reaction have not been
met by the absence of dead cells in the reperfused tissue. It is important to realize
that these data indicate that the human intestine is more resistant to IR than
initially thought. Its ability to shed damaged epithelial cells and repair its ever
important barrier function without triggering massive inflammation can be seen
as one of the key features that prevents the gut from inflammation following
splanchnic hypoperfusion as occurs in situations with circulatory redistribution in
favour of the brain and crucial organs. Moreover this specific property of the gut
enables surgical interventions such as prolonged mesenteric clamping.
Taken together, our data suggest that the ability of the small intestine to
shed cells damaged by ischemia and reperfusion into the exterior environment
of the intestinal lumen protects the surviving tissue from the exposition to
highly pro-inflammatory DAMPS or alarmins originating from dead cells. A new
physiological rescue mechanism is revealed by which acute pro-inflammatory
stimuli are safely eliminated and discarded into the intestinal lumen following
moderate ischemia of the small gut, explaining the absence of a cytokine
response and neutrophil recruitment. Other organs might well exhibit similar
responses with limiting success. The kidney for example discards its damaged
tubular epithelial cells into its tubular lumen in response to IR, acute tubular
necrosis or toxic ingestion. The limited space in the tubules might restrict the
effect of this process.
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The intestinal mucosa is responsible for the absorption of nutrients from the
lumen on the one hand and for the separation of the potentially toxic luminal
content (external environment) from the host (internal environment) on the
other hand. Disruption of this delicate balance at the mucosal interface occurs
in numerous (intestinal) diseases. Assessment of gut wall integrity loss in
clinical practice is still a challenge, since it is difficult to evaluate gut condition
non-invasively with the currently available diagnostic tools. Moreover, non-
invasive, rapid diagnostic means to assess intestinal condition are also needed
in the follow-up of many intestinal diseases for evaluation of the effects of
treatment on the recovery of the disorder. Furthermore, primarily experimental
animal studies have shown that gut wall integrity loss is involved in the
development of various inflammatory syndromes, including post-operative or
post-traumatic systemic inflammatory response syndrome (SIRS), sepsis and
multiple organ failure (MOF) 1,2.
In this thesis, markers for human gut wall integrity were evaluated as tools
for diagnosis and follow-up in patient studies. Next, the development of gut
wall integrity loss in critically ill patients and patients undergoing major surgery
was investigated to study whether gut barrier loss is of importance in the
development of post-operative complications. Finally, as intestinal ischemia-
reperfusion was proven to be present in critically ill patients and in patients
undergoing major surgery and was related to the onset of gut wall integrity loss,
the sequelae of intestinal ischemia-reperfusion were investigated in a novel
human model.
The first aim of this thesis was to gain more insight in characteristics of
markers that are potentially useful for the assessment of gut wall integrity loss,
namely tests for enterocyte damage and tight junction loss.
This thesis focussed on markers for enterocyte damage, more specifically
on the family of fatty acid binding proteins (FABP), since these proteins are
tissue specific 3. Three isoforms of FABP are present in the intestine: intestinal
(I)-FABP, liver (L)-FABP, ileal-bile acid binding protein (I-BABP) 3. Results of
previous experimental animal studies and some human (pilot-)studies have
shown that FABP are potentially useful as plasma- and/or urinary markers to
detect enterocyte damage, as occurs after ischaemia or inflammation 4,5. To
gain insight in FABP plasma and urinary concentrations, the exact localization
of these proteins in the gut was investigated. The expression of I-FABP and L-
FABP in the different segments of the human intestine, obtained during routine
surgery, was evaluated (in the second paragraph of chapter 2). I-FABP and L-
FABP are expressed in the mucosa of the entire small intestine and have a
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predominant expression in the jejunum. I-BABP is specifically present in the
ileum with a mean (±SEM) concentration of 303 (±113) µg I-BABP/gr tissue
(data not shown). I-FABP, L-FABP and I-BABP are in particular highly expressed
in cells present on the top of the villi. The presence of FABP on the top of the
villi, the initial site of destruction in numerous intestinal diseases, makes
circulating FABP potentially useful plasma markers in early stages of intestinal
diseases. Subsequently, the release of I-FABP and L-FABP into the circulation of
patients with obvious intestinal epithelial damage, i.e. patients with celiac
disease, was investigated. This pilot-study showed that I- and L-FABP circulating
levels were significantly increased in untreated celiac disease compared to
healthy volunteers. Furthermore, I- and L-FABP concentration normalized after
implementation of the therapy for celiac disease (gluten-free diet) in all but one
patient. However, one has to bear in mind that L-FABP shows a multi-tissue
expression, in contrast to I-FABP. Besides the expression in the intestine, L-FABP
is also present in hepatocytes and tubular cells of the kidney 3. Increased
circulating and/or urinary L-FABP levels can therefore be derived from other
organs than the intestine.
Subsequently, the release and clearance of FABP was investigated in
patients undergoing liver resection for secondary tumors in an otherwise
healthy liver (as is described in paragraph 3, chapter 2). Plasma levels of L-FABP
increased early during surgery, namely during liver manipulation. Other
classical liver injury markers (alpha glutathione s-transferase (GSTa) and
aspartate amino transferase (AST) showed a similar rise. L-FABP and GSTa levels
decreased immediately postoperatively, whereas AST gradually kept increasing.
As a consequence, L-FABP and GSTa are probably more sensitive for detecting
ongoing hepatocyte injury and impending liver failure than AST. To prove this
assumption, however, a large prospective study is needed.
Next, the release and clearance of FABP was investigated in the same
study by collection of blood from efferent and afferent vessels of the intestine,
liver and kidney during surgery. Arterial renal venous concentration gradients
showed that the kidneys remove approximately 30% of L-FABP in a single pass,
leading to a calculated L-FABP half-life of 11 minutes. In conclusion, the
immediate postoperative decline of L-FABP is a result of its rapid renal
clearance. This further emphasizes that FABP is an accurate marker for actual
cell damage and that urinary concentration are potentially useful in reflecting
this damage, since FABP are rapidly cleared by the kidneys.
As the epithelial barrier is constituted by both enterocytes and tight
junctions, the next study was directed at finding a marker for the assessment of
tight junction damage. In chapter 2, paragraph 4 was studied whether an
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important tight junction protein, i.e. claudin-3 6, can be used as a non-invasive
marker to study the condition of tight junctions. In a translational study, using
both a rat hemorrhagic shock model and a human setting of patients with active
inflammatory bowel disease (IBD), the immunohistochemically visualized loss
of claudin-3 from intestinal tissue resulted quickly in the appearance of this
protein into urine. This is the first study to report that measurement of the status
of tight junctions can be performed non-invasively.
In conclusion, the results of chapter 2 showed that non-invasive (i.e. urine
based) assessment of the condition of the epithelial layer of the gut, which is
responsible for the barrier between external environment and host, is possible
with the use of proteins originating form cytoplasma of damaged enterocytes
(FABP) and from disrupted tight junctions (claudin-3) (Figure 1).
Figure 1: the leakage of FABP and claudin, reflecting the condition of the epithelial layer of the
gut.
The second aim of this thesis was to analyse the usefulness of markers for
compromised gut wall in patients with overt gut damage and in patients with
suspected intestinal disease to distinguish the target disease from other
pathologies.
Diagnostic tests aim at discriminating between clinically “normal” and
“abnormal”. New diagnostic tests should subsequently answer the following 4
questions before implementation of the new test in daily clinical practice can
be contemplated 7.
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Question 1: Do patients with the target disorder have different test results from
normal individuals? The answer requires comparison of test results among
individuals with the disease and individuals that are disease-free. In chapter 3,
paragraph 2, a 2-year-old girl with rhabdomyosarcoma is presented, who suffered
from three episodes of gastrointestinal mucositis and bacteraemia following two
cytostatic treatments consisting of ifosfamide, vincristine, and actinomycin D (IVA).
This is a well-known and potentially harmful complication of chemotherapy,
which is difficult to diagnose and of which the pathophysiology is poorly
understood. Gastrointestinal mucositis presented as abdominal complaints,
fever, which was accompanied by raised C-reactive protein levels, and positive
blood culture for coagulase-negative staphylococci. The signs and symptoms
and laboratory results were preceded by increased plasma levels of intestinal
fatty acid binding protein (I-FABP), reflecting enterocyte damage. Next, the
relationship between enterocyte mass and enterocyte loss was explored by
examining citrulline serum levels (reflecting functional enterocyte mass) 8,9 and
by assessing circulating I-FABP and I-BABP (assessing enterocyte loss) in adult
patients with haematological malignancy receiving allogeneic HSCT and
preceding myeloablative conditioning, consisting of idarubicin, cyclophos-
phamide and total body irradiation (chapter 3, paragraph 3). This regimen is
known to induce oral and intestinal mucosal barrier injury 10. A decline in
circulating citrulline concentrations was found with the nadir 19 days after the
start of the myeloablative regimen. This is in line with previous studies and
shows a clear transient reduction in the small intestinal epithelial cell mass.
Interestingly, an almost simultaneous reduction in circulating levels of I-FABP
and I-BABP were observed. The baseline circulating levels of FABP are
considered to represent the continuous loss or, in other words, the turnover of
enterocytes, since the main loss of enterocytes in the healthy intestine consists
of senescent enterocytes which release FABP upon detachment or death into
the gut lumen at the end of their lifespan. Surprisingly, these data showed that
less cytosolic content of enterocytes is released into the circulation after
intensive myeloablative conditioning than under normal, healthy circumstances,
indicating a decreased rate of dying enterocytes. This, in turn, suggests a
reduced turnover of enterocytes after myeloablative conditioning. Furthermore,
this is the first study to report on specific changes in I-BABP levels, representing
specific jejunal and ileal enterocyte loss, using a newly developed ELISA for
measurement of serum and plasma I-BABP.
Question 2: Are patients with certain test results more likely to have the
target disorder than patients with other test results? This question is also answered
by comparison of test results among patients with the targetdisease and healthy
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individuals, but now test characteristics as sensitivity, specificity and likelihood
ratios are estimated. As discussed above in this chapter, the potential usefulness of
assessing circulating concentrations of FABP in a pilot study of patients with celiac
disease, which is characterized by intestinal mucosal damage, was reported
(chapter 2, paragraph 2). The results of the study suggest that besides a possible
additional role for FABP in the diagnosis of celiac disease, assessment of
plasma/urinary concentration of FABP may provide a new important non-invasive
tool to monitor the short-term response to a gluten-free diet and in this way
contribute importantly to the follow-up of celiac patients. However, further
studies are necessary to determine whether assessment of intestinal epithelial cell
damage by FABP analysis can replace the invasive procedure of endoscopy and
mucosa biopsy. Next, the usefulness of plasma markers for neutrophil activation
products was explored, since gut damage irrevocably leads to gut wall
inflammation, which implies the recruitment of leukocytes into the intestinal wall.
Acute appendicitis (AA) is an intestinal disease, characterized by gut damage and
massive infiltration of neutrophils into the gut wall, for which the diagnosis is
often delayed due to its aspecific clinical presentation and lack of adequate
laboratory markers. The circulating neutrophil activation product calprotectin
showed the most promising results; it was found to be significantly increased in
51 patients with proven AA compared to 9 patients without proven AA and 27
healthy volunteers (chapter 3, paragraph 4). This yielded an overall accuracy of
the test, summarized using area under the receiver operating characteristics curve
(AUC), of 0.91. This is considered to be clinical relevant.
Question 3: Among patients in whom it is clinically sensible to suspect
the target disorder, does the test result distinguish those with and without target
disorder? To obtain the appropriate answer, a consecutive series of such patients
should be studied. This phase in the evaluation of diagnostic tests was applied
to the potential improvement of the diagnostic accuracy of necrotizing
enterocolitis (NEC), a serious intestinal neonatal disease with high morbidity
and mortality rates, as is reflected in chapter 3, paragraph 6 and 7. In urine and
faeces of 29 consecutively included neonates suspected for NEC proteins
representing important (histo-)pathological factors of NEC were measured:
epithelial integrity loss (urinary I-FABP and urinary claudin-3) and gut wall
inflammation (faecal calprotectin). In the 12 neonates suspected for NEC, who
ultimately developed NEC, the levels of the studied markers were significantly
higher than in the neonates who finally had other diagnoses (mainly sepsis).
Areas under the receiver operating characteristic curve of urinary I-FABP,
urinary claudin-3 and faecal calprotectin were 1.0, 0.84 and 0.94, respectively.
These data are considered to be clinically relevant.
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Question 4: Do patients who undergo the diagnostic test fare better (in their
ultimate health outcomes) than similar patients who do not? The question has to
be answered by randomizing patients to undergo the test of interest or another
(or no) test. However, it is disputable whether unravelling phase 4 questions is
valid and efficient with this design (randomised comparison of the test OR:
randomised assignment of patients to the test), since this study design evaluates
both the test and different treatment strategies following the tests 11. Furthermore,
a large number of patients is needed. Therefore, an alternative study design for
phase 4 questions is to move the point of randomisation from the decision point
whether or not to test, to what to do with the test result, i.e. to apply the test to
all patients before randomisation, irrespective of the result 11. If the costs of the
test are low compared with the costs of following up patients and monitoring
outcome, randomising only test-negative patients potentially offers a more
efficient design. Moreover, if the trial is sufficiently powered, assessment of the
effectiveness separately in test-positive and test-negative patients can lead to
evidence-based practice recommendations.
In conclusion, the potential usefulness of new markers (FABP, claudin-3,
calprotectin) in the early diagnosis of intestinal diseases was shown. It is of
importance that most of the tests can be performed in non-invasively collected
material, such as urine and faeces. Especially in neonates and children this is a
great advantage, since blood collection for diagnostic purposes is traumatic for
all children and a major cause for anaemia in neonates. All studies have to be
continued into the following phase of the evaluation of new diagnostic tests.
For the neonates suspected for NEC, question 4 has to be answered for which
the considerations regarding the design have been described.
The third aim of this thesis was to evaluate the development of gut wall
integrity loss in critically ill patients and in people undergoing major (non-
abdominal) surgery.
Experimental animal studies have generated the hypothesis that the
intestines are central in the origin of post-operative and post-traumatic sequelae
1,2,12-14. It is hypothesized that major surgery or trauma leads to a redistribution
of blood to the vital organs (brain, heart) at the expense of the intestines.
Especially the mature intestinal mucosal cells are susceptible to hypoperfusion
and ischemia. Damage of intestinal mucosa can lead to local inflammation,
impaired barrier function, and thereupon potentially to translocation of micro-
organisms 1,2. Moreover, cell injury leads to the release of immunostimulatory
proteins or nucleotides, so-called danger signals that activate the immune
system and induce systemic inflammation 15. The translocation can result in a
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derailment of local inflammation and subsequently amplification of a systemic
inflammatory response, as is mainly shown in animal studies. With the use of
the markers for gut wall integrity, which were characterized in previous studies,
the involvement of the gut in patients undergoing major surgery was
investigated. This is of utmost importance as different opinions exist. First, the
development of intestinal hypoperfusion, objectivated by gastric mucosal
PiCO2, was explored and its relationship with intestinal epithelial cell damage,
assessed by circulating levels of I-FABP, in patients admitted to the intensive
care unit (ICU) because of postoperative abdominal sepsis (chapter 4,
paragraph 2). Splanchnic hypoperfusion in the early phase of abdominal sepsis
correlated strongly with intestinal mucosal damage. Moreover, elevated plasma
I-FABP values on admission to the ICU were associated with a poor outcome in
patients with abdominal sepsis. Next, in children with meningococcal sepsis it
was shown in chapter 4, paragraph 3 that half of the patients presented with
intestinal epithelial cell damage at admission to the paediatric ICU and that the
children who died were characterized by continued presence of gut damage,
while in all survivors this injury came to an end within 12 hours after starting
intensive treatment.
In addition to these two clinical retrospective studies showing intestinal
epithelial cell damage in a large number of patients immediately upon admission
to the ICU, the development of gut wall integrity loss during surgery in two
clinical prospective studies was investigated (chapter 4, paragraph 4 and 5).
Two of the most extensive and complex surgical procedures are open
surgical repair of thoracic aortic aneurysms (TAA) and thoracoabdominal aortic
aneurysms (TAAA) that are associated with significant postoperative morbidity
and mortality. In order to prevent peroperative ischemic injury of visceral
organs, extracorporeal circulation (ECC) technique has been implemented in
open TAA repair to provide (retrograde) distal aortic perfusion (DAP) via the
femoral artery. In case of TAAA repair involving the origin of visceral arteries,
ECC with DAP is combined with selective organ perfusion catheters (DAP and
SP) to provide designated visceral arteries directly with blood. In chapter 4,
paragraph 4 it was shown that intestinal mucosal cell injury, but not hepatic or
renal tubular cell injury, occurred in patients undergoing elective open TAA
(n=8) or TAAA (n=22) repair, despite artificial visceral perfusion. The extent of
intestinal injury and following pro-inflammatory reaction was more pronounced
in patients undergoing DAP and SP. The most likely explanation for the
difference in intestinal injury is a more prominent hypoperfusion of the intestines
during ECC with DAP and SP. Furthermore, intestinal injury correlated positively
with markers of systemic inflammation (IL-6 and IL-8). Next, the development
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of gut wall integrity loss in patients undergoing major spinal fusion surgery was
studied, which is characterized by long duration of surgical procedure,
significant blood loss, prolonged systemic hypotension and the potential
development of postoperative complications (chapter 4, paragraph 5). This type
of surgery was chosen because it does not directly compromise the intestines by
intestinal manipulation or the use of extracorporeal circulation. In a significant
number of patients increased circulating levels of I-FABP and I-BABP and
elevated urinary values of claudin-3 were observed, indicating the development
of gut wall integrity loss. Furthermore, a significant inverse association between
mean arterial pressure and succeeding plasma levels of I-FABP and I-BABP was
found, which indicates that systemic hypotension is correlated with intestinal
mucosal cell injury, detected 1⁄2 hour later. The systemic hypotension is mainly
caused by anaesthetics, causing a decreased systemic vascular resistance.
Finally, splanchnic hypoperfusion (gastric mucosal PiCO2 and Pr-aCO2-gap)
correlated strongly with intestinal mucosal damage (plasma I-FABP) at all
observed time-points during surgery.
In conclusion, the results of these studies in patients undergoing TAA(A)-
repair and spinal fusion repair show for the first time the relation between
altered splanchnic perfusion and the development of intestinal mucosal cellular
damage in patients undergoing major surgery. Collectively, these findings shed
a new light on the potential role of intestinal barrier compromise during major
surgery, which was deduced from numerous animal studies, but now for the
first time reported in relatively healthy children and adolescents undergoing
major (non-abdominal) surgery. Furthermore, these results indicate a need to
re-examine currently accepted criteria of haemodynamic parameters, both
regarding the use of ECC and accepted systemic hypotension, in patients
undergoing major surgery.
True, the presence of intestinal damage does not show any cause-and-
effect relationship with the development of sepsis or multiple organ failure
(MOF). Moreover, intestinal damage may be part of more generalized tissue
damage with epithelial barrier dysfunction in lung, liver and kidney 16,17. These
studies are however the basis for further research to clarify the onset of
intestinal damage, since direct measurement of intestinal damage has shown
interesting results. In addition, assessment of intestinal epithelial damage in
patients with sepsis or undergoing major surgery may have important clinical
implications. Evaluation of intestinal tissue damage in the early phase of sepsis
is an adequate predictor for survival. Furthermore, the adequacy of treatment of
circulatory failure in sepsis is currently monitored using indirect parameters of
tissue perfusion and oxygenation. However, these parameters do not reflect the
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actual defects in (peripheral) tissue perfusion and subsequent tissue damage.
Assessment of plasma I-FABP levels offers the possibility to monitor the
presence of intestinal epithelial cell damage as a consequence of splanchnic
hypoperfusion, which could help to monitor treatment directed at restoration of
peripheral perfusion and prevention of organ damage. Further studies are
needed to clarify the diagnostic potential of assessment of plasma I-FABP in
monitoring the treatment of sepsis in the acute phase and during follow-up.
As reported in the chapter 4, altered splanchnic perfusion was observed
during major surgery and in critically ill patients, which was related to the
development of gut wall integrity loss. Therefore, the final aim of this thesis was
to set up a model, which enabled us to study the pathophysiological
consequences of controlled intestinal ischemia-reperfusion (IR) in detail in
man. Moreover, acute mesenteric ischemia is a disease entity itself, which is
accompanied by high morbidity and mortality rates because of its aspecific
presentation and the lack of accurate markers. A human model for intestinal IR
potentially would also give the opportunity to study new diagnostic tests. A
pancreatico-duodenectomy is a procedure in which a variable length of
jejunum is removed. This enabled us to study IR induced cell damage in a
harmless human jejunal IR model. Isolated jejunum (6 cm) was subjected to 30
minutes ischemia followed by reperfusion, which is described in chapter 5,
paragraph 2.
Mean (SEM) arteriovenous concentration gradients of I-FABP across the
jejunum revealed rapid epithelial cell damage, which was dependent on the
mannose-binding lectin (MBL) genotype of the patient (chapter 5, paragraph 3
and 4). Overall, I-FABP release significantly increased from 290 (46) pg/ml
before ischemia towards 3997 (554) pg/ml immediately after ischemia
(p<0.001) and declined gradually to 1143 (237) pg/ml within 1 hour
reperfusion (p<0.001). However, in patients with MBL null alleles no mucosal
cell damage, assessed by arteriovenous concentration gradients of I-FABP, was
observed immediately after 30 minutes of ischemia, while the highest increase
of I-FABP was found in the MBL homozygous wildtype individuals. Directly
after ischemia the intestinal epithelial lining was microscopically normal in all
patients, while subepithelial spaces appeared at the villus top, caused by
contraction of the basement membrane, which demarcates epithelium from
lamina propria. However, after 25 minutes reperfusion, apoptosis, visualized by
M30 immunostaining, was observed at the villus top accompanied by shedding
of mature epithelial cells into the lumen and loss of I-FABP staining of epithelial
cells, indicating membrane integrity loss. Interestingly, within 60 minutes
269
Summary and discussion
Joep Derikx druk:proefschrift  20-04-2009  16:12  Pagina 269
reperfusion the epithelial barrier resealed, while debris of apoptotic, shedded
epithelial cells was observed in the lumen. At the same time, both apoptosis
and inflammation were absent in intact epithelium (chapter 5, paragraph 5).
In conclusion, this is the first human study to clarify jejunal IR induced cell
damage and repair and its direct consequences. It reveals a unique, endogenous
clearing mechanism for injured enterocytes upon 30 minutes of ischemia: rapid
detachment of damaged apoptotic enterocytes into the lumen. This process is
quickly followed by repair of the epithelial continuity, resulting in a normal
epithelial lining, which is hypothesized to be a key factor in the prevention of
the development of inflammation. Our results might explain why the gut can
tolerate 30 minutes of ischemia in events as exercise, trauma, sepsis, repair of a
(thoraco-)abdominal aneurysm of the aorta, and cardiopulmonary bypass. It is of
importance to understand the maximal time of ischemia, which the gut can bear
by utilization of its repair mechanism for injured cells.
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Nederlandse samenvatting
Dit proefschrift gaat ten eerste over het herkennen van darmziekten en ten
tweede over de rol van de darm tijdens grote chirurgische ingrepen en bij
ernstig zieke patiënten op de intensive care unit.
De voornaamste functie van de darm is de opname van voedingsstoffen.
Daarom moet de darmwand doorlaatbaar zijn voor voeding, nodig voor energie
en als bouwstof. De inname van voedsel gaat echter ook gepaard met de
blootstelling van de darm aan een grote hoeveelheid lichaamsvreemde voedings-
stoffen en micro-organismen. De tweede functie van de darm is dan ook om een
effectieve barrière te vormen tegen deze potentieel schadelijke inhoud van de
darm. Er bestaan vele mechanismen om deze barrière in stand te houden,
welke besproken worden in hoofdstuk 1, paragraaf 3. Er zijn situaties waarin de
barrière verstoord wordt en dit leidt dan vaak tot darmziekten en mogelijk tot
andere gevaarlijke aandoeningen als bloedvergiftiging. Het is voor artsen soms
lastig om vast te stellen of een darmziekte aanwezig is bij een patiënt die zich
presenteert met buikklachten. Dit komt, doordat veel ziekten gepaard gaan met
buikklachten, ook al is de darm er niet bij betrokken. Hierdoor is de diagnostiek
van darmaandoeningen vertraagd en dientengevolgde ook de correcte
behandeling, hetgeen leidt tot hogere morbiditeit en mortaliteit. Er is derhalve
behoefte aan laboratoriumtesten die duidelijk maken of de darm beschadigd is.
In aansluiting op deze diagnostische uitdaging, wordt de nabehandeling van
darmziekten soms ook gehinderd door de afwezigheid van een niet-invasieve,
snelle diagnostische test, die kan vaststellen of de therapie, gericht op herstel
van de darmschade, succesvol is. In dit proefschrift werd een aantal potentiële
testen geëvalueerd, die met name schade aan de darmcellen die de barrière
vormen aantonen. Onderzoek naar markers voor myocardischemie gaf
aanknopings-punten waaraan markers voor darmschade moesten voldoen.
Troponine T is daarbij het meest treffende voorbeeld. Het is een klein eiwit dat
karakteristiek voorkomt in het doelorgaan (hart) en snel de cel verlaat bij
schade. Analoog hieraan komen in de darm eiwitten tot expressie, die behoren
tot de familie van fatty acid binding proteins (FABP’s). FABP’s hebben normaliter
een functie in het transcellulaire transport van langeketenvetzuren en
galzouten, zijn in het cytosol gelokaliseerd, in water oplosbaar en hebben een
laag moleculair gewicht (14-15 kDa). Deze eigenschappen zorgen ervoor dat
ze de cel gemakkelijk verlaten na verlies van de integriteit van de celmembraan
en terechtkomen in de circulatie. In de darm komen de isovormen intestinal (I)-
FABP, liver (L)-FABP en ileal-bile acid binding protein (I-BABP) voor. (Pilot-
)studies van andere onderzoekers wezen uit dat necrose van de darm
vroegtijdig vastgesteld kan worden door in plasma en/of urine eiwitten te
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bepalen die afkomstig zijn uit het cytosol van darmepitheel. Om de plasma
en/of urine concentraties van deze eiwitten te begrijpen, was inzicht nodig in
de exacte lokatie van deze eiwitten in de darmwand. In hoofdstuk 2, paragraaf
2 wordt beschreven dat FABP’s in de hele darm tot expressie komen en met
name in de dunne darm. Microscopisch zijn deze eiwitten gelokaliseerd in de
epitheelcellen. Bij patiënten met coeliakie, een ziekte die onder andere
gekenmerkt wordt door epitheelschade door glutenovergevoeligheid, werd
gevonden dat I-FABP en L-FABP concentraties in het bloed bruikbare markers
zijn voor het vaststellen van met histologisch onderzoek geobjectiveerde
darmschade. Ook bleken deze markers potentieel waardevol zijn in de
evaluatie van het dieeteffect. Teneinde de klaringsdynamiek van FABP’s te
bepalen werd vervolgens peroperatief bij chirurgische patiënten bloed
verzameld uit de aan- en afvoerende vaten van darmen, lever en nieren. Na
analyse van pre- en postrenaal plasma werd vastgesteld dat FABP’s door de nier
werden geklaard (fractionele renale extractie: 28%); berekend werd dat de
plasma halfwaardetijd elf minuten bedroeg (hoofstuk 2, paragraaf 3).
Hieruit wordt geconcludeerd dat er sterke aanwijzingen zijn dat circulerend
en urinair FABP’s waardevolle markers zijn om darmschade aan te tonen.
Vervolgens werden deze testen gebruikt om zuigelingen, verdacht van de
ernstige darmontsteking necrotiserende enterocolitis (NEC), vroegtijdig op te
sporen. NEC komt voornamelijk voor bij te vroeg geboren, fles-gevoede
kinderen. Deze aandoening kent een hoog sterftecijfer: 20-40% van de
kinderen met NEC overlijdt aan deze aandoening. Gebrek aan goede,
betrouwbare (vroeg)diagnostische mogelijkheden is mede de oorzaak van de
hoge mortaliteit en morbiditeit. Therapeutische modaliteiten worden daardoor
te laat geïnitieerd. De belangrijkste bevinding is dat deze testen, die uitgevoerd
kunnen worden in materiaal dat op niet-invasieve manier werd verkregen (te
weten urine en faeces), in staat blijken om vast te stellen of zuigelingen die
verdacht werden van NEC deze ziekte, daadwerkelijk hadden of niet (hoofdstuk
3, paragraaf 6 en 7). Dit is klinisch erg relevant, omdat zuigelingen zodoende
voortaan sneller een adequatere behandeling kunnen krijgen.
Vervolgens werd onderzoek gedaan naar de hypothese, die voortkomt uit
proefdierstudies en die stelt dat verlies van de darm barrière betrokken is bij het
ontstaan van ontstekingsreacties, zoals kan plaatsvinden bij postoperatieve of
posttraumatische complicaties, bloedvergiftiging (sepsis) en meervoudig
orgaanfalen (multiple organ failure (MOF)). Deze proefdierstudies laten zien
dat grote operaties of ernstig trauma leiden tot een verminderde doorbloeding
van de darm, waarbij ontstekingsfactoren vrijkomen en de barrière van de
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darmwand verloren gaat. Bovendien komen door celschade alarmsignalen uit
het cytsoplasma van de cel vrij, die een ontstekingsrepons opwekken. Verlies van
de darm barrière kan resulteren in de passage van schadelijke voedingsstoffen en
micro-organismen en hun toxinen door de darmwand heen en het vrijkomen
ervan in het lichaam. Dientengevolge kan een ongecontroleerde hevige
ontstekingsreactie ontstaan, waardoor ziektebeelden als sepsis kunnen
ontstaan. Voorgaand onderzoek naar bovenstaande hypothese in patiënt-
gebonden studies liet uiteenlopende resultaten zien. Daarom werd in dit
proefschrift de vraag bestudeerd of de darm aangedaan is als gevolg van grote
chirurgische ingrepen; de resultaten worden in hoofdstuk 4 gepresenteerd.
Patiënten die op de intensive care unit terechtkwamen vanwege sepsis als
complicatie na een grote buikoperatie bleken darmschade te hebben. Deze
schade was gerelateerd aan de mate van doorbloeding van de darm. De
hoeveelheid darmschade was een goede voorspeller voor de mortaliteit in deze
groep patiënten. Twee studies waarin achtereenvolgens patiënten geïncludeerd
werden die een langdurige operatie aan hun aorta of aan hun scoliose
ondergingen, lieten zien dat darmschade en barrière verlies ontstond bij deze
patiënten. De darmschade was gecorreleerd met doorbloedingsveranderingen
van de darm en de erop volgende ontstekingsreactie.
Aangezien aangetoond werd dat de doorbloeding van de darm een
belangrijke factor is voor de instandhouding van de barrière, werd een
experimenteel model ontwikkeld waardoor de gevolgen van doorbloedings-
stoornissen (ischaemie) van de darm in de mens bestudeerd konden worden
(hoofdstuk 5). Daarenboven is darmischaemie een ziekte-entiteit, die ontstaat door
thromboembolie, en die gepaard gaat met hoge morbiditeit en mortaliteit door de
aspecifieke klinische presentatie en een gebrek aan accurate diagnostische
mogelijkheden. In het nieuw ontwikkelde model voor darmischaemie kunnen
derhalve ook nieuwe testen voor de vroegdiagnostiek van darmischaemie worden
geevalueerd. In patiënten, die een pancreatico-duodenectomie ondergingen, werd
gebruik gemaakt van het feit dat in deze procedure een variabele lengte dunne
darm (jejunum) wordt verwijderd. Hierdoor ontstond een voor de patiënt
risicoloos humaan jejunum ischaemie-reperfusie (IR) model. Geïsoleerd jejunum
(6cm) werd onderworpen aan 30 minuten ischaemie, gevolgd door reperfusie.
Arterioveneuze concentratiegradiënten van I-FABP over bestudeerd jejunum liet
het ontstaan van epitheliale celschade zien, die afhankelijk was van het mannose-
bindend lectine genotype van de patiënt. Direct na ischaemie was de intestinale
epitheliale bekleding microscopisch intact, terwijl subepitheliale ruimtes
ontstonden in de villus top door terugtrekking van de basaal membraan. Echter, na
25 minuten reperfusie werd massale afstoting van de mature epitheliale cellen in
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het lumen waargenomen, gepaard gaand met apoptose. Vervolgens was de
epitheliale continuïteit hersteld binnen 60 minuten reperfusie en apoptose
afwezig. Darmbarrièrefalen, gemeten door de concentraties van afbraakprodukten
van bacteriën over het geïsoleerde stuk darm, en een ontstekingsreactie werden
niet waargenomen. Concluderend; dit is de eerste humane studie die intestinale IR
geïnduceerde celschade en de directe consequenties opheldert, waarin een uniek,
endogeen beschermingsmechanisme beschadigde cellen elimineert en het
ontstaan van barrièreverlies of inflammatie voorkomt.
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• Derikx JP, De Backer A, van de Schoot L, Aronson DC, de Langen ZJ, van
den Hoonaard TL, Bax NM, van der Staak F, van Heurn LW.
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• Derikx JP, Poeze M, van Bijnen AA, Buurman WA, Heineman E.
Evidence for intestinal and liver epithelial cell injury in the early phase of
sepsis.
Shock. 2007;28:544-8.
• van de Poll MC, Derikx JP, Buurman WA, Peters WH, Roelofs HM,
Wigmore SJ, Dejong CH.
Liver manipulation causes hepatocyte injury and precedes systemic
inflammation in patients undergoing liver resection.
World J Surg. 2007;31:2033-8.
• Derikx JP, Evennett NJ, Degraeuwe PL, Mulder TL, van Bijnen AA, van
Heurn LW, Buurman WA, Heineman E.
Urine based detection of intestinal mucosal cell damage in neonates with
suspected necrotising enterocolitis.
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Dam RM, Dejong CH, Buurman WA.
Rapid reversal of human intestinal ischemia-reperfusion induced damage
by shedding of injured enterocytes and reepithelialisation.
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Intestinal cytoskeleton degradation precedes tight junction loss following
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• Derikx JP, Blijlevens NM, Donnelly JP, Fujii H, Kanda T, van Bijnen AA,
Heineman E, Buurman WA.
Loss of enterocyte mass is accompanied by diminished turnover of
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• Bosch SF, Derikx JP, Thuijls G, van Bijnen AA, van Waardenburg DA, van
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• Derikx JP, Vreugdenhil AC, Van den Neucker AM, Grootjans J, van Bijnen
AA, Damoiseaux JG, van Heurn LW, Heineman E, Buurman WA
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• Derikx JP, Bijker EM, Vos GD, van Bijnen AA, Heineman E, Buurman WA,
van Waardenburg DA
Gut mucosal damage in the early phase of children with meningococcal
sepsis.
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• Maarten Kappelle Stichting, ‘Gut wall integrity failure in prematures with
necrotiscing enterocolitis’: 2005.
• Stichting Jules Coenegracht sr., ‘Chemotherapy-induced loss of gut wall
integrity in children’: 2005.
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Geen enkele (ouder van een) patiënt heeft geweigerd om deel te nemen aan
een van de studies, beschreven in dit proefschrift, terwijl we geen enkele
patiënt direct konden helpen met de onderzoeken. De reden die alle (ouders
van) patiënten gaven om toch mee te doen aan de studies was zonder
uitzondering: ‘Het onderzoek is niet schadelijk voor mij en ik kan er in de
toekomst toch veel mensen in een zelfde positie als de mijne mee van dienst
zijn.’ Ongelooflijk veel dank ben ik verschuldigd aan de patiënten (en hun
ouders).
Mijn promotores Erik Heineman en Wim Buurman wil ik van harte
danken voor de kans die ze me hebben gegeven om het onderzoek naar
‘Compromised gut in neonates and children’ mee op te starten, voor de
begeleiding en haast onvoorwaardelijke steun. Erik, jouw enthousiasme en
positivisme hebben me gestimuleerd om zo veel mogelijk te doen. Wim, jij
hebt me onder andere geleerd om klinische wetenschap met een basale blik
tegemoet te treden. Ook wil ik Simone en Jeanette, de echtgenotes van mijn
promotores, bedanken voor hun hartelijke ontvangst in Cadier en Keer en
Eijsden tijdens de vele besprekingen.
Ernst, jou dank ik voor de gelegenheid die je me gaf om het Nederlandse
na-onderzoek te doen naar patiënten geopereerd aan een sacrococcygeaal
teratoom en om de resultaten te presenteren op menig congres. Daarna heb je
me geholpen om de begeerde promotieplek te krijgen bij de (kinder)chirurgie.
Ook tijdens mijn promotie hebben we een aantal studies samen kunnen doen.
De andere Mestreechter (kinder)chirurgen wil ik bedanken voor hun
bijdrage en belangstelling: Dr Sie (ook voor het leuke congresbezoek in Turijn
en Istanbul), Dr Van Gemert, Dr Verhoeven.
Daarnaast wil ik de kinderartsen en neonatologen bedanken voor hun
inzet om van de gemeenschappelijke studies een succes te maken. Met name
Prof. Zimmerman, Dr. Mulder, Dr. Degraeuwe, Dr. Kramer, Dr. Van der
Hoeven, Dr. Moonen en Dr. Van Waardenburg, Dr. Van den Neucker, Dr.
Vreugdenhil en Dr. Granzen waren nauw betrokken bij onze studies.
Kees Dejong en Ronald van Dam, dankzij jullie konden de Chef en ik erg
gaaf onderzoek doen naar darmischaemie. Prof. Greve, Dr. Bemelmans, Jan en
Antje: dank dat jullie ons altijd altijd zo enthousiast welkom heetten als we op
de operatiekamer kwamen voor deze studie.
Martijn Poeze wil ik bedanken voor de ondersteuning om snel een artikel
voor elkaar te krijgen. Daarnaast wil ik de Nijmeegese darm-geïnteresseerden
Nicole Blijlevens en Peter Donnelly bedanken voor het mooie stuk dat we
hebben gemaakt. I want to thank Dr. Fujii and Dr. Kanda for their help in
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constructing (anti-)I-BABP. Prof. De Bruïne wil ik danken, omdat we altijd
binnen mochten lopen met nieuwe coupes en voor zijn betrokkenheid bij het
darmischaemie-stuk. Dr. Van Rhijn, Dr. Van Ooij, Dr. Willigers en Dick van
Waardenburg wil ik danken voor het hechte team dat we vormden wat betreft
de scoliose-studie. Verder dank aan alle andere mede-auteurs op de stukken.
Dan kon dit onderzoek ook niet plaats hebben gevonden zonder de steun
van de verpleegkundigen van de NICU (eerst onder leiding van Mark, later van
Jos) en PICU. Gelukkig hebben jullie onze studies vanaf het begin warm
ontvangen en jullie betrokken gevoeld. Ook wil ik de operatie-asistenten en
anaesthesiemedewerkers bedanken voor hun medewerking als we weer eens
met een kar of apparaat de operatiekamer op kwamen. Jullie toonden zonder
uitzondering interesse in het onderzoek.
De beoordelingscommissie dank ik voor het beoordelen van dit
proefschrift.
Toen ik op het lab kwam, wist ik niet hoe te pipetteren, hoe een computer
werkte, wat een PCR/ELISA/IHC/WB is, hoe een paper te submitten, hoe een
koffiezetapparaat werkte en wat te doen met alle vrije tijd. Gelukkig werd ik
daarbij goed en vakkundig geholpen door enkele doorgewinterde collegae. Ik
heb lang getwijfeld of ik echte namen ga noemen in het dankwoord of de
namen, zoals ze op het lab in zwang zijn. Ik heb besloten beide eens op te
schrijven, zodat vast ligt wie nu precies wie is. Dit zal voor veel collegae
handig zijn, aangezien een enkeling nog steeds niet weet of Hans nu Bas is of
dat Bas Hans is, wie nu Ruud of Tim is en of er een verschil is tussen Sjeng, Chef
en Sjaak.
De voorgangers die me de goede weg wezen, wil ik danken: Bart (de
Vriescoupekoning), Marcel, Yvonne (Yf), Misha (DJ Daiper, Dr Luyer). Robert
(eerst Koffert, later de Chef) wil ik danken voor de mooie tijd: menig mooi
tochtje op de fiets, naar congres en Arhus; samen begonnen, samen klaar! Sjeng
(Tim, Prof. Tip, de PCR-koning) wil ik danken voor de gelijkenis op Erwin,
André Kuijpers en Gaston. Bij vrijwel alles wat op het lab gebeurt, ben je
betrokken en we hebben als buurmannen veel leuks meegemaakt: oa skitrips,
voetbalpartijtjes en nog wat experimenten, waarvoor heel veel dank! Dan komt
daar een van de grootste steunpilaren van het lab: Mo. Hadfoune, wat een
mannetje ben je ook: een uitgesproken mening, die je ook ter discussie wilt
stellen, gekoppeld aan een schaterlach waar iedereen vanzelf vrolijk van wordt.
Dank aan Geertje (kortweg Geert) voor de vele brainstormsessies over onze
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studies, het uitvoeren van veel werk dat we samen bedachten en voor de
aangename congresbezoekjes. Dank ook aan Joepie (de Direkteur): ik was blij
dat je op mijn mail reageerde en al vroeg bij ons op het lab onderzoek kwam
doen en bent gebleven! Je bent daardoor snel een vaste waarde geworden met
een grote nieuwsgierigheid naar alles wat op en rondom het lab plaatsvindt.
Tim (Ruud) wil ik danken voor de Top(pers)-muziek die hij heeft gedraaid in de
gaafste, succesvolste en mannelijkste kamer van het lab. Tine, dank dat je de
kar zo voortvarend hebt getrokken van de NEC-studie op de NICU. Jacco-Juri
(Sjaak), leuk je nu ook als co-assistent en collega te kennen. Ook Kim
(Kimmerd) wil ik danken voor de gezelligheid en voor het beheren van de
agenda van Wim (voor zover dat mogelijk is). Daarbij wil ik dan meteen Anouk,
Nicole en Sandra, de secretaresses van Erik, danken, die altijd een gaatje
vrijmaakten in zijn agenda als ik wilde langskomen. Dan wil ik ook de rest van
de voormalige collegae bedanken: Trudi, Sarah (Rinsy), Kees, Jeroen
(Nijhuisman), Sylvia, Martien, Nicole, Nicholas, Bas (Hans, zeker ook voor het
fraaie stuk over TAAA), Hans (HPLC-Hans), Dennis (v/d Ven) en Dennis (Jaap),
Loes, Kirsten, Marcella, Paul, Gabri, Mariëlle, Yvette, Mick, Albert, Ayhan,
Bart(je Boterzuur), Iris, Femke, Yanti, Sander (Rens), Froukje (Goukje, Sjoukje),
Caroline (Houdini), Dian (Dianski), Kaatje, Johanne, Kim, Maarten, Eva, Ruben,
Maartje, Nina, Kirsten. Dank aan alle studenten, die hebben bijgedragen aan
dit proefschrift: Bregje, Fredje, Arianne, Sofie, Job&Rinske, Caroline/Tine,
Sander, Kim, Joepie, Marianne, Vera/Caroline, Else. Lest, best: Annemarie,
zonder jouw kennis en kunde waren onze studies onmogelijk geweest.
Ongelooflijk veel dank ben ik je verschuldigd voor het consciëntieus uitvoeren
en analyseren van de experimenten, voor het ordenen van alle samples en voor
het soepele, ongecompliceerde team dat we vormden.
Dank aan de pulmo’s (onze buren, mn Ramon, Harry, Jos en Juanita) voor
de vele team-buildingsmomenten van ons lab waar jullie graag lijdend
voorwerp wilden zijn.
De assistenten en chirurgen uit Sittard bedank ik voor de goede, warme
na-onderzoekse opvang. Ik vond het spannend om aan de opleiding te
beginnen. Het team waarin ik terecht ben gekomen, zorgt ervoor dat ik me als
een vis in het water voel, ongelooflijk veel leer en met veel plezier naar ons
mooie ziekenhuis kom.
Alle mannetjes van het creatieve, slimme, lompe en sportieve dispuut
Rusticus wil ik danken voor de onvergetelijke studententijd in Maastricht,
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gehucht aan de Maas, stad van Hogeschool Maastricht, stad van Universiteit
Maastricht, stad van de Inkom! In het bijzonder wil ik danken de mannen van
het eerste uur (en even daarna): Martijn (10us), Jasper, Raph (de Sambaschurk),
Tim (de Haas Jansen, 16 jaar), Marc (de pauw/rups); TSS10a/JSD(&P): Stijn (de
PPP), Dussie, Pier(lalalaaa) en als laatste de leden van EUR: Stijn, Jacco-Juri
(Sjaak), Laurent (Stobbe), Rolf (Koning Loch), en af en toe Joepie (Praloupie).
Gao staon ajje veur Rusticus bin!
Dank ook aan Léon en Alexander van fietsclub SMS en hun vrouwen voor
de inspannende ontspannen trainingsritjes op zondagochtend.
Ik wil de leden van kook- en eetclub ’t Klaoske bedanken voor de
topavonden. Klaske en Joost (vaste deel van de kookclub): ik heb veel
bewondering voor de maaltijden die jullie altijd weer van overal ter wereld op
tafel toveren, die Marieke&Dave en Monique&ik (vaste deel van de eetclub)
dan weer met veel verwondering opeten.
Alles heb ik natuurlijk te danken aan mijn familie. Ook al lijk je je vaak
weg te cijferen voor de rest van ons gezin, toch ben jij het middelpunt en degene
die ons bindt, papa. Met veel trots zien jij, Max en ik dat we uit hetzelfde hout
zijn gesneden. Samen met mama heb jij altijd het klimaat geschapen waarin
Max en ik konden doen wat we wilden. Jullie hebben ons de weg gewezen, en
later heb je met Marianne ons los gelaten, maar we zijn elkaar nooit kwijt
geraakt. Dat komt vast doordat we elke dag geprobeerd hebben het gouden
randje te vinden, zoals jij en mama dat aan Max en mij geleerd hebben. Ik ben
blij dat jij, Marianne, weer zorgde voor uitbreiding van ons gezin door met
Alexander en Dikkie bij ons te komen wonen. Niet alleen papa bloeide daarvan
op en heeft er veel van geleerd. Dan natuurlijk ook veel dank aan mijn broertje,
Max, en zijn Jo voor alle interesse, steun en de gezellige weekendjes
Breda/Haarlem/Maastricht. Ook Alexander, Dikkie en Jona dank voor jullie
interesse. Ook de rest van de femieje dank ik: omes, tantes, naefkes en nichskes:
Zitterd allein! De sjweierfamielje oes Kirchrao zijn mij en Monique op veel
momenten en veel manieren tot steun geweest en hebben altijd met veel zorg
bijgedragen aan ons geluk: veel dank! Daarbij wil ik meteen ook Maurice en
Yvette danken voor hun oprechte (en gedeelde) interesse en alle leuke
bezoekjes, boekjes en stukken vlaai. Als laatst wil ik hier melden dat ik erg
benieuwd ben naar de feestelijke kleding van Peggy en naar de mening van
Ronald over het boekje en de promotie. Dank dat jullie met zijn tweeën van
dichtbij betrokken zijn geweest bij mijn doen en laten door de jaren heen.
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‘My smile is my make-up, I wear since my wake-up with you’. Lieve Monique,
Pluijmpje, duizend maal dank voor je liefde, zorgzaamheid en gesjnep, die me
zo blij, gelukkig en vrolijk maken.
Kirchröadsjer meadsjer, kiek ze diech aa.
Kiek wie ze laache, ze laache diech aa.
Hant muulsjere, die zint 't puutsje wead,
hant beks-jere mollieg en ronk.
Ze zint vuur tse klauwe, zoeë wie me dat zeat,
zoeë meadsje dat maat diech jezonk.
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Covidien
Greiner Bio-One
Danone
Johnson & Johnson
B Braun
Hycult Biotechnology
Stichting Jules Coenegracht sr.
AGIKO-stipendium 920-03-438, the Netherlands Organisation for Health
Research and Development (ZonMw)
Stichting Sint Annadal
MaatschapHeelkunde Orbis Medisch Centrum Sittard
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